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Abstract 
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand [TRAIL or Apo-2 
ligand (L)] is a member ofthe TNF superfamily of ligands that can induce cellular 
responses such as activation, proliferation, differentiation, migration and 
apoptosis. Recombinant (r) soluble TRAIL is currently being developed as a most 
promising natural immune molecule for trial in cancer patients since it selectively 
induces apoptosis in transformed or stressed cells, but not in most normal cells. 
Unlike TNF and FasL (CD95L), that both exert significant systemic toxicities, 
rTRAIL has been shown to be relatively non-toxic and to exert potent anti-tumor 
functions when administered in vivo to tumor-bearing mice and non-human 
primates. Moreover, whilst radiation and most deoxy ribonucleic acid (DNA)-
damaging chemotherapeutic drugs induce tumor cell apoptosis in a p53-dependent 
manner, TRAIL-mediated apoptosis is p53-independent. Treatment with rTRAIL 
might therefore be expected to circumvent resistance to conventional 
chemotherapy and radiotherapy in cancer patients lacking p53 function. 
Despite great interest in TRAIL as a cancer therapeutic, either as a sole agent or in 
combination with irradiation or chemotherapeutic drugs, what has undeniably been 
lacking is an in depth understanding of the natural physiological role of TRAIL. 
This knowledge is fundamental if TRAIL is to be used safely and with efficacy in 
the clinic. Very recently, constitutive TRAIL expression has been identified on a 
small subset of liver natural killer (NK) cells in adult mice. TRAIL expression can 
also be induced on interferon (IFN)-a-stimulated peripheral blood T cells, IFN-
stimulated human monocytes and dendritic cells (DCs), and NK cells stimulated 
with interleukin (IL)-2, IFNs or IL-15. We and others have reported that TRAIL-
expressing liver NK cells play a role in suppression of TRAIL-sensitive liver 
tumor metastasis in vivo, suggesting that TRAIL might play a role in tumor 
surveillance. In a small number of preliminary studies, TRAIL has also been 
identified to suppress autoimmune disease induction. 
The focus of this thesis has been to help elucidate the roles of endogenous host 
TRAIL in disease. The research described herein provides the first detailed 
e v i d e n c e  o f  t h e  l e u k o c y t e  e x p r e s s i o n  a n d  f u n c t i o n  o f  m o u s e  T R A I L .  W e  d e s c r i b e  
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CHAPTER ONE 
LITERATURE REVIEW 
1 . 1  I n t r o d u c t i o n  
T h e  f o l l o w i n g  l i t e r a t u r e  r e v i e w  p r o v i d e s  a n  e x t e n s i v e  i n s i g h t  i n t o  o u r  c u r r e n t  
u n d e r s t a n d i n g  o f  N K  c e l l  biology~ w i t h  a  s p e c i f i c  f o c u s  o n  m e m b e r s  o f  t h e  T N F  
s u p e r f a m i l y .  T h e s e  e l e m e n t s  o f  t h e  i m m u n e  s y s t e m  h a v e  t h e  c a p a c i t y  t o  m a i n t a i n  
t h e  i m m u n e  s y s t e m  i n  a d d i t i o n  t o  o r c h e s t r a t i n g  a n d  r e g u l a t i n g  i n n a t e  a n d  
a d a p t i v e  i m m u n i t y ,  a u t o i m m u n e  d i s e a s e  a n d  t u m o r i g e n e s i s .  T h i s  r e v i e w  a l s o  
d e t a i l s  t h e  p r o m i s e  o f  T R A I L  a s  a  p o t e n t i a l  c a n c e r  t h e r a p e u t i c  a n d  h i g h l i g h t s  o u r  
c u r r e n t l y  l i m i t e d  k n o w l e d g e  o f  t h e  t r u e  p h y s i o l o g i c a l  r o l e  o f  T R A I L ,  k n o w l e d g e  
t h a t  i s  f u n d a m e n t a l  i f  t h e  T R A I L  p a t h w a y  i s  t o  b e  m a n i p u l a t e d  s a f e l y  a n d  w i t h  
e f f i c a c y  i n  t h e  c l i n i c .  
U n d e r s t a n d i n g  h o w  N K  c e l l  f u n c t i o n  i s  r e g u l a t e d ,  t h e  p a t h w a y s  u s e d  b y  N K  c e l l s  
t o  e l i m i n a t e  c a n c e r o u s  a n d  v i r u s - i n f e c t e d  h o s t  c e l l s ,  a n d  t h e  c o m p l e x  n e t w o r k  o f  
i n t e r a c t i o n s  b e t w e e n  N K  c e l l s  a n d  o t h e r  i m m u n e  c e l l s  h a s  b e e n  a  g r e a t  
u n d e r t a k i n g  f o r  N K  c e l l  b i o l o g i s t s .  T h e  c o n t i n u e d  d i s c o v e r y  o f  n e w  m e m b e r s  o f  
t h e  T N F  s u p e r f a m i l y ,  t h e i r  i m p o r t a n t  f u n c t i o n  i n  m o d u l a t i n g  b o t h  i n n a t e  a n d  
a d a p t i v e  i m m u n i t y ,  a n d  t h e i r  a n t i - c a n c e r  p o t e n t i a l  h a s  e m p h a s i z e d  m o r e  t h a n  e v e r  
t h e  c r i t i c a l  n e e d  t o  u n d e r s t a n d  t h e  b i o l o g i c a l  r o l e s  o f  t h e s e  p r o t e i n s .  
T h e  T N F  s u p e r f a m i l y  h a s  b e e n  d e s c r i b e d  a s  r e p r e s e n t i n g  a  d o u b l e - e d g e d  s w o r d  
( A g g a r w a l ,  2 0 0 3 ) ,  s i n c e  w h i l e  t h e y  a r e  e s s e n t i a l  f o r  n o r m a l  p h y s i o l o g i c a l  
r e s p o n s e s ,  i n a p p r o p r i a t e  e x p r e s s i o n  a n d  f u n c t i o n  o f  s o m e  m e m b e r s  c a n  b e  
h a r m f u l  a s  i l l u s t r a t e d  i n  a u t o i m m u n e  d i s e a s e  ( D e s p l a t - J e g o  e t  a l . ,  2 0 0 2 ;  J o o s t e n  
e t  a l . ,  1 9 9 6 ;  M a i n i  e t  a l . ,  1 9 9 5 ;  W i l l i a m s  e t  a l . ,  1 9 9 2 ) .  I n  a n  a t t e m p t  t o  f u r t h e r  
u n d e r s t a n d  t h e  p h y s i o l o g i c a l  r o l e ( s )  o f  T R A I L ,  t h i s  t h e s i s  d e s c r i b e s  t h e  f i r s t  
r e p o r t e d  c h a r a c t e r i z a t i o n  o f  a  T R A I L  g e n e - t a r g e t e d  m o u s e  b y  d e t e r m i n i n g  a  r o l e  
f o r  T R A I L  i n  t h e  r e g u l a t i o n  o f  t u m o r  d e v e l o p m e n t ,  h o m e o s t a s i s  o f  t h e  i m m u n e  
s y s t e m ,  a n d  c o n t r o l  o f  a u t o i m m u n e  d i s e a s e  i n d u c t i o n .  
2  
1.2 Natural Killer (NK) cells 
NK cells are a unique subset of lymphocytes that represent a crucial component 
of the innate immune system. NK cells comprise ~5% of splenic lymphocytes, 
~10% of liver lymphocytes, ~5-20% ofPBL and are present at lower frequencies 
in the thymus, BM and lymph nodes (LN s ). Whereas T cell development occurs 
in the thymus, the site of mainstream NK cell development in the adult is the BM 
(Lian and Kumar, 2002). NK cells lack rearranged receptors, but express a 
myriad of immunoglobulin (!g)-like and C-type lectin receptors [CTLR(s)] that 
deliver a finely tuned balance of inhibitory and activating signals to regulate NK 
cell function (Borrego et al., 2002; Takei et al., 1997). A number of these 
receptors recognize transformed and virus-infected cells and can stimulate NK 
cell cytokine production, secretion of cytotoxic granules and expression of 
ligands that enable the NK cells to control virus infection and tumor initiation and 
spread. 
A defining feature of NK cells is their ability to lyse tumor targets which lack 
class I MHC expression (Ljunggren and Karre, 1985; van den Broek et al., 1995) 
allowing them to often spontaneously kill cancerous or virus-infected host cells 
that have down-regulated class I MHC expression in order to evade the adaptive 
immune response (Algarra et al., 2000). Unlike T cells that require previous 
exposure to antigen in order to become activated, NK cells can mediate 
spontaneous killing of tumor cells and play an important role in the body's 
defense against microbial infection (Cerwenka and Lanier, 2001; Smyth et al., 
2002b; Trinchieri, 1989; Trinchieri, 1995). NK cells, unlike T cells, are incapable 
of "memory'' when they are exposed to tumor cells or virus-infected cells and 
therefore cannot generate an accelerated immune response, nor a larger number 
of effector cells on secondary exposure to the same tumor. In general, NK cells 
can only prevent the outgrowth of small numbers of tumor cells and are easily 
overwhelmed by larger challenges of tumor cells, thus presenting a problem in 
eliminating larger tumor masses (Wu and Lanier, 2003). 
N K  c e l l s  h a v e  a  v a r i e t y  o f  e f f e c t o r  m e c h a n i s m s  e n a b l i n g  t h e m  t o  m o u n t  a  p o t e n t  
a n t i - t u m o r  r e s p o n s e .  A l t h o u g h  N K  c e l l s  c a n  m e d i a t e  s p o n t a n e o u s  k i l l i n g  o f M H C  
c l a s s  ! - d e f i c i e n t  t u m o r  c e l l s ,  r e s t i n g  N K  c e l l s  i n  t h e  p e r i p h e r y  q u i c k l y  b e c o m e  
a c t i v a t e d  a n d  p r o l i f e r a t e  u p o n  s t i m u l a t i o n  w i t h  a  v a r i e t y  o f  c y t o k i n e s  s u c h  a s  I L -
2 ,  I L - 1 2 ,  I L - 1 5 ,  I L - 1 8 ,  I L - 2 1 ,  I F N - a  a n d  IFN-~. T h i s  i s  w e l l  d o c u m e n t e d  i n  t h e  
h o s t  r e s p o n s e  t o  v i r u s ,  w h e n  h i g h  l e v e l s  o f  t y p e  I  I F N  a r e  p r o d u c e d .  N K  c e l l s  c a n  
b e  e x c l u s i v e l y  r e s p o n s i b l e  f o r  r e j e c t i n g  t u m o r s  b y  d i r e c t l y  k i l l i n g  t u m o r  c e l l s  
( K a r r e  e t  a l . ,  1 9 8 6 ;  v a n  d e n  B r o e k  e t  a l . ,  1 9 9 5 )  o r  a l t e r n a t i v e l y ,  t h e y  c a n  s t i m u l a t e  
c o m p o n e n t s  o f  t h e  a d a p t i v e  i m m u n e  s y s t e m  t o  e l i m i n a t e  t u m o r s  ( K e l l y  e t  a l . ,  
2 0 0 2 b ;  W u  e t  a l . ,  1 9 9 5 ) .  F o r  e x a m p l e ,  N K  c e l l s  m a y  e v o k e  T  c e l l  i m m u n i t y  
a g a i n s t  s e c o n d a r y  M H C  c l a s s  ! - s u f f i c i e n t  t u m o r s  w h e n  p r i m a r y  r e j e c t i o n  i n v o l v e s  
C D 2 7  ( K e l l y  e t  a l . ,  2 0 0 2 a )  o r  N K G 2 D  ( D i e f e n b a c h  e t  a l . ,  2 0 0 1 )  e x p r e s s e d  o n  N K  
c e l l s .  I n  a d d i t i o n ,  M H C  c l a s s  I
1
o w  t u m o r s  h a v e  b e e n  d e m o n s t r a t e d  t o  a c t i v a t e  N K  
c e l l s  i n  v i v o  a n d  s u b s e q u e n t l y  p r i m e  D C s  t o  i n d u c e  p r o t e c t i v e  C D 8 +  T  c e l l  
r e s p o n s e s  ( M o c i k a t  e t  a l . ,  2 0 0 3 ) .  T h e s e  l i n k s  b e t w e e n  N K  c e l l s  a n d  a d a p t i v e  
i m m u n i t y  r e m a i n  p o o r l y  d e f i n e d  a t  a  m o l e c u l a r  l e v e l ,  b u t  a r e  l i k e l y  i m p o r t a n t  i n  
a n t i - t u m o r  r e s p o n s e s .  A c t i v a t e d  N K  c e l l s  t h e m s e l v e s  c a n  a l s o  p r o d u c e  a  v a r i e t y  
o f  c y t o k i n e s  a n d  c h e m o k i n e s  t h a t  c a n  h a v e  a  d i r e c t  e f f e c t  o n  t u m o r  g r o w t h  a n d  
p r i m e  i m m u n e  e f f e c t o r  c e l l s  t h a t  a r e  c r u c i a l  f o r  s u b s e q u e n t  a d a p t i v e  i m m u n e  
r e s p o n s e s .  N K  c e l l s  u s e  t w o  m a j o r  m e c h a n i s m s  t o  i n d u c e  t a r g e t  c e l l  a p o p t o s i s ,  
t h e  g r a n u l e  e x o c y t o s i s  p a t h w a y  ( T r a p a n i  e t  a l . ,  2 0 0 0 ;  T r a p a n i  a n d  S m y t h ,  2 0 0 2 )  
a n d  t h e  D R  p a t h w a y  ( N a g a t a  a n d  G o l s t e i n ,  1 9 9 5 ;  S m y t h  e t  a l . ,  2 0 0 3 ) .  W h i l s t  t h e  
p f p / g r z  g r a n u l e  e x o c y t o s i s  p a t h w a y  h a s  b e e n  e x t e n s i v e l y  s t u d i e d ,  l e s s  i s  k n o w n  
a b o u t  N K  c e l l  d e a t h  l i g a n d  f u n c t i o n .  
1 . 2 . 1  N K  c e l l  d e v e l o p m e n t  
N K  c e l l  d e v e l o p m e n t  i n  t h e  a d u l t  i s  t h y m u s - i n d e p e n d e n t  a n d  o c c u r s  i n  t h e  B M  
( L i a n  a n d  K u m a r ,  2 0 0 2 ) .  D u r i n g  f e t a l  d e v e l o p m e n t ,  h e m a t o p o i e t i c  s t e m  c e l l s  
( H S C )  c o l o n i z e  t h e  f e t a l  l i v e r  b e f o r e  m i g r a t i n g  t o  t h e  B M  w h e r e  a d u l t  
h e m a t o p o i e s i s  o c c u r s  ( C u m a n o  a n d  G o d i n ,  2 0 0 1 ) .  H S C  g i v e  r i s e  t o  a  c o m m o n  
l y m p h o i d  p r o g e n i t o r  ( C L P )  p o p u l a t i o n  t h a t  c a n  d e v e l o p  i n t o  N K ,  T  a n d  B  c e l l s  
( K o n d o  e t  a l . ,  1 9 9 7 ;  M a c D o n a l d  e t  a l . ,  2 0 0 1 ) .  A  p o p u l a t i o n  o f  C D 1 2 2 + N K I . r  
4  
DXY committed NK cell progenitors have been identified in adult BM by 
Rosmaraki and colleagues (Rosmaraki et al., 2001). These NK cell precursors 
(NKPs) lack cytotoxic activity and transcripts for pfp and grzB, but can be 
stimulated to express NKl.l and DX5 and gain cytotoxic function upon culture in 
high-dose IL-2. Importantly, NKPs fail to develop into T or B cells, illustrating a 
unique commitment to the NK cell lineage. NK cell progenitors have also been 
identified in fetal thymus (lkawa et al., 1999; Michie et al., 2000; Rodewald et 
al., 1992) and NK cells can develop in FTOC (Carlyle and Zuniga-Pflucker, 
1998), although the relevance of this developmental pathway is unclear given that 
NK cell development is normal in athymic nude mice (Herberman et al., 1975). 
IL-15 secreted by the BM stroma is essential for NK cell development in humans 
and in mice and plays a role in driving the final maturation process (Kennedy et 
al., 2000; Mrozek et al., 1996). IL-lS-deficient mice have low numbers of BM 
NKl.l + NK cells that are mature, cytotoxic and secrete cytokines (Colucci et al., 
2003). Interaction between membrane-bound LT on NK cells with the LT-~ 
receptor (LT~R) expressed on stromal elements is necessary to stimulate stromal 
cells to provide a microenvironment permissive for NK cell development (Iizuka 
et al., 1999; Wu et al., 2001). Although not essential, cytokines such as stem cell 
factor, FLT3 ligand and IL-7, can also promote NK cell development (Colucci et 
al., 2003; Lian and Kumar, 2002). 
The cytokines that regulate specific developmental steps and the phenotype and 
functional characteristics of each intermediate towards NK cell maturation have 
been of great interest to NK cell biologists. Initially, researchers likened human 
NK cell development to that observed for T cells where CD4+ T helper cells 
differentiate into THl (IFN-y-producing) and TH2 (IL-4-, IL-5- and IL-13-
producing) subsets, driven by IL-12 and IL-4 respectively (Mosmann and Sad, 
1996). Human NK cells were reported to differentiate into NKl and NK2 subsets 
after culture in type 1 (riL-12 + anti-IL-4 mAb) or type 2 (riL-4 + anti-IL-12 
mAb) inducing conditions (Peritt et al., 1998) (Figure l.lA). Whilst the NKl 
subset was shown to produce IFN-y and IL-10, the NK2 subset produced IL-5 
and IL-13 (Peritt et al., 1998) analogous to the THl and TH2 T cell subsets. 
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F i g u r e  1 . 1 .  P r o g r e s s i v e  m o d e l s  o f  N K  c e l l  d e v e l o p m e n t .  ( A )  T y p e  1 - t y p e  2  p a r a d i g m .  S i m i l a r  
t o  t h e  d i f f e r e n t i a t i o n  o f T H  p r e c u r s o r s  ( p r e - T H )  i n t o  T H l  a n d  T H 2  s u b s e t s ,  N K  c e l l  p r e c u r s o r s  ( p r e -
N K )  w e r e  o r i g i n a l l y  t h o u g h t  t o  d i f f e r e n t i a t e  i n t o  e i t h e r  t y p e  1  ( N K l )  o r  t y p e  2  ( N K 2 )  c y t o k i n e  
p r o d u c i n g  N K  c e l l s  d r i v e n  b y  I L - 1 2  a n d  I L - 4  r e s p e c t i v e l y .  ( B )  L i n e a r  d i f f e r e n t i a t i o n  m o d e l .  
I m m a t u r e ,  t y p e  2  c y t o k i n e  p r o d u c i n g  N K  c e l l s  h a v e  n o w  b e e n  s h o w n  t o  p r o l i f e r a t e  i n  t h e  
p r e s e n c e  o f  I L - 4  a n d  d i f f e r e n t i a t e  i n t o  i n t e r m e d i a t e  ( t y p e  0 )  N K  c e l l s  w h e n  c u l t u r e d  i n  t h e  
p r e s e n c e  o f  I L - 1 2 .  I n t e r m e d i a t e  N K  c e l l s  p r o d u c e  b o t h  I L - 1 3  a n d  I F N - y  a n d  f u r t h e r  d i f f e r e n t i a t e  
i n t o  m a t u r e  ( t y p e  1 )  N K  c e l l s  u p o n  s t i m u l a t i o n  w i t h  I L - 1 2 .  T y p e  1  N K  c e l l s  p r o d u c e  I F N - y  a n d  
a r e  c a p a b l e  o f  p t p - m e d i a t e d  c y t o t o x i c i t y .  A s  N K  c e l l s  d i f f e r e n t i a t e ,  t h e y  l o s e  T R A I L  e x p r e s s i o n  
a n d  a c q u i r e  t h e  a b i l i t y  t o  e x e r t  F a s L - a n d  p t p - d e p e n d e n t  c y t o x i c i t y .  A d a p t e d  f r o m  ( C o l o n n a ,  
2 0 0 1 ;  L o z a  a n d  P e r u s s i a ,  2 0 0 1  ) .  
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Meanwhile, immature NK cells isolated from human umbilical cord blood were 
identified to be CD56-CD161+, to lack the IFN-y transcript and to exert TRAIL-
rather than pfP- and grz-mediated apoptosis (Bennett et al., 1996; Zamai et al., 
1998). A similar population of immature NK cells was later identified in human 
PBL and demonstrated to secrete IL-5/IL-13 and to proliferate rapidly in response 
to IL-4 (Loza and Perussia, 2001). A linear differentiation pathway for human 
NK cell development has now been proposed by Perussia and colleagues (Loza 
and Perussia, 2001) (Figure 1.1 B). The previously identified immature IL-13/IL-
5-producing, TRAIL-expressing NK cells were defined as 'Immature' (type 2) 
and were revealed to proliferate rapidly in the presence of IL-4. Upon IL-12 
stimulation, 'Immature' NK differentiate into 'Intermediate' (type 0) NK cells 
that can produce both IL-13 and IFN-y and exert TRAIL-, FasL- and pfP-
mediated cytotoxicity. IL-12 stimulated, 'Intermediate' NK cells further 
differentiate into 'Mature' (type 1) NK cells that produce IFN-y and mediate 
apoptosis by FasL and pfP. 
The individual stages of murine NK cell development have been identified on the 
basis of functional, phenotypic and proliferative capacities of NK cell 
developmental intermediates. Yokoyama and colleagues suggested five putative 
stages of NK cell maturation in mice (Kim et al., 2002) (Table 1.1 ). The earliest 
lineage-committed precursors (stage I) were characterized by expression of the 
IL-2 and IL-15 receptor common ~ subunit (IL-2-IL-15R~ or CD122). This is 
followed by sequential acquisition of NK1.1 and CD94-NKG2 receptor 
expression and the integrin av subunit in stage II of maturation. Stage III NK 
cells gain Ly49 and c-Kit expression and this is followed by an NK cell 
expansion stage (IV) that is characterized by an upregulation of DX5 expression 
and downregulation of the integrin av subunit. During the final stage of NK cell 
maturation (stage V), NK cells upregulate Mac-1 and CD43 expression and 
mature functionally, producing high levels of IFN-y and exerting high levels of 
cytotoxicity. 
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+  +  +  +  
L y 4 9  
-
-
+  +  +  
c - K i t  
N A  
- +  +  +  1 -
a v  N A  h i  
h i  l o  
D X 5  N A  l o  l o  h i  h i  
M a c - 1  N A  l o  l o  
l o  
h i  
C D 4 3  N A  
l o  l o  l o  h i  
C y t o t o x i c i t y  
N A  
N A  
N A  
l o  h i  
I F N - y  
N A  N A  N A  
l o  h i  
T a b l e  1 . 1 .  S t a g e s  o f  i n  v i v o  m u r i n e  N K  c e l l  d e v e l o p m e n t .  B M  N K  c e l l  d e v e l o p m e n t a l  s t a g e s  
p r o g r e s s  f r o m  t h e  i m m a t u r e  l i n e a g e - c o m m i t t e d  p r e c u r s o r  ( s t a g e  I )  t o  m a t u r e  N K  c e l l  ( s t a g e  V ) .  
T h e  p r e s e n c e  ( + )  o r  a b s e n c e  ( - )  o f  v a r i o u s  e x p r e s s i o n  m a r k e r s  a n d  N K  c e l l  f u n c t i o n  i s  n o t e d  a t  
e a c h  s t a g e  o f  d e v e l o p m e n t .  F o r  s o m e  m a r k e r s ,  e x p r e s s i o n  i s  q u a n t i t a t e d  a s  h i g h  ( h i )  o r  l o w  ( l o ) .  
N A ,  n o t  a p p l i c a b l e .  A d a p t e d  f r o m  ( K i m  e t  a l . ,  2 0 0 2 ) .  
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1.2.2 Regulation ofNK cell killing 
NK cell function is controlled by a balance of NK cell inhibitory and activating 
signals (Figure 1.2). NK cell inhibitory receptors bind to self-MHC class I 
molecules, whereas NK cell activating receptors bind to ligands expressed on 
stressed, transformed, and virus-infected cells. Three inhibitory receptor families 
exist: the killer cell Ig-like receptors (KIRs) which are expressed in humans; the 
Ly-49 lectin-like homodimers, which are expressed in mice; and the CD94-
NKG2A lectin-like receptors which are expressed in both mice and humans. 
Following NK cell inhibitory receptor ligation to MHC class I molecules, the 
immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic tail of 
these receptors is phosphorylated at tyrosine residues, allowing recruitment of the 
tyrosine phosphatases SHP1 or SHP2, which deliver an inhibitory signal to the 
NK cell. A wide variety ofNK cell activating receptors exist, many of these have 
short cytoplasmic domains and interact with transmembrane signaling adaptor 
molecules (DAP12, DAP10, FcRy and CD3~) to activate NK cell function. The 
cytoplasmic domains of these adaptor molecules contain immunoreceptor 
tyrosine based activating motifs (ITAMs) (Reth, 1989) or YxxN motifs, which 
upon stimulation, recruit ZAP70/SYK and phosphatidylinositol-3 kinase (PBK) 
(Billadeau et al., 2003; Chang et al., 1999; Lanier et al., 1998; Wu et al., 1999b) 
respectively, delivering an activating signal to the NK cell. The NK cell 
activation state is therefore determined by the balance of positive and negative 
signals to the NK cell. 
1.2.2.1 Classical maJor histocompatibility complex (MHC) class I 
receptors 
A number of NK cell receptors primarily recogmze classical MHC class I 
molecules. In humans, these include the KIRs and in mice the Ly49 receptors. To 
date, 14 KIRs have been described in humans as well as 2 non-expressed 
pseudogenes (Martinet al., 2000; Wilson et al., 2000). The majority of humans 
express between 6 and 14 of these genes (Uhrberg et al., 1997; Witt et al., 1999). 
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F i g u r e  1 . 2 .  N K  c e l l  a c t i v a t i n g  r e c e p t o r s  a n d  l i g a n d s .  N K  c e l l  a c t i v a t i n g  r e c e p t o r s  p l a y  a n  
i m p o r t a n t  r o l e  i n  N K  c e l l  r e c o g n i t i o n  a n d  e l i m i n a t i o n  o f  t u m o r s  a n d  s t r e s s e d  c e l l s .  A  w i d e  v a r i e t y  
o f  a c t i v a t i n g  r e c e p t o r s  e x i s t ,  w i t h  s o m e  r e c e p t o r s  ( e g .  N K G 2 D )  e x p r e s s e d  o n  t h e  c e l l  s u r f a c e  o f  
b o t h  m o u s e  a n d  h u m a n  N K  c e l l s .  N K  c e l l  a c t i v a t i n g  r e c e p t o r s  a r e  s h o w n  w i t h i n  t h e  N K  c e l l  a n d  
N K - c e l l  a c t i v a t i n g  l i g a n d s  a r e  s h o w n  o u t s i d e  t h e  N K  c e l l .  A b b r e v i a t i o n s :  H A ,  h a e m a g l u t i n i n ;  
H N ,  h a e m a g l u t i n i n  n e u r a m i n i d a s e ;  H L A ,  h u m a n  l e u k o c y t e  a n t i g e n ;  M C M V ,  m o u s e  
c y t o m e g a l o v i r u s ;  R a e - 1 ,  r e t i n o i c  a c i d  e a r l y  t r a n s c r i p t  1 ;  M I C ,  M H C  c l a s s - 1 - c h a i n  r e l a t e d  p r o t e i n ;  
U L B P ,  U L 1 6 - b i n d i n g  p r o t e i n .  
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At least 16 Ly49 genes and pseudogenes (Ly49A-Ly49Q) have been described in 
mice (Wilhelm et al., 2002). 
The KIRs are type I transmembrane glycoproteins that contain 2 or 3 
extracellular C2-type Ig domains (Colonna and Samaridis, 1995; D'Andrea et al., 
1995; Wagtmann et al., 1995). Members of the KIR family share greater than 
90% sequence identity and recognize polymorphic epitopes on the human MHC 
class I molecules HLA-A, HLA-B and HLA-C. Inhibitory KIRs contain ITIMs in 
their cytoplasmic tails, and activating KIRs possess a shorter cytoplasmic tail and 
a positively charged residue in the transmembrane region that allows them to 
interact with activating adaptor proteins (Lanier, 1998; Long, 1999). 
The murine Ly49s are type II transmembrane glycoproteins and members of the 
CTLR superfamily. The Ly49s appear to be functionally equivalent to the human 
KIRs and recognize polymorphic epitopes on the murine MHC class I molecules 
H-2D and H-2K (Takei et al., 1997; Yokoyama et al., 1995). The majority of 
Ly49s are inhibitory receptors that contain ITIMs in their cytoplasmic tails 
(Brennan et al., 1996; Hanke et al., 1999; Karlhofer et al., 1992). Ly49D and 
Ly49H are activating receptors that associate with membrane-bound DAP12 to 
activate NK cells via the ZAP70/SYK pathway (Smith et al., 1998). Ly49C/I 
inhibitory receptor blockade augmented both in vitro NK cell cytotoxicity and in 
vivo anti-tumor activity (Koh et al., 2001) demonstrating the importance of 
inhibitory receptors for dampening the NK cell response. 
1.2.2.2 Non-classical MHC class I receptors 
The heterodimeric CD94/NKG2 receptors are conserved throughout the species 
and recognize the non-classical MHC class I molecules HLA-E (in humans) and 
Qa-1b (in rodents). Members of the NKG2 family are type II integral membrane 
proteins and require dimerization with CD94 glycoprotein for stable cell surface 
expression. HLA-E and Qa-1b bind to signal peptides derived from classical 
MHC class I molecules and their cell surface expression is transporter associated 
w i t h  a n t i g e n  p r o c e s s i n g  ( T A P ) - 1 - d e p e n d e n t  ( L e e  e t  a l . ,  1 9 9 S ;  O ' C a l l a g h a n  e t  a l . ,  
1 9 9 S ) .  
N K G 2 A  i s  a n  i n h i b i t o r y  r e c e p t o r  t h a t  c o n t a i n s  2  c y t o p l a s m i c  I T I M s  t h a t  a l l o w  
t r a n s m i s s i o n  o f  a n  N K  c e l l  i n h i b i t o r y  s i g n a l  u p o n  r e c o g n i t i o n  o f  H L A - E  o r  Q a - 1  b  
( B o r r e g o  e t  a l . ,  1 9 9 S ;  B r a u d  e t  a l . ,  1 9 9 S ;  V a n c e  e t  a l . ,  1 9 9 S ) .  I n  v i v o ,  g r o w t h  o f  
Q a - 1  b  t r a n s f e c t e d  T A P - d e f i c i e n t  R M A - S  t u m o r  i s  i n c r e a s e d  c o m p a r e d  w i t h  
u n t r a n s f e c t e d  R M A - S ,  s u g g e s t i n g  t h a t  N K  c e l l  a c t i v i t y  i s  i n h i b i t e d  b y  
C D 9 4 / N K G 2 A - Q a - l b  i n t e r a c t i o n  ( J i a  e t  a l . ,  2 0 0 0 ) .  N K G 2 C  a n d  N K G 2 E  a r e  
a c t i v a t i n g  r e c e p t o r s  t h a t  a s s o c i a t e  w i t h  D A P 1 2  b y  i n t e r a c t i o n  w i t h  c h a r g e d  
t r a n s m e m b r a n e  r e s i d u e s  ( Y o k o y a m a  a n d  P l o u g a s t e l ,  2 0 0 3 ) .  T h i s  a l l o w s  
r e c r u i t m e n t  o f  Z A P - 7 0 / S Y K  a n d  a c t i v a t i o n  o f  a  s i g n a l  c a s c a d e  t h a t  l e a d s  t o  N K  
c e l l  a c t i v a t i o n .  
1 . 2 . 2 . 3  N K G 2 D  
N K G 2 D  i s  a  t y p e  I I  d i s u l p h i d e - l i n k e d  d i m e r  t h a t  c o n t a i n s  a  l e c t i n - l i k e  
e x t r a c e l l u l a r  d o m a i n  b u t  i s  o n l y  d i s t a n t l y  r e l a t e d  t o  t h e  o t h e r  N K G 2  f a m i l y  
m e m b e r s .  U n l i k e  o t h e r  N K G 2  r e c e p t o r s ,  N K G 2 D  d o e s  n o t  a s s o c i a t e  w i t h  C D 9 4  
b u t  e x i s t s  i n d e p e n d e n t l y  a t  t h e  c e l l  s u r f a c e  a s  a  h o m o d i m e r  ( D i n g  e t  a l . ,  1 9 9 9 ) .  I n  
t h e  m o u s e ,  N K G 2 D  i s  e x p r e s s e d  n o t  o n l y  o n  f r e s h l y  i s o l a t e d  N K  c e l l s ,  b u t  a l s o  
o n  l y m p h o k i n e  a c t i v a t e d  k i l l e r  ( L A K )  c e l l s ,  a c t i v a t e d  C D S +  T  c e l l s  a n d  
m a c r o p h a g e s  a s  w e l l  a s  s u b s e t s  o f  N K T  a n d  y 8  T  c e l l s  ( J a m i e s o n  e t  a l . ,  2 0 0 2 ;  
D i e f e n b a c h  e t  a l . ,  2 0 0 0 ) .  H u m a n  N K G 2 D  i s  e x p r e s s e d  b y  m o s t  N K ,  C D S +  a n d  y 8  
T  c e l l s  ( B a u e r  e t  a l . ,  1 9 9 9 ) .  
N K G 2 D  r e c o g n i z e s  a n t i g e n s  e x p r e s s e d  o n  s t r e s s e d ,  v i r u s - a n d  b a c t e r i a - i n f e c t e d ,  
a b n o r m a l  o r  c a n c e r o u s  c e l l s  ( G r o h  e t  a l . ,  1 9 9 S ;  V e t t e r  e t  a l . ,  2 0 0 2 ) .  H u m a n  
N K G 2 D  r e c o g n i z e s  M I C A ,  M I C B  a n d  t h e  U L B P s  1 - 4  ( B a u e r  e t  a l . ,  1 9 9 9 ;  
C o s m a n  e t  a l . ,  2 0 0 1 )  w h e r e a s  m u r i n e  N K G 2 D  r e c o g n i z e s  t h e  m i n o r  
h i s t o c o m p a t i b i l i t y  m o l e c u l e  H 6 0 ,  m e m b e r s  o f  t h e  R a e - I  f a m i l y  ( C e r w e n k a  e t  a l . ,  
2 0 0 0 ;  D i e f e n b a c h  e t  a l . ,  2 0 0 1 )  a n d  t h e  U L B P - l i k e  m o l e c u l e ,  M U L T - I  
( C a r a y a n n o p o u l o s  e t  a l . ,  2 0 0 2 ) .  I n  v i t r o ,  N K G 2 D  l i g a n d - e x p r e s s i n g  t u m o r  c e l l s  
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can stimulate nitric oxide synthesis and TNF-a transcription by activated murine 
macrophages (Diefenbach et al., 2000) and tumor cell lysis by human "(O T cell 
clones is increased when these cells are cross-linked with anti-NKG2D mAb 
(Bauer et al., 1999). In vivo rejection of NKG2D ligand-expressing tumor cells is 
mediated by NK and CDS+ T cells (Cerwenka et al., 2001; Diefenbach et al., 
2001), is largely pfp-dependent and appears independent of DR signaling or 
cytokine production (Hayakawa et al., 2002a). 
NKG2D has been identified as an activating receptor that signals by associating 
with DAP1 0, thereby triggering the PI3K pathway (Wu et al., 1999b ). In 
addition, NKG2D has been reported to act as a co-stimulatory molecule on T 
cells (Groh et al., 2001). These functional differences observed for NKG2D are 
possibly explained by the existence of two NKG2D isoforms [NKG2D-long (L) 
and NKG2D-short (S)] (Diefenbach et al., 2002). High levels of NKG2D-L 
messenger ribonucleic acid (mRNA) are found in freshly isolated naive NK cells 
and in stimulated CDS+ T cells, whereas NKG2D-S mRNA is upregulated in 
activated NK cells and CDS+ T cells. Using immunoprecipitation studies, the 
same researchers demonstrated that while NKG2D associated with both DAP1 0 
and DAP12 in activated NK cells, NKG2D only associated with DAP10 in 
activated CDS+ T cells. Moreover, DAP1 0 preferentially associated with 
NKG2D-L to mediate a co-stimulatory signal (as occurs in both NK and CDS+ T 
cells), whereas DAP12 associated with NKG2D-S to initiate an activating signal 
(as occurs in NK cells). These findings were supported by experiments 
undertaken by Colonna and colleagues who demonstrated a complete abrogation 
of NKG2D function in CDS+ T cells isolated from DAP1 0-deficient mice, but 
only partially impaired NKG2D function in activated NK cells (Gilfillan et al., 
2002). In contrast, NKG2D in DAP12-deficient mice was functional in T cells, 
but impaired in NK cells (Diefenbach et al., 2000). These data demonstrate the 
importance of NKG2D signaling for the provision of both stimulatory and co-
stimulatory signals to NK cells and a co-stimulatory signal in activated CDS+ T 
cells. 
1 . 2 . 2 . 4  N o n - M H C  c l a s s  I  r e c e p t o r s  
A l t h o u g h  a  n u m b e r  o f  N K  c e l l  r e c e p t o r s  r e c o g n i z e  a n d  b i n d  c l a s s i c a l  a n d  n o n -
c l a s s i c a l  M H C - c l a s s  I  m o l e c u l e s ,  m e m b e r s  o f  t h e  N K R P 1  a n d  n a t u r a l  
c y t o t o x i c i t y  r e c e p t o r  ( N C R )  f a m i l i e s  o f  r e c e p t o r s  b i n d  n o n - M H C  l i g a n d s  s u c h  a s  
c - t y p e  l e c t i n  r e l a t e d  ( C l r )  m o l e c u l e s  a n d  v i r a l  p r o t e i n s .  M a n y  o f  t h e  l i g a n d s  f o r  
t h e s e  r e c e p t o r s  r e m a i n  u n d i s c o v e r e d  a n d  t h e  c e l l u l a r  l i g a n d s  e x p r e s s e d  b y  t u m o r  
c e l l s  a r e  y e t  t o  b e  d e f i n e d .  
T h e  N C R s  N K p 3 0  a n d  N K p 4 4  ( i n  h u m a n s )  a n d  N K p 4 6  ( i n  m i c e  a n d  h u m a n s )  a r e  
s e l e c t i v e l y  e x p r e s s e d  o n  N K  c e l l s .  W h e r e a s  N K p 4 6  a n d  N K p 3 0  a r e  e x p r e s s e d  o n  
r e s t i n g  a n d  a c t i v a t e d  N K  c e l l s ,  N K p 4 4  i s  s e l e c t i v e l y  e x p r e s s e d  o n  a c t i v a t e d  N K  
c e l l s .  T h e  N C R s  a r e  a c t i v a t i n g  N K  r e c e p t o r s  t h a t  f u n c t i o n  b y  c o u p l i n g  w i t h  
I T A M  c o n t a i n i n g  a d a p t o r  p r o t e i n s  s u c h  a s  D A P 1 2  ( f o r  N K p 4 4 )  o r  CD3~ a n d  
F c £ R i y  ( f o r  N K p 3 0  a n d  N K p 4 6 )  ( C a n t o n i  e t  a l . ,  1 9 9 9 ;  P e s s i n o  e t  a l . ,  1 9 9 8 ) .  T o  
d a t e ,  t h e  i n f l u e n z a  p r o t e i n  H A  a n d  t h e  H N  p r o t e i n  o f  p a r a i n f l u e n z a  v i r u s  h a v e  
b e e n  i d e n t i f i e d  a s  l i g a n d s  f o r  N K p 4 6  a n d  N K p 4 4 ,  s u g g e s t i n g  a n  i m p o r t a n t  r o l e  
f o r  t h e  N C R s  i n  N K - m e d i a t e d  a n t i - v i r a l  r e s p o n s e s  ( A m o n  e t  a l . ,  2 0 0 1 ;  
M a n d e l b o i m  e t  a l . ,  2 0 0 1 ) .  T u m o r  l i g a n d s  f o r  t h e  N C R s  a r e  y e t  t o  b e  d i s c o v e r e d ,  
a l t h o u g h  a  n u m b e r  o f  s t u d i e s  a d v o c a t e  t h a t  t h e  N C R s  p l a y  a  r o l e  i n  t u m o r  
e l i m i n a t i o n .  F i r s t l y ,  a  d i r e c t  c o r r e l a t i o n  e x i s t s  b e t w e e n  c e l l  s u r f a c e  N C R  
e x p r e s s i o n  o n  N K  c e l l s  a n d  t h e  c y t o l y t i c  c a p a b i l i t y  o f  t h e s e  c e l l s  i n  a n  a n t i - t u m o r  
r e s p o n s e  ( S i v o r i  e t  a l . ,  1 9 9 9 ) .  S e c o n d l y ,  b l o c k i n g  t h e  f u n c t i o n  o f  o n e  o r  m o r e  
N C R s  w i t h  s p e c i f i c  a n t a g o n i s t i c  m A b s  d i m i n i s h e s  h u m a n  N K  c e l l  k i l l i n g  o f  a  
n u m b e r  o f  h u m a n  t u m o r  c e l l  l i n e s  ( M o r e t t a  e t  a l . ,  2 0 0 0 ;  P e n d e  e t  a l . ,  1 9 9 9 ;  S i v o r i  
e t  a l . ,  1 9 9 7 ;  V i t a l e  e t  a l . ,  1 9 9 8 ) .  
T h e  N K R P 1  f a m i l y  c o n t a i n s  b o t h  a c t i v a t i n g  a n d  i n h i b i t o r y  r e c e p t o r s  a n d  b i n d  t o  
s p e c i f i c  C l r  m o l e c u l e s  s u c h  a s  C l r b  ( o s t e o c l a s t  i n h i b i t o r y  l e c t i n  o r  O c i l )  a n d  C l r g .  
C l r g  i s  p r e d o m i n a n t l y  e x p r e s s e d  o n  D C s  a n d  m a c r o p h a g e s  ( C a r l y l e  e t  a l . ,  2 0 0 4 ;  
I i z u k a  e t  a l . ,  2 0 0 3 ) .  C l r b  i s  e x p r e s s e d  o n  t h e  m a j o r i t y  o f  h a e m a t o p o i e t i c  c e l l s  
e x c l u d i n g  r e d  b l o o d  c e l l s  a n d  c a n  i n h i b i t  N K  c e l l  k i l l i n g  w h e n  e x p r e s s e d  o n  
M H C  c l a s s  ! - d e f i c i e n t  t u m o r  c e l l s  ( C a r l y l e  e t  a l . ,  2 0 0 4 ;  I i z u k a  e t  a l . ,  2 0 0 3 ) .  A  
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single human member of the NKRPl family exists, NKR-P1A, which is 
expressed on a subset of mature NK cells and acts as an activatory receptor 
(Lanier et al., 1994). Four NKRP1 receptors have been described in C57BL/6 
mice, including NK1.1 (NKRPI c), a common cell surface marker used to identify 
NK cells. NKl.l associates with FccRiy, transmitting an activation signal to the 
NK cell (Arase et al., 1997). Similarly, NKRP1a and NKRP1f are thought to be 
activating receptors on account of the presence of a charged transmembrane 
residue in these receptors (Plougastel et al., 2001). The cytoplasmic tails of 
NKRP1d and NKRPlb (expressed in SJL/J and SWR mice) contain ITIM 
sequences and act as inhibitory receptors (Carlyle et al., 1999; Kung et al., 1999). 
1.2.2.5 Co-stimulatory molecules 
NK cell co-receptors interact with ligands expressed on target cells and provide 
co-stimulatory signals to the NK cell that range from enhancement of 
proliferation and cytokine production to the triggering of cytotoxicity. The role of 
the co-receptors is to amplify NK cell activation. Co-stimulatory molecules have 
been extensively characterized in T cells and demonstrated to be of great 
importance in the T cell anti-tumor response. 
CD28 is an NK cell activation receptor that interacts with CD80 (B7-1) and 
CD86 (B7-2) on targets cells and provides a co-stimulatory signal in both human 
and mouse NK cells (Galea-Lauri et al., 1999; Nandi et al., 1994; Wilson et al., 
1999). Expression of CD80 in the highly metastatic mouse T lymphoma cell line 
BW-Li renders them more sensitive to NK cell-mediated cytotoxicity and 
decreases tumor metastases in mice (Geldhof et al., 1995). Similarly, CD80 
expression on class !-deficient RMA-S tumor cells promoted NK cell-mediated 
tumor rejection and at higher tumor doses promoted both NK cell- and T cell-
mediated tumor rejection (Kelly et al., 2002b ). CD80 stimulated NK cell-
mediated tumor rejection was not observed in IFN-y1- or pfP_1_ mice illustrating 
the importance of these molecules in the CD SO-mediated tumor rejection process. 
Furthermore, NK cell-mediated rejection of RMA-S-CD80 stimulated tumor-
specific T cell immunity against subsequent tumor challenge. 
A n o t h e r  i m p o r t a n t  N K  c e l l  c o - s t i m u l a t o r y  r e c e p t o r  i s  C D 2 7  t h a t  i s  r e p o r t e d l y  
e x p r e s s e d  b y  m o s t  m u r i n e  N K  c e l l s  a n d  b y  a  p r o p o r t i o n  o f  h u m a n  N K  c e l l s  
( S u g i t a  e t  a l . ,  1 9 9 2 ;  T a k e d a  e t  a l . ,  2 0 0 0 b  ) .  C D 2 7  i s  a  m e m b e r  o f  t h e  T N F  
s u p e r f a m i l y  o f  r e c e p t o r s  a n d  r a t h e r  t h a n  t r i g g e r i n g  c y t o t o x i c i t y  p l a y s  a n  
i m p o r t a n t  r o l e  i n  t h e  s t i m u l a t i o n  o f  N K  c e l l  p r o l i f e r a t i o n  a n d  I F N - y  p r o d u c t i o n  
( T a k e d a  e t  a l . ,  2 0 0 0 b  ) .  E x p r e s s i o n  o f  t h e  C D 2 7  l i g a n d  C D 7 0  o n  M H C  c l a s s  ! -
d e f i c i e n t  R M A - S  t u m o r  c e l l s  e n h a n c e d  p r i m a r y  N K  c e l l - m e d i a t e d  t u m o r  
r e j e c t i o n  i n  v i v o  ( K e l l y  e t  a l . ,  2 0 0 2 a ) .  T u m o r  r e j e c t i o n  m e d i a t e d  b y  N K  c e l l s  w a s  
I F N - y - a n d  p f p - d e p e n d e n t  a n d  e v o k e d  a  s e c o n d a r y  T  c e l l - m e d i a t e d  i m m u n e  
r e s p o n s e  t o  p a r e n t a l  M H C  c l a s s  ! - s u f f i c i e n t  R M A  t u m o r  ( K e l l y  e t  a l . ,  2 0 0 2 a ) .  
T h e s e  k e y  s t u d i e s  r e v e a l e d  t h e  i m p o r t a n c e  o f  C D 2 7 - C D 7 0  i n t e r a c t i o n s  i n  
p r o v i d i n g  a  l i n k  b e t w e e n  i n n a t e  a n d  a d a p t i v e  i m m u n i t y .  
T h e  N K  c e l l  c o - r e c e p t o r  2 B 4  ( C D 2 4 4 )  i s  a  7 0  k D a  p r o t e i n  t h a t  b i n d s  C D 4 8 ,  a  
b r o a d l y  e x p r e s s e d  c e l l - s u r f a c e  g l y c o p r o t e i n .  2 B 4  s e r v e s  a  d u a l  r o l e  a n d  c a n  
t r a n s d u c e  e i t h e r  a n  i n h i b i t o r y  o r  a c t i v a t i n g  N K  c e l l  s i g n a l  d e p e n d i n g  o n  
e x p r e s s i o n  o f  s i g n a l i n g  l y m p h o c y t e  a c t i v a t i o n  m o l e c u l e - a s s o c i a t e d  p r o t e i n  ( S A P )  
( P a r o l i n i  e t  a l . ,  2 0 0 0 ) ,  a  d o w n s t r e a m  s i g n a l i n g  m o l e c u l e .  G i v e n  s u f f i c i e n t  S A P  
e x p r e s s i o n  w i t h i n  t h e  N K  c e l l ,  2 B 4  t r a n s d u c e s  a n  a c t i v a t i n g  s i g n a l ,  b u t  i n  t h e  
a b s e n c e  o f  S A P ,  S H 2 - d o m a i n  c o n t a i n i n g  p r o t e i n  t y r o s i n e  p h o s p h a t a s e - 2  ( S H P - 2 )  
b i n d s  2 B 4  g e n e r a t i n g  a n  i n h i b i t o r y  s i g n a l  ( T a n g y e  e t  a l . ,  1 9 9 9 ) .  2 B 4  i s  t h o u g h t  t o  
c o - o p e r a t e  w i t h  I T  A M - c o n t a i n i n g  N K  c e l l  r e c e p t o r s  ( S i v o r i  e t  a l . ,  2 0 0 0 )  a n d  t o  
a u g m e n t  i n t e g r i n - d e p e n d e n t  N K  c e l l  a c t i v a t i o n  ( B a r b e r  a n d  L o n g ,  2 0 0 3 )  v i a  
a s s o c i a t i o n  w i t h  t h e  c y t o s k e l e t o n  ( W a t z l  a n d  L o n g ,  2 0 0 3 ) .  O t h e r  r e p o r t s  s u g g e s t  
t h a t  2 B 4  c a n  t r i g g e r  N K  c e l l  I F N - y  a n d  I L - 2  p r o d u c t i o n  a s  w e l l  a s  c y t o t o x i c i t y  
( G a m i - W a g n e r  e t  a l . ,  1 9 9 3 ;  M a t h e w  e t  a l . ,  1 9 9 3 ) .  T h e  i m p o r t a n c e  o f  2 B 4 -
m e d i a t e d  N K  c e l l  a c t i v a t i o n  i s  c l e a r l y  i l l u s t r a t e d  i n  p a t i e n t s  w i t h  X - l i n k e d  
p r o l i f e r a t i v e  ( X L P )  s y n d r o m e  ( d e t a i l e d  i n  C h a p t e r  1 ,  S e c t i o n  1 . 2 . 6 ) .  
1 . 2 . 2 . 6  A n t i b o d y - d e p e n d e n t  c e l l u l a r  c y t o t o x i c i t y  ( A D C C )  
N K  c e l l s  c a n  b e  a c t i v a t e d  t o  i n d u c e  A D C C  b y  e n g a g e m e n t  o f  t h e i r  l o w  a f f i n i t y  
c e l l  s u r f a c e  F c y R I I I  r e c e p t o r s  w i t h  t h e  F e  p o r t i o n  o f  a n t i b o d i e s  b o u n d  t o  t a r g e t  
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cell-associated antigens. In humans, NK cell FcrRIIIA exists as a multimeric 
complex consisting of a ligand binding a subunit (CD16), which associates with 
homo- or hetero-dimers ofr or~ (Anderson et al., 1989; Kurosaki et al., 1991; 
Kurosaki and Ravetch, 1989; Lanier et al., 1989). IT AMs in the 'Y and ~ subunits 
can recruit intracellular signaling molecules which ultimately lead to activation of 
the NK cell (Cambier, 1995; Reth, 1989). Murine FerRill receptors contain only 
'Y-'Y homodimers (Kurosaki and Ravetch, 1989) and NK cells from y1-, but not ~-/­
mice lack the ability to mediate ADCC (Liu et al., 1993; Takai et al., 1994). 
Upon ligation of Fc-yRIII receptors, protein tyrosine kinases (PTKs) become 
activated. The Src-family PTKs (Lck, Fyn, Ye and Lyn) and the Syk-family 
PTKs (ZAP-70 and Syk) have been identified as mediators of proximal signaling 
in NK cells and inhibition of PTK activation has been demonstrated to block 
ADCC (Einspahr et al., 1991; O'Shea et al., 1992). Downstream of PTK 
activation, PLC-'Y (Azzoni et al., 1992; Ting et al., 1992), PBK (Kanakaraj et al., 
1994), Ras, Vav (Xu and Chong, 1996), PLA2, Erk2 (Milella et al., 1997) and 
nuclear factor of activated T cells (Aramburu et al., 1995) have been implicated 
as intracellular mediators of ADCC. 
Her2/Neu (c-erb-B-2) encodes a protein tyrosine kinase (Ross and Fletcher, 
1998) that is expressed on approximately 20% of breast adenocarcinomas. NK 
cells isolated from breast cancer patients and cultured in vitro with IL-2 or IL-15, 
demonstrate high levels of ADCC against Her2/neu positive tumor cells coated 
with Herceptin, a mAb to Her2/Neu (Carson et al., 2001). NK cells isolated from 
patients administered with low dose IL-2 and then incubated in vitro with 
Her2/neu positive tumor targets coated with Herceptin also demonstrated 
increased ADCC when compared with NK cells isolated from patients prior to 
IL-2 therapy (Carson et al., 2001). An anti-MUC1-scFv-Fc-IL-2 antibody-
cytokine fusion protein has also been developed that binds MUC-1 on tumor cells 
and induces proliferation of pre-activated lymphocytes and activation ofNK cells 
via the IL-2 moiety (Heuser et al., 2003). In vitro, NK cells activated by the 
fusion protein were demonstrated to lyse MUC-1 positive tumors (Heuser et al., 
2003). Recently, researchers at Chiron Corp. (Emeryville, CA, USA) 
d e m o n s t r a t e d  t h a t  p a t i e n t s  w i t h  a d v a n c e d - s t a g e  n o n - H o d g k i n  l y m p h o m a  w h o  
w e r e  t r e a t e d  w i t h  t h e  a n t i - C D 2 0  m A b  r i t u x i m a b  a n d  r i L - 2  d e v e l o p e d  i n c r e a s e d  
n u m b e r s  o f  N K  c e l l s  t h a t  c o u l d  r e c o g n i z e  a n d  e l i m i n a t e  a n t i b o d y - c o a t e d  c a n c e r  
c e l l s  ( O ' H a n l o n ,  2 0 0 4 ) .  T u m o r s  w e r e  c o m p l e t e l y  e l i m i n a t e d  i n  s o m e  p a t i e n t s  a n d  
d e c r e a s e d  2 5 - 5 0 %  i n  s i z e  f o r  o t h e r s .  C o l l e c t i v e l y ,  t h e s e  s t u d i e s  i l l u s t r a t e  t h e  
i m p o r t a n c e  o f N K  c e l l  c o n t r o l  o f  t u m o r  g r o w t h  m e d i a t e d  b y  A D C C .  
1 . 2 . 3  P e r f o r i n  ( p f p  ) / g r a n z y m e  ( g r z )  e x o c y t o s i s  
G r a n u l e  e x o c y t o s i s  i s  t h e  m a j o r  p a t h w a y  u s e d  b y  N K  c e l l s  t o  e l i m i n a t e  c a n c e r o u s  
a n d  v i r u s - i n f e c t e d  h o s t  c e l l s  ( F i g u r e  1 . 3 ) .  U p o n  a c t i v a t i o n ,  N K  c e l l s  r e l e a s e  
c y t o p l a s m i c  g r a n u l e s  t h a t  c o n t a i n  a  n u m b e r  o f  l y t i c  p r o t e i n s  i n c l u d i n g  p : t p  a n d  a  
f a m i l y  o f  s t r u c t u r a l l y  r e l a t e d  s e r i n e  p r o t e a s e s  ( g r z  o r  g r a n u l e  e n z y m e s ) .  T h e  g r z  
a r e  p r o c e s s e d  f r o m  i n a c t i v e  p r o - e n z y m e s  i n t o  a c t i v e  e n z y m e s  e i t h e r  o n  r o u t e  t o ,  
o r  i n ,  t h e  g r a n u l e s  b y  c a t h e p s i n  C  ( a l s o  k n o w n  a s  d i p e p t i d y l  p e p t i d a s e  I )  ( S m y t h  
e t  a l . ,  1 9 9 5 ) ,  b u t  r e m a i n  i n a c t i v e  d u e  t o  t h e  a c i d i c  p H  w i t h i n  t h e  g r a n u l e s .  O n c e  
r e l e a s e d  a n d  t r a n s f e r r e d  i n t o  t h e  t a r g e t  c e l l  c y t o s o l  ( w h i c h  h a s  a  r e l a t i v e l y  n e u t r a l  
p H  o f  a p p r o x i m a t e l y  7 ) ,  t h e  g r z s  g a i n  m a x i m a l  a c t i v i t y  a n d  c a n  a c t i v a t e  a p o p t o t i c  
c y s t e i n e  p r o  t e a s e s  (  c a s p a s e s )  o r  e x e r t  o t h e r  f u n c t i o n s  l e a d i n g  t o  t a r g e t  c e l l  d e a t h .  
I n  a d d i t i o n  t o  p : t p  a n d  g r z s ,  N K  c e l l  g r a n u l e s  a l s o  c o n t a i n  c a t h e p s i n  B ,  a  
l y s o s o m a l  p r o t e a s e  t h a t  u p o n  d e g r a n u l a t i o n  i s  s e q u e s t e r e d  o n  t h e  e f f e c t o r  c e l l  
m e m b r a n e  a n d  m a y  i n a c t i v a t e  p : t p  m o l e c u l e s  t h a t  d i f f u s e  b a c k  u p o n  t h e  e f f e c t o r  
c e l l  s u r f a c e  ( B a l a j i  e t  a l . ,  2 0 0 2 ) .  
T h e  g r z s  a r e  a  f a m i l y  o f  s e r i n e  p r o t e a s e s  e x p r e s s e d  b y  N K  c e l l s  a n d  c y t o t o x i c  T  
l y m p h o c y t e s  ( C T L s ) .  M a n y  o f  t h e  g r z s  h a v e  b e e n  s h o w n  t o  i n d u c e  a p o p t o s i s ,  
a l t h o u g h  s o m e  s e r v e  a d d i t i o n a l  f u n c t i o n s  a n d  a r e  i n c a p a b l e  o f  i n d u c i n g  a  d e a t h  
s i g n a l  ( B r u n n e r  e t  a l . ,  1 9 9 0 ;  I r m l e r  e t  a l . ,  1 9 9 5 ;  S o w e r  e t  a l . ,  1 9 9 6 ;  S u i d a n  e t  a l . ,  
1 9 9 4 ;  S u i d a n  e t  a l . ,  1 9 9 6 ) .  F i v e  g r z s  h a v e  b e e n  d e s c r i b e d  i n  h u m a n s  ( g r z A ,  B ,  H ,  
K  a n d  M )  a n d  t e n  i n  m i c e  ( g r z A - G ,  K ,  M  a n d  N )  ( L i e b e r m a n ,  2 0 0 3 ) .  G r z B ,  t h e  
m o s t  p o w e r f u l  p r o - a p o p t o t i c  m e m b e r  o f  t h e  g r z  f a m i l y ,  i s  a n  a s p a s e  a n d  c l e a v e s  
a f t e r  s p e c i f i c  a s p a r t i c  a c i d  r e s i d u e s  s u c h  a s  t h o s e  f o u n d  i n  s e v e r a l  p r o c a s p a s e s  
a n d  d o w n s t r e a m  c a s p a s e  s u b s t r a t e s  ( D a r m o n  e t  a l . ,  1 9 9 5 ;  P o e  e t  a l . ,  1 9 9 1 ) .  G r z A  






caspases Cytochrome c 
NM23-H1 (3, 6 or?)' + 
~ ~ Caspase9 
Figure 1.3. Granule exocytosis pathway. (A) Upon recognition of activating ligands such as 
NKG2D, NK cells can secrete granule contents to induce apoptosis by both caspase-dependent 
and caspase-independent mechanisms. Cellular proteins such as the serine protease inhibitor P-19 
and Bcl-2 can inhibit some of the mechanisms utilized by grz. (B) Granule contents are thought to 
exist in a macromolecular serglycin complex that is taken up into the target cell by receptor-
mediated endocytosis. The grz are then liberated from endosomes via membrane pores produced 
by pip. Once grzA has entered the cytoplasm, it degrades the SET complex, which rapidly 
translocates to the nucleus, where NM23-H1 nicks chromosomal DNA. GrzB, on the other hand, 
cleaves BH3-interacting domain death agonist (Bid), which translocates to the mitochondria and 
stimulates the release of mitochondrial contents. Cytochrome c released from the mitochondria 
binds to the apoptotic protease-activating factor 1 ( AP AF -1) and caspase 9, forming the 
apoptosome, which proceeds to activate the executioner caspases, 3, 6 and 7. GrzB can also 
directly cleave the executioner caspases and other cellular substrates to induce apoptosis. 
Abbreviations: Bak, Bcl-2 antagonist/killer; Bax, Bcl-2-associated X protein. 
a n d  K  a r e  t r y p t a s e s  a n d  a r e  p r e d i c t e d  t o  c l e a v e  a f t e r  a r g i n i n e  a n d  l y s i n e  r e s i d u e s  
( S a t t a r  e t  a l . ,  2 0 0 3 ;  S i m o n  a n d  K r a m e r ,  1 9 9 4 ) ,  g r z H  i s  a  c h y m a s e  a n d  c l e a v e s  
a f t e r  p h e n y l a l a n i n e  a n d  t y r o s i n e  r e s i d u e s  ( E d w a r d s  e t  a l . ,  1 9 9 9 )  a n d  g r z M  i s  a  
m e t a s e  t h a t  c a n  c l e a v e  a f t e r  m e t h i o n i n e ,  l e u c i n e  a n d  n o r l e u c i n e  r e s i d u e s  ( S m y t h  
e t  a l . ,  1 9 9 2 ) .  
G r z A  a n d  B  a r e  t h e  m o s t  a b u n d a n t  g r z  i n  m i c e  a n d  h u m a n s .  G r z B  i n d u c e s  c e l l  
d e a t h  i n  a  c a s p a s e - d e p e n d e n t  m a n n e r  b y  d i r e c t l y  c l e a v i n g  a n d  a c t i v a t i n g  
e x e c u t i o n e r  c a s p a s e s  ( D a r m o n  e t  a l . ,  1 9 9 5 )  a n d  b y  c l e a v i n g  B i d  t o  i n d u c e  
m i t o c h o n d r i a l  d i s r u p t i o n  a n d  r e l e a s e  o f  p r o - a p o p t o t i c  m e d i a t o r s  s u c h  a s  
c y t o c h r o m e  c  a n d  S m a c / D i a b l o  ( S u t t o n  e t  a l . ,  2 0 0 0 ) .  G r z B  h a s  a l s o  b e e n  r e p o r t e d  
t o  i n d u c e  c a s p a s e - i n d e p e n d e n t  c e l l  d e a t h  i n  b o t h  a  B i d - d e p e n d e n t  ( L i  e t  a l . ,  2 0 0 1 ;  
L i e b e r m a n ,  2 0 0 3 )  a n d  B i d - i n d e p e n d e n t  m a n n e r  ( A l i m o n t i  e t  a l . ,  2 0 0 1 ;  
M a c D o n a l d  e t  a l . ,  1 9 9 9 ) .  G r z A  c a n  i n d u c e  a p o p t o s i s  i n  a  c a s p a s e - i n d e p e n d e n t  
m a n n e r  b y  d i r e c t l y  c l e a v i n g  n u c l e a r  p r o t e i n s  t o  f a c i l i t a t e  t h e  f o r m a t i o n  o f  s i n g l e -
s t r a n d e d  D N A  n i c k s  ( Z h a n g  e t  a l . ,  2 0 0 1 a ;  Z h a n g  e t  a l . , 2 0 0 1 b )  a n d  b y  d e g r a d i n g  
t h e  n e w l y  d e s c r i b e d  S E T  c o m p l e x ,  a l l o w i n g  N M 2 3 - H 1  t o  b e c o m e  a c t i v a t e d  a n d  
n i c k  c h r o m o s o m a l  D N A  ( B e r e s f o r d  e t  a l . ,  1 9 9 9 ;  B e r e s f o r d  e t  a l . ,  2 0 0 1 ;  F a n  e t  a l . ,  
2 0 0 3 a ;  F a n  e t  a l . ,  2 0 0 2 ;  F a n  e t  a l . ,  2 0 0 3 b ;  S a r i n  e t  a l . ,  1 9 9 7 ;  T r a p a n i  e t  a l . ,  1 9 9 8 ) .  
A l t h o u g h  i t  i s  k n o w n  t h a t  p i p  a n d  t h e  g r z s  c a n  a c t  s y n e r g i s t i c a l l y  t o  i n d u c e  t a r g e t  
c e l l  a p o p t o s i s ,  e x a c t l y  h o w  t h e y  a c h i e v e  t h i s  h a s  b e e n  a  t o p i c  o f  g r e a t  d e b a t e .  I n  
t h e  e a r l y  1 9 8 0 s ,  p u r i f i e d  p i p  w a s  t h o u g h t  t o  f o r m  p o l y p e r f o r i n  p o r e s  i n  t a r g e t  c e l l  
m e m b r a n e s ,  i n d u c i n g  o s m o t i c  i n s t a b i l i t y  a n d  l y s i s  o f  t h e  t a r g e t  c e l l  ( P o d a c k  a n d  
K o n i g s b e r g ,  1 9 8 4 ) .  I n  t h e  1 9 9 0 s ,  d i s c o v e r y  o f  t h e  g r z s  a n d  t h e i r  a b i l i t y  t o  i n d u c e  
c e l l  d e a t h  c o - o p e r a t i v e l y  w i t h  p i p  r e s u l t e d  i n  a  m o d i f i c a t i o n  o f  t h e  o r i g i n a l  
m o d e l .  G r z s  w e r e  t h o u g h t  t o  g a i n  e n t r y  i n t o  t h e  t a r g e t  c e l l  b y  p a s s i v e  d i f f u s i o n  
t h r o u g h  p i p  p o r e s .  F u r t h e r  r e s e a r c h  s u g g e s t e d  t h a t  t h i s  m o d e l  w a s  u n l i k e l y  f o r  
s e v e r a l  r e a s o n s .  F i r s t l y ,  t h e  p r o - a p o t o t i c  f u n c t i o n  o f  p i p  a n d  g r z s  c o u l d  n o t  b e  
r e p l i c a t e d  b y  r e p l a c i n g  p i p  w i t h  t h e  c o m p l e m e n t  m e m b r a n e - a t t a c k  c o m p l e x  o r  
o t h e r  m e m b r a n e - d i s r u p t i n g  p r o t e i n s ,  w h i c h  f o r m  s t r u c t u r a l l y  s i m i l a r  p o r e s  
( B r o w n e  e t  a l . ,  1 9 9 9 ;  P o d a c k  e t  a l . ,  1 9 8 8 ) .  S e c o n d l y ,  r e s e a r c h e r s  h a v e  
d e m o n s t r a t e d  t h a t  p i p  a n d  g r z s  a r e  s e q u e s t e r e d  t o  t h e  t a r g e t  c e l l  s u r f a c e  a s  a  
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single macromolecular complex associated with the proteoglycan serglycin 
(Metkar et al., 2002). Moreover, cytosolic delivery of grzs was demonstrated to 
occur independently of plasma membrane pore formation (Metkar et al., 2002). 
Thirdly, several groups have demonstrated that grz entry into the target cell 
occurs via receptor-mediated endocytosis and does not require pfp (Froelich et 
al., 1996; Pinkoski et al:, 1998; Shi et al., 1997; Trapani et al., 1998). Recently, 
the mannose 6-phosphate receptor (MPR) has been demonstrated to act as a 
receptor for grzB uptake when it is overexpressed on the cell surface (Motyka et 
al., 2000). However, the physiological relevance of this interaction has been 
questioned given that only low levels of MPR are normally found on the cell 
surface (Trapani and Smyth, 2002; Trapani et al., 2003). 
1.2.4 Death receptor (DR) pathway 
The TNF superfamily of ligands and receptors modulate innate and adaptive 
immune responses by inducing cellular activation, proliferation, survival, 
differentiation, migration and apoptosis (Smith et al., 1994; Van Parijs and 
Abbas, 1996) (Figure 1.4). Within this family, TRAIL/Apo2L, FasL, TNF and 
LT-a have been characterized as major mediators of apoptosis. TNF superfamily 
members exert apoptosis by engaging target cell DRs that contain cytoplasmic 
death domains (DDs). These DDs mediate interaction between the DR and 
adaptor proteins such as Fas-associated death domain (FADD) that can activate 
caspases and initiate apoptosis. TNF superfamily receptors can also activate 
nuclear factor-kappaB (NF-KB), a transcription factor implicated in suppression 
of apoptosis, cell survival, proliferation, viral replication, inflammation, bone 
resorption, tumorigenesis and metastasis. Other pathways activated by the TNF 
superfamily include JUN N-terminal kinase (JNK), p42/p44 mitogen-activated 
protein kinase (MAPK) and p38 MAPK. Some TNF superfamily receptors 
contain truncated DDs or lack cytosolic regions that may allow them to act as 
'decoys' and compete for binding with cognate ligands. DR- mediated apoptosis 
is discussed in greater detail in Chapter 1, Sections 1.3.2 and 1.3.4. 
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F i g u r e  1 . 4 .  T N F  s u p e r f a m i l y  r e c e p t o r s  a n d  l i g a n d s .  M a n y  o f  t h e  T N F - s u p e r f a m i l y  o f  l i g a n d s  
( t o p )  c a n  b i n d  t o  m u l t i p l e  r e c e p t o r s  ( b o t t o m )  a n d  s o m e  l i g a n d s s u c h  a s  T N F  a n d  L T - a  e v e n  s h a r e  
c o m m o n  r e c e p t o r s .  A r r o w s  i n d i c a t e  i n t e r a c t i o n s  b e t w e e n  T N F - s u p e r f a m i l y  l i g a n d s  a n d  t h e i r  
c o r r e s p o n d i n g  r e c e p t o r / s .  Q u e s t i o n  m a r k s  i n d i c a t e  r e c e p t o r s  f o r  w h i c h  t h e  c o g n a t e  l i g a n d  i s  y e t  t o  
b e  i d e n t i f i e d .  C y s t e i n e - r i c h  r e c e p t o r  d o m a i n s  a r e  r e p r e s e n t e d  b y  r e d  o v a l s  a n d  c y t o p l a s m i c  D D s  
f o r  r e c e p t o r s  a r e  r e p r e s e n t e d  b y  g r e e n  r e c t a n g l e s .  A b b r e v i a t i o n s :  A P R I L ,  a  p r o l i f e r a t i o n - i n d u c i n g  
l i g a n d ;  B A F F ,  B - e e n - a c t i v a t i n g  r e c e p t o r ;  B C M A ,  B - c e l l  m a t u r a t i o n  a n t i g e n ;  D e ,  D e c o y ;  E D A ,  
e c t o d e r m a l  d y s p l a s i n ;  E D A R ,  e c t o d y p l a s i n - A - r e c e p t o r ;  G I T R ,  g l u c o c o r t i c o i d - i n d u c e d  T N F R  
f a m i l y  r e c e p t o r ;  O P G ,  o s t e o p r o t e g e r i n ;  R A N K ,  r e c e p t o r  a c t i v a t o r  o f  n u c l e a r  factor~KB; T A C I ,  
t r a n s m e m b r a n e  a c t i v a t o r  a n d  c y c l o p h i l i n  l i g a n d  i n t e r a c t o r ;  T W E A K ,  T N F - l i k e  w e a k  i n d u c e r  o f  
a p o p t o s i s ;  X E D A R ,  X - l i n k e d  e c t o d e r m a l  d y s p l a s i a  r e c e p t o r .  A d a p t e d  f r o m  ( A s h k e n a z i ,  2 0 0 2 ) .  
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1.2.5 NK cell cytokine production 
Upon activation, NK cells themselves can produce a variety of cytokines [IFN-y, 
GM-CSF, G-CSF, M-CSF, TNF-a, IL-5, IL-10, IL-13 and others (Peritt et al., 
1998)] and chemokines [CXCLI, CCLI, CCL3, CCL4, CCL5, CCL22, CXCL8 
and others (Robertson, 2002)] which can have a direct effect on tumor growth, 
induce inflammatory and anti-viral responses, regulate hematopoietic cell 
differentiation and prime immune effector cells that are crucial for subsequent 
adaptive immune responses (Figure 1.5). For example, IFN-y produced by NK 
cells can directly stimulate the development of CTL and lead to the development 
of immunological memory against the tumor (Kelly et al., 2002a; Smyth and 
Kelly, 1999). NK cell IFN-ycan also promote the development ofCD4+ T helper 
cells that subsequently aid CTL generation (Smyth et al., 2002b ). Activated NK 
cells can also stimulate the maturation of DCs, allowing them to present antigen 
to CTLs in LNs (Cooper et al., 2004; Gerosa et al., 2002). In addition, cytokines 
produced by NK cells may also regulate B cell production of anti-tumor 
antibodies (Yuan et al., 1994; Yuan et al., 1992). 
NK cells are important contributors to the innate defense against viral infection. 
NK cell IFN-y responses have been observed during influenza virus (Monteiro et 
al., 1998) and MCMV infection (Orange and Biron, 1996a; Orange and Biron, 
1996b; Orange et al., 1995; Ruzek et al., 1997). NK cell IFN-yproduction during 
infection occurs as early as hours to days after the primary infection and is 
dependent upon virus-induced IL-12 (Monteiro et al., 1998; Orange and Biron, 
1996a; Orange and Biron, 1996b ). TNF produced by NK cells might also have an 
anti-viral function, although a number of cells can produce TNF during the early 
stages ofviral infection (Orange and Biron, 1996b). 
NK cells produce an important early source of IFN -y in response to malaria 
- infection (Artavanis-Tsakonas and Riley, 2002; Mohan et al., 1997). Production 
of IFN -y is IL-12-dependent and partially IL-lS-dependent (Artavanis-Tsakonas 
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F i g u r e  1 . 5 .  N e t w o r k  o f  t h e  a n t i - t u m o r  i m m u n e  r e s p o n s e .  T h e  i m m u n e  s y s t e m  i n v o l v e s  a  
c o m p l e x  n e t w o r k  o f  c e l l s  t h a t  " c o m m u n i c a t e "  w i t h  e a c h - o t h e r  t o  f o r m  a n  a n t i - t u m o r  r e s p o n s e .  
N K  c e l l s  c a n  r e c o g n i z e  s t r e s s  l i g a n d s  e x p r e s s e d  b y  t u m o r  c e l l s  a n d  m e d i a t e  e i t h e r  d i r e c t  
k i l l i n g  o r  p r o d u c e  I F N - y  t o  s u p p r e s s  t u m o r  c e l l  a n g i o g e n e s i s .  I m m a t u r e  D C s  t a k e  u p  t u m o r  
a n t i g e n s  a n d  t h e n  m i g r a t e  t o  t h e  r e g i o n a l  L N  w h e r e  t h e y  p r e s e n t  a n t i g e n  t o  C D 4 +  a n d  C D S +  T  
c e l l s .  C D 4 +  T  c e l l s  h e l p  g e n e r a t e  c y t o l y t i c  C D S +  T  c e l l s  t h a t  c a n  m i g r a t e  t o  t h e  t u m o r  s i t e  a n d  
k i l l  t u m o r  c e l l s .  C D 4 +  T  c e l l s  a l s o  r e g u l a t e  B  c e l l  p r o d u c t i o n  o f  a n t i - t u m o r  a n t i b o d i e s  ( A b s ) .  
C D 2 5 + C D 4 +  T  r e g u l a t o r y  c e l l s  s u p p r e s s  a n t i - t u m o r  i m m u n i t y  b y  t h e  s e c r e t i o n  o f  
i m m u n o m o d u l a t o r y  c y t o k i n e s  s u c h  a s  TGF-~. S t i m u l a t e d  N K  c e l l s  a i d  N K  c e l l  m a t u r a t i o n ,  
w h i l s t  D C  s e c r e t e d  c y t o k i n e s  h e l p  f u r t h e r  a c t i v a t e  N K  c e l l s .  D C s  c a n  a l s o  p r e s e n t  g l y c o l i p i d s  
i n  t h e  c o n t e x t  o f  C D l d ,  a c t i v a t i n g  N K T  c e l l s ,  w h i c h  i n  t u m  f u r t h e r  a c t i v a t e  N K  c e l l s  a n d  
a d a p t i v e  i m m u n i t y .  
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and Riley, 2002) and acts synergistically with TNF to stimulate nitric oxide 
production (Jacobs et al., 1996) that is important for malaria parasite killing 
(Rockett et al., 1991). NK cell IFN-y production has also been associated with 
early host resistance against infection with Mycobacterium tuberculosis 
(Junqueira-Kipnis et al., 2003; Vankayalapati et al., 2004). A recent study 
proposed that NK cell IFN-y stimulates secretion of IL-15 and IL-18 by 
monocytes which in tum favors the expansion of CD8+IFN-y+ T cells that can 
lyse infected cells (Vankayalapati et al., 2004). 
Two distinct human NK cell subsets have been identified which can be 
distinguished by cell surface density expression of CD56. CD56bright NK cells 
comprise approximately 10% of human NK cells and CD56dim NK cells that 
express high levels of FcyRIII (CD16) comprise approximately 90% of the 
population (Lanier et al., 1986). Resting CD56dim NK cells demonstrate enhanced 
cytotoxicity against NK-sensitive targets compared with CD56bright resting NK 
cells (Nagler et al., 1989), although both NK cell subsets exhibit similar levels of 
NK cell cytotoxicity after stimulation with cytokines such as IL-2 or IL-12 (Ellis 
and Fisher, 1989; Nagler et al., 1989; Robertson et al., 1992). CD56bright NK cells 
are potent producers of a variety of cytokines (IFN-y, TNF-a, TNF-~, IL-10, IL-
13 and GMCSF) in response to monocyte-derived cytokines (monokines) 
(Cooper et al., 2001). This suggests that CD56bright and CD56dim NK cells 
represent two functionally distinct subsets of NK cells in humans, one with 
relatively poor cytolytic capacity but the capability to produce large amounts of 
cytokines and the other which exhibits enhanced natural cytotoxicity but produce 
significantly less cytokines. Mouse NK cells do not express CD56, precluding 
comparative studies being undertaken in mice. 
NK cell maturation studies have identified 3 stages of NK cell differentiation 
(detailed in Chapter 1, Literature Review, Section 1.2.1). The most immature 
_ (type 2) NK cells produce type 2 cytokines such as IL-13 and IL-5, intermediate 
(type 0) NK cells are reported to produce both IL-13 and IFN-y and the most 
mature (type 1) NK cells produce IFN-y (Loza and Perussia, 2001). Mature IFN-
y-producing NK cells were CD56bright whereas immature NK cells that did not 
p r o d u c e  I F N - " {  w e r e  C D 5 6 d i r n  ( L o z a  a n d  P e r u s s i a ,  2 0 0 1 ) ,  i n  a g r e e m e n t  w i t h  
s t u d i e s  i l l u s t r a t i n g  t h a t  C D 5 6 b r i g h t  N K  c e l l s  a r e  m o r e  p o t e n t  c y t o k i n e  p r o d u c e r s  
( C o o p e r  e t  a l . ,  2 0 0 1 ) .  
1 . 2 . 6  T u m o r  r e j e c t i o n  b y  N K  c e l l s  
I n  t h e  1 9 7 0 s ,  N K  c e l l s  w e r e  d e f i n e d  a s  w h i t e  b l o o d  c e l l s  t h a t  c o u l d  s p o n t a n e o u s l y  
l y s e  t h e  t u m o r  t a r g e t s  Y  A C - 1  ( A / S n  m o u s e  M o l o n e y  t u m o r  v i r u s - i n d u c e d  
l y m p h o m a  c e l l  l i n e )  ( K i e s s l i n g  e t  a l . ,  1 9 7 5 )  a n d  K 5 6 2  ( h u m a n  c h r o n i c  m y e l o i d  
l e u k e m i a  c e l l  l i n e )  ( O r t a l d o  e t  a l . ,  1 9 7 7 ) .  S u b s e q u e n t l y ,  c y t o k i n e - ( I L - 2 ,  1 F N - a ,  
IFN-~) a c t i v a t e d  N K  c e l l s  w e r e  d e m o n s t r a t e d  t o  e x h i b i t  e n h a n c e d  c y t o l y t i c  
f u n c t i o n  a n d  t o  k i l l  a  b r o a d e r  r a n g e  o f  t u m o r  t a r g e t s ,  i n c l u d i n g  s o m e  t u m o r s  t h a t  
w e r e  r e s i s t a n t  t o  l y s i s  b y  r e s t i n g  N K  c e l l s  ( G r i m m  e t  a l . ,  1 9 8 2 ;  H e n n e y  e t  a l . ,  
1 9 8 1 ;  P h i l l i p s  a n d  L a n i e r ,  1 9 8 6 ) .  N K  c e l l s  a r e  n o w  r e c o g n i z e d  a s  l y m p h o c y t e s  
w i t h  t h e  u n i q u e  a b i l i t y  t o  l y s e  c l a s s  I  M H C - d e f i c i e n t  t u n i o r  c e l l s  a n d  t h e i r  
m e t a s t a s e s  ( W h i t e s i d e  a n d  H e r b e r m a n ,  1 9 9 5 ) ,  a  s k i l l  t h a t  e n a b l e s  t h e m  t o  k i l l  
c a n c e r o u s  c e l l s  t h a t  h a v e  d o w n r e g u l a t e d  c l a s s  I  M H C  t o  e v a d e  t h e  a d a p t i v e  
i m m u n e  r e s p o n s e .  
T h e  i m p o r t a n c e  o f  N K  c e l l s  i n  t h e  a n t i - t u m o r  r e s p o n s e  h a s  b e e n  c l e a r l y  
e s t a b l i s h e d  i n  a  n u m b e r  o f  e x p e r i m e n t a l  t u m o r  m o d e l s .  M a n y  o f  t h e s e  s t u d i e s  
h a v e  u s e d  N K  c e l l  d e p l e t i o n  p r i o r  t o  t u m o r  t r a n s p l a n t a t i o n  t o  d e m o n s t r a t e  m o r e  
a g g r e s s i v e  t u m o r  g r o w t h  i n  t h e  a b s e n c e  o f N K  c e l l s  ( G r u b e r  e t  a l . ,  2 0 0 2 ;  L i a o  e t  
a l . ,  1 9 9 1 ;  S m y t h  e t  a l . ,  1 9 9 9 ) .  O t h e r s  h a v e  u s e d  c y t o k i n e s  ( I L - 2 ,  I L - 2 1 ,  I L - 1 2 ,  I L -
1 5 ,  I L - 1 8  a n d  I F N s )  t o  b o o s t  t h e  N K  c e l l  a n t i - t u m o r  r e s p o n s e ,  d e m o n s t r a t i n g  t h a t  
e n h a n c e d  N K  c e l l  f u n c t i o n  l e a d s  t o  m o r e  e f f i c i e n t  e l i m i n a t i o n  o f  t u m o r  g r o w t h  
( B r a d y  e t  a l . ,  2 0 0 4 ;  S m y t h  e t  a l . ,  2 0 0 0 a ;  T a l m a d g e  e t  a l . ,  1 9 8 7 ;  T r i n c h i e r i ,  1 9 9 8 ;  
W a n g  e t  a l . ,  2 0 0 3 ;  W i l t r o u t  e t  a l . ,  1 9 8 5 ) .  A d o p t i v e  t r a n s f e r  o f N K  c e l l s  h a s  a l s o  
c l e a r l y  d e m o n s t r a t e d  t h e  a b i l i t y  o f  N K  c e l l s  t o  m o u n t  a n  a n t i - t u m o r  r e s p o n s e  
( B a r l o z z a r i  e t  a l . ,  1 9 8 3 ;  K u p p e n  e t  a l . ,  2 0 0 1 ;  Y a s u m u r a  e t  a l . ,  1 9 9 4 ) .  
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It has previously been shown that NK cell-mediated rejection of spontaneous 
tumor development in a variety of murine models is largely mediated by pfp and 
IFN-y (Street et al., 2001). IFN-y produced by NK cells might play a role in the 
regulation of killing by DRs by downregulating the expression of intracellular 
FLICE inhibitory proteins (FLIPs) (lrmler et al., 1997; Thome et al., 1997), or by 
upregulating expression of caspases that are essential for the execution of OR-
mediated apoptosis (Griffith et al., 1998). IFN-yproduced by NK cells and NKT 
cells is essential for the anti-angiogenic effects of a-GalCer on tumor growth, and 
NK cell depletion partially inhibits angiogenesis in vivo (Hayakawa et al., 
2002b ). IL-12-mediated inhibition of tumor angiogenesis has also been 
demonstrated to be mediated by NK cells (Yao et al., 1999), although it has been 
shown that low doses of IL-12 preferentially activates NKT cells rather than NK 
cells (Smyth et al., 2000a; Takeda et al., 2000a). 
Although the importance ofNK cells in control of tumor growth has been studied 
extensively, establishing whether NK cells can protect against tumor initiation 
has been more difficult. Early on, "NK cell defective" beige mice were used, 
however these mice have a defect in cytoplasmic granule formation that is also 
known to affect CTLs and macrophages (Ashman and Papadimitriou, 1991; 
Roder, 1979). Numerous studies have been undertaken using anti-NK1.1 mAb to 
deplete NK cells, however this antibody deletes both NK cells and NKT cells and 
the NK1.1 marker is only expressed on NK cells from mice of specific 
backgrounds. Patients lacking NK cells have been described, however, these 
patients are extremely susceptible to viral infection and die at an early age (Ballas 
et al., 1990; Biron et al., 1989). Familial haemophagocytic lymphohistiocytosis 
(FHL) patients who possess pfp mutations and lack NK cell activity have also 
been described, but die at a young age unless rescued by a BM transplant (BMT) 
(Stepp et al., 1999). 
Key studies performed by Smyth and colleagues demonstrated that mice depleted 
of NK cells were more susceptible to spontaneous tumor growth initiated by 
methylcholanthrene (MCA) (Smyth et al., 2001b; Smyth et al., 2000b). NK cells 
are also capable of rejecting spontaneous ~2~-deficient B cell lymphomas in a 
p f p - d e p e n d e n t  m a n n e r .  R e c e n t l y ,  a  s p o n t a n e o u s  r e s i s t a n c e / c o m p l e t e  r e s i s t a n c e  
( S R / C R )  m o u s e  w a s  i d e n t i f i e d  b y  C u i  a n d  c o l l e a g u e s  ( C u i  e t  a l . ,  2 0 0 3 ) .  T h e  
o r i g i n a l  f o u n d e r  m o u s e  w a s  i d e n t i f i e d  d u e  t o  a  f a i l u r e  t o  d e v e l o p  a s c i t e s  a f t e r  
r e p e a t e d  i n j e c t i o n  w i t h  S 1 8 0  s a r c o m a  c e l l s .  B r e e d i n g  e x p e r i m e n t s  r e v e a l e d  t h e  
t r a i t  w a s  a  d o m i n a n t  g a i n  o f  f u n c t i o n  m u t a t i o n  a n d  f u r t h e r  a n a l y s i s  r e v e a l e d  a n  
a g e - d e p e n d e n t  s p o n t a n e o u s  r e g r e s s i o n  o f  a d v a n c e d  c a n c e r s .  Y o u n g  m i c e  (  6  
w e e k s  o f  a g e )  d i s p l a y e d  a  C R  p h e n o t y p e ,  5 0 %  o f  m i c e  1 2  w e e k s  o f  a g e  d i s p l a y e d  
a  C R  p h e n o t y p e  a n d  5 0 %  d i s p l a y e d  a  S R  p h e n o t y p e  a n d  t h e  m a j o r i t y  o f  2 2  w e e k  
o l d  m i c e  d i s p l a y e d  a  S R  p h e n o t y p e .  R e s i s t a n c e  i n  t h e s e  m i c e  w a s  a s s o c i a t e d  w i t h  
a n  i n f i l t r a t i o n  o f  i n n a t e  l e u k o c y t e s  i n c l u d i n g  N K  c e l l s ,  n e u t r o p h i l s  a n d  
m a c r o p h a g e s  i n t o  t h e  p e r i t o n e u m .  T h i s  m o d e l  s u g g e s t s  t h a t  a  h o s t  r e s i s t a n c e  
m e c h a n i s m  a g a i n s t  c a n c e r  m a y  e x i s t ,  t h a t  t h e  m e c h a n i s m  m a y  i n v o l v e  N K  c e l l s  
a n d  t h a t  r e s i s t a n c e  m a y  d e c l i n e  w i t h  a g e .  
N K  c e l l s  i s o l a t e d  f r o m  c a n c e r  p a t i e n t s  e x h i b i t  i m p a i r e d  N K  c e l l  c y t o t o x i c i t y ,  
p r o l i f e r a t i o n ,  p r o l i f e r a t i o n  a n d  r e s p o n s e  t o  I F N s  a n d  p a t i e n t s  w i t h  h i g h e r  l e v e l s  o f  
N K  c e l l  a c t i v i t y  p o s t  t r e a t m e n t  a r e  r e p o r t e d  t o  r e m a i n  c a n c e r - f r e e  l o n g e r  t h a n  
p a t i e n t s  w i t h  l o w  N K  c e l l  a c t i v i t y  ( W h i t e s i d e  a n d  H e r b e r m a n ,  1 9 9 4 ;  W h i t e s i d e  e t  
a l . ,  1 9 9 8 ) .  T h e  i m p o r t a n c e  o f  N K  c e l l s  i n  c o n t r o l  o f  t u m o r  d e v e l o p m e n t  i s  a l s o  
i l l u s t r a t e d  i n  p a t i e n t s  w i t h  X L P  s y n d r o m e .  T h e s e  p a t i e n t s  h a v e  d e f e c t i v e  S A P  
t h a t  p r e v e n t s  N K  c e l l  a c t i v a t i o n  t h r o u g h  C D 2 4 4  ( 2 B 4 )  ( B e n o i t  e t  a l . ,  2 0 0 0 ;  
N a k a j i m a  e t  a l . ,  2 0 0 0 ;  N i c h o l s  e t  a l . ,  1 9 9 8 ;  S a y o s  e t  a l . ,  1 9 9 8 ) .  A s  a  c o n s e q u e n c e ,  
S H P - 1  i s  s t a b l y  a s s o c i a t e d  w i t h  2 B 4  i n  p a t i e n t  N K  c e l l s ,  c a u s i n g  2 B 4  t o  a c t  a s  a n  
i n h i b i t o r y  r a t h e r  t h a n  a n  a c t i v a t i n g  r e c e p t o r  ( P a r o l i n i  e t  a l . ,  2 0 0 0 ) .  X L P  p a t i e n t s  
a r e  h i g h l y  s u s c e p t i b l e  t o  E p s t e i n  B a r r  v i r u s  ( E B V )  i n f e c t i o n  a n d  d e v e l o p  B - c e l l  
l y m p h o m a s  s u g g e s t i n g  t h a t  N K  c e l l s  m a y  c o n t r o l  E B V  i n f e c t i o n  i n  t h e s e  p a t i e n t s  
( W u  a n d  L a n i e r ,  2 0 0 3 ) .  
B M T  i s  c o m m o n l y  u s e d  t o  t r e a t  l e u k e m i a  p a t i e n t s  a t  l e s s  a d v a n c e d  s t a g e s  o f  
d i s e a s e ,  h o w e v e r ,  t u m o r  r e l a p s e  r e m a i n s  a  s e r i o u s  i s s u e .  R e c e n t l y ,  V e l a r d i  a n d  
c o l l e a g u e s  d e m o n s t r a t e d  t h a t  B M T  u s i n g  h a p l o i d e n t i c a l ,  b u t  K I R  m i s m a t c h e d  
d o n o r s  i n d u c e d  N K  c e l l  a l l o r e a c t i o n s  t h a t  c o u l d  m e d i a t e  a  G V L  e f f e c t  a n d  
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prevent tumor relapse in patients (Figure 1.6) (Ruggeri et al., 2002). Moreover, 
higher rates of engraftment were obtained and graft-versus-host disease was 
prevented, most likely via elimination of host antigen-presenting cells (APCs). 
Another study suggested that KIR mismatch provides no advantage in mediation 
of GVL effects (Davies et al., 2002), however these differences might be 
explained by numbers of stem cells transplanted, post-grafting immune 
suppression and T cell depletion. NK cells may also play a role in IFN-a-
mediated treatment of chronic myelogenous leukaemia (CML) as NK cells 
isolated from patients treated with IFN-a exhibit increased cytotoxicity against 
autologous CML blasts (de Castro et al., 2003; Pawelec et al., 1995). 
In some cases, NK cells may co-operate with other immune effector cells to 
eliminate tumor. For example, both CD8+ T cells and NK cells are required to 
protect mice from in vivo growth of Bl6-CD80 transfectants (Wu et al., 1995). 
NK cells also facilitate an adaptive anti-tumor immune response by producing 
IFN-y and other cytokines to activate DCs, T cells and B cells (Smyth et al., 
2002b) (detailed in Chapter 1, Literature Review, Section 1.2.5). 
1.2.6.1 a-Galactosylceramide ( a-GalCer) and bystander NK cell 
activation 
(2S,3S,4R)-1-0-( a-D-galactopyranosyl)-2-(N-hexacosanoyl-amino )-1 ,3,4octade-
canetriol ( a-galactosylceramide or a-GalCer) is a CD 1 d-binding glycolipid 
originally identified in an extract from the marine sponge Age/as mauritianus 
(Morita et al., 1995) (Figure 1. 7). Since these early studies, a-GalCer has been 
shown to act as a specific CD1d restricted ligand for Va14 invariant-NKT 
(iNKT) cells, powerfully stimulating them to produce high levels of IFN-y and 
IL-4 (Kawano et al., 1997). 
The anti-tumor activity of a-GalCer has been demonstrated for a wide variety of 
tumors of different origins including; breast, lung, kidney and colon carcinomas, 
melanoma as well as hematopoietic malignancies (Morita et al., 1995; Kawamura 
F i g u r e  1 . 6 .  N K  c e l l s  i n  G V L .  ( A )  W h e n  d o n o r  a n d  r e c i p i e n t  a r e  h a p l o i d e n t i c a l ,  i n h i b i t o r y  K I R  
r e c e p t o r s  c a n  b i n d  t o  H L A  m o l e c u l e s  o f  t h e  s a m e  s u p e r t y p e ,  t h e r e b y  s e n d i n g  a n  i n h i b i t o r y  s i g n a l  
t o  d o n o r  N K  c e l l s  u p o n  b i n d i n g  t o  l e u k e m i a  t a r g e t s .  I n  t h i s  e x a m p l e ,  K I R 2 D L I  i s  i n h i b i t e d  b y  
g r o u p  2  H L A - C  a l l e l e s  ( H L A - C w 2 , 4 , 5  a n d  6 )  a n d  t h e  H L A - C w 2  e x p r e s s i n g  N K  c e l l  i s  p r e v e n t e d  
f r o m  k i l l i n g  t h e  H L A - C w 6  e x p r e s s i n g  l e u k e m i a  c e l l .  ( B )  W h e n  t h e  d o n o r  a n d  r e c i p i e n t  a r e  K I R  
m i s m a t c h e d  ( i n  t h i s  e x a m p l e  t h e  r e c i p i e n t  e x p r e s s e s  t h e  g r o u p  1  H L A - C  a l l e l e  H L A - C w l ) ,  t h e  
H L A - C w 2  e x p r e s s i n g  K I R 2 D L I  +  N K  c e l l s  a r e  n o  l o n g e r  i n h i b i t e d  a n d  k i l l  t h e  l e u k e m i a  c e l l .  ( C )  
N K  c e l l s  a l s o  r e d u c e  g r a f t - v e r s u s - h o s t  d i s e a s e  b y  e l i m i n a t i n g  K I R  m i s m a t c h e d  h o s t  a n t i g e n -
p r e s e n t i n g  c e l l s .  
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F i g u r e  1 . 7 .  S t r u c t u r e  o f  a - G a i C e r .  T h e  a - a n o m e r i c  c o n f o n n a t i o n  o f  t h e  s u g a r  m o i e t y  i s  
c r i t i c a l  f o r  o p t i m u m  i N K T  c e l l  a c t i v a t i o n .  T h e  l e n g t h  o f  t h e  l o n g  c h a i n  s p h i n g o s i n e  b a s e  
( C
1 4
)  a n d  f a t t y  a c y l  c h a i n  ( C
2 6
)  i s  c o n s i d e r e d  s u i t a b l e  f o r  b i n d i n g  t o  C D l d  v i a  h y d r o p h o b i c  
i n t e r a c t i o n s  
3 2  
et al., 1998; Kobayashi et al., 1995; Nakagawa et al., 1998; Smyth et al., 2001a; 
Yamaguchi et al., 1996). a-GalCer has also been shown to inhibit tumor initiation 
in several spontaneous tumor models including; MCA-treated mice, p53-deficient 
mice and Her-2/neu transgenic mice (Hayakawa et al., 2004). 
Cross-talk between a-GalCer-stimulated iNKT and other immune cells is crucial 
for amplification of the a-GalCer response. Although stimulation of iNKT with 
a-GalCer results in rapid production of Th1 and Th2 cytokines, this is followed 
by a massive IFN-y-dependent proliferation and activation ofNK cells (Bendelac 
et al., 1997; Camaud et al., 1999; Eberl and MacDonald, 2000; Hong et al., 1999; 
Kawano et al., 1997; Singh et al., 1999) and NK cell IFN -Y production 
(Hayakawa et al., 2001). Moreover, the anti-metastatic effects of a-GalCer are 
impaired in IFN-y1- and NK cell-depleted mice (Hayakawa et al., 2001; Smyth et 
al., 2002a) and a-GalCer-induced in vitro cytotoxicity is ameliorated in hepatic 
MNC isolated from IFN-y1- and NK cell-depleted mice (Hayakawa et al., 2001). 
Furthermore, NKT cell IFN -y production alone is not sufficient to mediate a 
significant anti-tumor response (Smyth et al., 2002a). In addition to NK cells, 
bystander activation of conventional T and B cells and DCs also occurs (Burdin 
et al., 1999; Camaud et al., 1999; Cui et al., 1999; Eberl and MacDonald, 2000; 
Kitamura et al., 2000; Nishimura et al., 2000; Singh et al., 1999). 
1.3 Death receptors (DRs) 
To date, eight members of the DR family have been identified: TNFR1 
(CD120a), CD95 (Fas/AP01), DR3 (AP0-3, LARD, TRAMP, WSL1), TRAIL-
R1 (AP0-2, DR4), TRAIL-R2 (DRS, KILLER, TRICK2), DR6, p75-NGFR and 
EDAR. Some TNF superfamily receptors contain truncated DDs or lack cytosolic 
regions that may allow them to act as 'decoys' and compete for binding with 
cognate ligands. 
1 . 3 . 1  S t r u c t u r e  
T h e  D R s  a r e  t y p e  I  t r a n s m e m b r a n e  p r o t e i n s .  T h e i r  e x t r a c e l l u l a r  d o m a i n s  a r e  
c h a r a c t e r i z e d  b y  3  o r  4  c y s t e i n e - r i c h  d o m a i n s  ( C R D s )  t h a t  a r e  p s e u d o - r e p e a t s  t h a t  
c o m m o n l y  c o n t a i n  6  c y s t e i n e  r e s i d u e s  e n g a g e d  i n  t h e  f o r m a t i o n  o f  3  d i s u l p h i d e  
b o n d s  ( B o d m e r  e t  a l . ,  2 0 0 2 ) .  T h e  a m i n o  t e r m i n a l  e x t r a c e l l u l a r  r e g i o n  h a s  a  h i g h  
d e g r e e  o f  h o m o l o g y  (  ~65% p r o t e i n  s e q u e n c e  i d e n t i t y ) .  R e c e p t o r  s t r u c t u r e  i s  
s t a b i l i z e d  b y  a  ' t w i s t e d  l a d d e r '  o f  d i s u l p h i d e  b r i d g e s  ( B o d m e r  e t  a l . ,  2 0 0 0 b  ) .  
S o l u b l e  f o r m s  o f  t h e  D R s  c a n  b e  g e n e r a t e d  b y  p r o t e o l y t i c  p r o c e s s i n g  ( e g .  
T N F R 1 )  ( G r u s s  a n d  D o w e r ,  1 9 9 5 )  o r  b y  a l t e r n a t i v e  s p l i c i n g  o f  t h e  e x o n  e n c o d i n g  
t h e  t r a n s m e m b r a n e  d o m a i n  ( e g .  F a s )  ( S m i t h  e t  a l . ,  1 9 9 4 ) .  
T h e  D R  l i g a n d s  a r e  t y p e  I I  t r a n s m e m b r a n e  p r o t e i n s  t h a t  s h a r e  a  c o n s e r v e d  (~30% 
p r o t e i n  s e q u e n c e  i d e n t i t y )  C - t e r m i n a l  T N F  h o m o l o g y  d o m a i n  ( T H D ) .  T h e  T H D  
b i n d s  t o  t h e  C R D s  o f  t h e  D R s  a l l o w i n g  t r a n s m i s s i o n  o f  t h e  d e a t h  s i g n a l .  W i t h  t h e  
e x c e p t i o n  o f  L  T  - a  t h a t  l a c k s  a  t r a n s m e m b r a n e  d o m a i n  a n d  i s  s e c r e t e d  a s  a  
h o m o t r i m e r ,  t h e  d e a t h  l i g a n d s  ( i n c l u d i n g  h e t e r o t r i m e r i c  L T a 1  ~2) c a n  b e  c l e a v e d  
f r o m  t h e  m e m b r a n e  b y  m e t a l l o p r o t e i n a s e s  t o  g e n e r a t e  s o l u b l e  f o r m s  t h a t  a r e  
r e l e a s e d  i n t o  t h e  e x t r a c e l l u l a r  s p a c e  ( B l a c k  e t  a l . ,  1 9 9 7 ;  C h e n  e t  a l . ,  2 0 0 1 b ;  L u m  
e t  a l . ,  1 9 9 9 ;  P o w e l l  e t  a l . ,  1 9 9 9 ;  S c h n e i d e r  e t  a l . ,  1 9 9 9 ) .  W h i l s t  t h e  f u n c t i o n  o f  
s o m e  l i g a n d s  i s  d e p e n d e n t  u p o n  s o l u b i l i z a t i o n ,  t h e  f u n c t i o n  o f  o t h e r s  s u c h  a s  
F a s L  i s  d o w n r e g u l a t e d  u p o n  c l e a v a g e  ( T a n a k a  e t  a l . ,  1 9 9 8 ) .  
T h e  c r y s t a l  s t r u c t u r e  o f  h u m a n  L T  - a  b o u n d  t o  i t ' s  r e c e p t o r ,  h u m a n  T N F R 1 ,  w a s  
p u b l i s h e d  b y  B a n n e r  a n d  c o l l e a g u e s  i n  1 9 9 3  ( B a n n e r  e t  a l . ,  1 9 9 3 ) .  T h r e e  
r e c e p t o r s  w e r e  i d e n t i f i e d  t o  a s s e m b l e  w i t h  3  l i g a n d s  f o r m i n g  a  h e x a m e r i c  
c o m p l e x .  A  s i m i l a r  c r y s t a l  s t r u c t u r e  w a s  a l s o  i d e n t i f i e d  f o r  T R A I L  b o u n d  t o  i t ' s  
r e c e p t o r  T R A I L - R 2  ( C h a  e t  a l . ,  2 0 0 0 ;  H y m o w i t z  e t  a l . ,  1 9 9 9 ;  M o n g k o l s a p a y a  e t  
a l . ,  1 9 9 9 )  w h e r e  3  r e c e p t o r s  w e r e  e s t a b l i s h e d  t o  b i n d  3  l i g a n d s ,  s u g g e s t i n g  t h a t  
t h e  3 : 3  s t o i c h i o m e t r y  i s  l i k e l y  t h e  b a s i s  o f  a  s i g n a l i n g  u n i t  f o r  t h e  D R s  a n d  t h e i r  
c o r r e s p o n d i n g  l i g a n d s .  
1.3.2 Signaling 
FasL or TRAIL induce target cell apoptosis by engaging and activating the DRs 
Fas and DR4/DR5 respectively (Figure 1.8). Upon activation, the receptors 
trimerize which allows clustering of the DDs located within their cytoplasmic 
regions and formation of the death-inducing signaling complex (DISC) (Kischkel 
et al., 1995; Kischkel et al., 2000). The adaptor protein F ADD is recruited to the 
clustered receptor DDs by homotypic DD interactions and recruits and activates 
caspase-8 and/or 10 (Bodmer et al., 2000a; Kischkel et al., 1995; Kischkel et al., 
2000; Kischkel et al., 2001; Sprick et al., 2000; Wang et al., 2001 b). This leads to 
proteolytic activation of executioner caspases such as caspase-3 and ultimately to 
death of the target cell. TNF binding to TNFR1 induces target cell apoptosis in a 
slightly different manner. Rather than directly recruiting F ADD to the receptor, 
the adaptor protein TNFR-associated death domain (TRADD) is initially 
recruited which secondarily recruits F ADD (Hsu et al., 1996). The cell death 
pathway mediated by DR/ligand interaction has been termed the 'cell-extrinsic' 
pathway (Ashkenazi, 2002). 
The DRs can also activate the 'cell-intrinsic' pathway (Ashkenazi, 2002) to 
induce target cell death via caspase-8-mediated cleavage of Bid (Gross et al., 
1999; Li et al., 1998; Luo et al., 1998; Yin et al., 1999) (Figure 1.8). Truncated 
Bid (tBid) translocates to the mitochondria where it interacts with Bax and Bak 
stimulating the release of cytochrome c and Smac/Diablo (Adams and Cory, 
1998; Eskes et al., 2000; Wei et al., 2000). Cytochrome c liberated from the 
mitochondria then binds to the adaptor protein APAFl, forming the apoptosome 
and activating caspase-9 which in tum activates executioner caspases leading to 
target cell death. Smac/Diablo promotes apoptosis by blocking inhibitor of 
apoptosis (lAP) proteins (Du et al., 2000; Verhagen et al., 2000). Cross-talk 
between the 'cell-extrinsic' and 'cell-intrinsic' pathways following DR activation 
may be important for amplification of the death signal in some cells. 
Signaling pathways downstream of the DRs can be regulated in a number of 
ways. Cellular FLICE-inhibitory proteins (c-FLIPs) are homologous to caspase-8 
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T R A I L  c a n  i n d u c e  t a r g e t  c e l l  a p o p t o s i s  b y  e n g a g i n g  a n d  a c t i v a t i n g  D R s  s u c h  a s  F a s  o r  D R 4 / D R 5 .  
D D s  w i t h i n  t h e  c y t o p l a s m i c  r e g i o n  o f  t h e s e  r e c e p t o r s  t h e n  e n g a g e  a d a p t o r  p r o t e i n s  s u c h  a s  F  A D D  
t h a t  c a n  r e c r u i t  a n d  a c t i v a t e  c a s p a s e s ,  u l t i m a t e l y  l e a d i n g  t o  d e a t h  o f  t h e  t a r g e t  c e l l .  F L I P s  c a n  
i n t e r f e r e  w i t h  t h e  g e n e r a t i o n  o f  a c t i v e  c a s p a s e - 8 .  ( B )  D R s  c a n  a c t i v a t e  b o t h  ' c e l l - i n t r i n s i c '  a n d  
' c e l l - e x t r i n s i c '  p a t h w a y s  t o  i n d u c e  t a r g e t  c e l l  d e a t h .  T h e  ' c e l l - e x t r i n s i c '  p a t h w a y  t r i g g e r s  
a p o p t o s i s  v i a  a c t i v a t i o n  o f  i n i t i a t o r  c a s p a s e s  ( 8  a n d  1  0 )  f o l l o w e d  b y  a c t i v a t i o n  o f  e x e c u t i o n e r  
c a s p a s e s  ( 3 ,  6  o r  7 ) .  D R s  c a n  a l s o  a c t i v a t e  t h e  ' c e l l - i n t r i n s i c '  p a t h w a y  v i a  c a s p a s e - 8 - m e d i a t e d  
c l e a v a g e  o f  B i d .  t B i d  t r a n s l o c a t e s  t o  t h e  m i t o c h o n d r i a  w h e r e  i t  i n t e r a c t s  w i t h  B a x  a n d  B a k  
s t i m u l a t i n g  t h e  r e l e a s e  o f  c y t o c h r o m e  c  a n d  S m a c /  D i a b l o .  C y t o c h r o m e  c  l i b e r a t e d  f r o m  t h e  
m i t o c h o n d r i a  t h e n  b i n d s  t o  t h e  a d a p t o r  p r o t e i n  A P  A F l ,  f o r m i n g  t h e  a p o p t o s o m e  a n d  a c t i v a t i n g  
c a s p a s e - 9  w h i c h  i n  t u m  a c t i v a t e s  e x e c u t i o n e r  c a s p a s e s  l e a d i n g  t o  t a r g e t  c e l l  d e a t h .  S m a c / D i a b l o  
p r o m o t e s  a p o p t o s i s  b y  b l o c k i n g  l A P  p r o t e i n s .  C r o s s t a l k  b e t w e e n  t h e  ' c e l l - e x t r i n s i c '  a n d  ' c e l l -
i n t r i n s i c '  p a t h w a y s  f o l l o w i n g  D R  a c t i v a t i o n  m a y  b e  i m p o r t a n t  f o r  a m p l i f i c a t i o n  o f  t h e  d e a t h  
s i g n a l  i n  s o m e  c e l l s .  
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and 10 (Tschopp et al., 1998) and can prevent recruitment of caspase-8 or 10 to 
the DISC and hence the activation of these caspases. Viral PUCE-inhibitory 
proteins (v-FLIPs) encoded by several members of the herpes virus family 
(Bertin et al., 1997; Hu et al., 1997; Searles et al., 1999; Thome et al., 1997) 
similarly protect against cell death induced by activation of members of the TNF 
receptor family. The poxvirus encoded protein ermA which is homologous to a 
serine protease inhibitor (serpin) also inhibits DR-mediated apoptosis by blocking 
caspases (Cassens et al., 2003; Kamiyama et al., 1996). Chaperones have been 
shown to modulate DR-mediated apoptosis, for example apoptosis induced by 
TNF can be blocked by the heat-shock protein Hsp70 (Jaattela et al., 1998). 
Protein kinase C (PKC) has been reported to inhibit the recruitment of DD-
containing proteins that are important for DR-mediated signaling (Harper et al., 
2003). In addition, MAPK (Frese et al., 2003) and Akt (Thakkar et al., 2001) 
activity have been demonstrated to affect TRAIL sensitivity. Expression of Bcl-
2/XL and Bax/Bak or lack thereof is particularly important for regulation of DR 
signaling via the 'cell-intrinsic' pathway (Bums and El-Deiry, 2001; LeBlanc et 
al., 2002; Scaffidi et al., 1998; Wei et al., 2001; Wen et al., 2000). 
In addition to apoptosis, the DRs also regulate a number of other cellular 
processes including proliferation, viral replication, suppression of apoptosis, cell 
survival, inflammation, bone resorption and differentiation via activation of 
pathways involving NFKB, JNK, p42/p44 MAPK and p38 MAPK (Degli-Esposti 
et al., 1997a; Hu et al., 1999; Lin et al., 2000; Natoli et al., 1998; Schneider et al., 
1997). 
1.3 .3 Cellular expression 
The TNF superfamily of ligands are expressed by a wide variety of cells within 
the immune system, including monocytes, NK, T, B and DCs (Table 1.2). TNF 
superfamily receptors are expressed by a variety of cell types including those of 
the immune system and others including lung, colon and epithelial cells (Table 
1.2). 
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R e c e p t o r  C e l l u l a r  e x p r e s s i o n  
T R A I L  
N K ,  T a n d  D C s  
D R 4 ,  D R 5 ,  
M o s t  n o r m a l  a n d  t r a n s f o r m e d  c e l l s  
D c R 1 ,  D c R 2 ,  O P G  M o s t  n o r m a l  a n d  t r a n s f o r m e d  c e l l s  
F a s L  
A c t i v a t e d  s p l e n o c y t e s ,  t h y m o c y t e s ,  F a s  
M o s t  n o r m a l  a n d  t r a n s f o r m e d  c e l l s  
i m m u n e  p r i \ A i e d g e d  s i t e s  s u c h  a s  
t h e  e y e  a n d  t e s t i s  
T N F  
M a c r o p h a g e s ,  N K ,  T  a n d  B  c e l l s  T N F R 1  
M o s t  n o r m a l  a n d  t r a n s f o r m e d  c e l l s  
T N F R 2  I m m u n e  c e l l s  a n d  e p i t h e l i a l  c e l l s  
L T - n  
N K ,  T  a n d  B  c e l l s  T N F R 1 ,  T N F R 2  Seeabo~oe 
LT-~ N K ,  T ,  B ,  D C s ,  m a c r o p h a g e s  
LT-~R 
N K ,  C D 4 +  a n d  C O B +  T  c e l l s  
T W E A K  
M : : J n o c y t e s  F N 1 4  R b r o b l a s t s  a n d  e n d o t h e l i a l  c e l l s  
L I G H T '  
T  c e l l s ,  D C s ,  m o n o c y t e s  a n d  g r a n u l o c y t e s  I - N  E M  T  c e l l s  
LT-~R 
N o n - l y m p h o i d  h a e r n a t o p o i e t i c  c e l l s  a n d  s t r o m a l  c e l l s  
D c R 3  L u n g  a n d  c o l o n  c e l l s  
C D 2 7 L  
N K ,  T  a n d  B  c e l l s  C D 2 7  C D 4 +  a n d  C O B +  T  c e l l s  
C D 3 0 L  
T  c e l l s  a n d  m o n o c y t e s  C D 3 0  
R e e d - S t e r n b e r g  c e l l s  
C D 4 0 L  
T a n d B c e l l s  
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B A F F  
~ c e l l s ,  D C s ,  m o n o c y t e s  a n d  m a c r o p h a g e s  B A F F R  
B  c e l l s ,  P B L s ,  L N s ,  s p l e e n  a n d  r e s t i n g  T  c e l l s  
T A C I  
B  c e l l s ,  P B L s ,  a c t i v a t e d  T  c e l l s ,  t h y m u s ,  s p l e e n ,  i n t e s t i n e  
B C r v \ 1 1 .  
B  c e l l s ,  P B L s ,  t h y m u s ,  s p l e e n ,  L N s ,  li~oer a n d  a d r e n a l s  
A P R I L  
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G I T R L  
N o t  d e t e r m i n e d  
G I T R  
C D 4 + C D 2 5 +  T  c e l l s  
R A N K L  
A c t i v a t e d  T  c e l l s  a n d  o s t e o b l a s t s  R A N K  
O s t e o c l a s i s ,  o s t e o b l a s t s  a n d  a c t i v a t e d  T  c e l l s  
O P G  O s t e o c l a s t  p r e c u r s o r s ,  e n d o t h e l i a l  c e l l s  
E D A 1  S k i n  
E D A R  E c t o d e r m a l  derivati~oe 
E D A 2  
S k i n  X E D A R  
E c t o d e r m a l  derivati~oe 
N o t  d e t e r m i n e d  
O R 6  R e s t i n g  T  c e l l s  
N o t  d e l e r m i n e d  R E L T  
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T a b l e  1 . 2 .  C e l l u l a r  e x p r e s s i o n  o f  T N F  s u p e r f a m i l y  l i g a n d s  a n d  t h e i r  c o g n a t e  r e c e p t o r s .  *  
B i n d s  t o  D c R 3 .  A d a p t e d  f r o m  ( A g g a r w a l ,  2 0 0 3 ) .  
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Although TRAIL mRNA had been identified in a number of tissues and in a 
variety of cell types (Wiley et al., 1995) less is known of TRAIL expression at 
the protein level. Initially, TRAIL was shown to be constitutively expressed by 
human CD4+ T cell clones and to mediate cytotoxicity against TRAIL-sensitive 
tumor cells in vitro (Kayagaki et al., 1999b; Thomas and Hersey, 1998). Later 
studies reported a lack of TRAIL expression by freshly isolated splenic 
lymphocytes, thymocytes and cells isolated from LNs (Kayagaki et al., 1999c). In 
the same study, stimulation of T cells using anti-CD3, PHA, CD40L, 
lipopolysaccharide and PMA plus ionomycin did not induce TRAIL expression, 
although TRAIL expression could be induced on splenic NK cells after 
stimulation with IL-2 or IL-15. Peripheral blood T cells stimulated with type I 
IFNs plus anti-CD3 were also identified to express TRAIL (Kayagaki et al., 
1999a), as were IFN-stimulated monocytes and DCs (Fanger et al., 1999; Griffith 
et al., 1999b). 
Key studies performed in our laboratory have identified TRAIL to be 
constitutively expressed on a proportion of mouse liver NK cells (Takeda et al., 
2001). IFN-·y-1- and IFN-yK1- mice lack TRAIL expression, although expression 
can be induced by administration of riFN-y. This study suggests that IFN-y 
regulates constitutive TRAIL expression in vivo (Takeda et al., 2001). More 
recently, constitutive TRAIL expression was identified on numerous human and 
mouse ocular tissues, including corneal endothelium and epithelium, the iris, 
ciliary epithelium and neurosensory retina (Lee et al., 2002). 
FasL is expressed on activated T cells (Suda et al., 1993), NK cells (Oshimi et al., 
1996) and on tumor cells (Hahne et al., 1996; O'Connell et al., 1996; Strand et al., 
1996; Tanaka et al., 1996). FasL is also expressed in several non-lymphoid cells 
and tissues including macrophages, DCs, epithelial cells and others (Bellgrau et 
al., 1995; French et al., 1997; Lu et al., 1997; Suss and Shortman, 1996). In 
addition, FasL expression has been reported in immune privileged sites including 
the CNS, testis, ovary and placenta (D'Alessio et al., 2001; French et al., 1996; 
Hunt et al., 1997) and like TRAIL is expressed on the corneal epithelium and 
retina of the eye (Ferguson and Griffith, 1997; Griffith et al., 1995). FasL 
e x p r e s s i o n  i n  i m m u n e  p r i v i l e g e d  s i t e s  i s  i m p o r t a n t  t o  p r o t e c t  t h e s e  t i s s u e s  f r o m  
c e l l u l a r  i m m u n e - m e d i a t e d  d a m a g e  ( G r i f f i t h  e t  a l . ,  1 9 9 5 ;  G r i f f i t h  e t  a l . ,  1 9 9 6 ) .  
T N F  i s  p r o d u c e d  b y  a c t i v a t e d  m a c r o p h a g e s  a n d  T  c e l l s ,  N K  c e l l s  a n d  B  c e l l s  
( C a r s w e l l  e t  a l . ,  1 9 7 5 ;  W a r e  e t  a l . ,  1 9 9 2 ) .  E x p r e s s i o n  o f T N F  i s  t r a n s i e n t  ( l a s t i n g  
o n l y  a  f e w  h o u r s ) ,  d e p e n d e n t  o n  T N F  g e n e  t r a n s c r i p t i o n  a n d  i s  r a p i d l y  i n d u c e d  
b y  s t i m u l i  t h a t  c a n  c h a r a c t e r i s t i c a l l y  a c t i v a t e  T  c e l l s  ( S m y t h  a n d  J o h n s t o n e ,  
2 0 0 0 ) .  T N F  p r o d u c e d  b y  a c t i v a t e d  m a c r o p h a g e s  a n d  C T L s  c a n  e x i s t  a s  b o t h  
m e m b r a n e - a s s o c i a t e d  a n d  p r o t e o l y t i c a l l y  r e l e a s e d  s o l u b l e  f o r m s  t h a t  a r e  s i m i l a r l y  
c a p a b l e  o f  k i l l i n g  T N F - s e n s i t i v e  t a r g e t s  ( D e c k e r  e t  a l . ,  1 9 8 7 ;  M o n a s t r a  e t  a l . ,  
1 9 9 6 ;  R a t n e r  a n d  C l a r k ,  1 9 9 3 ) .  T w o  m a j o r  s u b s e t s  o f  T N F - p r o d u c i n g  a c t i v a t e d  
C D S +  T  c e l l s  e x i s t  ( H a m a n n  e t  a l . ,  1 9 9 7 ) .  T h e  f i r s t  ' m e m o r y - t y p e '  p o p u l a t i o n  
e x p r e s s  e l e v a t e d  l e v e l s  o f  F a s  a n d  s e c r e t e  T N F ,  I F N - y  a n d  I L - 4 .  T h e  s e c o n d ,  
' C T L - t y p e '  p o p u l a t i o n ,  e x p r e s s  C D 4 5 R A ,  l a c k  c o - s t i m u l a t o r y  m o l e c u l e  
e x p r e s s i o n ,  s e c r e t e  b o t h  T N F  a n d  I F N - y  a n d  a r e  h i g h l y  c y t o l y t i c  ( p r o d u c e  p f p  a n d  
g r z B ) .  
1 . 3 . 4  D R - m e d i a t e d  a p o p t o s i s  a n d  a n t i - t u m o r  a c t i v i t y  
C e l l  d e a t h  ( a p o p t o s i s )  c a n  b e  a c t i v a t e d  b y  a  n u m b e r  o f  s t i m u l i  i n c l u d i n g  u l t r a -
v i o l e t  o r  y - i r r a d i a t i o n ,  c h e m o t h e r a p e u t i c  d r u g s ,  g r o w t h  f a c t o r  w i t h d r a w a l  a n d  b y  
a c t i v a t i o n  o f  t h e  D R s .  T h e  D R s  a r e  p a r t  o f  t h e  T N F  s u p e r f a m i l y  a n d  c o n t a i n  a n  
i n t r a c e l l u l a r  D D  t h a t  i s  e s s e n t i a l  f o r  t r a n s d u c t i o n  o f  a n  a p o p t o t i c  s i g n a l .  A l t h o u g h  
t h e  D R s  i n i t i a t e  a p o p t o s i s  v i a  t h e  ' c e l l - e x t r i n s i c '  p a t h w a y ,  t h e  a p o p t o t i c  s i g n a l  
c a n  b e  a m p l i f i e d  b y  c r o s s - t a l k  w i t h  t h e  ' c e l l - i n t r i n s i c '  p a t h w a y  ( d e t a i l e d  i n  
C h a p t e r  1 ,  L i t e r a t u r e  R e v i e w ,  S e c t i o n  1 . 3 . 2 ) .  T h e  D R s  h a v e  b e e n  i m p l i c a t e d  i n  
t h e  c o n t r o l  o f  t u m o r  g r o w t h ,  h o m e o s t a s i s  o f  t h e  i m m u n e  s y s t e m  a n d  s o m e  a p p e a r  
t o  p l a y  a  r o l e  i n  c o n t r o l  o f  a u t o i m m u n e  d i s e a s e .  M a n y  o f  t h e s e  f u n c t i o n s  c a n  b e  
a t t r i b u t e d  t o  D R - m e d i a t e d  i n d u c t i o n  o f  a p o p t o s i s .  
A n  o u t s t a n d i n g  q u e s t i o n  p o s e d  b y  i m m u n o l o g i s t s  i s  w h y  e x p r e s s i o n  o f  t h e  T N F  
s u p e r f a m i l y  r e c e p t o r s  d o e s  n o t  a l w a y s  c o n f e r  s u s c e p t i b i l i t y  t o  l i g a n d - m e d i a t e d  
s t i m u l a t i o n .  F o r  e x a m p l e ,  T N F R 1  i s  e x p r e s s e d  b y  a l l  c e l l s  y e t  t h e  g r o w t h  o f  o n l y  
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a portion of these cells is modulated by TNF (Sugarman et al., 1985). 
Furthermore, TNFR1 is capable of functioning in all cells as NFKB activation is 
uniformly mediated by TNF. Some reports suggest that the presence of decoy 
receptors can inhibit ligand stimulation (Marsters et al., 1997; Mongkolsapaya et 
al., 1998; Pan et al., 1998b; Sheridan et al., 1997), although decoy receptor 
expression does not always correlate with an inhibition of signaling (Clodi et al., 
2000; Griffith et al., 1998; Griffith et al., 1999a; Zhang et al., 1999). The 
presence or absence of signaling molecules downstream of the DRs, such as the 
c-FLIPs and lAPs might also play a role in controlling susceptibility to DR-
mediated apoptosis. Indeed, studies have shown a correlation between the levels 
of these proteins and cell death (Griffith et al., 1998; Guo et al., 2002; Kim et al., 
2000). Activation of c-Myc has also been shown to sensitize cells to induction of 
apoptosis by TNFR1, Fas and TRAIL receptors (Hueber et al., 1997; Klefstrom et 
al., 1994; Lutz et al., 1998). 
1.3.4.1 TRAIL 
TRAIL is a type II transmembrane protein and member of the TNF-superfamily 
of ligands. In humans, TRAIL binds to two death-inducing receptors, 
DR4/TRAIL-R1 (Pan et al., 1997b) and DR5/TRAIL-R2/KILLER (Pan et al., 
1997a; Sheridan et al., 1997; Walczak et al., 1997; Wu et al., 1997). TRAIL has 
also been shown to bind 3 decoy receptors, DcR1/TRID/TRAIL-R3 (Degli-
Esposti et al., 1997b; Pan et al., 1997a; Sheridan et al., 1997), DcR2/TRAIL-R4 
(Degli-Esposti et al., 1997a; Marsters et al., 1997) and a soluble receptor OPG 
that was originally identified as a receptor for OPGLIRANKL (Emery et al., 
1998). DcRI completely lacks a cytosolic region and is linked to the plasma 
membrane by a glycophospholipid moiety, DcR2 has a truncated cytoplasmic DD 
and cannot exert apoptosis. In the mouse, only one death-inducing receptor has 
been described that shares homology to human TRAIL-R2 (mouse DR5) (Wu et 
al., 1999a). Two murine decoy receptors have also been described for TRAIL 
(mDcTrailrl and mDcTrailr2) (Schneider et al., 2003). 
A  n u m b e r  o f  s t u d i e s  u s i n g  r T R A I L  h a v e  d e m o n s t r a t e d  s e l e c t i v e  a b i l i t y  o f  T R A I L  
t o  i n d u c e  a p o p t o s i s  i n  t r a n s f o r m e d  a n d  v i r u s - i n f e c t e d  c e l l s ,  b u t  n o t  i n  m o s t  
n o r m a l  c e l l s ,  m a k i n g  i t  p a r t i c u l a r l y  a t t r a c t i v e  a s  a  p o t e n t i a l  c a n c e r  t h e r a p e u t i c  
( A s h k e n a z i  e t  a l . ,  1 9 9 9 ;  W a l c z a k  e t  a l . ,  1 9 9 9 )  ( d e t a i l e d  i n  C h a p t e r  1 ,  L i t e r a t u r e  
R e v i e w ,  S e c t i o n  1 . 4 ) .  H o w e v e r ,  l i t t l e  i s  k n o w n  o f  t h e  t r u e  p h y s i o l o g i c a l  r o l e  o f  
n a t u r a l  T R A I L  o r  t h e  e x p r e s s i o n  o f  T R A I L  a t  t h e  . p r o t e i n  l e v e l .  I t  w a s  n o t  u n t i l  
t h e  d e v e l o p m e n t  o f  t h r e e  k e y  r e a g e n t s ,  t h e  a n t i - m o u s e  ( m ) T R A I L  m A b  ( N 2 B 2 )  
( K a y a g a k i  e t  a l . ,  1 9 9 9 c ) ,  s o l u b l e  T R A I L  r e c e p t o r  ( D R S )  ( S o n g  e t  a l . ,  2 0 0 0 )  a n d  
t h e  T R A I L - d e f i c i e n t  m i c e  d e s c r i b e d  i n  t h i s  s t u d y ,  t h a t  t h e s e  q u e s t i o n s  h a v e  
b e g u n  t o  b e  a d d r e s s e d .  
A l t h o u g h  a  n u m b e r  o f  s t u d i e s  h a v e  s h o w n  t h a t  h u m a n  T  c e l l  c l o n e s  a n d  c y t o k i n e  
s t i m u l a t e d  N K  c e l l s  c a n  k i l l  t u m o r  c e l l s  i n  a  T R A I L - m e d i a t e d  f a s h i o n  ( K a y a g a k i  
e t  a l . ,  1 9 9 9 b ;  K a y a g a k i  e t  a l . ,  1 9 9 9 c ;  T h o m a s  a n d  H e r s e y ,  1 9 9 8 ) ,  t h e  a n t i - t u m o r  
a c t i v i t y  o f  T R A I L  i n  v i v o  h a s  b e e n  l e s s  w e l l  s t u d i e d .  K e y  s t u d i e s  i n  o u r  
l a b o r a t o r y  h a v e  s h o w n  t h a t  f r e s h l y  i s o l a t e d  ( u n s t i m u l a t e d )  T R A I L - e x p r e s s i n g  
l i v e r  N K  c e l l s  c a n  m e d i a t e  T R A I L - d e p e n d e n t  s p o n t a n e o u s  c y t o t o x i c i t y  a g a i n s t  
t u m o r  t a r g e t s  i n  v i t r o  ( T a k e d a  e t  a l . ,  2 0 0 1 ) .  T R A I L - e x p r e s s i n g  l i v e r  N K  c e l l s  
w e r e  a l s o  s h o w n  t o  p l a y  a  r o l e  i n  s u p p r e s s i o n  o f  T R A I L - s e n s i t i v e  L 9 2 9 ,  L B 2 7 . 4  
a n d  R e n c a  l i v e r  m e t a s t a s i s  i n  v i v o .  T h i s  k e y  s t u d y  w a s  t h e  f i r s t  t o  i d e n t i f y  a  r o l e  
f o r  n a t u r a l  T R A I L  i n  t u m o r  i m m u n e  s u r v e i l l a n c e .  
1 . 3 . 4 . 2  T N F  
T N F  w a s  o r i g i n a l l y  d i s c o v e r e d  a s  a  s e r u m  f a c t o r  t h a t  c o u l d  k i l l  c a n c e r  c e l l s  i n  
m i c e  ( C a r s w e l l  e t  a l . ,  1 9 7 5 ;  H e l s o n  e t  a l . ,  1 9 7 5 ;  O ' M a l l e y  e t  a l . ,  1 9 6 2 ) .  T N F  
b i n d s  a s  a  h o m o t r i m e r  t o  t w o  r e c e p t o r s ,  T N F R 1  ( p 5 5 )  a n d  T N F R 2  ( p 7 5 )  ( L e w i s  
e t  a l . ,  1 9 9 1 ) .  T N F - a  i s  a  t y p e  I I  t r a n s m e m b r a n e  p r o t e i n  t h a t  h a s  a l s o  b e e n  
r e p o r t e d  t o  e x i s t  i n  a  s o l u b l e  ( p r o t e o l y t i c a l l y  r e l e a s e d )  f o r m  a n d  i s  p r o d u c e d  b y  
m a c r o p h a g e s ,  N K ,  T  a n d  B  c e l l s  ( C a r s w e l l  e t  a l . ,  1 9 7 5 ;  W a r e  e t  a l . ,  1 9 9 2 ) .  T h e  
a p p a r e n t  n o n - s p e c i f i c  t o x i c i t y  o f  T N F  m i g h t  b e  d u e  t o  t h e  e x p r e s s i o n  o f  T N F R 1  
b y  a l l  c e l l s .  
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TNF1- and TNFR1-/- mice have been reported to lack B-cell follicles and germinal 
center (GC) formation (Komer et al., 1997a; Pasparakis et al., 1996) which has 
been attributed to defects in induction of lymphocyte homing chemokines (Ngo et 
al., 1999). To investigate the effect of TNF on lymphoaccumulation, C57BL/6 
g/d TNF1- have been generated and TNF signaling was shown to amplify some 
aspects of the g/d phenotype including lymphoaccumulation and premature death 
(Komer et al., 2000). In this scenario, TNF may induce the expression of 
chemokines that regulate the trafficking and accumulation of tumor cells into 
LNs. 
To date there is little information to suggest that NK cells use TNF to directly 
exert anti-tumor activity, although TNF may contribute in effector cell migration 
to the tumor site. In vivo elimination of i.p. administered class I deficient RMA-S 
and RM-1 tumor is defective in TNF1- mice (Smyth et al., 1998). In this study, 
TNF was suggested to play a role in recruitment ofNK cells into the peritoneum. 
TNF1- mice displayed reduced numbers of NK cells in the peritoneum that 
correlated with a defective NK cell anti-tumor response in these mice (Smyth et 
al., 1998). Similarly, TNF has also been shown to play a role in recruitment of 
NK cells to liver parenchyma (Pilaro et al., 1994). 
Although TNF was originally discovered as a cytokine which had the ability to 
kill tumor cells, it is now evident that TNF can play a role in tumor promotion by 
regulating tumor cell proliferation, survival signals and stromal interactions 
which facilitate tumor invasion and metastasis (Frater-Schroder et al., 1987; 
Hideshima et al., 2001; Jourdan et al., 1999; Thomas et al., 1998). TNF is thought 
to exert this wide variety of functions by activating pathways involving NF-KB, 
JNK and p38MAPK (Baud and Karin, 2001; Chen and Goeddel, 2002; Garg and 
Aggarwal, 2002; Migone et al., 2002; Pan et al., 1998a; Wajant et al., 2003). 
1.3.4.3 FasL 
FasL is a 40-kDa type II cell surface glycoprotein and member of the TNF-
superfamily of ligands. FasL is expressed on activated T cells (Suda et al., 1993), 
N K  c e l l s  ( O s h i m i  e t  a l . ,  1 9 9 6 )  a n d  a t  s i t e s  o f  i m m u n e  p r i v i l e g e  ( D ' A l e s s i o  e t  a l . ,  
2 0 0 1 ;  F r e n c h  e t  a l . ,  1 9 9 6 ;  G r i f f i t h  e t  a l . ,  1 9 9 5 ;  H u n t  e t  a l . ,  1 9 9 7 ) .  F a s L  
e x p r e s s i o n  h a s  b e e n  r e p o r t e d  o n  a  n u m b e r  o f  t u m o r s  ( H a h n e  e t  a l . ,  1 9 9 6 ;  
O ' C o n n e l l  e t  a l . ,  1 9 9 6 ;  S t r a n d  e t  a l . ,  1 9 9 6 ;  T a n a k a  e t  a l . ,  1 9 9 6 )  a n d  m a y  p l a y  a  
r o l e  i n  ' t u m o r  c o u n t e r a t t a c k '  ( M a h e r  e t  a l . ,  2 0 0 2 )  w h e r e b y  F a s L - e x p r e s s i n g  
t u m o r s  e l i m i n a t e  F a s  p o s i t i v e  l y m p h o c y t e s  e n a b l i n g  t h e  t u m o r s  t o  a v o i d  r e j e c t i o n  
b y  t h e  i m m u n e  s y s t e m .  F a s L  h a s  o n l y  o n e  r e c e p t o r ,  a  4 5 - k D a  t y p e  I  
t r a n s m e m b r a n e  p r o t e i n ,  F a s  ( C D 9 5 / A p o 1 )  t h a t  i s  e x p r e s s e d  o n  m o s t  n o r m a l  a n d  
t r a n s f o r m e d  c e l l s .  
L p r  ( l y r n p h o p r o l i f e r a t i o n )  a n d  g l d  ( g e n e r a l i z e d  l y r n p h o p r o l i f e r a t i v e  d i s e a s e )  
m i c e ,  t h a t  h a v e  n a t u r a l  l o s s  o f  f u n c t i o n  m u t a t i o n s  i n  t h e  F a s  a n d  F a s L  g e n e s  
r e s p e c t i v e l y  ( d e t a i l e d  i n  C h a p t e r  1 ,  L i t e r a t u r e  R e v i e w ,  S e c t i o n s  1 . 7 . 2  a n d  1 . 7 . 3 ) ,  
e x h i b i t  a n  i n c r e a s e d  i n c i d e n c e  o f  t u m o r  d e v e l o p m e n t  w h e n  b a c k c r o s s e d  t o  E J . . L -
m y c  o r  b c l - 2  t r a n s g e n i c  m i c e  ( P e n g  e t  a l . ,  1 9 9 6 ;  Z o m i g  e t  a l . ,  1 9 9 5 ) ,  s u g g e s t i n g  
t h a t  a  d e f e c t i v e  F a s / F a s L  p a t h w a y  a l l o w s  t h e  a c c u m u l a t i o n  o f  m u t a t i o n s  t h a t  
i n i t i a t e  t u m o r  d e v e l o p m e n t ,  b u t  a l o n e  a r e  w e a k  i n d u c e r s  o f  t u m o r i g e n e s i s .  
P a s - s e n s i t i v e  m e l a n o m a s  h a v e  b e e n  d e m o n s t r a t e d  t o  m e t a s t a s i z e  t o  t h e  l u n g  i n  
g l d  m i c e  b u t  n o t  i n  w i l d - t y p e  ( W T )  m i c e  ( O w e n - S c h a u b  e t  a l . ,  2 0 0 0 ;  O w e n -
S c h a u b  e t  a l . ,  1 9 9 8 )  a n d  I L - 1 8 - m e d i a t e d  s u p p r e s s i o n  o f  t u m o r  m e t a s t a s e s  i n  m i c e  
i s  p r e d o m i n a n t l y  m e d i a t e d  b y  F a s L - e x p r e s s i n g  N K  c e l l s  ( H a s h i m o t o  e t  a l . ,  1 9 9 9 ) .  
T h e s e  d a t a  d e m o n s t r a t e  t h e  i m p o r t a n c e  o f  t h e  F a s / F a s L  p a t h w a y  i n  t h e  c o n t r o l  o f  
t u m o r  s p r e a d .  
A l t h o u g h  h i g h  l e v e l s  o f  F a s  e x p r e s s i o n  h a v e  b e e n  r e p o r t e d  o n  s o m e  c o l o n ,  o v a r y ,  
b r e a s t ,  p r o s t a t e  a n d  l i v e r  t u m o r s  ( N a g a t a ,  1 9 9 6 ;  N a g a t a  a n d  G o l s t e i n ,  1 9 9 5 ) ,  
m a n y  t u m o r  c e l l s  d o  n o t  c o n s t i t u t i v e l y  e x p r e s s  F a s .  N K  c e l l s  h a v e  b e e n  
d e m o n s t r a t e d  t o  s t i m u l a t e  F a s  e x p r e s s i o n  o n  t u m o r  c e l l s  i n  v i t r o  a n d  t o  
s u b s e q u e n t l y  i n d u c e  P a s - d e p e n d e n t  a p o p t o s i s  i n  t h e s e  t a r g e t s  ( S c r e p a n t i  e t  a l . ,  
2 0 0 1 ) .  T u m o r  c e l l s  l a c k i n g  F a s  e x p r e s s i o n  h a v e  a l s o  b e e n  s h o w n  t o  u p r e g u l a t e  
F a s  w h e n  p a s s a g e d  i n  v i v o  ( S c r e p a n t i  e t  a l . ,  2 0 0 1 ) .  E x p r e s s i o n  o f  F L I P  o r  C r m A  
i n  P a s - s e n s i t i v e  t u m o r s  h a s  b e e n  s h o w n  t o  p r o t e c t  t h e m  f r o m  P a s - m e d i a t e d  
4 4  
apoptosis, suggesting that FLIP and CrmA may function as tumor progression 
factors, protecting class-! deficient tumors from NK-cell mediated rejection in 
vivo (Screpanti et al., 2001; Seki et al., 2003). Collectively, these data indicate 
that FasL-mediated apoptosis might be an important means of NK cell-mediated 
tumor clearance. 
Fas/FasL interactions are critical for homeostatic regulation of the immune 
system and play an important role in peripheral tolerance. Lpr and gld mice 
(detailed in Chapter 1, Literature Review, Section 1.7.2 and 1.7.3) develop 
lymphoaccumulation and have increased mortality due to an accumulation of 
B220+ DN T cells in LNs and spleen (Cohen and Eisenberg, 1991; Davidson et 
al., 1986) that are typically eliminated by Fas/FasL interactions. Fas/FasL 
interactions are also important in the activation induced cell death (AICD) ofT 
cells (Ju et al., 1995; Kabe1itz et al., 1993) that occurs after repeated CD3/TCR 
stimulation of the T cell and acts as a feedback mechanism to terminate ongoing 
immune responses. Similarly, activated T cells express both Fas and FasL, 
enabling them to kill each-other or commit suicide to dampen an immune 
response (Nagata and Golstein, 1995). Some reports suggest a role for Fas at high 
but not low intensity TCR stimulation in negative selection (Kishimoto et al., 
1998). Together, these studies illustrate the significance of FasL-mediated 
apoptosis in T cell homeostasis. 
The Fas/FasL pathway not only regulates T cell responses, but also plays a major 
role in elimination of activated B cells and may inhibit B cell tumor growth. 
Upon activation, B cells upregulate Fas and become sensitive to FasL-induced 
apoptosis (Daniel and Krammer, 1994; Onel et al., 1995; Stalder et al., 1994; 
Watanabe et al., 1995). FLIP-transduced A20 B cell tumor cells exhibit increased 
tumor growth in vivo compared with untransfected A20 cells, suggesting that Fas 
can control malignant B cell tumor growth in vivo (Djerbi et al., 1999). In 
addition, tumor cells isolated from a number of B cell malignancies are resistant 
to Fas-induced death even though they express adequate cell surface Fas receptor 
(Owen-Schaub et al., 1993; Plumas et al., 1998; Westendorfet al., 1995; Xerri et 
al., 1998). Moreover, FasL mutant gld mice develop B cell lymphomas with age 
I  '  
I  
( D a v i d s o n  e t  a l . ,  1 9 9 8 )  ( d e t a i l e d  i n  C h a p t e r  1 ,  L i t e r a t u r e  R e v i e w ,  S e c t i o n  1 . 7 . 2 )  
a n d  A L P S  p a t i e n t s  w i t h  F a s  m u t a t i o n s  a r e  d i a g n o s e d  w i t h  n o n - H o d g k i n ' s  a n d  
H o d g k i n ' s  B  c e l l  m a l i g n a n c i e s  a t  1 4  a n d  5 1  f o l d  t h e  n o r m a l  i n c i d e n c e s ,  
r e s p e c t i v e l y  ( L i n ,  1 9 9 5 )  ( d e t a i l e d  i n  C h a p t e r  1 ,  L i t e r a t u r e  R e v i e w ,  S e c t i o n  1 . 7 . 1 ) .  
T o g e t h e r ,  t h e s e  d a t a  s u g g e s t  t h a t  F a s  p l a y s  a n  i m p o r t a n t  r o l e  i n  c o n t r o l  o f  B  c e l l  
t u m o r  g r o w t h .  
1 . 4  R e c o m b i n a n t  ( r ) T R A I L / A p o 2 L  
R e c o m b i n a n t  s o l u b l e  T R A I L  i s  c u r r e n t l y  b e i n g  d e v e l o p e d  a s  o n e  o f  t h e  m o s t  
p r o m i s i n g  n a t u r a l  i m m u n e  m o l e c u l e s  p r o p o s e d  f o r  t r i a l s  i n  c a n c e r  p a t i e n t s .  
T R A I L  s h o w s  p a r t i c u l a r  p r o m i s e  g i v e n  t h e  u n i q u e  a b i l i t y  o f  T R A I L  t o  s e l e c t i v e l y  
i n d u c e  d e a t h  i n  c a n c e r  c e l l s ,  b u t  n o t  i n  m o s t  n o r m a l  c e l l s .  T o  d a t e ,  s e v e r a l  
r e c o m b i n a n t  v e r s i o n s  o f  h u m a n  T R A I L  h a v e  b e e n  g e n e r a t e d  a n d  t e s t e d  f o r  t h e i r  
a b i l i t y  t o  i n d u c e  t u m o r  c e l l  d e a t h  i n  v i t r o  a n d  i n  v i v o  u s i n g  m u r i n e  c a n c e r  
x e n o g r a f t  m o d e l s .  I n i t i a l l y ,  a m i n o  a c i d s  1 1 4 - 2 8 1  o f  T R A I L  w e r e  f u s e d  t o  a n  
a m i n o - t e r m i n a l  p o l y h i s t i d i n e  t a g  ( P i t t i  e t  a l . ,  1 9 9 6 ) .  A  s e c o n d  v a r i a n t  c o m p r i s e s  
a m i n o  a c i d s  9 5 - 2 8 1  o f  T R A I L  f u s e d  a m i n o  t e r m i n a l l y  t o  a  m o d i f i e d  y e a s t  G a l - 4  
l e u c i n e  z i p p e r  ( L Z )  t h a t  p r o m o t e s  t r i m e r i z a t i o n  o f  t h e  l i g a n d  ( W a l c z a k  e t  a l . ,  
1 9 9 9 ) .  A  t h i r d  v a r i a n t  c o n t a i n i n g  a m i n o  a c i d s  9 5 - 2 8 1  f u s e d  t o  a n  a m i n o - t e r m i n a l  
' F l a g '  e p i t o p e  t a g  r e q u i r e d  c r o s s l i n k i n g  w i t h  a n  a n t i - F l a g  a n t i b o d y  f o r  e n h a n c e d  
t u m o r i c i d a l  a c t i v i t y  ( B o d m e r  e t  a l . ,  2 0 0 0 b ;  C h e n  e t  a l . ,  2 0 0 1 a ;  G o n g  a n d  
A l m a s a n ,  2 0 0 0 ) .  T h e  m o s t  r e c e n t  r e c o m b i n a n t  v e r s i o n  o f  h u m a n  T R A I L  c o n t a i n s  
a m i n o  a c i d s  1 1 4 - 2 8 1  w i t h o u t  a n y  a d d e d  e x o g e n o u s  s e q u e n c e s  ( A s h k e n a z i  a n d  
D i x i t ,  1 9 9 9 )  d e c r e a s i n g  t h e  p o t e n t i a l  f o r  i m m u n o g e n i c i t y  i n  h u m a n s .  
B o t h  T N F  a n d  F a s L  h a v e  b e e n  s h o w n  t o  i n d u c e  s e r i o u s  t o x i c  e f f e c t s  a f t e r  
s y s t e m i c  a d m i n i s t r a t i o n  ( G a l l e  e t  a l . ,  1 9 9 5 ;  H e r s h  e t  a l . ,  1 9 9 1 ;  O g a s a w a r a  e t  a l . ,  
1 9 9 3 ;  T i m m e r  e t  a l . ,  2 0 0 2 ) .  T h e r e  i s  a l s o  a  c o n c e r n  t h a t  s o m e  r T R A I L  v a r i a n t s  
m a y  a l s o  i n d u c e  s y s t e m i c  t o x i c i t y ,  h i g h l i g h t i n g  t h e  i m p o r t a n c e  o f  p r e c l i n i c a l  
a s s e s s m e n t  u s i n g  t h i s  l i g a n d .  P o l y h i s t i d i n e  t a g g e d  r e c o m b i n a n t  h u m a n  T R A I L  
h a s  b e e n  s h o w n  t o  i n d u c e  a p o p t o s i s  i n  n o r m a l  h u m a n  h e p a t o c y t e s ,  b u t  n o t  i n  
h e p a t o c y t e s  i s o l a t e d  f r o m  d i f f e r e n t  s p e c i e s  ( J o  e t  a l . ,  2 0 0 0 ) .  B o t h  r e c o m b i n a n t  
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human LZ and polyhistidine tagged TRAIL have been shown to induce apoptosis 
in normal keratinocytes (Leverkus et al., 2000; Qin et al., 2001) and recombinant 
human LZ TRAIL is cytotoxic to human astrocytes in vitro (Walczak et al., 
1999). In contrast, rTRAIL that lacks exogenous sequences does not induce 
apoptosis in normal human or cynomolgus monkey hepatocytes (Lawrence et al., 
2001), human mammary, renal or prostatic epithelial cells, umbilical vein 
endothelial cells, lung fibroblasts, colon smooth muscle cells, astrocytes or 
keratinocytes and appears to be the most promising candidate for future clinical 
trials (Ashkenazi et al., 1999; Qin et al., 2001). 
Production and purification of untagged rTRAIL has been optimized by the 
addition of zinc, the reducing agent dithiothreitol and a neutral pH, which ensures 
maximal stability of TRAIL homotrimers and activity (Kelley et al., 2001; 
Lawrence et al., 2001). Tagged versions of rTRAIL can aggregate and/or 
precipitate at high concentration and might therefore be able to induce apoptosis 
in normal cells by over-multimerizing DRs and surpassing the signal threshold 
required for activation of apoptosis in these cells (Ashkenazi, 2002; Lawrence et 
al., 2001). Untagged rTRAIL is largely homogeneous (99% trimer) and therefore 
cannot over-multimerize DRs in normal cells (Lawrence et al., 2001). 
Preliminary studies using non-human primates (chimpanzees and cynomolgus 
monkeys) suggest that short-term (5-7 days) i.v. administration of untagged 
rTRAIL does not induce detectable toxicity (Ashkenazi et al., 1999; Lawrence et 
al., 2001). Although further animal safety studies need be undertaken to fully 
establish the effects of long term TRAIL administration, these preliminary 
toxicity studies provide real hope for the safe use of rTRAIL in clinical trials. 
Like rTRAIL, a number of agonistic mAbs that functionally engage human and 
murine TRAIL receptors have been developed and investigated for anti-tumor 
potential. A number of agonistic mAbs to human DR4 [clones 4H6 (mouse IgG 1) 
and 4G7 (mouse IgG2a)] (Chuntharapai et al., 2001) and DR4 and DRS (Griffith 
et al., 1999a) have been developed, although these required cross-linking for 
activity. Agonistic mAbs that do not require cross-linking have also been 
d e s c r i b e d  f o r  h u m a n  D R S  [ T R A - 8  ( m o u s e  l g G 1 ) ]  ( I c h i k a w a  e t  a l . ,  2 0 0 1 )  a n d  
D R 4  a n d  D R S  [ a n t i - D R 4  m A b  ( D R 4 - A )  a n d  a n t i - D R S  m A b  ( D R S - A )  b o t h  m o u s e  
I g G 1 ]  ( W a n g  e t  a l . ,  2 0 0 4 ) .  O n l y  o n e  a g o n i s t i c  m A b  h a s  b e e n  d e s c r i b e d  f o r  m o u s e  
D R S  ( M D S - 1 )  ( T a k e d a  e t  a l . ,  2 0 0 4 ) .  U n l i k e  s o m e  f o r m s  o f  r T R A I L  ( J o  e t  a l . ,  
2 0 0 0 ) ,  t h e  a n t i - h u m a n  D R S  a n t i b o d y  ( T R A - 8 )  a n d  a n t i - m o u s e  D R S  m A b  h a v e  
b e e n  r e p o r t e d  t o  l a c k  h e p a t o t o x i c i t y  ( I c h i k a w a  e t  a l . ,  2 0 0 1 ;  T a k e d a  e t  a l . ,  2 0 0 4 ) .  
1 . 4 . 1  A n t i - t u m o r  a c t i v i t y  
r T R A I L  c a n  i n d u c e  a p o p t o s i s  i n  a  w i d e  v a r i e t y  o f  h u m a n  c a n c e r  c e l l  l i n e s ,  
i n c l u d i n g ;  b r e a s t ,  b l a d d e r ,  o v a r y ,  l u n g ,  p r o s t a t e ,  c o l o n ,  k i d n e y ,  C N S ,  p a n c r e a t i c  
a n d  h e m a t o p o i e t i c  c e l l s  ( A s h k e n a z i  e t  a l . ,  1 9 9 9 ;  C h e n  e t  a l . ,  2 0 0 1 a ;  G a z i t t ,  1 9 9 9 ;  
K e a n e  e t  a l . ,  1 9 9 9 ;  L i n c z  e t  a l . ,  2 0 0 1 ;  L i u  e t  a l . ,  2 0 0 1 ;  M i t s i a d e s  e t a l . ,  2 0 0 1 a ;  
M i t s i a d e s  e t  a l . ,  2 0 0 1  b ;  M i t s i a d e s  e t  a l . ,  2 0 0 2 ;  M i t s i a d e s  e t  a l . ,  2 0 0 1  c ;  M i z u t a n i  
e t  a l . ,  1 9 9 9 ;  R i e g e r  e t  a l . ,  1 9 9 8 ;  S n e l l  e t  a l . ,  1 9 9 7 ;  T h o m a s  a n d  H e r s e y ,  1 9 9 8 ;  
W a l c z a k  e t  a l . ,  1 9 9 9 ;  Y u  e t  a l . ,  2 0 0 0 ) .  I n  v i t r o ,  A s h k e n a z i  a n d  c o l l e a g u e s  
d e m o n s t r a t e d  t h a t  r T R A I L  h a d  a  c y t o s t a t i c  e f f e c t  o n  1 6  o f  3 9  t u m o r  c e l l  l i n e s  
t e s t e d ,  i n h i b i t i n g  c e l l  g r o w t h  b y  S 0 - 1  0 0 %  ( A s h k e n a z i  e t  a l . ,  1 9 9 9 ) .  T h e  s a m e  
r e s e a r c h e r s  o b s e r v e d  t h a t  r T R A I L  e x e r t e d  a  c y t o t o x i c  e f f e c t  o n  1 6  a d d i t i o n a l  
t u m o r  c e l l  l i n e s ,  r e d u c i n g  c e l l  n u m b e r s  b y  S 0 - 1  0 0 %  ( A s h k e n a z i  e t  a l . ,  1 9 9 9 ) .  
B o t h  i . p .  a n d  i . v .  m o d e s  o f  r T R A I L  a d m i n i s t r a t i o n  h a v e  b e e n  s h o w n  t o  i n h i b i t  
t u m o r  g r o w t h  w i t h  t h e  a n t i - t u m o r  e f f e c t  o f  T R A I L  a p p e a r i n g  d o s e - d e p e n d e n t  
( W a l c z a k  e t  a l . ,  1 9 9 9 ) .  R e c o m b i n a n t  h u m a n  a n d  m u r i n e  L Z  T R A I L  l y s e  T R A I L -
s e n s i t i v e  m u r i n e  L B 2 7 . 4  t u m o r  c e l l s  e q u i v a l e n t l y ,  a l t h o u g h  t h e  T R A I L - s e n s i t i v e  
h u m a n  J u r k a t  c e l l  l i n e  i s  s l i g h t l y  m o r e  s e n s i t i v e  t o  l y s i s  b y  h u m a n  L Z  T R A I L  
c o m p a r e d  w i t h  m u r i n e  L Z  T R A I L  ( W a l c z a k  e t  a l . ,  1 9 9 9 ) .  T h e s e  s t u d i e s  s u g g e s t  a  
s i g n i f i c a n t  c r o s s - s p e c i e s  a c t i v i t y  f o r  r T R A I L ,  p e r m i t t i n g  e x t e n s i v e  p r e c l i n i c a l  
a s s e s s m e n t  o f  t h i s  p r o t e i n  i n  a n i m a l  m o d e l s .  
I n  v i v o ,  r T R A I L  h a s  d e m o n s t r a t e d  r e m a r k a b l e  a n t i - t u m o r  a c t i v i t y  a g a i n s t  c o l o n  
c a r c i n o m a  ( A s h k e n a z i  e t  a l . ,  1 9 9 9 ;  L e B l a n c  e t  a l . ,  2 0 0 2 ) ,  g l i o m a  ( F u l d a  e t  a l . ,  
2 0 0 2 ;  P o l l a c k  e t  a l . ,  2 0 0 1 ) ,  m u l t i p l e  m y e l o m a  ( M i t s i a d e s  e t  a l . ,  2 0 0 1 a )  a n d  b r e a s t  
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carcinoma xenografts (Walczak et al., 1999), in established models of cancer. 
Furthermore, rTRAIL induced apoptosis in established xenografts (Ashkenazi et 
al., 1999; Walczak et al., 1999). Moreover, cells isolated from tumors that re-
emerge after an initial regression following TRAIL administration remain 
TRAIL-sensitive in vitro, suggesting that further treatment with rTRAIL might 
eliminate these tumors (Walczak et al., 1999). Not only can rTRAIL suppress the 
growth of cell-line based cancer xenografts in mice, but also xenografts of human 
tumor cells isolated from patients and grown only briefly in culture before 
transplantation into mice (Ashkenazi, 2002). 
Several in vitro studies have demonstrated the cytotoxic activity of agonistic DR4 
and DRS mAbs against tumor targets in vitro, although receptor cross-linking has 
been required in a number of these studies (Chuntharapai et al., 2001; Griffith et 
al., 1999a; Ichikawa et al., 2001; Takeda et al., 2004). A number of tumor 
xenograft studies have also demonstrated the capability of agonistic mAbs that 
engage human DR4 or DRS to exert anti-tumor activity in vivo (Chuntharapai et 
al., 2001; Ichikawa et al., 2001; Wang et al., 2004). A mAb to murine DRS 
(MDS-1) has recently been reported,to inhibit spontaneous 4T1.2 and R331lung 
and liver metastasis in vivo by recruiting Fe receptor-expressing innate immune 
cells (Takeda et al., 2004). The anti-metastatic effect of MDS-1 was inhibited for 
FLIP-transfected R331 tumors, suggesting that the anti-metastatic effects of 
MDS-1 are primarily mediated by caspase-dependent signaling via DRS rather 
than complement-mediated lysis or ADCC (Takeda et al., 2004). Together, these 
studies illustrate that the TRAIL pathway can be manipulated not only by 
administration of rTRAIL, but also agonistic TRAIL receptor mAbs to inhibit 
tumorigenesis. 
A recent study by Wang and colleagues demonstrated that overexpression of the 
MYC oncogene in a number of human cell types of epithelial and mesenchymal 
origin sensitized them to apoptosis induced by rTRAIL and TRAIL death 
receptor (DRS) agonists (Wang et al., 2004). Myc sensitized cells to TRAIL/DRS 
agonist mediated apoptosis by upregulating cell surface expression of DRS and 
stimulating autocatalytic processing of pro-caspase 8. DRS agonists were also 
d e m o n s t r a t e d  t o  i n h i b i t  t h e  g r o w t h  o f  M y c - e x p r e s s i n g  t u m o r  x e n o g r a f t s  i n  v i v o  
( W a n g  e t  a l . ,  2 0 0 4 ) .  
1 . 4 . 2  S y n e r g y  w i t h  c h e m o t h e r a p y  a n d  r a d i o t h e r a p y  
p 5 3  i s  c o m m o n l y  i n a c t i v a t e d  i n  p r o g r e s s i n g  h u m a n  c a n c e r s  a n d  i n  p a t i e n t s  
r e c e i v i n g  c o n v e n t i o n a l  t r e a t m e n t s  s u c h  a s  c h e m o t h e r a p y  a n d  r a d i o t h e r a p y .  
R a d i a t i o n  a n d  m o s t  D N A - d a m a g i n g  c h e m o t h e r a p e u t i c  d r u g s  r e q u i r e  p 5 3  f u n c t i o n  
f o r  a c t i v i t y  ( L e v i n e ,  1 9 9 7 )  a n d  a r e  i n e f f e c t i v e  i n  t h e s e  p a t i e n t s .  T R A I L  c a n  
i n d u c e  a p o p t o s i s  i n  t r a n s f o r m e d  c e l l s  r e g a r d l e s s  o f  t h e i r  p 5 3  s t a t u s  ( A s h k e n a z i  e t  
a l . ,  1 9 9 9 ) ,  p r o v i d i n g  a  u n i q u e  t h e r a p e u t i c  s t r a t e g y  t o  c i r c u m v e n t  r e s i s t a n c e  t o  
t h e r a p y  i n  p a t i e n t s  l a c k i n g  p 5 3  f u n c t i o n  ( E l - D e i r y ,  2 0 0 1 ;  S h e i k h  e t  a l . ,  1 9 9 8 ) .  
p 5 3  i s  k n o w n  t o  r e g u l a t e  D R 5  g e n e  t r a n s c r i p t i o n  ( W u  e t  a l . ,  1 9 9 7 ) ,  r a i s i n g  t h e  
p o s s i b i l i t y  t h a t  p 5 3 - a c t i v a t i n g  a g e n t s  m a y  a c t  i n  s y n e r g y  w i t h  r T R A I L  b y  
u p r e g u l a t i n g  D R S  e x p r e s s i o n  a n d  s e n s i t i z i n g  c e l l s  t o  T R A I L - m e d i a t e d  a p o p t o s i s .  
T h i s  k n o w l e d g e  h a s  s t i m u l a t e d  r e s e a r c h  f o c u s e d  o n  t h e  i n v e s t i g a t i o n  o f  c o m b i n e d  
r T R A I L  a n d  c h e m o t h e r a p e u t i c  d r u g  a d m i n i s t r a t i o n .  T R A I L  h a s  b e e n  s h o w n  t o  
a c t  i n  s y n e r g y  w i t h  r a d i a t i o n  ( C h i n n a i y a n  e t  a l . ,  2 0 0 0 ;  G o n g  a n d  A l m a s a n ,  2 0 0 0 )  
a n d  c h e m o t h e r a p e u t i c  d r u g s  s u c h  a s  a d r i a m y c i n ,  c i s p l a t i n ,  c i s -
d i a m i n e d i c h l o r o p l a t i n u m  ( I I )  ( C D D P ) ,  a c t i n o m y c i n - D .  d o x o r u b i c i n ,  e t o p o s i d e ,  
c a m p t o t h e c i n ,  f l u o r o u r a c i l  a n d  l o m u s t i n e  ( A s h k e n a z i  e t  a l . ,  1 9 9 9 ;  B o n a v i d a  e t  a l . ,  
1 9 9 9 ;  G l i n i a k  a n d  L e ,  1 9 9 9 ;  K e a n e  e t  a l . ,  1 9 9 9 ;  M i z u t a n i  e t  a l . ,  1 9 9 9 ;  M o r r i s o n  
e t  a l . ,  2 0 0 2 ;  N a g a n e  e t  a l . ,  2 0 0 1 ;  N a g a n e  e t  a l . ,  2 0 0 0 ;  O l s s o n  e t  a l . ,  2 0 0 1 ;  W e n  e t  
a l . ,  2 0 0 0 )  i n  a  v a r i e t y  o f  c a n c e r s  i n c l u d i n g  b l a d d e r ,  g l i o m a ,  c o l o n  a n d  b r e a s t .  
U p r e g u l a t i o n  o f  D R S  e x p r e s s i o n  o r  d o w n r e g u l a t i o n  o f  c F L I P  e x p r e s s i o n  b y  t h e s e  
d r u g s  m a y  b e  r e s p o n s i b l e  f o r  e n h a n c e d  T R A I L  a c t i v i t y  i n  t h e s e  i n  v i t r o  a n d  i n  
v i v o  s t u d i e s .  
X e n o g e n e i c  m o u s e  t u m o r  m o d e l s  h a v e  a l s o  b e e n  u s e d  t o  d e m o n s t r a t e  t h e  s y n e r g y  
b e t w e e n  T R A I L  a n d  c h e m o t h e r a p e u t i c  d r u g s .  T R A I L  c o m b i n e d  w i t h  5 -
f l u o r o u r a c i l  o r  c a m p t o s a r  a c t s  s y n e r g i s t i c a l l y  t o  c a u s e  r e g r e s s i o n  a n d  e v e n  
r e m i s s i o n  o f  e s t a b l i s h e d  h u m a n  c o l o n  c a r c i n o m a s  i n  x e n o g r a f t e d  n u d e  m t c e  
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(Ashkenazi et al., 1999) and CDDP co-administered with TRAIL acts 
synergistically to suppress formation and growth of established human 
glioblastoma xenografts in nude mice (Nagane et al., 2000). Some mismatch-
repair (MMR)-deficient tumors evade TRAIL-mediated apoptosis by inactivating 
Bax, and thus the 'cell-intrinsic' TRAIL apoptotic pathway. Recent studies have 
demonstrated that a combination of TRAIL and chemotherapeutic agents can 
restore TRAIL sensitivity in Bax-/- human colon cancer cells (LeBlanc et al., 
2002; Wang and El-Deiry, 2003). This restoration of TRAIL sensitivity was 
demonstrated to be p53-dependent, with p53-stirnulation of DRS expression 
playing an important role in the process (Wang and El-Deiry, 2003). 
1.5 The thymus 
The thymus is a hi-lobed organ found in the thorax in the anterior mediastinum 
and is the site of mainstream T-cell development, where BM-derived stern cells 
undergo a series of maturation events and exit as self-MHC restricted, self-
tolerant, na'ive T cells. Each thymic lobe comprises numerous lobules separated 
by fibroblast-rich trabeculae that extend inwards from the subcapsule. These 
lobules can be further divided two major regions, an outer cortex that hosts early 
thymocyte development and an inner medulla that is important for late T cell 
development (Boyd et al., 1993). For the purposes of this literature review, an 
overview ofT cell development is presented, with a focus on negative selection, 
as this area is most relevant to this thesis. 
In addition to T, B and NKT lymphocytes, the thymus is also comprised of a non-
lymphocytic component broadly termed the thymic stroma. The thymic stroma is 
made up of cells of endodermal, ectodermal and mesodermal origin (endothelial, 
epithelial and mesenchymal cells and fibroblasts) as well as rnacrophages and 
DCs (Boyd et al., 1993). Together, these cells provide a variety of known and as 
yet undefined soluble factors, extracellular matrix elements and cell surface 
molecules that are essential for various stages ofT -cell development (Anderson 
et al., 1996; Shortrnan and Wu, 1996). 
H e m a t o p o i e t i c  s t e m  c e l l s  f r o m  t h e  B M  e n t e r  t h e  t h y m u s  i n  a  n a r r o w  r e g i o n  o f  t h e  
p e r i m e d u l l a r y  c o r t e x  a n d  m i g r a t e  o u t w a r d s  a c r o s s  t h e  c o r t e x  t o  a c c u m u l a t e  i n  t h e  
s u b c a p s u l a r  z o n e  ( S C Z )  ( L i n d  e t  a l . ,  2 0 0 1 ) .  M i g r a t i o n  o f  t h e  b l o o d - d e r i v e d  
p r e c u r s o r s  b e t w e e n  d i f f e r e n t  r e g i o n s  o f  t h e  c o r t e x  c o r r e l a t e s  w i t h  d e f i n e d  s t a g e s  
o f  e a r l y  l y m p h o i d  d e v e l o p m e n t  ( L i n d  e t  a l . ,  2 0 0 1 ) .  F o u r  p h e n o t y p i c a l l y  d i s t i n c t  
s t a g e s ,  b a s e d  o n  e x p r e s s i o n  o f  C D 2 5  ( I L - 2 - R a  c h a i n )  a n d  t h e  a d h e s i o n  m o l e c u l e  
C D 4 4  ( G o d f r e y  a n d  Z l o t n i k ,  1 9 9 3 )  a r e  u s e d  t o  d e s c r i b e  t h e  m a t u r a t i o n  s t a t e  o f  
c e l l s  i n  t h i s  r e g i o n .  I n  o r d e r  o f  i n c r e a s i n g  m a t u r i t y ,  t h e s e  a r e  C D 2 5 - C D 4 4 +  
[ d o u b l e  n e g a t i v e  ( D N ) 1 ] ,  C D 2 5 + C D 4 4 +  ( D N 2 ) ,  C D 2 5 + C D 4 4 - ( D N 3 )  a n d  C D 2 5 -
C D 4 4 - ( D N 4 )  ( G o d f r e y  e t  a l . ,  1 9 9 3 ) .  B r o a d l y  s p e a k i n g ,  t h e s e  c e l l s  a r e  C D 3 -
1 1 0
,  
C D 4 -
1 1 0  
a n d  C D S - .  
T h e  D N 1  p o p u l a t i o n  c o n t a i n s  c e l l s  w i t h  m u l t i - l i n e a g e  p o t e n t i a l  a n d  r e q u i r e s  I L - 7  
a n d  s t e m  c e l l  f a c t o r  f o r  c o n t i n u e d  d e v e l o p m e n t  ( D i  S a n t o  a n d  R o d e w a l d ,  1 9 9 8 ;  
R o d e w a l d  e t  a l . ,  1 9 9 7 ) .  T h e  D N 1  p o p u l a t i o n  d i f f e r e n t i a t e s  i n t o  D N 2  c e l l s  t h a t  a r e  
t h o u g h t  t o  c o m m e n c e  T C R - y  a n d  TCR-~ g e n e  r e a r r a n g e m e n t  a s  t h e y  t r a n s i t  f r o m  
t h e  D N 2  i n t o  t h e  D N 3  c o m p a r t m e n t  ( D u d l e y  e t  a l . ,  1 9 9 4 ;  G o d f r e y  e t  a l . ,  1 9 9 4 ) .  
F o l l o w i n g  r e c o m b i n a t i o n  o f  t h e  TCR-~ l o c u s ,  t h e  TCR-~ c h a i n  a s s e m b l e s  w i t h  
t h e  p r e - T C R - a  ( p T a )  p r o t e i n  a n d  t h e  C D 3  c o m p l e x  ( F e h l i n g  a n d  v o n  B o e h m e r ,  
1 9 9 7 ) .  I n  a  p r o c e s s  t e r m e d  ~-selection, s i g n a l i n g  t h r o u g h  t h e  TCR-~-pTa-CD3 
c o m p l e x  v i a  C D 3  a n d  l c k  ( B o r o w s k i  e t  a l . ,  2 0 0 4 ;  S a i n t - R u f  e t  a l . ,  2 0 0 0 )  t h e n  
s t i m u l a t e s  t h e  c e l l s  t o  p r o c e e d  t h r o u g h  t h e  D N 4  t o  t h e  C D 4 + C D 8 +  d o u b l e  p o s i t i v e  
( D P )  s t a g e  o f  t h y m o c y t e  m a t u r a t i o n ,  t o  u n d e r g o  p r o l i f e r a t i o n  a n d  t o  c o m m e n c e  
T C R - a  c h a i n  g e n e  r e a r r a n g e m e n t  ( D u d l e y  e t  a l . ,  1 9 9 4 ) .  P r i o r  t o  e x p o r t  f r o m  t h e  
t h y m u s ,  D P  t h y m o c y t e s  u n d e r g o  t h y m i c  s e l e c t i o n  t o  e n s u r e  t h a t  t h e  m a j o r i t y  o f  
t h y m o c y t e s  e n t e r i n g  t h e  p e r i p h e r y  a r e  c a p a b l e  o f  i n t e r a c t i n g  w i t h  s e l f - M H C  w i t h  
l o w  a f f i n i t y  f o r  s e l f - a n t i g e n s  ( F i g u r e  1 . 9 ) .  
1 . 5 . 1  M e c h a n i s m s  o f t h y m i c  s e l e c t i o n  
D P  t h y m o c y t e s  t h a t  e x p r e s s  T C R s  w i t h  a  l o w  a f f i n i t y  f o r  p e p t i d e - M H C  u n d e r g o  
p o s i t i v e  s e l e c t i o n  ( A n d e r s o n  e t  a l . ,  1 9 9 3 )  a n d  c a n  e x i t  t o  t h e  p e r i p h e r y  w h e r e  t h e y  
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Figure 1.9. Schematic overview ofT cell development in the thymus. Following precursor 
entry into the thymus at the corticomedullary junction (CMJ), DN thymocytes proliferate, 
undergo TCR-~ gene rearrangement and migrate across the cortex to accumulate in the 
subcapsular zone, under the control of thymic stromal cells. After TCR-a gene rearrangement has 
occurred, developing DP thymocytes migrate back towards the medulla and interact with cortical 
epithelial cells [cTEC(s)] to receive survival signals or undergo programmed cell death. Positively 
selected thymocytes upregulate a~TCR and CD69 as they migrate towards the medulla, during 
which time they are susceptible to negative selection induced by DCs and medullary (m)TECs. 
Following final maturation events in the medulla, functionally competent thymocytes are exported 
from the thymus through vessels at the CMJ. (Figure courtesy of Dr Jason Gill). 
c i r c u l a t e  t h r o u g h o u t  t h e  s e c o n d a r y  l y m p h o i d  o r g a n s  a w a i t i n g  e n c o u n t e r  w i t h  
a n t i g e n  ( G o l d r a t h  a n d  B e v a n ,  1 9 9 9 ) .  D P  t h y m o c y t e s  t h a t  e x p r e s s  T C R s  w i t h  a  
h i g h  a f f i n i t y  f o r  s e l f  p e p t i d e - M H C  u n d e r g o  n e g a t i v e  s e l e c t i o n ,  l e a d i n g  t o  
a p o p t o s i s  ( P a l m e r ,  2 0 0 3 ) .  A p p r o x i m a t e l y  9 0 %  o f  a l l  D P  t h y m o c y t e s  f a i l  p o s i t i v e  
s e l e c t i o n  a n d  u n d e r g o  a p o p t o s i s  d u e  t o  ' d e a t h  b y  n e g l e c t '  ( H u e s m a n n  e t  a l . ,  
1 9 9 1 )  ( F i g u r e  1 . 9 ) .  T h i s  f o r m  o f  d e a t h  o c c u r s  w h e n  t h y m o c y t e  a f 3 T C R  f a i l s  t o  
e n g a g e  a  p e p t i d e - M H C  l i g a n d  w i t h  s u f f i c i e n t  a v i d i t y  t o  p r o v i d e  a p p r o p r i a t e  
s u r v i v a l  s i g n a l i n g .  C o l l e c t i v e l y ,  t h e  p o s i t i v e  a n d  n e g a t i v e  s e l e c t i o n  p r o c e s s e s  
e n s u r e  t h e  g e n e r a t i o n  o f  a  l a r g e l y  s e l f - M H C  r e s t r i c t e d ,  s e l f - t o l e r a n t  p e r i p h e r a l  T  
c e l l  r e p e r t o i r e .  
A p p r o x i m a t e l y  5 %  o f  t o t a l  D P  t h y m o c y t e s  ( p r e - s e l e c t i o n )  a r e  t h o u g h t  t o  
r e c o g n i z e  p e p t i d e - M H C  l i g a n d s  w i t h  a  l o w  a f f i n i t y  a n d  u n d e r g o  p o s i t i v e  
s e l e c t i o n  ( v a n  M e e r w i j k  e t  a l . ,  1 9 9 7 ) .  I t  i s  n o w  c l e a r  t h a t  a  l o w  a f f i n i t y  M H C  
i n t e r a c t i o n  a l o n e  i s  n o t  s u f f i c i e n t  f o r  p o s i t i v e  s e l e c t i o n  t o  o c c u r ,  a s  w h i l e  c o r t i c a l  
e p i t h e l i a l  c e l l s  c a n  m e d i a t e  p o s i t i v e  s e l e c t i o n ,  M H C  e x p r e s s i n g  s t r o m a l  c e l l s  
f r o m  o t h e r  t i s s u e s  c a n n o t  ( A n d e r s o n  e t  a l . ,  1 9 9 4 ) .  T h i s  s u g g e s t s  t h a t  a n  a s  y e t  
u n d i s c o v e r e d  c o - r e c e p t o r  p r e s e n t  o n l y  o n  c o r t i c a l  s t r o m a  m a y  b e  r e q u i r e d  t o  h e l p  
s t i m u l a t e  p o s i t i v e  s e l e c t i o n  i n  v i v o  ( C h i d g e y  a n d  B o y d ,  2 0 0 1 ;  H a r e  e t  a l . ,  2 0 0 2 ) .  
D P  t h y m o c y t e s  t h a t  r e c e i v e  a  s u s t a i n e d  p o s i t i v e  s e l e c t i o n  s i g n a l  ( W i l k i n s o n  e t  a l . ,  
1 9 9 5 )  u p r e g u l a t e  C D 6 9  a n d  T C R ,  d o w n r e g u l a t e  R A G  e x p r e s s i o n  a n d  m i g r a t e  
f r o m  t h e  t h y m i c  c o r t e x  t o  t h e  m e d u l l a .  I n  t h e  m e d u l l a ,  S P  t h y m o c y t e s  c o n t i n u e  t o  
d i f f e r e n t i a t e  i n t o  a  p o p u l a t i o n  w i t h  a  p h e n o t y p e  t h a t  c l o s e l y  r e s e m b l e s  p e r i p h e r a l  
T  c e l l s  ( d o w n r e g u l a t e d  C D 6 9  a n d  H S A  a n d  u p r e g u l a t e d  C D 6 2 L  a n d  Q a 2 )  ( G a b o r  
e t  a l . ,  1 9 9 7 ;  L u c a s  e t  a l . ,  1 9 9 4 ;  W a l l  a c e  e t  a l . ,  1 9 9 2 ) .  
T w o  d i s t i n c t  m o d e l s  h a v e  b e e n  p r o p o s e d  f o r  t h e  c o m m i t m e n t  o f  D P  t h y m o c y t e s  
t o  t h e  C D 4  o r  C D S  l i n e a g e  ( G e r m a i n ,  2 0 0 2 ) .  T h e  i n s t r u c t i v e  m o d e l  p r o p o s e s  t h a t  
i n t e r a c t i o n  b e t w e e n  C D 4  o r  C D S  c o - r e c e p t o r s ,  w i t h  p e p t i d e - M H C  c l a s s  I  o r  I I  
r e s p e c t i v e l y ,  i n d u c e s  c o m m i t m e n t  o f  t h e  D P  t h y m o c y t e  t o  t h e  C D 4  o r  C D S  
l i n e a g e  a n d  i n h i b i t s  t r a n s c r i p t i o n  o f  t h e  ' i n a p p r o p r i a t e '  c o - r e c e p t o r .  T h e  
s t o c h a s t i c  m o d e l  s u g g e s t s  t h a t  D P  t h y m o c y t e s  a r e  e i t h e r  p r e - c o m m i t t e d  t o  t h e  
C D 4  o r  C D S  l i n e a g e  o r  m a k e  a  l i n e a g e  c h o i c e  a t  t h e  s t a r t  o f  p o s i t i v e  s e l e c t i o n  
independently of the specificity of their TCR. In this model, after one co-receptor 
is lost, further T cell maturation is dependent on signals that require a match 
between the MHC-class specificity of the remaining co-receptor and the cell's 
TCR selection. 
Negative selection is essential for deletion of potentially self-reactive thymocytes 
and the generation of a largely self-tolerant peripheral T cell repertoire. 
Approximately S% of total DP thymocytes (pre-selection) are believed to express 
a TCR potentially capable of recognizing self-peptide-MHC ligands with 
sufficiently high affinity that they would be a potentially autoreactive T cell 
clone. These cells are instead targeted for negative selection (van Meerwijk et al., 
1997). Depending on the model system used, negative selection appears to occur 
at the immature DP stage of thymocyte differentiation and/or later at the single 
positive (SP) HSA hi semi-mature stage when thymocytes transit through the CMJ 
(Stockinger, 1999) (Figure 1.9). Mature SP HSA10 thymocytes within the medulla 
appear to be functionally similar to naive T cells in the periphery and are 
generally resistant to negative selection (Kishimoto and Sprent, 1997). 
In addition to a high affinity MHC interaction, negative selection is thought to 
require an additional co-stimulation signal(s), although the identity of such a 
signal remains elusive (Page et al., 1993; Punt et al., 1994). A number of groups 
have used activating antibodies to co-stimulatory molecules to investigate the 
role of these molecules in negative selection. Activating antibodies to CD28 can 
co-stimulate apoptosis induction in DP thymocytes (Kishimoto and Sprent, 1999; 
Punt et al., 1994) suggesting a potential role for this molecule in negative 
selection. Similarly, activating antibodies to CD28, CDS, and CD43 have been 
reported to enhance apoptosis of semi-mature (CD4 SP HSA hi) thymocytes 
(Kishimoto and Sprent, 1999). Another report used blocking antibodies to 
illustrate a role for CDS, CD80, CD86 and TNF in co-stimulation of negative 
selection (Page, 1999). In that study, addition of blocking antibodies to FTOC 
rescued the CD4+ SP thymocytes from negative selection (Page, 1999). 
I n  c o n t r a s t  t o  t h e  i n  v i t r o  a n t i b o d y  s t u d i e s  t h a t  s u g g e s t e d  t h a t  C D 2 8 ,  C D S ,  C D 8 6  
a n d  C D 8 0  c a n  c o - s t i m u l a t e  n e g a t i v e  s e l e c t i o n ,  C D 2 8 _
1
_ ,  C D S -
1
- ,  C D Y
1
- C D 2 8 _
1
_  a n d  
C D 8 0 -
1
- C D 8 6 _
1
_  m i c e  e x h i b i t e d  n o r m a l  n e g a t i v e  s e l e c t i o n  ( L i  a n d  P a g e ,  2 0 0 1 ;  
W a l u n a s  e t  a l . ,  1 9 9 6 ;  W i l l i a m s  e t  a l . ,  2 0 0 2 ) .  T h e s e  d i s c o r d a n t  r e s u l t s  s u g g e s t  a  
r e d u n d a n t  r o l e  f o r  t h e s e  m o l e c u l e s  i n  v i v o ,  o r  a l t e r n a t i v e l y  t h e  r e q u i r e m e n t  f o r  
c o - s t i m u l a t i o n  m i g h t  b e  d e p e n d e n t  o n  t h e  a f f i n i t y  o f t h e  T C R  s i g n a l  r e c e i v e d .  
1 . 5 . 2  S i g n a l i n g  f a c t o r s  c r i t i c a l  f o r  n e g a t i v e  s e l e c t i o n  
T h e  s e a r c h  f o r  t h e  a p o p t o s i s  s i g n a l i n g  p a t h w a y ( s )  i n  t h y m o c y t e  n e g a t i v e  
s e l e c t i o n  h a s  b e e n  a  l o n g - t e r m  q u e s t  f o r  T  c e l l  i m m u n o l o g i s t s .  B o t h  t h e  D R  
p a t h w a y  ( S h i ,  2 0 0 2 )  ( d e t a i l e d  i n  C h a p t e r  1 ,  L i t e r a t u r e  R e v i e w ,  S e c t i o n  1 . 5 . 3 )  a n d  
t h e  m i t o c h o n d r i a l / b c l - 2  r e g u l a t e d  p a t h w a y  t r i g g e r e d  b y  v a r i o u s  s t r e s s  s t i m u l i ,  
s u c h  a s  d e v e l o p m e n t a l  s i g n a l s  a n d  g r o w t h  f a c t o r  d e p r i v a t i o n  ( S t r a s s e r  e t  a l . ,  
2 0 0 0 ;  W a n g ,  2 0 0 1 ) ,  h a v e  b e e n  i m p l i c a t e d  i n  t h y m o c y t e  n e g a t i v e  s e l e c t i o n .  
A l t h o u g h  t h e  s i g n a l i n g  p a t h w a y ( s )  t h a t  m e d i a t e  n e g a t i v e  s e l e c t i o n  a r e  n o t  f u l l y  
u n d e r s t o o d ,  a  n u m b e r  o f  f a c t o r s  h a v e  b e e n  i d e n t i f i e d  ( F i g u r e  1 . 1  0 ) .  
V a r i o u s  s t u d i e s  s u p p o r t  a  r o l e  f o r  t h e  M A P K  p a t h w a y  i n  n e g a t i v e  s e l e c t i o n .  H i g h  
a f f i n i t y  e n g a g e m e n t  o f  t h e  T C R  w i t h  p e p t i d e - M H C  l i g a n d  l e a d s  t o  t h e  
p h o s p h o r y l a t i o n  o f  l i n k e r  f o r  a c t i v a t i o n  o f T  c e l l s  ( L A  T ) .  P h o s p h o r y l a t i o n  o f  t h e  
t y r o s i n e  a t  p o s i t i o n  1 3 6  h a s  b e e n  h y p o t h e s i z e d  t o  p l a y  a  r o l e  i n  n e g a t i v e  
s e l e c t i o n ,  a s  m u t a t i o n  o f  t h i s  t y r o s i n e  t o  a  p h e n y l a l a n i n e  r e s u l t s  i n  a u t o i m m u n e  
d i s e a s e  d e v e l o p m e n t  i n  m i c e  ( A g u a d o  e t  a l . ,  2 0 0 2 ;  S o m m e r s  e t  a l . ,  2 0 0 2 ) .  
P h o s p h o r y l a t e d  L A T  r e c r u i t s  g r o w t h - f a c t o r  r e c e p t o r - b o u n d  p r o t e i n  2  ( G R B 2 )  
t h a t  i s  t h o u g h t  t o  b e  i m p o r t a n t  f o r  n e g a t i v e  b u t  n o t  p o s i t i v e  s e l e c t i o n  ( G o n g  e t  a l . ,  
2 0 0 1 )  r e s u l t i n g  i n  a c t i v a t i o n  o f M A P K  s i g n a l i n g  p a t h w a y s  s u c h  a s  J N K  a n d  p 3 8 .  
C D 3  m A b - i n d u c e d  a p o p t o s i s  o f  J N K 2 _
1
_  t h y m o c y t e s  i s  p a r t i a l l y  d e f e c t i v e  
( S a b a p a t h y  e t  a l . ,  2 0 0 1 ) ,  J N K 1  d o m i n a n t - n e g a t i v e  m i c e  h a v e  d e f e c t s  i n  a p o p t o s i s  
I  
f o l l o w i n g  a d m i n i s t r a t i o n  o f  n e g a t i v e - s e l e c t i n g  p e p t i d e  ( R i n c o n  e t  a l . ,  1 9 9 8 )  a n d  a  
p 3 8  i n h i b i t o r  i n t e r f e r e s  w i t h  n e g a t i v e  s e l e c t i o n  i n  F T O C  e x p e r i m e n t s  ( S u g a w a r a  
e t  a l . ,  1 9 9 8 ) .  A l t h o u g h  t h e s e  e x p e r i m e n t s  i m p l i c a t e  t h e  M A P K  s i g n a l i n g  p a t h w a y  
i n  n e g a t i v e  s e l e c t i o n ,  f u r t h e r  e x p e r i m e n t s  a r e  r e q u i r e d  t o  d e t e r m i n e  t h e  i n t e r p l a y  
5 6  
Figure 1.10. Negative selection signaling pathways. A number of signaling pathways have 
been implicated in thymocyte negative selection. High affinity engagement of the TCR with 
peptide-MHC ligand, coupled with co-stimulation begins the process. This initiates the activation 
of downstream MAPK signaling pathways that are known to play a role in negative selection. 
The pro-apoptotic Bcl-2 family proteins Bim, Bax and Bak are also key mediators of negative 
selection and may lead to death of autoreactive thymocytes by activating caspases. Within the 
nucleus, members of the Nurr77/Nurrl/Norl transcription family, that are under the control of 
the upstream regulatory elements HDAC-7 and MEF2D (Dequiedt et al., 2003), promote 
negative selection, whereas NFKB is thought to inhibit the process. The question of whether 
TRAIL plays a role in negative selection is investigated in this study. Abbreviations: Bim, Bcl-2 
interacting mediator of cell death; ERK, extracellular-signal-regulated kinase; HDAC7, Histone 
deacetylase 7; IKBNS, inhibitor ofNFKB; MEF2D, myocyte enhancer factor 20; Norl, neuron-
derived orphan receptor 1; Nur77, nuclear receptor 77; RARa, retinoic-acid receptor a. Figure 
courtesy of Adam Uldrich, adapted from (Palmer, 2003). 
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between MAPK signaling pathways and other signaling cascades that ultimately 
lead to induction of negative selection. 
Both RNA and protein synthesis are important for clonal deletion (Osborne et al., 
1994). Members of the Nurr77/Nurrl/Norl transcription family promote negative 
selection, whereas NFK:B is thought to inhibit the process. Interestingly, Nur77 
does not appear to be involved in positive selection, highlighting that positive and 
negative selection are distinct processes and not outcomes of the one signaling 
pathway (Amsen et al., 1999). Stimulation of the TCR in thymocytes activates 
Nur77 transcription and negative selection is inhibited in thymocytes isolated 
from Nur77 dominant-negative mice (Calnan et al., 1995) suggesting an 
important role for this transcription factor in clonal deletion. Nur77 and family 
member Nor-1 have been shown to be structurally and functionally redundant 
(Cheng et al., 1997), which might explain the lack of a negative selection defect 
in Nur7T1- mice (Lee et al., 1995). Within the nucleus, IKBNS inhibits NFKB-
mediated transcription promoting negative selection (Fiorini et al., 2002). 
Furthermore, transcription of IKBNS is stimulated by peptides that induce 
negative selection and DP thymocytes that are sensitive to negative selection lack 
NFKB transcriptional activity (Simon et al., 2000). 
Death induced by the mitochondrial cell death pathway involves members of the 
Bcl-2 family of proteins. In resting cells, anti-apoptotic molecules of the Bcl-2 
family (Bcl-2, Bcl-xL, Bcl-w, Boo, A1, Bcl-B and Mcl-1) sequester pro-apoptotic 
'BH3-only' Bcl-2 family members such as Bim, Bad, Bid, Bik and Bmf 
(Puthalakath and Strasser, 2002) preventing them from inducing apoptosis. Upon 
receipt of an apoptotic signal, the 'BH3-only' proteins are released, allowing 
them to activate a third group of Bcl-2 family members, the pro-apoptotic 
'multidomain' or 'BH123' proteins (Bax, Bak and others). Bax and Bak can then 
permeabilize the mitochondrial outer membrane, stimulating the release of 
cytochrome c. Cytochrome c liberated from the mitochondria then binds to the 
adaptor protein AP AF -1, forming the apoptosome and activating caspase-9 which 
in turn then activates executioner caspases leading to target cell death (Green, 
2003). 
T h e  p r o - a p o p t o t i c  B c l - 2  f a m i l y  m e m b e r  B i m  i s  c r i t i c a l  f o r  t h y m i c  n e g a t i v e  
s e l e c t i o n .  B i r o - d e f i c i e n t  t h y m o c y t e s  a r e  p r o t e c t e d  f r o m  n e g a t i v e  s e l e c t i o n  
i n d u c e d  b y  T C R - C D 3  s t i m u l a t i o n  i n  v i t r o  a n d  i n  v i v o ,  s t i m u l a t i o n  w i t h  t h e  
s u p e r a n t i g e n  S E B  i n  v i t r o  o r  i n  v i v o  a n d  i n j e c t i o n  w i t h  a n t i g e n i c  p e p t i d e  i n  v i v o  
( B o u i l l e t  e t  a l . ,  2 0 0 2 ;  V i l l u n g e r  e t  a l . ,  2 0 0 4 ) .  M o r e o v e r ,  B i m  i s  r e q u i r e d  f o r  t h e  
d e l e t i o n  o f  a u t o r e a c t i v e  H Y  m a l e  a n t i g e n - s p e c i f i c  t h y m o c y t e s  i n  H Y - T C R  
t r a n s g e n i c  m i c e  ( B o u i l l e t  e t  a l . ,  2 0 0 2 ) .  T h e  p r o - a p o p t o t i c  m o l e c u l e s  B a x  a n d  B a k ,  
r e q u i r e d  b y  B i m  t o  e l i c i t  a p o p t o s i s  ( Z o n g  e t  a l . ,  2 0 0 1 ) ,  a l s o  p l a y  a  r o l e  i n  c l o n a l  
d e l e t i o n .  T h y m o c y t e s  d e f i c i e n t  i n  b o t h  B a x  p l u s  B a k  a r e  r e s i s t a n t  t o  n e g a t i v e  
s e l e c t i o n  i n d u c e d  b y  T C R - C D 3  s t i m u l a t i o n  i n  v i t r o  a n d  e n d o g e n o u s  r e t r o v i r a l  
s u p e r a n t i g e n s  i n  v i v o  ( R a t h m e l l  e t  a l . ,  2 0 0 2 ) .  T o g e t h e r ,  t h e s e  s t u d i e s  i l l u s t r a t e  t h e  
i m p o r t a n c e  o f  t h e  m i t o c h o n d r i a l / b c l - 2  r e g u l a t e d  p a t h w a y  i n  n e g a t i v e  s e l e c t i o n .  
1 . 5 . 3  R o l e  o f  t h e  T N F  s u p e r f a m i l y  i n  n e g a t i v e  s e l e c t i o n  
M e m b e r s  o f  t h e  T N F  s u p e r f a m i l y  p l a y  a  w e l l  e s t a b l i s h e d  r o l e  i n  T  c e l l  a p o p t o s i s  
w i t h i n  p e r i p h e r a l  t i s s u e s ,  h o w e v e r ,  t h e i r  r o l e  i n  t h e  t h y m u s  i s  l e s s  c l e a r .  A  
m u l t i t u d e  o f t h e s e  r e c e p t o r s  a n d  l i g a n d s  ( i n c l u d i n g :  F a s ,  T N F ,  L T ,  L I G H T ,  D R 3 ,  
C D 3 0 )  h a v e  b e e n  i n v e s t i g a t e d  f o r  t h e i r  r o l e  i n  n e g a t i v e  s e l e c t i o n  ( D e Y o u n g  e t  a l . ,  
2 0 0 0 ;  P a g e  e t  a l . ,  1 9 9 8 ;  S p r e n t  a n d  K i s h i m o t o ,  2 0 0 2 ;  W a n g  e t  a l . ,  2 0 0 1 a ;  W a n g  
e t  a l . ,  2 0 0 1 c ) .  B l o c k a d e  o f  t h e  c o - s t i m u l a t o r y  m o l e c u l e  L I G H T  u s i n g  L T j 3 R - I g  
i n h i b i t e d  n e g a t i v e  s e l e c t i o n  o f  t h y m o c y t e s ,  a n d  a p o p t o s i s  w a s  i n c r e a s e d  i n  t h e  
t h y m u s  o f  L I G H T  t r a n s g e n i c  m i c e  s u g g e s t i n g  t h a t  L I G H T  p l a y s  a  r o l e  i n  t h y m i c  
n e g a t i v e  s e l e c t i o n  ( W a n g  e t  a l . ,  2 0 0 1 c ) .  T h e  r o l e  o f  C D 3 0  i n  n e g a t i v e  s e l e c t i o n  
h a s  b e e n  c o n t r o v e r s i a l ,  w i t h  o n e  r e p o r t  s u g g e s t i n g  t h a t  C D 3 0 _
1
_  m i c e  h a v e  
i m p a i r e d  n e g a t i v e  s e l e c t i o n  o f  t h y m o c y t e s  ( A m a k a w a  e t  a l . ,  1 9 9 6 )  a n d  a n o t h e r  
s u g g e s t i n g  t h a t  n e g a t i v e  s e l e c t i o n  i s  n o r m a l  i n  t h e s e  m i c e  ( D e Y o u n g  e t  a l . ,  2 0 0 0 ) .  
M o r e o v e r ,  o n e  s t u d y  s u g g e s t e d  t h a t  C D 3 0  a c t s  a s  a  c o - s t i m u l a t o r y  m o l e c u l e  f o r  
n e g a t i v e  s e l e c t i o n  ( C h i a r l e  e t  a l . ,  1 9 9 9 ) ,  w h i l s t  a n o t h e r ,  u s i n g  a n  a c t i v a t i n g  a n t i -
C D 3 0  a n t i b o d y  s u g g e s t e d  t h a t  C D 3 0  d o e s  n o t  p r o v i d e  c o - s t i m u l a t o r y  a c t i v i t y  f o r  
a p o p t o s i s  o f  D P  t h y m o c y t e s  i n  v i t r o  ( K i s h i m o t o  a n d  S p r e n t ,  1 9 9 9 ) .  F u r t h e r  
d e t a i l e d  s t u d i e s  o f  C D 3 0 _
1
_  m i c e  a r e  n e e d e d  t o  f u l l y  d e t e r m i n e  t h e  r o l e  o f  C D 3 0  i n  
n e g a t i v e  s e l e c t i o n .  
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The TNF superfamily DRs have also been investigated. TNF blockade prevented 
the negative selection of CD4+ SP thymocytes in FTOC (Page, 1999), although 
normal negative selection has been reported in TNF1- mice (Grech et al., 2000). 
Curiously, TNFK1- mice displayed impaired negative selection in some models 
and normal negative selection in others (Page et al., 1998). Conflicting results are 
also evident for DR3, the receptor for TL1A. DR3-deficient mice exhibit normal 
negative selection in some models, but impaired negative selection in others 
(Wang et al., 2001a). A role for Fas has been reported at high, but not low, 
intensity TCR stimulation (Kishimoto et al., 1998). LT-a has also been 
investigated, but does not appear to play a role in clonal deletion (Grech et al., 
2000). Furthermore, studies by Newton and colleagues and Smith and colleagues 
suggest that negative selection occurs normally in F ADD dominant-negative 
mice (Newton et al., 1998) and in transgenic mice lacking caspase-8 function 
(Smith et al., 1996). Given that the DRs utilize these pathways to induce 
apoptosis, one might expect that these receptors do not play a role in negative 
selection. These discrepancies are difficult to explain and further studies are 
needed to explain the role of the DRs in negative selection. 
1.5 .4 Link between negative selection defects and autoimmune 
disease 
A breakdown of immunological tolerance to self-tissue may lead to the 
development of autoimmune disease. As negative selection is responsible for the 
removal of potentially autoreactive thymocytes during development, defects in 
negative selection might allow the release of self-reactive T cells into the 
peripheral pool, predisposing an individual to autoimmune disease. 
A direct relationship between failures of negative selection and the release of 
autoreactive T cells from the thymus has been demonstrated in a number of 
different models. For example, failure to delete autoreactive thymocytes, due to 
mutation of the pro-apoptotic molecule Bim, generally leads to the development 
of spontaneous autoimmune glomerulonephritis (Bouillet et al., 1999). 
Autoimmune regulator (AIRE) is a transcription factor expressed in rare thymic 
s t r o m a l  c e l l s  t h a t  i s  t h o u g h t  t o  p r o m o t e  t h e  e x p r e s s i o n  o f  s e l f - a n t i g e n s  w h o s e  
e x p r e s s i o n  i s  o t h e r w i s e  l i m i t e d  t o  t h e  p e r i p h e r y  ( H e i n o  e t  a l . ,  1 9 9 9 ) .  A I R E -
d e p e n d e n t  e x p r e s s i o n  o f  p e r i p h e r a l  a n t i g e n s  i n  t h e  t h y m u s  i s  p r e s u m e d  t o  l e a d  t o  
t h e  d e l e t i o n  o f  s e l f - r e a c t i v e  T  c e l l s ,  p r e s u m a b l y  t h r o u g h  n e g a t i v e  s e l e c t i o n .  T h u s ,  
d e f e c t s  i n  A I R E  f u n c t i o n  m a y  d i s t u r b  t h i s  p r o c e s s ,  a l l o w i n g  t h e  p e r s i s t e n c e  o f  
a u t o r e a c t i v e  T  c e l l s  t h a t  w o u l d  t y p i c a l l y  b e  n e g a t i v e l y  s e l e c t e d .  C o n s i s t e n t  w i t h  
t h i s ,  A I R E - d e f i c i e n t  m i c e  e x h i b i t  r e d u c e d  e c t o p i c  e x p r e s s i o n  o f  p e r i p h e r a l  
a n t i g e n s  b y  t h y m i c  e p i t h e l i a l  c e l l s  i n  t h e  m e d u l l a  a n d  d e v e l o p  a  s p e c t r u m  o f  
o r g a n - s p e c i f i c  a u t o i m m u n i t y  ( A n d e r s o n  e t  a l . ,  2 0 0 2 ) .  S i m i l a r l y ,  p a t i e n t s  
e x p r e s s i n g  a  d e f e c t i v e  f o r m  o f  A I R E  o f t e n  d e v e l o p  a  m u l t i - o r g a n  a u t o i m m u n e  
d i s e a s e  c a l l e d  a u t o i m m u n e  p o l y e n d o c r i n e  s y n d r o m e  t y p e  1 ,  c o n s i s t e n t  w i t h  a  l o s s  
o f  t o l e r a n c e  t o  a  v a r i e t y  o f  p e r i p h e r a l  s e l f - a n t i g e n s  ( N a g a m i n e  e t  a l . ,  1 9 9 7 ) .  
M o r e o v e r ,  a u t o r e a c t i v e  C D 4 +  T  c e l l s  w i t h  h i g h  a f f i n i t y  f o r  a  t r a n s g e n i c a l l y -
e x p r e s s e d  p a n c r e a t i c  a n t i g e n  w e r e  n o r m a l l y  d e l e t e d  i n  t h e  t h y m u s ,  b u t  w h e n  m i c e  
w e r e  b a c k c r o s s e d  t o  a n  A I R E - d e f i c i e n t  b a c k g r o u n d ,  n e g a t i v e  s e l e c t i o n  o f  t h e  
d e v e l o p i n g  c e l l s  w a s  i m p a i r e d  ( L i s t o n  e t  a l . ,  2 0 0 3 ) .  T h e s e  s t u d i e s  a r e  t h e  f i r s t  
d i r e c t  e v i d e n c e  t h a t  a u t o i m m u n i t y ,  a s  o p p o s e d  t o  t h e  s i m p l e  s u r v i v a l  o f  s e l f -
r e a c t i v e  T  c e l l s ,  c a n  b e  i n d u c e d  b y  a  d e f e c t  i n  n e g a t i v e  s e l e c t i o n .  
1 . 6  A u t o i m m u n e  d i s e a s e  
A u t o i m m u n e  d i s e a s e  r e s u l t s  f r o m  a  b r e a k d o w n  o f  i m m u n o l o g i c a l  t o l e r a n c e  t o  
s e l f - a n t i g e n s  a n d  i n c l u d e s  d i s e a s e s  o f  t h e  n e r v o u s ,  g a s t r o i n t e s t i n a l ,  a n d  e n d o c r i n e  
s y s t e m s ,  a s  w e l l  a s  s k i n  a n d  o t h e r  c o n n e c t i v e  t i s s u e s ,  e y e s ,  b l o o d ,  a n d  b l o o d  
v e s s e l s .  A p p r o x i m a t e l y  7 5  p e r c e n t  o f  a u t o i m m u n e  d i s e a s e s  o c c u r  i n  w o m e n ,  
m o s t  f r e q u e n t l y  d u r i n g  t h e  c h i l d b e a r i n g  y e a r s  ( A m e r i c a n  A u t o i m m u n e  R e l a t e d  
D i s e a s e s  A s s o c i a t i o n ) .  M a i n t e n a n c e  o f  s e l f - t o l e r a n c e  i s  a c h i e v e d  b y  a  n u m b e r  o f  
m e c h a n i s m s  i n c l u d i n g ;  n e g a t i v e  s e l e c t i o n  ( d e t a i l e d  i n  C h a p t e r  1 ,  s e c t i o n  1 . 5 . 2  
a n d  1 . 5 . 3 ) ,  s u p p r e s s i o n  o f  a u t o r e a c t i v e  l y m p h o c y t e s  a n d  f u n c t i o n a l  i n a c t i v a t i o n  
( a n e r g y ) .  M e m b e r s  o f  t h e  T N F  s u p e r f a m i l y  a r e  p o t e n t  i n d u c e r s  o f  a p o p t o s i s  a n d  
h a v e  b e e n  i m p l i c a t e d  i n  t h e  r e g u l a t i o n  o f  a u t o i m m u n e  d i s e a s e .  M u c h  o f  w h a t  i s  
u n d e r s t o o d  o f t h e  p a t h o p h y s i o l o g y  o f  a u t o i m m u n e  d i s e a s e  c a n  b e  a t t r i b u t e d  t o  t h e  
d e v e l o p m e n t  o f  e x p e r i m e n t a l  m o d e l s  o f  a u t o i m m u n e  d i s e a s e  i n  a n i m a l s .  
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1.6.1 Role of TNF superfamily molecules in autoimmune disease 
The TNF superfamily has been described as representing a double-edged sword 
(Aggarwal, 2003): whilst they are essential for normal physiological responses, 
inappropriate expression and function can be harmful as illustrated by their 
involvement in autoimmune disease. Over the last decade, much research has 
focused on understanding the role of the TNF superfamily cytokines and 
receptors in experimental models of autoimmune disease. Most of these studies 
have focused on dissecting the roles that TNF, Fas, TRAIL and LT-a play in 
EAE, autoimmune arthritis and autoimmune diabetes. Whilst TRAIL has been 
shown by a number of research groups to inhibit autoimmune disease in a variety 
of animal models, the function of other TNF superfamily members and the roles 
they might play in the control of autoimmune disease has been more 
controversial. These conflicting results may indicate the complexity of 
involvement of the TNF superfamily receptors and cytokines in autoimmune 
disease. 
Drawing a consensus from the literature regarding the roles for various TNF 
superfamily members in autoimmune disease is difficult. TNF exacerbates a 
number of autoimmune diseases by contributing to important inflammatory 
processes. TNF inhibitors ameliorate arthritis in mice by inhibiting joint 
inflammation and damage (Joosten et al., 1996; Maini et al., 1995; Williams et 
al., 1992) and are successfully being used to treat rheumatoid arthritis in humans 
(Maini et al., 1995). TNF-blockade in patients with Crohn's disease significantly 
decreases inflammation of the mucosa that is associated with disease (D'Haens, 
2003). TNF also plays a critical role in the CNS inflammatory process of mice 
immunized to develop EAE (detailed in Chapter 1, Literature Review, Section 
1.6.3.1.1) (Selmaj et al., 1995; Selmaj et al., 1991). 
The role that FasL plays in autoimmune disease is complex and might be 
explained if FasL plays a dual role in the disease process. For example, FasL 
appears to play a role in CNS destruction during the initiation stage of EAE but 
during the recovery. stage regulates autoreactive T cell activity (detailed in 
C h a p t e r  1 ,  L i t e r a t u r e  R e v i e w ,  S e c t i o n  1 . 6 . 3 . 1 . 3 )  ( D i t t e l  e t  a l . ,  1 9 9 9 ;  S a b e l k o -
D o w n e s  e t  a l . ,  1 9 9 9 ) .  F a s L - m e d i a t e d  a p o p t o s i s  o f  T  a n d  B  c e l l s  a p p e a r s  t o  
c o m m o n l y  p l a y  a  r o l e  i n  a u t o i m m u n e  d i s e a s e .  F o r  e x a m p l e ,  m i c e  a n d  h u m a n s  
w i t h  m u t a t i o n s  i n  F a s / F a s L  g e n e s  d e v e l o p  s y s t e m i c  a u t o i m m u n e  d i s e a s e s  a n d  
p r o d u c e  h i g h  l e v e l s  o f  a u t o a n t i b o d i e s  ( B e t t i n a r d i  e t  a l . ,  1 9 9 7 ;  C o h e n  a n d  
E i s e n b e r g ,  1 9 9 1 ;  S n e l l e r  e t  a l . ,  1 9 9 7 )  t h a t  m a y  t y p i c a l l y  b e  i n h i b i t e d  b y  F a s L -
m e d i a t e d  a p o p t o s i s  o f  a u t o r e a c t i v e  T  c e l l s  a n d  a n t i b o d y  p r o d u c i n g  a u t o i m m u n e  B  
c e l l  c l o n e s  r e s p e c t i v e l y  ( R i e u x - L a u c a t  e t  a l . ,  2 0 0 3 ) .  
T R A I L  h a s  c o n s i s t e n t l y  b e e n  s h o w n  t o  i n h i b i t  a u t o i m m u n e  d i s e a s e  i n  a  n u m b e r  
o f  a n i m a l  m o d e l s ,  a l t h o u g h  t h e  r o l e  i t  p l a y s  i n  e a c h  d i s e a s e  a p p e a r s  t o  v a r y .  
S t u d i e s  u s i n g  T R A I L - / - m i c e ,  s o l u b l e  T R A I L  r e c e p t o r  ( s D R 5 )  t o  b l o c k  T R A I L  
f u n c t i o n  o r  T R A I L  a d e n o v i r u s  h a v e  d e m o n s t r a t e d  t h a t  T R A I L  i n h i b i t s  
a u t o i m m u n e  a r t h r i t i s  ( L a m h a m e d i - C h e r r a d i  e t  a l . ,  2 0 0 3 b ;  S o n g  e t  a l . ,  2 0 0 0 )  a n d  
c y c l o p h o s p h a m i d e  a n d  s t r e p t o z a t o c i n - i n d u c e d  d i a b e t e s  i n  m i c e  ( L a m h a m e d i -
C h e r r a d i  e t  a l . ,  2 0 0 3 a ;  L a m h a m e d i - C h e r r a d i  e t  a l . ,  2 0 0 3 b  ) .  I n  t h e s e  s t u d i e s ,  
T R A I L  w a s  s u g g e s t e d  t o  p l a y  a  v a r i e t y  o f  r o l e s  r a n g i n g  f r o m  i n h i b i t i n g  c y t o k i n e  
a n d  a n t i b o d y  p r o d u c t i o n  t o  i n h i b i t i n g  i n f l a m m a t i o n  a n d  c e l l  c y c l e  p r o g r e s s i o n .  
M o r e  r e c e n t  s t u d i e s  h a v e  d e m o n s t r a t e d  t h a t  i n d u c t i o n  o f  T R A I L  e x p r e s s i o n  o n  
c o l l a g e n - p u l s e d  D C s  c a n  s u p p r e s s  a u t o i m m u n e  a r t h r i t i s  i n  m i c e ,  o f f e r i n g  n e w  
a n d  e x c i t i n g  p o s s i b i l i t i e s  f o r  c e l l - b a s e d  t r e a t m e n t  o f  p a t i e n t s  w i t h  a u t o i m m u n e  
d i s e a s e  ( L i u  e t  a l . ,  2 0 0 3 ) .  
1 . 6 . 2  M u l t i p l e  S c l e r o s i s  ( M S )  
M S  i s  t h e  m o s t  c o m m o n  n e u r o l o g i c a l  d i s e a s e  a f f e c t i n g  y o u n g  a d u l t s  t o d a y .  T h e  
a v e r a g e  a g e  o f  o n s e t  f o r  M S  i s  b e t w e e n  2 0 - 4 0  y e a r s  o f  a g e  a n d  w o m e n  a r e  m o r e  
c o m m o n l y  a f f e c t e d  t h a n  m e n  ( D u q u e t t e  e t  a l . ,  1 9 9 2 ;  L o w i s ,  1 9 9 0 ;  S a d o v n i c k  a n d  
E b e r s ,  1 9 9 3 ) .  M S  i s  a n  a u t o i m m u n e  d i s e a s e  t h a t  i n v o l v e s  b o t h  c e l l u l a r  a n d  
h u m o r a l  r e s p o n s e s  d i r e c t e d  a g a i n s t  p r o t e i n s  o f  t h e  m y e l i n  s h e a t h ,  s u c h  a s  M O G ,  
m y e l i n  b a s i c  p r o t e i n  ( M B P )  a n d  p r o t e o l i p i d  p r o t e i n  ( P L P )  ( A b o  e t  a l . ,  1 9 9 3 ;  
M o k h t a r i a n  e t  a l . ,  1 9 8 4 ;  S c h l u e s e n e r  e t  a l . ,  1 9 8 7 ;  S t e i n m a n ,  1 9 9 6 ) .  T h e  d i s e a s e  i s  
c h a r a c t e r i z e d  b y  a n  i n f i l t r a t i o n  o f  i n f l a m m a t o r y  c e l l s  i n t o  t h e  C N S ,  a c c o m p a n i e d  
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by localized destruction of the myelin sheath and loss of oligodendrocytes that 
form the myelin sheath (Ewing and Bernard, 1998). MS lesions contain activated 
CD4 + T cells that secrete a variety of cytokines such as IFN -y and TNF -a, B cells 
and macrophages and most patients have oligoclonal IgG bands with a specificity 
for myelin proteins in their cerebrospinal fluid (Ewing and Bernard, 1998; Raine, 
1991). Myelin-specific T cells are present in healthy individuals as well as MS 
patients, suggesting that T cell regulatory mechanisms may be defective in 
affected individuals (Markovic-Plese et al., 2001; Pette et al., 1990). 
MS symptoms include, paresis and paralysis, ataxia, fatigue, impaired vision, 
sensations of burning or prickling, cognitive impairment and incontinence (Camp 
et al., 1999; Tienari, 1994). Although the disease course is highly variable, most 
MS patients can be classed as developing either chronic progressive MS (CP-MS) 
or relapsing-remitting MS (RR-MS) (Tienari, 1994). The cause of MS is not 
known, although a genetic component exists (family members of MS patients 
have a higher probability of developing the disease) (Doolittle et al., 1990), 
environmental factors play a role (there is an increased incidence of MS with 
latitude away from the equator) (McLeod et al., 1994) and significant variations 
exist in some ethnic groups (Kurtzke, 1985). It is generally believed that the 
autoreactivity associated with MS is caused by either a failure of self-tolerance, 
or molecular mimicry, where microbe-specific T cells cross the blood-brain 
barrier and cross-react with myelin proteins (Ewing and Bernard, 1998). 
1.6.2.1 TRAIL and MS 
Most therapies for MS have focused on the use of steroids to suppress the 
inflammatory response associated with the disease (Griffiths and Newman, 
1994). Perhaps the most promising therapy currently available for MS patients is 
IFN-J3. IFN-J3 was the first drug approved by the US-FDA for the treatment of 
MS and has been shown to decrease the rate of clinical relapse in patients and 
delay disability (Ruuls and Sedgwick, 1998). The mechanism by which IFN-J3 
inhibits disease is currently being investigated, but recently TRAIL has been 
identified as a potential response marker for IFN-J3 therapy (Wandinger et al., 
1 -
I .  
2 0 0 3 ) .  P a t i e n t s  w i t h  r a i s e d  l e v e l s  o f  s o l u b l e  T R A I L  i n  t h e i r  s e r a  p r i o r  t o  IFN-~ 
t h e r a p y  a n d  t h o s e  w h o  s h o w e d  e a r l y  a n d  s u s t a i n e d  T R A I L  i n d u c t i o n  a f t e r  t h e r a p y  
w e r e  m o s t  l i k e l y  t o  r e s p o n d  t o  t r e a t m e n t  ( W a n d i n g e r  e t  a l . ,  2 0 0 3 ) .  P B L s  i s o l a t e d  
f r o m  M S  p a t i e n t s  h a v e  a l s o  b e e n  r e p o r t e d  t o  e x p r e s s  h i g h e r  l e v e l s  o f  T R A I L  t h a n  
h e a l t h y  c o n t r o l  s u b j e c t s  ( H u a n g  e t  a l . ,  2 0 0 0 ) ,  b u t  i t  h a s  y e t  t o  b e  i n v e s t i g a t e d  
w h e t h e r  l e v e l s  o f  P B L  T R A I L  e x p r e s s i o n  c o r r e l a t e  w i t h  r e s p o n s e  t o  IFN-~ 
t h e r a p y .  
R e s e a r c h e r s  h a v e  s h o w n  t h a t  a l t h o u g h  t h e  d e a t h - i n d u c i n g  T R A I L  r e c e p t o r s  
T R A I L - R 1  a n d  T R A I L - R 2  a r e  e x p r e s s e d  o n  h u m a n  M B P - s p e c i f i c  T  c e l l s  l i n e s  
d e r i v e d  f r o m  M S  p a t i e n t s  a n d  h e a l t h y  d o n o r s ,  t h e s e  c e l l s  w e r e  n o t  s u s c e p t i b l e  t o  
T R A I L - m e d i a t e d  a p o p t o s i s  i n d u c e d  b y  r T R A I L  ( W e n d l i n g  e t  a l . ,  2 0 0 0 ) .  I n  f a c t ,  
u p o n  a c t i v a t i o n  o f  t h e s e  T  c e l l s  w i t h  a n t i - C D 3  a n d  a n t i - C D 2 8 ,  e x p r e s s i o n  o f  
T R A I L - R 1  a n d  T R A I L - R 2  a c t u a l l y  d e c r e a s e d  w h e r e a s  T R A I L  e x p r e s s i o n  w a s  
i n c r e a s e d  o n  t h e s e  c e l l s  ( W e n d l i n g  e t  a l . ,  2 0 0 0 ) .  T h e s e  d a t a  s u g g e s t  t h a t  t h e  r o l e  
o f  t h e  T R A I L  r e c e p t o r s  e x p r e s s e d  o n  a u t o r e a c t i v e  T  c e l l s  i n  M S  p a t i e n t s  m i g h t  
n o t  i n v o l v e  r e g u l a t i o n  o f T  c e l l  s e n s i t i v i t y  t o  d e a t h .  
1 . 6 . 3  E x p e r i m e n t a l  a u t o i m m u n e  e n c e p h a l o m y e l i t i s  ( E A E )  
E A E  i s  a n  a n i m a l  m o d e l  w i t h  m a n y  c l i n i c a l  a n d  h i s t o p a t h o l o g i c a l  s i m i l a r i t i e s  t o  
M S .  E A E  c a n  b e  i n d u c e d  i n  a  v a r i e t y  o f  a n i m a l  s p e c i e s  i n c l u d i n g ;  m o u s e ,  r a t ,  
g u i n e a - p i g  a n d  m o n k e y .  L i k e  M S ,  E A E  i s  c h a r a c t e r i z e d  b y  a n  e a r l y  b r e a c h  o f  t h e  
b l o o d - b r a i n  b a r r i e r ,  i n f i l t r a t i o n  o f  i n f l a m m a t o r y  c e l l s  i n t o  t h e  C N S  a n d  
d e m y e l i n a t i o n  t h a t  u l t i m a t e l y  l e a d s  t o  p a r a l y s i s  o f  t h e  a n i m a l  ( B e r n a r d  e t  a l . ,  
1 9 9 2 ;  R a i n e ,  1 9 9 0 ) .  
I n  m i c e ,  E A E  c a n  b e  i n d u c e d  b y  i m m u n i z a t i o n  w i t h  m y e l i n  o r  m y e l i n  
c o m p o n e n t s ,  i n c l u d i n g  M B P ,  P L P  o r  m y e l i n  p e p t i d e s  s u c h  a s  M O G .  E A E  i s  a l s o  
i n d u c e d  b y  a d o p t i v e  t r a n s f e r  o f  M B P ,  P L P ,  o r  M O G - s p e c i f i c  C D 4 +  T h 1  T  c e l l s  
i n t o  n a i v e  r e c i p i e n t s .  T C R  t r a n s g e n i c  m i c e  t h a t  a r e  s p e c i f i c  f o r  M B P ,  P L P  a n d  
M O G  h a v e  a l s o  b e e n  g e n e r a t e d  ( L a f a i l l e  e t  a l . ,  1 9 9 4 ;  M e n d e l  e t  a l . ,  2 0 0 4 ;  
W a l d n e r  e t  a l . ,  2 0 0 0 ) .  P L P  t r a n s g e n i c  m i c e  d e v e l o p e d  s p o n t a n e o u s  E A E  
compared with only a proportion of the MBP transgenic mice, although 100% of 
the MBP transgenic mice developed spontaneous disease when crossed to RAG-
1-deficient mice. MOG transgenic mice require peptide immunization in order to 
develop the disease. 
Immune responses to MOG have been identified as critical for the development 
of demyelinating forms of EAE (Lebar et al., 1986), which might not be 
surprising, given that MOG is an oligodendrocyte transmembrane protein present 
on the outermost lamellae of the myelin sheath (Brunner et al., 1989; Lebar et al., 
1986; Linnington et al., 1984). MOG-specific antibodies, but not PLP or MBP-
specific antibodies can mediate demyelination in vitro and in vivo (Kerlero de 
Rosbo et al., 1990; Linington et al., 1988; Linington et al., 1992; Piddlesden et 
al., 1993; Schluesener et al., 1987). The immunodominant T cell responses to 
MOG in rodents are to sequences 1-20 and 35-55 (Bernard et al., 1997; Linington 
et al., 1993; Slavin et al., 1998). MOG3s-ss peptide induces a relapsing-remitting 
form of EAE in NOD/Lt mice and a chronic non-remitting paralytic disease in 
C57BL/6 mice, which is characterized by MNC infiltration into the CNS and 
multifocal demyelination in the brain and spinal cord (Bernard et al., 1997; 
Slavin et al., 1998). The relapsing-remitting course of EAE that develops in 
NOD/Lt mice is thought to best approximate the MS disease profile in humans. 
Both NK and NKT cells have been demonstrated to regulate EAE. Mice depleted 
of NK cells using anti-NK1.1 mAb, develop a more severe form of EAE 
associated with relapse and have increased MOG-specific T cell proliferation and 
cytokine production (Zhang et al., 1997). Because anti-NK1.1 mAb treatment 
deletes both NK cells and NKT cells, P2m_1_ mice lacking class !-restricted cells 
including NKT cells, CDS+ T cells and CD4-CD8- T cells were also investigated. 
Disease augmentation upon administration of anti-NK1.1 mAb also occurred in 
these mice, suggesting that NK cells can regulate EAE independently ofT, B or 
NKT cells (Zhang et al., 1997). Moreover, TCR Va14-Ja281 transgenic NOD/Lt 
mice that are enriched in CD 1 d-restricted NKT cells are protected from EAE, 
suggesting that NKT cells can naturally inhibit EAE (Mars et al., 2002). In 
addition, the therapeutic efficacy of a-GalCer (detailed in Chapter 1, Literature 
R e v i e w ,  S e c t i o n  1 . 2 . 6 . 1 )  o n  E A E  h a s  b e e n  r e c o g n i z e d  a s  N K T  c e l l - d e p e n d e n t  
( F u r l a n  e t  a l . ,  2 0 0 3 ) .  
1 . 6 . 3 . 1  R o l e  o f T N F  s u p e r f a m i l y  m o l e c u l e s  i n  E A E  
T N F  s u p e r f a m i l y  m e m b e r s  p l a y  a n  i m p o r t a n t  r o l e  i n  t h e  r e g u l a t i o n  o f  a  m u l t i t u d e  
o f  a u t o i m m u n e  d i s e a s e s  i n  h u m a n s  a n d  i n  a n i m a l  m o d e l s  o f  a u t o i m m u n e  d i s e a s e  
( d e t a i l e d  i n  C h a p t e r  1 ,  L i t e r a t u r e  R e v i e w ,  S e c t i o n  1 . 6 . 1 ) .  A b n o r m a l  r e g u l a t i o n  o f  
a p o p t o s i s  a n d  i n f l a m m a t i o n  o f  t h e  C N S  h a v e  b e e n  i m p l i c a t e d  i n  E A E .  M e m b e r s  
o f  t h e  T N F  s u p e r f a m i l y  o f  r e c e p t o r s  a n d  l i g a n d s  p l a y  a n  i m p o r t a n t  r o l e  i n  
a p o p t o s i s  a n d  m a n y  p o s s e s s  p r o - i n f l a m m a t o r y  a c t i v i t y  t h a t  m i g h t  i n f l u e n c e  t h e  
s e v e r i t y  o f  M S / E A E .  G i v e n  t h e  m u l t i t u d e  o f  c y t o k i n e s  k n o w n  t o  p l a y  a  r o l e  i n  
r e g u l a t i o n  o f  E A E  s e v e r i t y  ( R u u l s  a n d  S e d g w i c k ,  1 9 9 8 ) ,  i t  i s  p l a u s i b l e  t h a t  s o m e  
o f  t h e s e  c y t o k i n e s  e x e r t  t h e i r  e f f e c t s  b y  r e g u l a t i n g  t h e  e x p r e s s i o n  a n d  f u n c t i o n  o f  
T N F  s u p e r f a m i l y  m e m b e r s .  
1 . 6 . 3 . 1 . 1  T N F  
T h e  p r o - i n f l a m m a t o r y  c y t o k i n e  T N F ,  h a s  l o n g  b e e n  k n o w n  t o  p l a y  a  c r i t i c a l  r o l e  
i n  t h e  C N S  i n f l a m m a t o r y  p r o c e s s  a s s o c i a t e d  w i t h  M S / E A E .  O n s e t  o f  E A E  i s  
d e l a y e d  i n  T N F
1
- m i c e  a n d  c e l l  m o v e m e n t  w i t h i n  t h e  C N S  f r o m  t h e  v a s c u l a t u r e  
i n t o  t h e  p a r e n c h y m a  i s  i n e f f i c i e n t  ( K a s s i o t i s  a n d  K o l l i a s ,  2 0 0 1 ;  K o m e r  e t  a l . ,  
1 9 9 7 c ;  S e a n  R i m i n t o n  e t  a l . ,  1 9 9 8 ) .  T N F  b l o c k a d e  u s i n g  a n t i - T N F  a n t i b o d y  
( R u d d l e  e t  a l . ,  1 9 9 0 ;  S e l m a j  e t  a l . ,  1 9 9 1 )  o r  s o l u b l e  f o r m s  o f  t h e  p 5 5  r e c e p t o r  
i n h i b i t  E A E  i f  a d m i n i s t e r e d  d u r i n g  t h e  e a r l y  s t a g e s  o f  d i s e a s e  ( B a k e r  e t  a l . ,  1 9 9 4 ;  
K o m e r  e t  a l . ,  1 9 9 5 ;  S e l m a j  e t  a l . ,  1 9 9 5 ;  S e l m a j  a n d  R a i n e ,  1 9 9 5 ) .  H o w e v e r ,  
e s t a b l i s h e d  f o r m s  o f  E A E  a r e  o n l y  m i n i m a l l y  i n h i b i t e d  b y  T N F  b l o c k a d e ,  
s u g g e s t i n g  t h a t  T N F  m i g h t  o n l y  b e  c r i t i c a l  i n  t h e  i n i t i a t i o n  p h a s e  o f  t h e  d i s e a s e  
( B a k e r  e t  a l . ,  1 9 9 4 ;  K l i n k e r t  e t  a l . ,  1 9 9 7 ;  K o m e r  e t  a l . ,  1 9 9 7 b ) .  M o r e o v e r ,  T N F  
n e u t r a l i z a t i o n  i n  p r o g r e s s i v e  M S  p a t i e n t s  e x a c e r b a t e d  d i s e a s e  ( v a n  O o s t e n  e t  a l . ,  
1 9 9 6 )  s u g g e s t i n g  t h a t  T N F  m a y  p l a y  a n  i n h i b i t o r y  r o l e  i n  t h e  l a t e r  s t a g e s  o f  
d i s e a s e .  
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Long-term EAE studies have revealed that although clinical symptoms are 
initially delayed in TNF1- mice, after recovery from the acute phase of disease 
TNF1- mice develop a chronic-progressive form of the disease, unlike WT and 
p7s-1- mice that stay in remission (Kassiotis and Kollias, 2001). These studies 
suggest that TNF signaling through the p55 receptor of TNF, has an 
immunosuppressive effect that is important for the induction of tolerance during 
the later stages of disease. These findings might clarify the exacerbation of MS 
observed in progressive patients administered with TNF blocking agents. The 
outstanding question is whether blocking the function of the p55 TNFR in 
patients will inhibit inflammation yet allow the important immunosuppressive 
effects of TNF to occur in the later stages of disease. 
1.6.3.1.2 Lymphotoxin (LT)-a 
Experiments investigating the effect of LT-a on experimental models of 
autoimmune disease are difficult to interpret for several possible reasons. Firstly, 
LT-a mice have immune deficiencies such as a lack of peripheral (p)LNs and 
impaired humoral immune responses that are important for disease induction (De 
Togni et al., 1994; Koni et al., 1997), implying that differences in disease 
induction cannot be attributed solely to cytokine activity alone. Secondly, the LT-
a gene is located within the mouse MHC (Muller et al., 1987) and backcrossing 
onto strains susceptible to autoimmune disease can be problematic (Steinman, 
1997). Thirdly, many experimental models of autoimmune disease require the 
administration of pertussis toxin, which can inhibit G protein-coupled 
chemokine-receptor signaling and LT is known to play a role in control of 
chemokine levels in secondary lymphoid tissues (Cyster and Goodnow, 1995; 
Ngo et al., 1999). 
Initial studies revealed that C57BL/6 LT-a-1- mtce were resistant to EAE 
induction (Sean Riminton et al., 1998), which was not surprising, given the lack 
of LNs and impaired humoral immunity in these mice. To address the issue of 
immunocompetence, BM chimeras were generated by transfer of LT -a-1- BM into 
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i r r a d i a t e d  R A G - 1 - / - m i c e  ( S e a n  R i m i n t o n  e t  a l . ,  1 9 9 8 ) .  E A E  p r o g r e s s e d  n o r m a l l y  
i n  t h e s e  m i c e ,  s u g g e s t i n g  t h a t  L  T  - a  d o e s  n o t  c o n t r i b u t e  t o  t h e  d i s e a s e  p r o c e s s .  
H o w e v e r ,  t h e s e  s t u d i e s  w e r e  r e b u k e d  d u e  t o  t h e  u s e  o f  p e r t u s s i s  t o x i n .  T o  a d d r e s s  
t h i s  i s s u e ,  G o m m e r m a n  a n d  c o l l e a g u e s  b l o c k e d  L T  f u n c t i o n  i n  W T  m i c e  u s i n g  a  
LT~R-Ig f u s i o n  p r o t e i n  a n d  i n d u c e d  E A E  i n  t h e  a b s e n c e  o f  p e r t u s s i s  t o x i n  
( G o m m e r m a n  e t  a l . ,  2 0 0 3 ) .  A d m i n i s t r a t i o n  o f  LT~R-Ig f u s i o n  p r o t e i n  i n h i b i t e d  
M B P - i n d u c e d  E A E  i n  L e w i s  r a t s  a n d  i n h i b i t e d  r e l a p s e  o f  P L P - i n d u c e d  E A E  i n  
S J L  m i c e .  I n h i b i t i o n  o f  d i s e a s e  w a s  a s s o c i a t e d  w i t h  a  d e f e c t  i n  T  c e l l  r e s p o n s e s  
a n d  m i g r a t i o n  i n  t h e s e  a n i m a l s .  T h e  s a m e  r e s e a r c h e r s  s h o w e d  t h a t  E A E  i n d u c e d  
i n  t h e  p r e s e n c e  o f  p e r t u s s i s  t o x i n  w a s  n o t  i n h i b i t e d  b y  a d m i n i s t r a t i o n  o f  LT~R-I g  
f u s i o n  p r o t e i n  ( G o m m e r m a n  e t  a l . ,  2 0 0 3 ) ,  r e v e a l i n g  t h a t  p e r t u s s i s  t o x i n  c a n  
i n d e e d  i n h i b i t  L T - a - m e d i a t e d  r e g u l a t i o n  o f E A E .  
1 . 6 . 3 . 1 . 3  F a s L  
A l t h o u g h  l p r  a n d  g l d  m i c e  d e v e l o p  s t r a i n - d e p e n d e n t  s y s t e m i c  a u t o i m m u n e  
d i s e a s e ,  v a r i o u s  r e p o r t s  s u g g e s t  t h a t  t h e s e  m i c e  a r e  r e l a t i v e l y  r e s i s t a n t  t o  M O O -
a n d  M B P - i n d u c e d  E A E  ( M a l i p i e r o  e t  a l . ,  1 9 9 7 ;  S a b e l k o  e t  a l . ,  1 9 9 7 ;  W a l d n e r  e t  
a l . ,  1 9 9 7 ) .  W h i l s t  p r o d u c t i o n  o f  T h 1  c y t o k i n e s  a n d  i n f i l t r a t i o n  o f  i n f l a m m a t o r y  
c e l l s  i n t o  t h e  C N S  w a s  r e p o r t e d  t o  b e  n o r m a l  i n  t h e s e  m i c e ,  d e c r e a s e d  n u m b e r s  o f  
a p o p t o t i c  c e l l s  w e r e  i d e n t i f i e d  i n  C N S  i n f l a m m a t o r y  l e s i o n s ,  i m p l i c a t i n g  F a s L  i n  
t h e  t i s s u e  d e s t r u c t i o n  a s s o c i a t e d  w i t h  E A E  ( S a b e l k o  e t  a l . ,  1 9 9 7 ;  W a l d n e r  e t  a l . ,  
1 9 9 7 ) .  I n  c o n t r a s t ,  o t h e r  r e p o r t s  s u g g e s t  t h a t  E A E  i n d u c t i o n  i s  n o r m a l  i n  l p r  a n d  
g l d  m i c e  ( D i t t e l  e t  a l . ,  1 9 9 9 ;  E l l i o t t  e t  a l . ,  1 9 9 6 ) .  
A  d u a l  r o l e  f o r  F a s / F a s L  i n t e r a c t i o n s  i n  t h e  r e g u l a t i o n  o f  E A E  m i g h t  b e  e x p l a i n e d  
i f  F a s L  w a s  a b l e  t o  i n d u c e  a p o p t o s i s  i n  t a r g e t  t i s s u e  a n d  c o n t r i b u t e  t o  t h e  
r e g u l a t i o n  o f  a u t o - r e a c t i v e  T  c e l l  e x p a n s i o n  i n  v i v o .  B o t h  g l i a l  c e l l s  a n d  M B P -
r e a c t i v e  T  c e l l s  i s o l a t e d  f r o m  r a t s  e x p r e s s  b o t h  F a s  a n d  F a s L ,  a n d  c e l l  d e a t h  c a n  
b e  i n d u c e d  i n  b o t h  p o p u l a t i o n s  i n  a  P a s - d e p e n d e n t  m a n n e r ,  s u p p o r t i n g  t h i s  t h e o r y  
( S u n  e t  a l . ,  1 9 9 8 ) .  I n  a d d i t i o n ,  F a s / F a s L  e x p r e s s i o n  i s  e l e v a t e d  i n  M S  l e s i o n s  
( B o n e t t i  a n d  R a i n e ,  1 9 9 7 ;  D o w l i n g  e t  a l . ,  1 9 9 6 )  a n d  M B P - s p e c i f i c  T  c e l l s  
i s o l a t e d  f r o m  M S  p a t i e n t s  e x p r e s s  F a s  ( D ' S o u z a  e t  a l . ,  1 9 9 6 ;  P e l f r e y  e t  a l . ,  1 9 9 5 ) .  
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The dual role idea was most elegantly tested in adoptive transfer experiments, 
where MBP-specific T cells were transferred into recipient mice to induce EAE. 
When transferred T cells were isolated from gld mice, or when lpr recipients 
were used, disease was attenuated (Dittel et al., 1999; Sabelko-Downes et al., 
1999). In comparison, transfer of WT T cells into gld recipients resulted in a 
prolonged and more severe form of the disease (Dittel et al., 1999; Sabelko-
Downes et al., 1999). These results implicate FasL in the T cell-mediated tissue 
destruction associated with EAE and suggest that FasL expressed by target tissue 
can dampen immune responses. Evidence of a dual role for Fas/FasL in EAE is 
also illustrated in studies using rats administered with anti-FasL mAb. Antibody 
treatment at the onset of disease was protective, whereas treatment during the 
peak of disease prevented spontaneous recovery (Wildbaum et al., 2000). 
Together, these data indicate that FasL plays a dual role as both an effector in the 
initiation of disease and regulator during recovery from EAE. FasL can interact 
with Fas expressed on CNS elements causing massive tissue destruction and on 
infiltrating T cells helping to regulate autoreactive T cell activity. 
1. 7 Lymphoproliferative disorders 
Homeostasis of the immune system is elegantly controlled at several stages of 
lymphocyte development. Autoreactive T cells are eliminated in the thymus by 
means of negative selection (discussed in detail in Chapter 1, Literature Review, 
Sections 1.5.2 and 1.5.3) (Sebzda et al., 1999) and in the periphery through 
excess stimulation by either foreign or self-antigens (Van Parijs and Abbas, 
1998). The importance of the Fas/FasL pathway in lymphocyte homeostasis is 
clearly demonstrated in mice carrying loss of function mutations in the Fas or 
FasL genes (Adachi et al., 1993; Takahashi et al., 1994; Watanabe-Fukunaga et 
al., 1992; Watson et al., 1992) or human ALPS patients who harbor Fas/FasL 
deficiencies (Fisher et al., 1995; Rieux-Laucat et al., 1995) (Drappa et al., 1996). 
Lymphoproliferative disease in lpr, gld and ALPS patients is uniquely 
characterized by an accumulation ofB220+ DN T cells in LNs and spleen (Cohen 
and Eisenberg, 1991; Rieux-Laucat et al., 1999; Sneller et al., 1997). A large 
n u m b e r  o f  t r e a t m e n t s  h a v e  b e e n  r e p o r t e d  t o  d e c r e a s e  l y m p h o p r o l i f e r a t i v e  d i s e a s e  
a n d  t h e  a c c u m u l a t i o n  o f  D N  T  c e l l s ;  n e o n a t a l  t h y m e c t o m y ,  s p l e n e c t o m y ,  c h r o n i c  
a d m i n i s t r a t i o n  o f  c y c l o s p o r i n  A ,  5 - a z a c y t i d i n e ,  o r  S E B  a n d  c h r o n i c  t r e a t m e n t  
w i t h  m A b  s p e c i f i c  f o r  C D 4 ,  C D 8 ,  B 2 2 0  o r  T C R  V f 3 8  o r  l g M  ( A s e n s i  e t  a l . ,  1 9 8 9 ;  
C e r n y  e t  a l . ,  1 9 8 9 ;  d e  A l b o r a n  e t  a l . ,  1 9 9 2 ;  J a b s  e t  a l . ,  1 9 9 2 ;  K i m  e t  a l . ,  1 9 9 1 ;  
M o u n t z  e t  a l . ,  1 9 8 7 ;  S a n t o r o  e t  a l . ,  1 9 8 8 ;  S t e i n b e r g  e t  a l . ,  1 9 8 0 ;  Y o s h i d a  e t  a l . ,  
1 9 9 0 ) .  S o m e  A L P S  p a t i e n t s  h a v e  b e e n  c u r e d  b y  a l l o g e n e i c  B M T  ( B e n k e r r o u  e t  
a l . ,  1 9 9 7 ) .  
1 .  7 . 1  A u t o i m m u n e  l y m p h o p r o l i f e r a t i v e  s y n d r o m e  ( A L P S )  
I n  1 9 6 7 ,  a  c o n d i t i o n  c h a r a c t e r i z e d  b y  n o n m a l i g n a n t  l y m p h a d e n o p a t h i e s  
a s s o c i a t e d  w i t h  a u t o i m m u n e  f e a t u r e s  i n  c h i l d r e n  w a s  d e s c r i b e d  b y  C a n a l e  a n d  
S m i t h  ( C a n a l e  a n d  S m i t h ,  1 9 6 7 ) .  D r i v e n  b y  t h e  d i s c o v e r y  o f  F a s  a n d  F a s L  
m u t a t i o n s  i n  m i c e ,  t h e s e  c h i l d r e n  w e r e  l a t e r  i d e n t i f i e d  t o  h a v e  F a s  p a t h w a y  
m u t a t i o n s  a n d  t h e  c o n d i t i o n  w a s  n a m e d  A L P S  o r  C a n a l e - S m i t h  s y n d r o m e  
( D r a p p a  e t  a l . ,  1 9 9 6 ;  F i s h e r  e t  a l . ,  1 9 9 5 ;  R i e u x - L a u c a t  e t  a l . ,  1 9 9 5 ) .  T h e  A L P S  
c o n d i t i o n  i s  c h a r a c t e r i z e d  b y  a t  l e a s t  t h r e e  o f  t h e  f o l l o w i n g  c r i t e r i a :  s p l e n o m e g a l y  
a n d / o r  l y m p h a d e n o p a t h y ,  p r e s e n c e  o f  C D 4 - C D 8 7 C R a f 3 +  D N  T  c e l l s  i n  t h e  
b l o o d ,  a u t o i m m u n e  f e a t u r e s  a n d  h y p e r g a m m a g l o b u l i n e m a  ( R i e u x - L a u c a t  e t  a l . ,  
2 0 0 3 ) .  A  l y m p h o p r o l i f e r a t i v e  d i s e a s e  w i t h  a n  A L P S - l i k e  c l i n i c a l  p a t t e r n ,  b u t  
w i t h o u t  e x p a n s i o n  o f  D N  T  c e l l s  h a s  a l s o  b e e n  d e s c r i b e d  ( R a m e n g h i  e t  a l . ,  2 0 0 0 ) .  
P a t i e n t s  d i a g n o s e d  w i t h  A L P S  c a n  b e  s u b d i v i d e d  i n t o  t h r e e  c l a s s i f i c a t i o n s ,  
d e f i n e d  f u n c t i o n a l l y  b y  t h e  s e n s i t i v i t y  o f  t h e i r  l y m p h o c y t e s  t o  P a s - i n d u c e d  
a p o p t o s i s .  A L P S  p a t i e n t s  c a n  e x h i b i t  c o m p l e t e  F a s  d e f i c i e n c y  ( A L P S  0 ) ,  p a r t i a l  
F a s  d e f i c i e n c y  ( A L P S  I a  a n d  I I )  o r  a b s e n c e  o f  a  F a s  d e f e c t  ( A L P S  I b  a n d  I I I ) .  
T h r e e  A L P S  0  p a t i e n t s  h a v e  b e e n  d e s c r i b e d  w i t h  h o m o z y g o u s  F a s  m u t a t i o n s .  
T w o  p a t i e n t s  p o s s e s s e d  m u t a t i o n s  i n  t h e  F a s  D D  a n d  o n e  p o s s e s s e d  a  s t o p  c o d o n  
i n  t h e  e x t r a c e l l u l a r  d o m a i n  o f  F a s  l e a d i n g  t o  a  c o m p l e t e  e x p r e s s i o n  d e f e c t  
( K a s a h a r a  e t  a l . ,  1 9 9 8 ;  R i e u x - L a u c a t  e t  a l . ,  1 9 9 5 ;  v a n  d e r  B u r g  e t  a l . ,  2 0 0 0 ) .  
T h e s e  p a t i e n t s  e x p e r i e n c e d  p r e n a t a l  o n s e t  o f  t h e  c o n d i t i o n  a n d  e x h i b i t e d  v e r y  
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severe lymphoproliferation accompanied by lymphocytic infiltration into the 
lung. 
ALPS Ia is the most common form of the ALPS and is usually less severe than 
ALPS 0. Patients with ALPS Ia have heterozygous mutations of the Fas gene, 
which often yield truncated products or modified sequences. In most cases, onset 
of the condition is at 6-12 months and is characterized by defective Pas-mediated 
apoptosis of T and B cells, lymphadenopathy, hepato-splenomegaly and 
autoimmune features (Le Deist et al., 1996; Rieux-Laucat et al., 2003). Patients 
with ALPS II have defects in the Fas signaling pathway. Some of these patients 
have been shown to have mutations in caspase-10, which plays an important role 
in Fas mediated apoptosis (Wang et al., 1999). Mutations in the signaling 
molecules of other ALPS II patients are not known (Rieux-Laucat et al., 2003). 
Only one case of ALPS lb has been described. The affected patient displayed 
normal Fas expression and function, but a heterozygous mutation in the FasL 
gene (Wu et al., 1996). It has been argued that the phenotype of this patient does 
not fit the traditional criteria of classical ALPS as splenomegaly and DN T cells 
were not observed. ALPS III patients exhibit normal Fas/FasL-mediated 
apoptosis, but also exhibit a mild form of the ALPS disease 
(hypergammaglobulinemia, DN T cells) (Rieux-Laucat et al., 2003). It is thought 
that these patients may have defects in apoptotic pathways other than Fas which 
play a role in lymphocyte homeostasis, although this has not been demonstrated. 
1.7.2 Generalized lymphoproliferative disease 
Gld mice have a naturally occurring mutation in the FasL gene on chromosome 1 
(Takahashi et al., 1994; Watson et al., 1992). This point mutation localizes to the 
carboxy-terminal region of the molecule and results in expression of non-
functional FasL in these mice. Gld mice exhibit lymphadenopathy and 
splenomegaly (due to an accumulation of a population of nonmalignant 
B220+TCRa~+CD4-CD8- DN T cells), hypergammaglobulinemia, produce high 
I  
l e v e l s  o f  a u t o a n t i b o d i e s  a n d  d e v e l o p  s t r a i n - d e p e n d e n t  a u t o i m m u n e  d i s e a s e  
( C o h e n  a n d  E i s e n b e r g ,  1 9 9 1 ;  D a v i d s o n  e t  a l . ,  1 9 S 6 ) .  
T h e  m a j o r i t y  o f  D N  T  c e l l s  a m a s s i n g  i n  g l d  m i c e  d e r i v e  f r o m  C D S +  p r e c u r s o r s  
w h i c h  a r e  s e l e c t e d  i n  t h e  t h y m u s  o n  M H C  c l a s s  I  m o l e c u l e s ,  t h e  r e m a i n d e r  
e x p r e s s  l o w  l e v e l s  o f  C D 4  a n d  a r i s e  i n d e p e n d e n t l y  o f  M H C  c l a s s  I  ( C h r i s t i a n s o n  
e t  a l . ,  1 9 9 6 ;  D a v i d s o n  e t  a l . ,  1 9 9 1 ;  G i e s e  a n d  D a v i d s o n ,  1 9 9 5 ;  M a l d o n a d o  e t  a l . ,  
1 9 9 5 ;  M i x t e r  e t  a l . ,  1 9 9 5 ) .  T o t a l  n u m b e r s  o f  C D 4 +  a n d  C D S +  T  c e l l s  a n d  B  c e l l s  
a r e  a l s o  i n c r e a s e d  1  0 - f o l d  i n  g l d  L N  a n d  a r e  e n r i c h e d  f o r  m e m o r y - t y p e  T  c e l l s  
a n d  a c t i v a t e d  B  c e l l s  ( B u d d  e t  a l . ,  1 9 9 1 ;  C o h e n  a n d  E i s e n b e r g ,  1 9 9 1 ;  D a v i d s o n  e t  
a l . ,  1 9 9 1 ;  D u m o n t  e t  a l . ,  1 9 S 5 ;  G i e s e  a n d  D a v i d s o n ,  1 9 9 2 ;  R e a p  e t  a l . ,  1 9 9 6 ) .  
T r e a t m e n t  o f  C 3 H  g l d  m i c e  w i t h  a n t i - C D S  m A b  h a s  b e e n  r e p o r t e d  t o  p r e v e n t  t h e  
a c c u m u l a t i o n  o f  D N  T  c e l l s ,  b u t  n o t  a u t o a n t i b o d y  p r o d u c t i o n ,  s u g g e s t i n g  t h a t  
C D S +  T  c e l l s  p l a y  a  c r u c i a l  r o l e  i n  t h e  a c c u m u l a t i o n  o f  D N  T  c e l l s  i n  t h e s e  m i c e  
( G i e s e  a n d  D a v i d s o n ,  1 9 9 4 ) .  
C 3 H  g l d  a n d  B A L B / c  g l d  m i c e  h a v e  b e e n  r e p o r t e d  t o  d e v e l o p  p l a s m a c y t o m a s  
w i t h  a g e  ( D a v i d s o n  e t  a l . ,  1 9 9 S ) ,  s u g g e s t i n g  a  r o l e  f o r  t h e  F a s / F a s L  p a t h w a y  i n  
t h e  i n h i b i t i o n  o f  t u m o r  d e v e l o p m e n t .  F i f t y - s e v e n  p e r c e n t  o f  B A L B / c  g l d  a n d  2 S %  
o f  C 3 H  g l d  m i c e  d e v e l o p e d  p l a s m a c y t o m a s  b y  t w e l v e  m o n t h s  o f  a g e .  T u m o r s  
f r o m  t h e s e  m i c e  c o u l d  b e  t r a n s f e r r e d  a n d  g r o w n  i n  s e v e r e - c o m b i n e d  
i m m u n o d e f i c i e n t  ( s c i d )  r e c i p i e n t s ,  b u t  w e r e  r e j e c t e d  i n  W T  m i c e .  T u m o r  g r o w t h  
w a s  r e p o r t e d  i n  t h e  s p l e e n  a n d  L N ,  a n d  m e t a s t a s i z e d  t o  t h e  l i v e r ,  l u n g s  a n d  
k i d n e y  i n  m o s t  m i c e .  S o m e  t u m o r s  w e r e  a l s o  r e p o r t e d  t o  g r o w  i n  t h e  o v a r i e s  a n d  
u t e r u s .  T h e s e  f i n d i n g s  s u p p o r t  t h e  c o n t e n t i o n  t h a t  i n  a d d i t i o n  t o  p l a y i n g  a n  
i m p o r t a n t  r o l e  i n  l y m p h o c y t e  h o m e o s t a s i s ,  F a s  m a y  a l s o  p l a y  a  m a j o r  r o l e  i n  
i n h i b i t i n g  t h e  g r o w t h  o f  B  c e l l  n e o p l a s m s  ( d e t a i l e d  i n  C h a p t e r  1 ,  L i t e r a t u r e  
R e v i e w ,  S e c t i o n  1 . 3 . 4 . 3 ) .  
1 . 7 . 3  L y m p h o p r o l i f e r a t i o n  
L p r  m i c e ,  h a v e  a  n a t u r a l l y  o c c u r r i n g  a u t o s o m a l  r e c e s s i v e  m u t a t i o n  i n  t h e  F a s  
g e n e  o n  c h r o m o s o m e  1 9 .  T h e s e  m i c e  h a v e  a n  i n s e r t i o n  o f  a  r e t r o v i r a l  t r a n s p o s o n ,  
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Etn, into the second intron of Fas, preventing normal gene transcription (Adachi 
et al., 1993; Watanabe-Fukunaga et al., 1992). Like gld mice, lpr mice also 
accumulate DN T cells in LN and spleen, develop hypergammaglobulinemia, 
produce high levels of autoantibodies and develop strain-dependent autoimmune 
disease (Cohen and Eisenberg, 1991; Davidson et al., 19S6). Similarly, total 
numbers ofCD4+ and CDS+ T cells and B cells are increased 10-fold in the LN of 
lpr mice and these cells are enriched for memory-type T cells and activated B 
cells (Budd et al., 1991; Cohen and Eisenberg, 1991; Davidson et al., 1991; 
Dumont et al., 19S5; Giese and Davidson, 1992; Reap et al., 1996). Fas-deficient 
mice have also been generated and develop /pr-like disease (Senju et al., 1996). 
Like C3H gld mice, 32% of C3H lpr mice developed plasmacytomas by 12 
months of age (Davidson et al., 199S). Moreover, there have been reports of 
lymphoma development in some families of ALPS patients who exhibit Fas 
deficiency (Drappa et al., 1996; Fisher et al., 1995; Nagata, 1997; Rieux-Laucat 
et al., 1995), suggesting that the Fas/FasL pathway may play a role in inhibition 
of tumor growth. 
Lpr mice treated with anti-CDS mAb (Giese and Davidson, 1994) and lpr J32-
microglobulin-deficient mice (Maldonado et al., 1995; Ohteki et al., 1995), which 
lack MHC class I molecules, exhibit greatly reduced numbers of DN T cells, 
supporting the hypothesis that DN T cells are derived from cells of the CDS 
lineage and are selected on MHC class I. MRL lpr mice develop an autoimmune 
disease characterized by the development of glomerulonephritis and systemic 
granulomatous arteritis which is similar to systemic lupus erythematosus in 
humans (Andrews et al., 197S; Steinberg et al., 19S4; Theofilopoulos and Dixon, 
19S1). Research shows that although CDS-deficient MRL lpr mice (Koh et al., 
1995) and MRL lpr mice treated with anti-CDS mAb (Merino et al., 1995) have 
decreased proportions of DN T cells, there is no significant effect on 
development of autoimmune disease. In contrast, DN T cells rapidly accumulate 
in CD4-deficent MRL lpr mice (Chesnutt et al., 199S; Koh et al., 1995) and MRL 
lpr mice treated with anti-CD4 mAb (Merino et al., 1995), however, autoimmune 
disease is inhibited. These data suggest that although CDS+ T cells are a major 
source ofDN T cells in lpr mice, DN T cells do not play a role in development of 
a u t o i m m u n e  d i s e a s e  i n  t h e s e  m i c e .  T y p e  I  i n t e r f e r o n  r e c e p t o r  ( I F N - I R r
1
- l p r  m i c e  
d e v e l o p  a  m i l d e r  f o r m  o f  r e n a l  d i s e a s e ,  e x h i b i t  d e c r e a s e d  a c c u m u l a t i o n  o f  D N  T  
c e l l s  i n  t h e  L N  a n d  s p l e e n  a n d  h a v e  2 - f o l d  d e c r e a s e d  c o n c e n t r a t i o n s  o f  s e r u m  I g G  
c o m p a r e d  t o  I F N - I R  s u f f i c i e n t  l p r  m i c e  ( B r a u n  e t  a l . ,  2 0 0 3 ) ,  s u g g e s t i n g  t h a t  t y p e  
I  I F N s  m a y  p l a y  a  r o l e  i n  t h e  r e g u l a t i o n  o f  a u t o i m m u n e  d i s e a s e  a n d  
l y m p h o a c c u m u l a t i o n  i n  l p r  m i c e .  
1 . 8  P r o j e c t  a i m s  
G i v e n  t h e  s e l e c t i v e  a b i l i t y  o f  r T R A I L  t o  i n d u c e  d e a t h  i n  c a n c e r  c e l l s ,  b u t  n o t  
n o r m a l  c e l l s ,  t r e m e n d o u s  e x c i t e m e n t  h a s  b e e n  g e n e r a t e d  r e g a r d i n g  t h e  p o t e n t i a l  
u s e  o f  s y n t h e t i c  T R A I L  a l o n e  o r  i n  c o m b i n a t i o n  w i t h  c h e m o t h e r a p y  o r  
r a d i o t h e r a p y  f o r  c a n c e r  p a t i e n t s .  W h a t  h a s  u n d e n i a b l y  b e e n  l a c k i n g  i s  a n  i n  d e p t h  
u n d e r s t a n d i n g  o f  t h e  n a t u r a l  p h y s i o l o g i c a l  r o l e  o f  T R A I L ,  t h e  s u b j e c t  o f  w h i c h  i s  
t h e  t o p i c  o f  t h i s  t h e s i s .  T h e  a i m s  o f  t h i s  s t u d y  w e r e :  
1 1  T o  c h a r a c t e r i z e  T R A I L  e x p r e s s i o n  o n  m o u s e  l e u k o c y t e s .  
2 /  T o  d e t e r m i n e  w h e t h e r  T R A I L  p l a y s  a  r o l e  i n  N K  c e l l - m e d i a t e d  t u m o r  
i m m u n i t y .  
3 /  T o  i n v e s t i g a t e  t h e  r o l e  o f  T R A I L  a n d  T N F  i n  i m m u n o r e g u l a t i o n .  
4 /  T o  d e t e r m i n e  w h e t h e r  T R A I L  p l a y s  a  r o l e  i n  E A E .  
5 1  T o  i n v e s t i g a t e  w h e t h e r  T R A I L  p l a y s  a  r o l e  i n  n e g a t i v e  s e l e c t i o n  o f  
t h y m o c y t e s .  
I n c r e a s e d  u n d e r s t a n d i n g  o f  t h e  p h y s i o l o g i c a l  r o l e  o f  T R A I L  i s  f u n d a m e n t a l  i f  t h e  
T R A I L  p a t h w a y  i s  t o  u l t i m a t e l y  b e  u s e d  s a f e l y  a n d  w i t h  e f f i c a c y  i n  t h e  c l i n i c .  
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CHAPTER TWO 
CHARACTERIZATION OF TRAIL EXPRESSION 
IN THE MOUSE 
2 . 1  A b s t r a c t  
P r e v i o u s  s t u d i e s  i n  o u r  l a b o r a t o r y  h a v e  s h o w n  t h a t  T R A I L  i s  c o n s t i t u t i v e l y  
e x p r e s s e d  o n  a  s m a l l  s u b s e t  o f  l i v e r  N K  c e l l s  i n  a d u l t  m i c e .  H e r e i n ,  w e  r e p o r t  t h a t  
T R A I L  i s  e x p r e s s e d  o n  D X 5
1
° C D 1 1 b
1 0
L y 4 9 - C D 9 4 h i  l i v e r  N K  c e l l s ,  a  s u r f a c e  
p h e n o t y p e  p r e v i o u s l y  r e p o r t e d  a s  i m m a t u r e .  T R A I L  e x p r e s s i o n  o n  p h e n o t y p i c a l l y  
i m m a t u r e  l i v e r  N K  c e l l s  w a s  d e c r e a s e d  i n  I F N - y - d e f i c i e n t  m i c e ,  i m p l i c a t i n g  I F N -
I '  i n  t h e  r e g u l a t i o n  o f  c o n s t i t u t i v e  T R A I L  e x p r e s s i o n  i n  v i v o .  M o r e o v e r ,  t h e  
m a j o r i t y  o f  l i v e r  N K  c e l l s  i n  f e t a l ,  n e o n a t a l  a n d  2  w e e k  o l d  m i c e  e x p r e s s e d  
T R A I L  a n d  p o s s e s s e d  t h e  u n i q u e  D X 5
1
° C D 1 1 b
1 0
L y 4 9 - C D 9 4 h i  p h e n o t y p e ,  
s u g g e s t i n g  t h a t  i m m a t u r e  N K  c e l l s  p r e d o m i n a t e  i n  t h e  l i v e r  o f  n e w b o r n  m i c e .  
T R A I L  e x p r e s s i o n  w a s  a l s o  d e t e c t e d  o n  f e t a l  a n d  n e o n a t a l  s p l e e n  N K  c e l l s  a n d  
o n  n o n - t y p e  I  l i v e r  N K T  c e l l s  i n  y o u n g  m i c e .  F e t a l  l i v e r  a n d  s p l e e n  N K  c e l l s  
p r e d o m i n a n t l y  e x e r t e d  T R A I L - d e p e n d e n t  c y t o t o x i c i t y ,  w h e r e a s  l i v e r  N K  c e l l s  
i s o l a t e d  f r o m  n e o n a t a l  m i c e ,  a n d  l i v e r  M N C  i s o l a t e d  f r o m  2  w e e k  o l d  m i c e  
d e m o n s t r a t e d  T R A I L - ,  F a s L - a n d  p f p - d e p e n d e n t  c y t o t o x i c i t y .  S p l e n i c  N K  c e l l s  
i s o l a t e d  f r o m  n e o n a t a l  m i c e  d e m o n s t r a t e d  T R A I L - a n d  p f p - d e p e n d e n t  
c y t o t o x i c i t y ,  h o w e v e r  T R A I L - d e p e n d e n t  c y t o t o x i c i t y  h a d  d i m i n i s h e d  b y  2  w e e k s  
o f  a g e .  T h e s e  f i n d i n g s  i n d i c a t e d  t h a t  T R A I L  i s  t h e  k e y  e f f e c t o r  m o l e c u l e  
e x p r e s s e d  o n  f e t a l  N K  c e l l s .  M o r e o v e r ,  o u r  d a t a  s u g g e s t e d  t h a t  N K  c e l l s  a c q u i r e  
t h e  e x p r e s s i o n  o f  L y 4 9  i n h i b i t o r y  r e c e p t o r s  w h e n  t h e y  a c q u i r e  p f p  a n d  F a s l  
e f f e c t o r  f u n c t i o n .  I m p o r t a n t l y ,  w e  a l s o  d e s c r i b e  t h e  i n i t i a l  c h a r a c t e r i z a t i o n  o f  
T R A I L - d e f i c i e n t  m i c e  g e n e r a t e d  b y  g e n e - t a r g e t i n g ,  a n d  s h o w  t h a t  l i v e r  a n d  
s p l e e n  M N C  i s o l a t e d  f r o m  t h e s e  m i c e  a r e  d e v o i d  o f  T R A I L  e x p r e s s i o n  a n d  
T R A I L - m e d i a t e d  c y t o t o x i c i t y .  A n a l y s i s  o f  T R A I L - d e f i c i e n t  m i c e  a d d i t i o n a l l y  
r e v e a l e d  t h a t  T R A I L  e x p r e s s i o n  w a s  n o t  n e c e s s a r y  f o r  N K  c e l l  d e v e l o p m e n t .  
T h e s e  m i c e  w i l l  u n d o u b t e d l y  b e  o f  g r e a t  u s e  t o  f u r t h e r  d i s s e c t  t h e  p h y s i o l o g i c a l  
a n d  p a t h o l o g i c a l  r o l e s  o f  T R A I L .  
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2.2 Introduction 
TRAIL is a type II transmembrane protein and member of the TNF superfamily 
of ligands. A number of studies using rTRAIL have demonstrated the selective 
ability of TRAIL to induce apoptosis in transformed and virus-infected cells, but 
not in most normal cells, making it particularly attractive as a potential cancer 
therapeutic (Ashkenazi et al., 1999; Walczak et al., 1999). However, less is 
known of the physiological role of TRAIL or the natural expression of TRAIL at 
the protein level. It was not until the development of two key research tools, a 
neutralizing anti-mTRAIL mAb (Kayagaki et al., 1999c) and a soluble TRAIL 
receptor (DRS) (Song et al., 2000), that these questions began to be addressed. 
Initially, TRAIL expression was identified on human CD4+ T cell clones and 
these cells were demonstrated to mediate cytotoxicity against TRAIL-sensitive 
tumor cells in vitro (Kayagaki et al., 1999b; Thomas and Hersey, 1998). Later 
studies revealed a lack of TRAIL expression on freshly isolated splenic 
lymphocytes, thymocytes and cells isolated from LNs (Kayagaki et al., 1999c). In 
the same study, stimulation of T cells using anti-CD3, PHA, CD40L, 
lipopolysaccharide or PMA plus ionomycin did not induce TRAIL expression, 
although TRAIL expression could be induced on splenic NK cells after 
stimulation with IL-2 or IL-15. Peripheral blood T cells stimulated with type I 
IFNs plus anti-CD3 mAb were also identified to express TRAIL (Kayagaki et al., 
1999a), as were IFN-stimulated monocytes and DCs (Fanger et al., 1999; Griffith 
et al., 1999). More recently, TRAIL mRNA and protein were shown to be 
constitutively expressed on numerous human and mouse ocular tissues, including 
corneal endothelium and epithelium, the iris, ciliary epithelium and neurosensory 
retina (Lee et al., 2002). 
Recent studies in our laboratory have shown that TRAIL is constitutively 
expressed on a small proportion of liver NK cells in adult mice (Takeda et al., 
2001). IFN-·y-1- and IFN-yK1- mice lacked TRAIL expression, however TRAIL 
expression could be induced upon administration of riFN-y (Takeda et al., 2001 ). 
T h i s  s u g g e s t e d  t h a t  I F N - y  r e g u l a t e s  c o n s t i t u t i v e  T R A I L  e x p r e s s i o n  i n  v i v o  
( T a k e d a  e t  a l . ,  2 0 0 1 ) .  
D u r i n g  N K  c e l l  m a t u r a t i o n ,  t h e  c y t o k i n e s  t h a t  r e g u l a t e  s p e c i f i c  d e v e l o p m e n t a l  
s t a g e s ,  a n d  t h e  p h e n o t y p i c  a n d  f u n c t i o n a l  c h a r a c t e r i s t i c s  o f  e a c h  d e v e l o p m e n t a l  
i n t e r m e d i a t e  i n  v i v o ,  a r e  n o t  c l e a r l y  d e f i n e d .  A l t h o u g h  a  p o p u l a t i o n  o f  
C D 1 2 2 + N K 1 . 1 - D X Y  c o m m i t t e d  N K  c e l l  p r o g e n i t o r s  h a v e  b e e n  i d e n t i f i e d  i n  a d u l t  
B M  ( R o s m a r a k i  e t  a l . ,  2 0 0 1 ) ,  s u b s e q u e n t  s t a g e s  o f  i n  v i v o  N K  c e l l  d e v e l o p m e n t ,  
i n c l u d i n g  t h e  a c q u i s i t i o n  o f  c y t o t o x i c  m o l e c u l e s  a r e  p o o r l y  u n d e r s t o o d .  A  r e c e n t  
r e p o r t  b y  K i m  a n d  c o l l e a g u e s  i d e n t i f i e d  a  h i g h  f r e q u e n c y  o f  p h e n o t y p i c a l l y  
i m m a t u r e  N K  c e l l s  i n  t h e  l i v e r  o f  a d u l t  m i c e  ( K i m  e t  a l . ,  2 0 0 2 ) ,  r a i s i n g  t h e  
p o s s i b i l i t y  t h a t  t h e  l i v e r  m a y  a c t  a s  a  r e s e r v o i r  f o r  l e s s  d i f f e r e n t i a t e d  N K  c e l l s .  I n  
p a r a l l e l ,  i m m a t u r e  C D 1 6 1  + C D 5 6 - N K  c e l l s  i s o l a t e d  f r o m  h u m a n  u m b i l i c a l  c o r d  
b l o o d  w e r e  r e p o r t e d  t o  e x e r t  T R A I L - d e p e n d e n t  a p o p t o s i s ,  w h e r e a s  m a t u r e  
C D 1 6 1 + C D 5 6 +  N K  c e l l s  e x e r t e d  p : f p - a n d  F a s L - d e p e n d e n t  c y t o t o x i c i t y  ( Z a m a i  e t  
a l . ,  1 9 9 8 ) .  A  s i m i l a r  p o p u l a t i o n  o f  i m m a t u r e  N K  c e l l s  w e r e  l a t e r  i d e n t i f i e d  i n  
h u m a n  P B L  a n d  d e m o n s t r a t e d  t o  s e c r e t e  I L - 5 / I L - 1 3  a n d  t o  p r o l i f e r a t e  r a p i d l y  i n  
r e s p o n s e  t o  I L - 4  ( L o z a  a n d  P e r u s s i a ,  2 0 0 1 ) .  
G i v e n  t h a t  h i g h  p r o p o r t i o n s  o f  i m m a t u r e  D X 5
1
° C D l l b
1 0
L y 4 9 - C D 9 4 h i  N K  c e l l s  
h a v e  b e e n  r e p o r t e d  i n  t h e  l i v e r  o f  a d u l t  m i c e  ( K i m  e t  a l . ,  2 0 0 2 ) ,  a n d  i m m a t u r e  
h u m a n  N K  c e l l s  m e d i a t e  T R A I L - d e p e n d e n t  c y t o t o x i c i t y  ( L o z a  a n d  P e r u s s i a ,  
2 0 0 1 ;  Z a m a i  e t  a l . ,  1 9 9 8 ) ,  w e  h y p o t h e s i z e d  t h a t  i m m a t u r e  D X 5
1
° C D 1 1 b
1 0
L y 4 9 -
C D 9 4 h i  l i v e r  N K  c e l l s  i n  a d u l t  m i c e  m i g h t  b e  t h e  p o p u l a t i o n  e x p r e s s i n g  T R A I L .  
I n d e e d ,  h e r e i n  w e  r e p o r t  t h a t  T R A I L  i s  e x p r e s s e d  o n  i m m a t u r e  
D X 5
1
° C D 1 1 b
1 0
L y 4 9 - C D 9 4 h i  l i v e r  N K  c e l l s  i n  a d u l t  m i c e .  M o r e o v e r ,  T R A I L -
e x p r e s s i n g  N K  c e l l s  c o m p r i s e d  t h e  m a j o r i t y  o f  l i v e r  N K  c e l l s  i n  f e t a l ,  n e o n a t a l  
a n d  2  w e e k  o l d  m i c e .  C o n s t i t u t i v e  T R A I L  e x p r e s s i o n  w a s  a l s o  d e t e c t e d  o n  f e t a l  
a n d  n e o n a t a l  s p l e e n  N K  c e l l s  a n d  o n  n o n - t y p e  I  l i v e r  N K T  c e l l s  i n  y o u n g  m i c e .  
O u r  s t u d y  p r o v i d e s  e v i d e n c e  t h a t  T R A I L  i s  t h e  k e y  e f f e c t o r  m o l e c u l e  e x p r e s s e d  
b y  f e t a l  a n d  n e o n a t a l  N K  c e l l s .  I m p o r t a n t l y ,  w e  a l s o  d e s c r i b e  t h e  i n i t i a l  
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characterization of TRAIL-deficient mice and show that these mice are devoid of 
surface TRAIL expression and function. 
2 . 3  M a t e r i a l s  a n d  M e t h o d s  
C e l l  c u l t u r e  
T h e  B A L B / c - d e r i v e d  r e n a l  a d e n o c a r c i n o m a  c e l l  l i n e ,  R e n c a  ( k i n d l y  p r o v i d e d  b y  
D r .  T h o m a s  J .  S a y e r s ,  N a t i o n a l  C a n c e r  I n s t i t u t e ,  F r e d e r i c k ,  M D ,  U S A ) ,  t h e  a n t i -
m T R A I L  h y b r i d o m a ,  N 2 B 2  ( K a y a g a k i  e t  a l . ,  1 9 9 9 c )  ( k i n d l y  p r o v i d e d  b y  D r .  
H i d e o  Y  a g i t a ,  J u n t e n d o  U n i v e r s i t y  S c h o o l  o f  M e d i c i n e ,  T o k y o ,  J a p a n ) ,  t h e  
B A L B / c - d e r i v e d  m a m m a r y  c a r c i n o m a  c e l l  l i n e  D A 3  ( k i n d l y  p r o v i d e d  b y  
P r o f e s s o r  I a n  M c K e n z i e ,  A u s t i n  R e s e a r c h  I n s t i t u t e ,  H e i d e l b e r g ,  V i c t o r i a ,  
A u s t r a l i a )  a n d  t h e  m o u s e  Y A C - 1  l y m p h o m a  c e l l  l i n e ,  w e r e  m a i n t a i n e d  a t  3 7 ° C  
a n d  5 %  c a r b o n  d i o x i d e  ( C 0 2 )  i n  R P M I  1 6 4 0  ( I n v i t r o g e n  L i f e  T e c h n o l o g i e s  C o r p ,  
C a r l s b a d ,  C A ,  U S A )  s u p p l e m e n t e d  w i t h  1 0 %  ( v / v )  f e t a l  c a l f  s e r u m  ( F C S )  
[ C o m m o n w e a l t h  S e r u m  L a b o r a t o r i e s  ( C S L ) ,  P a r k v i l l e ,  V i c t o r i a ,  A u s t r a l i a ]  a n d  2  
m M  L - g l u t a m i n e  ( J R H  B i o s c i e n c e s ,  I : , e n e x a ,  K S ,  U S A ) .  T h e  6 - t h i o g u a n i n e  ( 6 -
T G ) - r e s i s t a n t  B A L B / c - d e r i v e d  m a m m a r y  c a r c i n o m a  c e l l  l i n e ,  4 T l . 2 ,  w a s  k i n d l y  
p r o v i d e d  b y  D r .  B e t h  P u l a s k i  ( D e p a r t m e n t  o f  B i o l o g i c a l  S c i e n c e s ,  U n i v e r s i t y  o f  
M a r y l a n d  B a l t i m o r e  C o u n t y ,  B a l t i m o r e ,  M D ,  U S A )  a n d  m a i n t a i n e d  a t  3 7 ° C  a n d  
5 %  C 0
2  
i n  a - M E M  ( I n v i t r o g e n  L i f e  T e c h n o l o g i e s  C o r p )  s u p p l e m e n t e d  w i t h  1 0 %  
F C S  a n d  2  m M  L - g l u t a m i n e .  T h e  L 9 2 9  m o u s e  f i b r o s a r c o m a  c e l l  l i n e  w a s  
m a i n t a i n e d  a t  3 7 ° C  a n d  5 %  C 0 2  i n  D u l b e c c o ' s  M o d i f i e d  E a g l e ' s  M e d i u m  
( D M E M )  ( I n v i t r o g e n  L i f e  T e c h n o l o g i e s  C o r p )  s u p p l e m e n t e d  w i t h  1 0 %  ( v / v )  F C S  
a n d  2  m M  L - g l u t a m i n e .  
M i c e  
M i c e  g e n e t i c a l l y  d e f i c i e n t  i n  T R A I L  ( T R A I L -
1
)  w e r e  g e n e r a t e d  a t  I m m u n e x  
C o r p o r a t i o n  ( S e a t t l e ,  W A ,  U S A )  b y  h o m o l o g o u s  r e c o m b i n a t i o n  i n  1 2 9 - d e r i v e d  
e m b r y o n i c  s t e m  ( E S )  c e l l s .  S e q u e n c e s  b e t w e e n  n u c l e o t i d e s  2 7 4 - 3 7 1 ,  e n c o d i n g  
a m i n o  a c i d s  7 6 - 1 1 0  o f  t h e  T R A I L  e D N A  ( W i l e y  e t  a l . ,  1 9 9 5 )  w e r e  r e p l a c e d  w i t h  
a  c a s s e t t e  c o n f e r r i n g  r e s i s t a n c e  t o ·  G 4 1 8 .  T h e  s t r u c t u r e  o f  t h e  m u t a t i o n  w a s  
c o n f i r m e d  b y  g e n o m i c  S o u t h e r n  b l o t t i n g  a n d  P C R  a n a l y s e s .  C h i m e r a s  g e n e r a t e d  
f r o m  T R A I L - t a r g e t e d  E S  c e l l s  w e r e  c r o s s e d  t o  C 5 7 B L / 6  m i c e  t o  a c h i e v e  g e r m  
l i n e  t r a n s m i s s i o n  o f  t h e  m u t a t i o n .  T h e  r e s u l t i n g  ( C 5 7 B L / 6  x  1 2 9 )  F
1  
h y b r i d s  
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were then successively backcrossed onto C57BL/6 or BALB/c backgrounds 5 
generations prior to further backcrossing at Peter Mac. 
Inbred BALB/c and C57BL/6 WT and BALB/c scid mice were purchased from 
The Walter and Eliza Hall Institute of Medical Research (WEHI) (Parkville, 
Victoria, Australia). The following gene-targeted mice were bred at Peter Mac: 
BALB/c pfP-deficient (BALB/c ptp·1-) (S back-crosses, speed mapped) (Smyth et 
al, 1999), BALB/c and C57BL/6 IFN-y-deficient (IFN-y1-) (> 10 backcrosses) 
(Dalton et al., 1993), C57BL/6 IL-12-deficient (IL-12-1) (> 10 backcrosses) 
(Magram et al., 1996), C57BL/6 IL-lS-deficient (IL-1S_1_) (> 10 backcrosses) 
(Takeda et al., 199S), C57BL/6 IL-4-deficient (IL-4_1_) (> 10 backcrosses) (The 
Jackson Laboratory, Bar Harbor, Maine, USA), C57BL/6 TNF-deficient (TNF1) 
mice (C57BL/6 ES cells) (Korner et al., 1997), C57BL/6 IFN-a-receptorl-
deficient (IFN-aRr1) (S backcrosses) and C57BL/6 IFN-a-receptor2-deficient 
(IFN-aR2·1-) (S backcrosses). C57BL/6 IFN-aR1_1_ and C57BL/6 IFN-aR2·/- mice 
were kindly provided by Drs. Paul Hertzog and Bernadette Scott (Center for 
Functional Genomics and Human Disease, Monash Institute of Reproduction and 
Development, Clayton, Victoria, Australia), C57BL/6 TNF1- mice were obtained 
from Dr. Heinrich Korner (Centenary Institute of Cancer Medicine and Cell 
Biology, Sydney, Australia). C57BL/6 RAG-2-deficient (RAG-T1) mice (Shinkai 
et al., 1992) were bred at the Juntendo University School of Medicine (Bunkyo-
ku, Tokyo, Japan). Adult mice 6-12 weeks of age were used in all experiments 
(unless otherwise stated) under specific pathogen-free conditions according to 
Animal Experimental Ethics Committee guidelines and approval. 
Reagents 
a-GalCer, a marine sponge glycolipid that activates CD 1 d-restricted NKT cells 
(Kawano et al., 1997), was provided by the Pharmaceutical Research 
laboratories, Kirin Brewery (Gunma, Japan) and prepared as described (Smyth et 
. al., 2001). a-GalCer was resuspended in saline supplemented with 0.5% 
polysorbate-20. Concanamycin A (CMA), which inhibits pfP-mediated 
cytotoxicity (Takeda et al., 2001), was purchased from Wako Pure Chemicals 
(Osaka, Japan). 
A s c i t e s  p r o d u c t i o n  a n d  p u r i f i c a t i o n  b y  c a p r y l i c  a c i d  
T o  p r o d u c e  a n t i - m T R A I L  ( N 2 B 2 )  a s c i t e s ,  6 - 1 2  w e e k  o l d  s c i d  m t c e  w e r e  
p r e t r e a t e d  w i t h  0 . 2  m l  p r i s t a n e  ( I C N  B i o m e d i c a l s  I n c ,  A u r o r a ,  O h i o ,  U S A )  o n  
d a y  - 1 0  a n d  i n j e c t e d  i . p .  o n  d a y  0  w i t h  2  x  1 0
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N 2 B 2  h y b r i d o m a  c e l l s .  M i c e  w e r e  
m o n i t o r e d  d a i l y  f o r  s i g n s  o f  a b d o m i n a l  s w e l l i n g  a n d  r u f f l e d  f u r .  A f t e r  a  p e r i o d  o f  
1 - 2  w e e k s ,  m i c e  w e r e  l i g h t l y  s e d a t e d  w i t h  m e t h o x y f l u o r a n e  ( M e d i c a l  
D e v e l o p m e n t s ,  S p r i n g v a l e ,  V i c t o r i a ,  A u s t r a l i a ) ,  a n d  a s c i t e s  f l u i d  ( 1  t o  1 . 5  m l  p e r  
m o u s e )  w a s  d r a i n e d  f r o m  t h e  p e r i t o n e u m  u s i n g  a  2 2  g a u g e  n e e d l e .  A f t e r  d r a i n i n g ,  
t h e  m i c e  w e r e  m o n i t o r e d  f o r  a n y  s i g n s  o f  s h o c k  d u e  t o  f l u i d  w i t h d r a w a l  s u c h  a s  
p a l e  e y e s ,  e a r s  a n d  m u z z l e  a n d  b r e a t h i n g  d i f f i c u l t y .  T w o  t o  t h r e e  d a y s  l a t e r ,  m i c e  
w e r e  s a c r i f i c e d  a n d  a l l  r e m a i n i n g  a s c i t e s  r e m o v e d  u s i n g  a  2 2  g a u g e  n e e d l e .  A t  
a n y  s t a g e ,  m i c e  t h a t  s h o w e d  s i g n s  o f  d e t e r i o r a t i o n  s u c h  a s  r u f f l i n g  o f  h a i r  c o a t ,  
h u d d l i n g ,  d i f f i c u l t y  i n  b r e a t h i n g ,  i n a c t i v i t y ,  l e t h a r g y  o r  l o s s  o f  w e i g h t  w e r e  
e u t h a n i z e d .  T u m o r  c e l l s  w e r e  r e m o v e d  f r o m  a s c i t e s  b y  c e n t r i f u g a t i o n  ( 2 5 0 0  r p m ,  
5  m i n . )  a n d  r e - i n j e c t e d  i n t o  o t h e r  p r i s t a n e  t r e a t e d  s c i d  m i c e .  T h i s  p r o c e d u r e  w a s  
u n d e r t a k e n  a c c o r d i n g  t o  A n i m a l  E x p e r i m e n t a l  E t h i c s  C o m m i t t e e  g u i d e l i n e s  a n d  
a p p r o v a l .  
T o  p u r i f y  a n t i - m T R A I L  ( N 2 B 2 )  m A b  f r o m  a s c i t e s ,  a n  e q u a l  v o l u m e  o f  6 0  m M  
s o d i u m  a c e t a t e  b u f f e r  ( p H  4 . 0 )  w a s  a d d e d  t o  t h e  a s c i t e s  a n d  t h e  p H  o f  t h e  t o t a l  
a n t i b o d y  p r e p a r a t i o n  a d j u s t e d  t o  4 . 8  w i t h  1  M  s o d i u m  h y d r o x i d e .  C a p r y l i c  a c i d  
( S i g m a  C h e m i c a l  C o . ,  S t L o u i s ,  M O ,  U S A )  w a s  a d d e d  t o  a  f i n a l  c o n c e n t r a t i o n  o f  
1 %  t o  p r e c i p i t a t e  t h e  m a j o r i t y  o f  p l a s m a  p r o t e i n s  w i t h o u t  a f f e c t i n g  I g G .  A f t e r  a  
p e r i o d  o f  3 0  m i n .  a t  r o o m  t e m p e r a t u r e  ( R T ) ,  t h e  a n t i b o d y  p r e p a r a t i o n  w a s  
c e n t r i f u g e d  ( 1 0 , 0 0 0  r p m ,  3 0  m i n . ,  4 ° C )  a n d  t h e  s u p e r n a t a n t  h a r v e s t e d .  O n e  m o l a r  
T r i s  ( p H  8 . 0 )  w a s  a d d e d  ( 1 / 1 0  o f  t h e  t o t a l  s u p e r n a t a n t  v o l u m e )  t o  m i n i m i z e  a c i d  
d e n a t u r a t i o n  a n d  t h e  a n t i b o d y  w a s  d i a l y z e d  a g a i n s t  p h o s p h a t e  b u f f e r e d  s a l i n e  
( P B S )  o v e r n i g h t .  A m m o n i u m  s u l p h a t e  w a s  a d d e d  ( 0 . 3 8 1  g  p e r  m l  o f  d i a l y z e d  
a n t i b o d y  s o l u t i o n ) ,  t h e  p r e p a r a t i o n  s t i r r e d  f o r  a  m i n i m u m  o f  1  h  a t  4 ° C  a n d  t h e n  
c e n t r i f u g e d  ( 1 0 , 0 0 0  r p m ,  1 5  m i n . ) .  T h e  a n t i b o d y - c o n t a i n i n g  p e l l e t  w a s  t h e n  
r e s u s p e n d e d  i n  a  m i n i m u m  v o l u m e  o f  P B S  a n d  r e - d i a l y z e d  a g a i n s t  P B S .  A f t e r  
p u r i f i c a t i o n ,  t h e  c o n c e n t r a t i o n  o f  a n t i b o d y  w a s  d e t e r m i n e d  b y  s p e c t r o p h o t o m e t r i c  
a n a l y s i s  o n  a n  E p p e n d o r f  B i o P h o t o m e t e r  ( E p p e n d o r f ,  H a m b u r g ,  G e r m a n y ) ,  a n d  
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the reactivity with mTRAIL protein tested using 2PK3-mTRAIL tranfectants and 
flow cytometric analysis. 
MNC preparation 
Spleen MNC were prepared by carefully placing the dissected spleen between 2 
glass slides and mechanically teasing out the spleen to produce a uniform cell 
suspension. Spleen cells were then washed in wash buffer (1 x PBS, 2% FCS, 
0.02% sodium azide) and resuspended in red blood cell lysis solution (Sigma 
Chemical Co.) for 5 min. to deplete red blood cells. Splenocytes were washed 
once more in wash buffer before use in all experiments. 
To isolate liver MNC, mice were asphyxiated by C02 and their livers 
immediately perfused by injection directly into the hepatic vein with 1 x PBS. 
After removal of the gall bladder, the liver was cut into small pieces, passed 
through 200 !liD wire mesh and the cells washed 3 times in wash buffer. Cells 
were then resuspended in isotonic Percoll™ (Amersham Biosciences, Uppsala, 
Sweden) (37%) and centrifuged at 693 x g for 12 min. at RT to separate 
lymphocytes from contaminating hepatocytes. Liver lymphocytes were then 
resuspended in red blood cell lysis solution for 5 min. to deplete red blood cells 
and washed prior to use in experiments. 
Flow cytometric analysis 
The following mAbs were used in multi-parameter flow cytometric analysis: anti-
mouse TRAIL-phycoerythrin (PE) or -biotin (N2B2), rat IgG2a isotype control-
PE or -biotin, anti-mouse CDllb-PE (Ml/70), anti-mouse CD3-fluoroscein 
isothiocyanate (FITC) or -Cy-Chrome (17 A2), anti-mouse NKl.l-FITC or -
biotin (PK136), anti-mouse CD49b-PE or -biotin (DX5), anti-mouse CD94-
biotin (18d3), anti-mouse Ly49A-FITC (AI), anti-mouse Ly49C/1-FITC (5E6), 
anti-mouse Ly49D-FITC (4E5), anti-mouse Ly49G2-FITC (4Dll) followed by 
incubation with streptavidin-PerCP, streptavidin-PE or streptavidin-
allophycocyanin (APC). To avoid non-specific binding of mAbs to FcyR, anti-
mouse CD16/32 (2.4G2) mAb was added to the mAb cocktail. Anti-mTRAIL-PE 
(N2B2) was obtained from e-Bioscience (San Diego, CA, USA), anti-CD8a-PE-
C y 5 . 5  f r o m  C a l t a g  L a b o r a t o r i e s  ( B u r l i n g a m e ,  C A ,  U S A )  a n d  t h e  r e m a i n i n g  
r e a g e n t s  w e r e  o b t a i n e d  f r o m  B e c t o n  D i c k i n s o n  ( B D )  B i o s c i e n c e s  P h a r m i n g e n  
( S a n  D i e g o ,  C A ,  U S A ) .  A f t e r  w a s h i n g  t h e  c e l l s  w i t h  P B S / F C S / a z i d e ,  c e l l s  w e r e  
a n a l y z e d  o n  a  F A C S c a n ™  o r  F A C S D i v a ™  ( B D  B i o s c i e n c e s  P h a r m i n g e n )  a n d  t h e  
d a t a  p r o c e s s e d  b y  e i t h e r  C E L L Q u e s t ™  ( B D  B i o s c i e n c e s  P h a r m i n g e n )  o r  F C S -
E x p r e s s  2  ( D e  N o v o  S o f t w a r e ,  T h r o m h i l l ,  O n t a r i o ,  C a n a d a )  s o f t w a r e .  P e r c e n t a g e  
o f  T R A I L +  c e l l s  w a s  d e t e r m i n e d  b y  g a t i n g  c e l l s  t h a t  s t a i n e d  p o s i t i v e  c o m p a r e d  t o  
i s o t y p e  c o n t r o l  s t a i n i n g  ( a s  d e p i c t e d  i n  F i g u r e  2 . 1 ) .  
I n t r a c e l l u l a r  f l o w  c y t o m e t r i c  a n a l y s i s  
T h e  C y t o f i x / C y t o p e r m  ™  k i t  ( B D  B i o s c i e n c e s  P h a r m i n g e n )  w a s  u s e d  t o  
p e r m e a b i l i z e  l i v e r  a n d  s p l e e n  M N C  f o r  s t a i n i n g  o f  i n t r a c e l l u l a r  p r o t e i n s .  B r i e f l y ,  
1  x  1 0
6  
f r e s h l y  i s o l a t e d  c e l l s  w e r e  w a s h e d  t w i c e  i n  s t a i n i n g  b u f f e r  ( P B S / 1 %  
F C S / 0 . 0 9 %  s o d i u m  a z i d e ) ,  t h e n  r e s u s p e n d e d  i n  C y t o f i x / C y t o p e r m ™  s o l u t i o n  f o r  
2 0  m i n .  a t  4 ° C .  C e l l s  w e r e  t h e n  w a s h e d  t w i c e  i n  P e r m / W a s h ™  s o l u t i o n ,  a n d  
i n c u b a t e d  i n  a p p r o p r i a t e  m A b  d i l u t e d  i n  P e r m / W a s h ™  s o l u t i o n  f o r  3 0 m i n .  a t  4 ° C .  
C e l l s  w e r e  t h e n  w a s h e d  t w i c e  i n  P e r m / W a s h ™  s o l u t i o n ,  r e s u s p e n d e d  i n  s t a i n i n g  
b u f f e r  a n d  a n a l y z e d  b y  f l o w  c y t o m e t r i c  a n a l y s i s .  
C e l l u l a r  c y t o t o x i c i t y  a s s a y  
T h e  c y t o t o x i c  a c t i v i t y  o f  s p l e e n  a n d  l i v e r  M N C  a g a i n s t  R e n c a ,  4 T l . 2 ,  L 9 2 9 ,  D A 3  
a n d  Y a e - l  t u m o r  t a r g e t s  w a s  t e s t e d  i n  a  5 ,  6  o r  8  h  
5 1
C r - r e l e a s e  a s s a y s .  T a r g e t  
c e l l s  ( 1  x  1  0
6
)  w e r e  h a r v e s t e d  a n d  w a s h e d  o n c e  i n  u n s u p p l e m e n t e d  R P M I  1 6 4 0  
( R e n c a ,  D A 3 ,  o r  Y a e - l ) ,  D M E M  ( L 9 2 9 )  o r  a - M E M  ( 4 T l . 2 ) .  C e l l s  w e r e  t h e n  
r e s u s p e n d e d  i n  1 0 0  I l l  u n s u p p l e m e n t e d  m e d i a  c o n t a i n i n g  1 0 0  ! l C i  s o d i u m  [
5 1
C r ]  
c h r o m a t e  ( A m e r s h a m  B i o s c i e n c e s )  a n d  i n c u b a t e d  f o r  1  h a t  3 7 ° C ,  5 %  C 0
2
•  F r e e  
5 1
C r  w a s  r e m o v e d  b y  w a s h i n g  c e l l s  3  t i m e s  i n  u n s u p p l e m e n t e d  m e d i a .  L a b e l e d  
t a r g e t  c e l l s  w e r e  t h e n  p l a t e d  o u t  i n  s u p p l e m e n t e d  m e d i a  i n  9 6 - w e l l  p l a t e s  a n d  
i n c u b a t e d  a t  v a r i o u s  e f f e c t o r  t o  t a r g e t  r a t i o s  w i t h  h e p a t i c  a n d  s p l e n i c  M N C  f o r  5 ,  
6  o r  8  h .  T h e  a s s a y  w a s  a l s o  p e r f o r m e d  i n  t h e  p r e s e n c e  o f  p u r i f i e d  c o n t r o l  r a t  
l g G 2 a  ( R 3 5 - 9 5 )  ( 1 0  ! l g / m l ) ,  a n t i - m T R A I L  ( N 2 B 2 )  m A b  ( 1 0  ! l g / m l ) ,  E G T A  ( 5  
m M )  ( S i g m a  C h e m i c a l  C o . ) ,  a n t i - m F a s L  m A b  ( M F L l )  ( 1 0  ! l g / m l )  ( k i n d l y  
p r o v i d e d  b y  D r .  H i d e o  Y  a g i t a ,  J u n t e n d o  U n i v e r s i t y  S c h o o l  o f  M e d i c i n e ,  T o k y o ,  
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Japan) and/or CMA (50 nM). After 5, 6 or 8 h incubation, plates were centrifuged 
and supernatants harvested to determine percentage 51 Cr release. Spontaneous 
51 Cr release was determined by incubating target cells in medium alone and 
maximum release was determined by the addition of sodium dodecyl sulphate to 
a final concentration of 5%. Cytotoxicity was expressed as percentage specific 
51 Cr release after subtraction of spontaneous 51 Cr release. 
Statistical analysis 
Data were analyzed using a two tailed, non-parametric, unpaired Mann Whitney 
test. P values < 0.05 were considered significant. 
2 . 4  R e s u l t s  
2 . 4 . 1  C o n s t i t u t i v e  T R A I L  e x p r e s s i o n  b y  a d u l t  l i v e r  N K  c e l l s  
P r e v i o u s l y ,  o u r  l a b o r a t o r y  h a s  d e m o n s t r a t e d  c o n s t i t u t i v e  T R A I L  e x p r e s s i o n  o n  a  
p r o p o r t i o n  o f  D X 5 + C D 3 - l i v e r  N K  c e l l s  i n  a d u l t  m i c e  ( T a k e d a  e t  a l . ,  2 0 0 1 ) .  T h e  
N K 1 . 1  m a r k e r  i s  c o m m o n l y  u s e d  t o  d e t e c t  N K  c e l l s  i n  a  n u m b e r  o f  m o u s e  
s t r a i n s .  A l t h o u g h  m o s t  l y m p h o c y t e s  t h a t  e x p r e s s  N K 1 . 1  a l s o  e x p r e s s  t h e  D X 5  
a n t i g e n ,  s m a l l  s u b s e t s  o f  D X Y N K 1 . 1  +  a n d  D X 5 + N K 1 . 1 - s u b s e t s  a r e  a l s o  f o u n d ,  
p a r t i c u l a r l y  a m o n g s t  t h e  C D 3 +  p o p u l a t i o n  ( A r a s e  e t  a l . ,  2 0 0 1 )  ( B D  B i o s c i e n c e s  
P h a r m i n g e n ,  u n p u b l i s h e d  r e s u l t s ) .  M o r e o v e r ,  D X 5  a n t i b o d y  s t a i n i n g  i s  f r e q u e n t l y  
s u b o p t i m a l  f o r  f l o w  c y t o m e t r i c  a n a l y s i s  ( o u r  o w n  u n p u b l i s h e d  o b s e r v a t i o n s ) .  
T h e r e f o r e ,  w e  c h o s e  t o  i n v e s t i g a t e  T R A I L  e x p r e s s i o n  i n  t h e  l i v e r  o f  a d u l t  
C 5 7 B L / 6  W T  m i c e  u s i n g  a n t i b o d i e s  t o  N K 1 . 1  a n d  C D 3 .  C o n s t i t u t i v e  T R A I L  
e x p r e s s i o n  w a s  d e t e c t e d  o n  a  p r o p o r t i o n  o f  f r e s h l y  i s o l a t e d  l i v e r  N K 1 . 1  + C D 3 -
c e l l s  ( 1 8 . 5  ±  4 . 5 % ) ,  b u t  n o t  o n  N K 1 T C D 3 + ,  N K 1 . 1 + C D 3 +  o r  N K 1 . 1 - C D 3 - c e l l s  
( F i g u r e  2 . 1  ) .  U s i n g  a n t i b o d i e s  t o  N K 1 . 1  a n d  C D 3 ,  w e  a l s o  s h o w e d  t h a t  T R A I L  i s  
n o t  e x p r e s s e d  o n  f r e s h l y  i s o l a t e d  s p l e e n  o r  B M  N K 1 . 1 + C D 3 - ,  N K l . r C D 3 + ,  
N K 1 . 1  + C D 3 +  o r  N K 1 . 1 - C D 3 - c e l l s  i n  a d u l t  C 5 7 B L / 6  W T  m i c e  ( F i g u r e  2 . 2 ) .  
2 . 4 . 2  I F N - y  r e g u l a t e s  c o n s t i t u t i v e  T R A I L  e x p r e s s i o n  i n  v i v o  
T o  a s c e r t a i n  w h e t h e r  c y t o k i n e s  r e g u l a t e  T R A I L  e x p r e s s i o n  o n  l i v e r  N K  c e l l s ,  
c o n s t i t u t i v e  T R A I L  e x p r e s s i o n  w a s  e v a l u a t e d  i n  v a r i o u s  c y t o k i n e - d e f i c i e n t  m i c e .  
A l t h o u g h  T a k e d a  a n d  c o l l e a g u e s  h a d  p r e v i o u s l y  r e p o r t e d  t h a t  a d u l t  I F N - ' ) ' -
d e f i c i e n t  m i c e  a r e  d e v o i d  o f  l i v e r  N K  c e l l  T R A I L  e x p r e s s i o n  ( T a k e d a  e t  a l . ,  
2 0 0 1 ) ,  w e  d e t e c t e d  T R A I L  e x p r e s s i o n  o n  a  m i n o r  p r o p o r t i o n  ( 5 . 5  ±  4 . 5 % )  o f  
l i v e r  N K  c e l l s  i n  a d u l t  I F N - ' ) ' - d e f i c i e n t  m i c e  ( F i g u r e  2 . 3 ) .  N o n e t h e l e s s ,  
p r o p o r t i o n s  o f  T R A I L +  h e p a t i c  N K  c e l l s  i n  a d u l t  C 5 7 B L / 6  I F N - y
1
- m i c e  w e r e  
s i g n i f i c a n t l y  d e c r e a s e d  c o m p a r e d  t o  C 5 7 B L / 6  W T  m i c e  ( 1 8 . 5  ±  4 . 5 % )  ( P  <  0 . 0 5 ,  
F i g u r e  2 . 3 ) .  T R A I L  e x p r e s s i o n  w a s  a d d i t i o n a l l y  e v a l u a t e d  i n  I L - 1 2 - ,  I L - 1 8 - ,  
I L 1 2  I L 1 8 - ,  I L - 4 - ,  T N F - ,  I F N a R 1 - a n d  I F N a R 2 - d e f i c i e n t  m i c e ,  a l t h o u g h  
d e f i c i e n c y  o f  t h e s e  c y t o k i n e s / c y t o k i n e  r e c e p t o r s  h a d  n o  s i g n i f i c a n t  e f f e c t  o n  a d u l t  
l i v e r  N K  c e l l  T R A I L  e x p r e s s i o n  ( A p p e n d i x  I ) .  T o g e t h e r ,  t h e s e  d a t a  s u g g e s t  t h a t  
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Figure 2.1. Constitutive TRAIL expression by mouse liver NK cells. Liver MNC isolated from 
adult C57BL/6 mice were stained with antibodies to CD3, NKl.l and TRAIL or isotype control 
mAb. The Rl gate comprises NK1.1+Co3- cells, R2 comprises NK1.1-CD3+ cells, R3 comprises 
NKl.l +CD3+ cells and R4 comprises NKl XCD3- cells. Histograms demonstrate TRAIL/isotype 
control antibody staining on the gated MNC populations (Rl-R4). Red lines represent staining 
with anti-mTRAIL mAb, black lines represent staining with isotype matched control mAb. 
Percentage of TRAie cells was determined by gating cells (see gate Ml) that stained positive 
compared to isotype control. Data are representative of over 20 independent experiments. 
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F l u o r e s c e n c e  I n t e n s i t y  
F i g u r e  2 . 2 .  A b s e n c e  o f  c o n s t i t u t i v e  T R A I L  e x p r e s s i o n  b y  s p l e e n  a n d  b o n e  m a r r o w  ( B M )  
m o n o n u c l e a r  c e l l s  ( M N C ) .  S p l e n o c y t e s  a n d  B M  M N C  i s o l a t e d  f r o m  a d u l t  C 5 7 B L / 6  m i c e  w e r e  
s t a i n e d  w i t h  a n t i b o d i e s  t o  C D 3 ,  N K l . l  a n d  T R A I L  o r  i s o t y p e  c o n t r o l  m A b .  H i s t o g r a m s  
d e m o n s t r a t e  T R A I L ! i s o t y p e  c o n t r o l  a n t i b o d y  s t a i n i n g  o n  N K l . l + C D 3 - ,  N K l . l + C D 3 \  N K l . r  
C D 3 +  a n d  N K l  X C D 3 - c e l l s  i s o l a t e d  f r o m  t h e  s p l e e n  a n d  B M .  R e d  l i n e s  r e p r e s e n t  s t a i n i n g  w i t h  
a n t i - m T R A I L  m A b ,  b l a c k  l i n e s  r e p r e s e n t  s t a i n i n g  w i t h  i s o t y p e  m a t c h e d  c o n t r o l  m A b .  D a t a  a r e  
r e p r e s e n t a t i v e  o f  6  i n d e p e n d e n t  e x p e r i m e n t s  f o r  s p l e e n  a n d  2  f o r  B M .  
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Figure 2.3. IFN-y regulates constitutive TRAIL expression in vivo. Liver MNC isolated from 
adult C57BL/6 and C57BL/6 IFN-"( mice were stained with antibodies to CD3, NKl.l and 
TRAIL or isotype control mAb. Histograms demonstrate TRAIL/isotype control staining on gated 
NK1.1+CD3' cells. Red lines represent staining with anti-mTRAIL mAb, black lines represent 
staining with isotype matched control mAb. Percentage of TRAIL+ cells was determined by 
gating cells that stained positive over isotype control staining. Data are representative of the 
analysis of 20 C57BL/6 and 10 C57BL/6 IFN-y1· mice. Numbers represent mean± standard error 
ofthe mean (SEM) ofpercentage TRAIL+ cells. 
e n d o g e n o u s l y  p r o d u c e d  I F N - y  i s  a n  i m p o r t a n t  m a i n t e n a n c e  f a c t o r  f o r  c o n s t i t u t i v e  
T R A I L  e x p r e s s i o n  i n  t h e  l i v e r .  
2 . 4 . 3  S u r f a c e  p h e n o t y p e  o f  T R A I L - e x p r e s s i n g  a d u l t  l i v e r  N K  c e l l s  
W e  n e x t  c h o s e  t o  i n v e s t i g a t e  w h e t h e r  T R A I L +  l i v e r  N K  c e l l s  i n  a d u l t  C 5 7 B L / 6  
W T  m i c e  d i s p l a y e d  a n  i m m a t u r e  p h e n o t y p e  a s  p r e v i o u s l y  d e f i n e d  b y  K i m  a n d  
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Figure 2.4. TRAIL expression by DX51°CD11b10Ly49-CD94hi liver NK cells. Liver MNC 
isolated from adult C57BL/6 mice were stained with combinations of antibodies to CD3, NKI.l, 
DX5, CDII b, Ly49s (A, C/1, G2, D), CD94, TRAIL or isotype control mAb. Histograms 
represent DX5, CDII b, Ly49s and CD94 staining (bold lines) or isotype control staining (thin 
lines) on whole liver NK cells (NKI.l +CD3"), TRAIL- liver NK cells and TRAIL+ liver NK cells. 
Percentage of positively stained cells was determined by gating cells that stained positive 
compared to isotype control staining. Data are representative of2 independent experiments. 
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2.4.5 Inter-strain comparison of TRAIL expression by NK cells 
We next compared constitutive TRAIL expression in the liver of adult C57BL/6 
WT and BALB/c WT mice. As NKl.l is not expressed in BALB/c WT mice, 
antibodies to IL-2 receptor ~ chain (IL-2R~) (CD122) and CD3 were used to 
investigate TRAIL expression in the liver. IL-2R~ is expressed on all NK cells, a 
subset of CDS+ spleen T cells, and a small population of resting B cells. 
Moreover, early NK cell precursors express the IL-2R~ chain before acquiring 
NKl.l expression (lkawa et al., 1999; Rosmaraki et al., 2001; Williams et al., 
2000; Williams et al., 1997). Constitutive TRAIL expression was demonstrated 
on a proportion of freshly isolated liver IL-2R~+CDT NK cells, but not on IL-
2RWCD3+, IL-2R~+CD3+ or IL-2RWCD3- cells in C57BL/6 WT and BALB/c 
WT mice (Figure 2.6). Although proportions and absolute cell numbers of IL-
2R~+CD3- liver NK cells were equivalent in both strains of mice, proportions of 
TRAIL+IL-2R~+CD3- liver NK cells were significantly higher in C57BL/6 WT 
(36.6 ± 0.9%) compared to BALB/c WT (7.5 ± 1.2%) mice (P < 0.05, Figure 
2.6). Phenotypic analysis confirmed that TRAIL expression was restricted to 
DXYIL-2R~+CD3- NK cells in C57BL/6 WT and BALB/c WT mice (Figure 
2. 7). TRAIL was expressed on a higher proportion of DX5-IL-2R~+CD3- NK 
cells in C57BL/6 WT (63.5 ± 0.5%) compared to BALB/c WT (26.9 ± 2.2%) 
mice (P < 0.05, Figure 2. 7). These data suggest that constitutive TRAIL 
expression detected on IL-2R~+CD3- liver NK cells is higher in C57BL/6 WT 
compared to BALB/c WT mice. 
2.4.6 Increased TRAIL expression by NK cells in young mice 
Given that TRAIL+ liver NK cells expressed a surface phenotype previously 
described as "immature", we examined whether such NK cells were prevalent in 
the early stages of immune system development in fetal and neonatal mice. Fetal 
and neonatal splenic NK cells are devoid of Ly49A/C/G2/D/ and I expression, 
although Ly49 expression gradually increases from 1 week of age and reaches 
adult levels by 6-8 weeks of age (Dorfman and Raulet, 1998; Salcedo et al., 2000; 
Sivakumar et al., 1997). In contrast, Ly49E is highly expressed on fetal NK cells, 
but decreases dramatically after birth (Van Beneden et al., 2001). In addition, 
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Figure 2.7. TRAIL expression by IL-2Rf3+CD3"DX5" cells within the liver. Liver MNC 
isolated from adult C57BL/6 or BALB/c mice were stained with antibodies to CD3, IL-2Rf3, DX5 
and TRAIL or isotype control mAb. Histograms demonstrate TRAIL/isotype control antibody 
staining on IL-2Rf3+CD3"DX5" and IL-2Rf3+CD3"DX5+ cells within the liver. Red lines represent 
staining with anti-mTRAIL mAb, black lines represent staining with isotype matched control 
mAb. Percentage ofTRAIL+ cells was determined by gating cells that stained positive compared 
to isotype control staining. Data are representative of2 independent experiments. 
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Figure 2.8. Increased constitutive TRAIL expression in the liver and spleen of young mice. 
Liver and spleen MNC isolated from fetal (embryo day 17), neonatal, and 2, 4 and 8 week old 
C57BL/6 mice were stained with antibodies to CD3, NKl.l and TRAIL or isotype control mAb. 
Histograms demonstrate TRAIL/isotype control antibody staining on NKl.l +CD3- cells. Red lines 
represent staining with anti-mTRAIL mAb, black lines represent staining with isotype matched 
control mAb. Percentage of TRAIL+ cells was determined by gating cells that stained positive 
compared to isotype control staining. Data are representative of the analysis of 4 mice at each 
time point. 
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were observed in the spleen compared to adult mice (Figure 2.1 0). This suggested 
that immature DX51°CD1lb10Ly49-CD94hi spleen NK cells express TRAIL, 
although these cells rapidly decreased in proportion after birth. 
Given that IFN-y had previously been implicated in the regulation of constitutive 
TRAIL expression in vivo (Takeda et al., 2001 ), we assessed liver NK cell 
TRAIL expression in C57BL/6 IFN-y1- mice at 2, 4 and 8 weeks of age. 
Proportions of TRAIL+ liver NK cells in 2 week old C57BL/6 IFN-y1- mice (45.4 
± 1.4%) and 4 week old C57BL/6 IFN-y1- mice (47.3 ± 2.4%) were significantly 
elevated compared to proportions of these cells in adult C57BL/6 IFN-y1- mice 
(5.5 ± 4.5%) (P < 0.03), but were decreased compared to C57BL/6 WT mice of 
the same age (Figure 2.11 ). These data confirm a requirement for IFN -y in the 
maintenance of constitutive TRAIL expression on liver NK cells during adult 
life. However, IFN-y is not absolutely required for constitutive TRAIL expression 
in vivo. 
2.4.7 TRAIL expression by non-type I natural killer T (NKT) cells in young 
mice 
To date, the only lymphocyte populations reported to constitutively express 
TRAIL are a proportion of liver NK cells in adult mice (Takeda et al., 2001) 
(Figure 2.1 ), and fetal/neonatal liver and spleen NK cells reported in the present 
study (Figure 2.8). As TRAIL expression is increased on NK cells isolated from 
fetal, neonatal and young mice, we examined whether TRAIL is expressed on 
other liver and spleen MNC populations in 2, 4 and 8 week old C57BL/6 WT 
mice. Our study determined that TRAIL was not expressed on NK1.1TD3+ or 
NK1.1-CD3- cells in the spleen or liver of 2, 4 or 8 week old mice, nor was 
TRAIL expressed on NK1.1+CD3+ cells in the spleen (data not shown). In 
contrast, TRAIL expression was detected on liver NK1.1 hiCD3hi cells in 2 week 
·old C57BL/6 mice (Figure 2.12A), although NK1.1 1°CD310 cells in 4 and 8 week 
old C57BL/6 mice lacked TRAIL expression (Figure 2.12A). TRAIL expression 
was also assessed on NK1.1 +CD3+ cells isolated from 2, 4 and 8 week old 
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S p l e e n  M N C  i s o l a t e d  f r o m  C 5 7 B L / 6  2  o r  > 8  w e e k s  o f  a g e  w e r e  s t a i n e d  w i t h  c o m b i n a t i o n s  o f  
a n t i b o d i e s  t o  C D 3 ,  N K l . l ,  D X 5 ,  C D l l  b ,  L y 4 9 s  ( A ,  C / I ,  G 2 ,  D ) ,  T R A I L  o r  i s o t y p e  c o n t r o l  m A b .  
H i s t o g r a m s  r e p r e s e n t  D X 5 ,  C D l l  b ,  a n d  L y 4 9 s  s t a i n i n g  o n  w h o l e  s p l e e n  N K  c e l l s  i s o l a t e d  f r o m  2  
a n d  8  w e e k  o l d  m i c e .  D a t a  a r e  r e p r e s e n t a t i v e  o f 2  i n d e p e n d e n t  e x p e r i m e n t s .  
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Figure 2.11. Decreased constitutive TRAIL expression in the liver of IFN-y-deficient mice. 
Liver MNC isolated from C57BL/6 WT or C57BL/6 IFN-y1- mice 2, 4 or > 8 weeks of age were 
stained with antibodies to CD3, NKl.l and TRAIL or isotype control mAb_ Percentage TRAIL 
expression on liver NKl.l +CD3- cells from C57BL/6 or C57BL/6 IFN-y1- mice is shown at 2, 4 
and >8 weeks of age. Data represent mean± SEM for 4 C57BL/6 and 4 C57BL/6 IFN-y-deficient 
mice at 2 and 4 weeks of age, and 8 C57BL/6 and 8 C57BL/6 IFN-y-deficient mice at 8 weeks of 
age. Asterisks indicate the groups if mice that are significantly different(* P < 0.03). 
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F i g u r e  2 . 1 2 .  C o n s t i t u t i v e  T R A I L  e x p r e s s i o n  b y  l i v e r  N K 1 . 1 + C D 3 +  c e l l s  i n  y o u n g  m i c e .  L i v e r  
M N C  i s o l a t e d  f r o m  C 5 7 B L / 6  o r  C 5 7 B L / 6  I F N - y
1
- m i c e  2 ,  4  o r  > 8  w e e k s  o f  a g e  w e r e  s t a i n e d  w i t h  
a n t i b o d i e s  t o  C D 3 ,  N K l . l  a n d  T R A I L  o r  i s o t y p e  c o n t r o l  m A b .  R e p r e s e n t a t i v e  C D 3  v e r s u s  N K l . l  
F  A C S  p r o f i l e s  a n d  h i s t o g r a m s  d e m o n s t r a t i n g  T R A I L ! i s o t y p e  c o n t r o l  a n t i b o d y  s t a i n i n g  o n  g a t e d  
N K l . l  + C D 3 +  c e l l s  f r o m  ( A )  C 5 7 B L / 6  m i c e  o r  ( B )  C 5 7 B L / 6  I F N - " (  m i c e  a t  2 ,  4  a n d >  8  w e e k s  o f  
a g e  a r e  s h o w n .  R e d  l i n e s  r e p r e s e n t  s t a i n i n g  w i t h  a n t i - m T R A I L  m A b ,  b l a c k  l i n e s  r e p r e s e n t  
s t a i n i n g  w i t h  i s o t y p e  m a t c h e d  c o n t r o l  m A b .  G a t e d  N K 1 . l + C D 3 +  c e l l s  a r e  s h o w n  o n  t h e  F A C S  
p r o f i l e s .  D a t a  a r e  r e p r e s e n t a t i v e  o f  t h e  a n a l y s i s  o f  a  m i n i m u m  o f  4  C 5 7 B L 6  a n d  4  C 5 7 B L / 6  I F N -
' " (  m i c e  a t  e a c h  t i m e  p o i n t .  
1 0 4  
C57BL/6 IFN-y1- mice (Figure 2.12B). Equivalent proportions of TRAIL-
expressing NK1.1 hiCD3hi cells were detected in 2 week old C57BL/6 IFN-y-
deficient mice (Figure 2.12B) compared to C57BL/6 WT mice at the same age 
(Figure 2.12A). This suggested that IFN-y was not critical for the regulation of 
constitutive TRAIL expression on mouse NK1.1 hiCD3hi cells. 
Although NK1.1 is considered a reliable marker for identification of NKT cells, 
some conventional CDSa~+ T cells can acquire NK1.1 expression upon 
activation (Emoto and Kaufmann, 2003). The vast majority of activated CDS+ T 
cells that acquire NK1.1 expression co-express CDSa and CDS~, whereas most 
CDS+ NKT cells express CDSa but not CDS~. To ascertain whether TRAIL-
expressing NK1.1 hiCD3hi cells in 2 week old mice were NKT cells or activated T 
cells that had acquired NK1.1 expression, CDSa and CDS~ expression was 
examined on these cell populations. A small proportion of NK1.1 hiCD3hi cells in 
2 week old mice expressed CD4 ( 4.6 .± 0.5 %), negligible NK1.1 hiCD3hi cells 
expressed CDS~ and 51.4 .± 1.3 % expressed CDSa (Figure 2.13). The lack of 
CDS~ staining on NK1.1 hiCD3hi cells in 2 week old mice suggested that these 
cells are NKT cells, rather than activated CDS+ T cells that have acquired NK1.1 
expressiOn. 
Classical (type I) NKT cells are CD4+ or CD4-cDs-, express the invariant Va14-
Ja1S TCR, are restricted by CD1d, and are most abundant in the liver (Emoto et 
al., 1995; Ohteki and MacDonald, 1994; Godfrey et al., 2004). Although the 
naturalligand(s) for classical (type I) NKT cells are unknown, a-GalCer isolated 
from a marine sponge can act as a specific CD 1 d-restricted ligand for these cells 
(Kawano et al., 1997). We therefore examined whether TRAIL is expressed on 
classical NKT cells in the liver of2 week old mice using a-GalCer-loaded CD1d 
tetramer to specifically identify these cells. a-GalCer tetramer bound to 1.9 ± 
0.3% of total liver MNC from 2 week old mice, whilst control unloaded tetramer 
did not bind (Figure 2.14A). Moreover, TRAIL was not detected on cells that 
C ! l . . .  
0 0  
0  
( )  
0 . 2 1  0 . 0 3  
9 4 . 7 2  5 . 0 4  
C D 4  
0  
0 0  
0  
( )  
C D 4  
F i g u r e  2 . 1 3 .  L i v e r  N K 1 . 1 + C D 3 +  c e l l s  i n  y o u n g  m i c e  e x p r e s s  C D 8 a  b u t  n o t  CDS~. L i v e r  M N C  
i s o l a t e d  f r o m  C 5 7 B L / 6  m i c e  2  w e e k s  o f  a g e  w e r e  s t a i n e d  w i t h  a n t i b o d i e s  t o  C D 3 ,  N K l . l ,  C D 4  
a n d  C D S  a  o r  CDS~. C D 4  v e r s u s  CDS~ a n d  C D 4  v e r s u s  C D S  a  F  A C S  p r o f i l e s  a r e  s h o w n  f o r  
N K l . l + C D 3 +  c e l l s .  
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Figure 2.14. Classical (type I) NKT cells in young mice do not express TRAIL. Liver MNC 
isolated from C57BL/6 mice 2 weeks of age were stained with a-GalCer-loaded or control 
unloaded COld tetramer and CD3, TRAIL or isotype control mAb. (A) Representative CD3 
versus control tetramer or CD3 versus a-GalCer tetramer staining on liver MNC, gate indicates 
tetramer positive cells. (B) Histogram demonstrating TRAIL (red) and isotype control mAb 
(black) staining on the gated a-GalCer tetramer positive classical (type I) NKT cell population. 
Results are representative of3 independent experiments. 
b o u n d  a - G a l C e r  t e t r a m e r  ( F i g u r e  2 . 1 4 B ) ,  s u g g e s t i n g  t h a t  T R A I L  i s  n o t  e x p r e s s e d  
o n  c l a s s i c a l  ( t y p e  I )  N K T  c e l l s .  
I n  a d d i t i o n  t o  c l a s s i c a l  ( t y p e  I )  N K T  c e l l s ,  n o n - t y p e  I  N K T  c e l l s  t h a t  e x p r e s s  a  
d i v e r s e  T C R  a n d  d o  n o t  b i n d  a G a l C e r  a l s o  e x i s t .  N o n - t y p e  I  N K T  c e l l s  a r e  
d i v i d e d  i n t o  TCRa/~ a n d  T C R y / 8  s u b s e t s  a n d  a r e  e i t h e r  C D S +  o r  C D 4 - c n s -
( E m o t o  e t  a l . ,  2 0 0 1 ;  E m o t o  e t  a l . ,  2 0 0 0 ) .  B o t h  s u b s e t s  o f  n o n - t y p e  I  N K T  c e l l s  
a r e  f o u n d  i n  t h e  l i v e r  a n d  a r e  p a r t i c u l a r l y  a b u n d a n t  d u r i n g  t h e  f i r s t  t w o  w e e k s  o f  
l i f e ,  w i t h  T C R y / 8  N K T  c e l l s  i n c r e a s i n g  i n  n u m b e r  b e f o r e  TCRa/~ N K T  c e l l s  
( E m o t o  e t  a l . ,  2 0 0 1 ;  E m o t o  e t  a l . ,  2 0 0 0 ) .  W e  h y p o t h e s i z e d  t h a t  T R A I L  m i g h t  b e  
e x p r e s s e d  o n  n o n - t y p e  I  N K T  c e l l s  t h a t  r e p r e s e n t  a  s u b s t a n t i a l  N K T  c e l l  s u b s e t  
e a r l y  i n  l i f e ,  b u t  d e c r e a s e  i n  p r o p o r t i o n  w i t h  a g e .  F l o w  c y t o m e t r i c  a n a l y s i s  
r e v e a l e d  t h a t  ~2-3% o f  t o t a l  l i v e r  M N C  i n  2  w e e k  o l d  m i c e  w e r e  n o n - t y p e  I  
TCRa/~ N K T  c e l l s ,  a n d  a  s i m i l a r  p r o p o r t i o n  w e r e  n o n - t y p e  I  T C R y / 8  N K T  c e l l s  
( F i g u r e  2 . 1 5 ) .  I m p o r t a n t l y ,  T R A I L  w a s  e x p r e s s e d  o n  TCRa/~ ( F i g u r e  2 . 1 5 A )  a n d  
T C R y / 8  n o n - t y p e  I  N K T  c e l l s  ( F i g u r e  2 . 1 5 B ) .  M o r e o v e r ,  T R A I L  w a s  e x p r e s s e d  
o n  b o t h  C D S +  a n d  C D 4  - e n s - s u b s e t s  o f  t h e s e  c e l l s  ( F i g u r e  2 . 1 5 ) .  T h e s e  f i n d i n g s  
p r o v i d e d  e v i d e n c e  t h a t  T R A I L  i s  c o n s t i t u t i v e l y  e x p r e s s e d  o n  n o n - t y p e  I  N K T  
c e l l s  i n  y o u n g  m i c e .  
2 . 4 . 8  C y t o t o x i c  a c t i v i t y  o f  l i v e r  N K  c e l l s  i s o l a t e d  f r o m  y o u n g  m i c e  
A s  w e  h a d  s h o w n  t h a t  T R A I L  i s  e x p r e s s e d  o n  f e t a l / n e o n a t a l  l i v e r  a n d  s p l e e n  N K  
c e l l s  ( F i g u r e  2 . S ) ,  w e  t h e n  e x a m i n e d  w h e t h e r  T R A I L  w a s  f u n c t i o n a l  o n  t h e s e  
c e l l s .  I n i t i a l l y ,  t h e  c y t o t o x i c i t y  o f  l i v e r  a n d  s p l e e n  N K  c e l l s  i s o l a t e d  f r o m  f e t a l  
a n d  n e o n a t a l  C 5 7 B L / 6  R A G - 2 - / - m i c e  w a s  t e s t e d  a g a i n s t  T R A I L - ,  F a s L - a n d  p i P -
s e n s i t i v e  L 9 2 9  t a r g e t  c e l l s .  F e t a l  l i v e r  a n d  s p l e e n  N K  c e l l s  p r e d o m i n a n t l y  e x e r t e d  
T R A I L - d e p e n d e n t  c y t o t o x i c i t y  ( F i g u r e  2 . 1 6 A  a n d  B ) .  I n  c o n t r a s t ,  n e o n a t a l  l i v e r  
N K  c e l l s  e x e r t e d  T R A I L - ,  F a s L - ,  a n d  p f P - d e p e n d e n t  c y t o t o x i c i t y  ( F i g u r e  2 . 1 7  A ) ,  
w h i l s t  n e o n a t a l  s p l e e n  N K  c e l l s  d e m o n s t r a t e d  T R A I L - a n d  p f P - d e p e n d e n t  
c y t o t o x i c i t y ,  b u t  d i d  n o t  e x e r t  F a s L - d e p e n d e n t  c y t o t o x i c i t y  ( F i g u r e  2 . 1 7 B ) .  T h e s e  
d a t a  s u g g e s t e d  t h a t  T R A I L  i s  t h e  o n l y  c y t o t o x i c  e f f e c t o r  m o l e c u l e  e x p r e s s e d  b y  







Figure 2.15. Constitutive TRAIL expression by non-type I liver NKT cells in young mice. 
Liver MNC isolated from C57BL/6 mice 2 weeks of age were stained with antibodies to TCR~, 
TCRy&, NKI.l, CDS and TRAIL or isotype control mAb. (A) TCR~ versus NKl.l FACS profile, 
and histograms demonstrating TRAIL!isotype control antibody staining on total NKl.l+TCR~+ 
(Rl), NKl.l"tTCR~+CD8- or NK1.1~CR~+CD8+ cells, (B) TCRy& versus NKl.l FACS profile, 
and histograms demonstrating TRAIL/isotype control antibody staining on total NKl.l+TCRy&+ 
(R2), NKl.l ~CRy&+ ens- or NKl.l ~CRy&+ CDS+ cells. Red lines represent staining with anti-
TRAIL mAb and black lines represent staining with isotype matched control mAb. Results are 
representative of2 independent experiments 
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E f f e c t o r :  T a r g e t  
F i g u r e  2 . 1 6  C y t o l y t i c  a c t i v i t y  o f  l i v e r  a n d  s p l e e n  M N C  f r o m  f e t a l  m i c e .  L i v e r  a n d  s p l e e n  
M N C  w e r e  i s o l a t e d  f r o m  f e t a l  ( E 1 7 )  C 5 7 B L / 6  R A G - 2 - / - m i c e  a n d  t h e i r  c y t o t o x i c i t y  t e s t e d  a g a i n s t  
L 9 2 9  t a r g e t  c e l l s  b y  a  6  h  
5 1
C r  r e l e a s e  a s s a y .  A s s a y s  w e r e  s e t  u p  a t  t h r e e  d i f f e r e n t  e f f e c t o r : t a r g e t  
r a t i o s ,  i n  t h e  p r e s e n c e  o r  a b s e n c e  o f  1 0  1 1 g / m l  c o n t r o l  l g ,  1 0  1 1 g / m l  a n t i - m F a s L  m A b ,  1 0  1 1 g / m l  
a n t i - m T R A I L  m A b  a n d / o r  5 0  n M  C M A .  ( A )  F e t a l  l i v e r  M N C  l y s i s ,  ( B )  f e t a l  s p l e e n  M N C  l y s i s  o f  
L 9 2 9  c e l l s  i s  s h o w n .  D a t a  r e p r e s e n t  m e a n ±  S E M  f o r  t r i p l i c a t e  s a m p l e s .  A s t e r i s k s  i n d i c a t e  g r o u p s  
t h a t  a r e  s i g n i f i c a n t l y  d i f f e r e n t  f r o m  c o n t r o l  l g  ( *  P  <  0 . 0 5 ) .  S i m i l a r  r e s u l t s  w e r e  o b t a i n e d  i n  3  
i n d e p e n d e n t  e x p e r i m e n t s .  
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Figure 2.17 Cytolytic activity of liver and spleen MNC from neonatal mice. Liver and spleen 
MNC were isolated from neonatal C57BL/6 RAG-T1- mice and their cytotoxicity tested against 
L929 target cells by a 6 h 51 Cr release assay. Assays were set up at three different effector:target 
ratios, in the presence or absence of 10 jlg/ml control lg, 10 jlg/ml anti-mFasL mAb, 10 jlg/ml 
anti-mTRAIL mAb and/or 50 nM CMA. (A) Neonatal liver MNC lysis, (B) neonatal spleen MNC 
lysis ofL929 cells is shown. Data represent mean± SEM for triplicate samples. Asterisks indicate 
groups that are significantly different from control Ig (* P < 0.05). Similar results were obtained 
in 3 independent experiments. 
f e t a l  N K  c e l l s ,  w h e r e a s  n e o n a t a l  l i v e r  N K  c e l l s  a c q u i r e  a d d i t i o n a l  e f f e c t o r  
m e c h a n i s m s  t o  i n d u c e  t a r g e t  c e l l  a p o p t o s i s .  
N e x t  w e  e x a m i n e d  t h e  c y t o t o x i c i t y  o f  l i v e r  M N C  i s o l a t e d  f r o m  2  w e e k  o l d  
C 5 7 B L / 6  W T  m i c e  a g a i n s t  T R A I L - ,  F a s L - a n d  p f p - s e n s i t i v e  D A 3  ( F i g u r e  2 . 1 8 A )  
a n d  L 9 2 9  ( F i g u r e  2 . 1 8 B )  t a r g e t  c e l l s .  L i v e r  M N C  p r e d o m i n a n t l y  e x e r t e d  T R A I L -
a n d  p f p - d e p e n d e n t  c y t o t o x i c i t y  t h a t  c o u l d  b e  b l o c k e d  b y  t h e  a d d i t i o n  o f  
n e u t r a l i z i n g  a n t i - m T R A I L  m A b  a n d  E G T A ,  r e s p e c t i v e l y .  W e a k  F a s L - d e p e n d e n t  
c y t o t o x i c i t y  w a s  a l s o  o b s e r v e d .  T h i s  s u g g e s t e d  t h a t  t h e  e f f e c t o r  m e c h a n i s m s  u s e d  
b y  n e o n a t a l  a n d  2  w e e k  o l d  l i v e r  N K  c e l l s  a r e  s i m i l a r .  L i v e r  M N C  i s o l a t e d  f r o m  
2  w e e k  o l d  C 5 7 B L / 6  m i c e  w e r e  a l s o  t e s t e d  a g a i n s t  p f p - a n d  F a s L - s e n s i t i v e  Y a e - l  
t a r g e t  c e l l s  ( F i g u r e  2 . 1 8 C )  a n d  s h o w n  t o  p r e d o m i n a n t l y  e x e r t  p f p - d e p e n d e n t  
c y t o t o x i c i t y  t h a t  c o u l d  b e  b l o c k e d  b y  t h e  a d d i t i o n  o f  E G T A ,  b u t  a l s o  w e a k  F a s L -
d e p e n d e n t  c y t o t o x i c i t y  t h a t  w a s  b l o c k e d  b y  t h e  a d d i t i o n  o f  n e u t r a l i z i n g  a n t i - F a s L  
m A b .  W e  a d d i t i o n a l l y  a n a l y z e d  t h e  c y t o t o x i c  a c t i v i t y  o f  s p l e e n  M N C  i s o l a t e d  
f r o m  2  w e e k  o l d  C 5 7 B L / 6  m i c e  a g a i n s t  T R A I L - ,  F a s L - a n d  p f p - s e n s i t i v e  D A 3  
t a r g e t  c e l l s  ( F i g u r e  2 . 1 9 ) .  U n l i k e  n e o n a t a l  s p l e e n  N K  c e l l s  t h a t  d e m o n s t r a t e d  
T R A I L - a n d  p f p - d e p e n d e n t  c y t o t o x i c i t y ,  s p l e n o c y t e s  i s o l a t e d  f r o m  2  w e e k  o l d  
m i c e  p r e d o m i n a n t l y  e x e r t e d  p f p - d e p e n d e n t  c y t o t o x i c i t y  ( F i g u r e  2 . 1 9 ) ,  w h i c h  i s  
c o n s i s t e n t  w i t h  a  d e c r e a s e  i n  T R A I L  e x p r e s s i o n  i n  t h e  s p l e e n  b y  2  w e e k s  o f  a g e  
( F i g u r e  2 . 8 ) .  T h e s e  d a t a  s u g g e s t  t h a t  T R A I L - d e p e n d e n t  c y t o t o x i c i t y  p e r s i s t s  i n  
t h e  l i v e r ,  b u t  s u b s i d e s  i n  t h e  s p l e e n  b y  2  w e e k s  o f  a g e .  
2 . 4 . 9  T R A I L - d e f i c i e n t  m i c e  l a c k  c o n s t i t u t i v e  T R A I L  e x p r e s s i o n  
M i c e  g e n e t i c a l l y  d e f i c i e n t  i n  T R A I L  w e r e  g e n e r a t e d  b y  h o m o l o g o u s  
r e c o m b i n a t i o n  i n  1 2 9  d e r i v e d  s t e m  c e l l s ,  a s  d e s c r i b e d  i n  M a t e r i a l s  a n d  M e t h o d s  
( S e c t i o n  2 . 3 ) ,  a n d  b a c k c r o s s e d  n = l  0  g e n e r a t i o n s  t o  C 5 7 B L / 6  a n d  B A L B / c  
b a c k g r o u n d s .  C 5 7 B L / 6  T R A I L _ ; _  a n d  B A L B / c  T R A I L - / - m i c e  d i s p l a y e d  n o  
o b v i o u s  p a t h o l o g i c a l ,  h e m a t o l o g i c a l  o r  r e p r o d u c t i v e  d e f e c t s  ( d a t a  n o t  s h o w n ) .  
T o  c o n f i r m  t h a t  C 5 7 B L / 6  T R A I L _ ; _  m i c e  l a c k e d  c o n s t i t u t i v e  T R A I L  e x p r e s s i o n ,  
l i v e r  M N C  i s o l a t e d  f r o m  t h e s e  m i c e  w e r e  s t a i n e d  w i t h  a n t i b o d i e s  t o  N K l . l ,  C D 3  
1 1 2  
40 
• Media A DEGTA 








en 30 ~ 
(.) 
~ 












50:1 20:1 1:1 
Effector: Target 
Figure 2.18 Cytolytic activity of liver MNC from 2 week old mice. Liver MNC were isolated 
from 2 week old C57BL/6 mice and their cytotoxicity tested against (A) DA3, (B) L929 or (C) 
Yae-l target cells by a 5 h 51Cr release assay. Assays were set up at three different effector:target 
ratios, in the presence or absence of 5 mM EGT A, 20 11g/ml anti-mFasL mAb or I 0 11g/ml anti-
mTRAIL mAb, or no inhibitor present (media). Data represent mean ± SEM for triplicate 
samples. Asterisks indicate groups that are significantly different from media alone (* P < 0.03). 
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F i g u r e  2 . 1 9 .  C y t o l y t i c  a c t i v i t y  o f  s p l e e n  M N C  i s o l a t e d  f r o m  2  w e e k  o l d  m i c e .  S p l e e n  M N C  
w e r e  i s o l a t e d  f r o m  2  w e e k  o l d  C 5 7 B L / 6  m i c e  a n d  t h e i r  c y t o t o x i c i t y  t e s t e d  a g a i n s t  D A 3  t a r g e t  
c e l l s  b y  a  5  h  
5 1
C r  r e l e a s e  a s s a y .  A s s a y s  w e r e  s e t  u p  a t  t h r e e  d i f f e r e n t  e f f e c t o r : t a r g e t  r a t i o s ,  i n  t h e  
p r e s e n c e  o r  a b s e n c e  o f  5  m M  E G T  A ,  2 0  1 1 g / m l  a n t i - m F a s L  m A b  o r  1 0  1 1 g / m l  a n t i - m T R A I L  m A b ,  
o r  n o  i n h i b i t o r  p r e s e n t  ( m e d i a ) .  D a t a  r e p r e s e n t  m e a n  ±  S E M  f o r  t r i p l i c a t e  s a m p l e s .  A s t e r i s k s  
i n d i c a t e  g r o u p s  t h a t  a r e  s i g n i f i c a n t l y  d i f f e r e n t  f r o m  m e d i a  a l o n e  ( *  P  <  0 . 0 3 ) .  
1 1 4  
and TRAIL or isotype control mAb. C57BL/6 WT and C57BL/6 TRAIL_;_ mice 
displayed similar proportions of liver NK, NKT and T cells (Figure 2.1 and 
2.20A). Whilst TRAIL was expressed on a subset of liver NK cells in C57BL/6 
mice (Figure 2.1), NK cells isolated from C57BL/6 TRAIL_;_ mice completely 
lacked TRAIL expression, as did NKl.l +CD3+, NK1.1-CD3+ and NK1.1-CD3-
cells (Figure 2.20A). TRAIL expression was also not detected in permeabilized 
liver MNC from C57BL/6 TRAIL_;_ mice (Figure 2.20B). These data confirmed 
that C57BL/6 TRAIL-/- mice do not express TRAIL protein in the liver. 
Although. TRAIL expression was not detected in the spleen of adult C57BL/6 
WT mice (Figure 2.2), low level TRAIL staining were observed on fetal/neonatal 
splenic NK cells and in young mice (Figure 2.8). To ensure that C57BL/6 
TRAIL_;_ completely lacked TRAIL expression, spleen MNC isolated from these 
mice were analyzed for TRAIL expression. C57BL/6 WT and C57BL/6 TRAIL_1_ 
mice displayed similar proportions of spleen NK, NKT and T cells (data not 
shown), and TRAIL was not detected on NKl.l +CD3-, NKl.l +CD3+, NKl. r 
CD3+ or NKl.rCD3- cells (Figure 2.21A). TRAIL was also not detected in 
spleen MNC from C57BL/6 TRAIL_;_ mice that had been permeabilized (Figure 
2.21B). These data confirmed that C57BL/6 TRAIC1- mice do not express 
TRAIL protein in the spleen. 
To confirm that BALB/c TRAIL_;_ mice lacked constitutive TRAIL expression, 
liver and spleen MNC isolated from these mice were stained with antibodies to 
IL-2Rj3, CD3 and TRAIL or isotype control mAb. BALB/c WT and BALB/c 
TRAIL-/- mice displayed similar proportions of liver NK, NKT and T cells (data 
not shown). Whilst TRAIL was expressed on a subset of liver NK cells in 
BALB/c WT mice (Figure 2.6), liver NK cells isolated from BALB/c TRAIC1-
mice lacked TRAIL expression, as did IL-2Rj3+CDf, IL-2RWCD3+ and IL-2RW 
CD3- cells (Figure 2.22A). TRAIL was also not detected on IL-2Rj3+CD3-, IL-
2Rj3+CD3+, IL-2RWCD3+ or IL-2RWCD3- cells in the spleen of these mice 
(Figure 2.22B). These data confirmed that BALB/c TRAIL_;_ mice do not express 
TRAIL protein in the liver or spleen. 
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F l u o r e s c e n c e  I n t e n s i t y  
F i g u r e  2 . 2 0 .  A b s e n c e  o f  T R A I L  e x p r e s s i o n  i n  t h e  l i v e r  o f  C 5 7 B L / 6  T R A I L - d e f i c i e n t  m i c e .  
L i v e r  M N C  i s o l a t e d  f r o m  a d u l t  C 5 7 B L / 6  T R A I L - / - m i c e  w e r e  p e r m e a b i l i z e d  o r  l e f t  
u n p e r m e a b i l i z e d  a n d  s t a i n e d  w i t h  a n t i b o d i e s  t o  C D 3 ,  N K l . l  a n d  T R A I L  o r  i s o t y p e  c o n t r o l  m A b .  
( A )  R e p r e s e n t a t i v e  C D 3  v e r s u s  N K l . l  F A C S  p l o t  f o r  u n p e r m e a b i l i z e d  l i v e r  M N C .  T h e  R l  g a t e  
c o m p r i s e s  N K l . l  + C D 3 .  c e l l s ,  R 2  c o m p r i s e s  N K l . l . C D 3 +  c e l l s ,  R 3  c o m p r i s e s  N K l . l  + C D 3 +  c e l l s  
a n d  R 4  c o m p r i s e s  N K 1 . 1 T D 3 - c e l l s .  H i s t o g r a m s  d e m o n s t r a t e  T R A I L / i s o t y p e  c o n t r o l  a n t i b o d y  
s t a i n i n g  o n  t h e  g a t e d  l i v e r  M N C  p o p u l a t i o n s  ( R l - R 4 ) ,  f o r  u n p e r m e a b i l i z e d  c e l l s .  ( B )  
R e p r e s e n t a t i v e  C D 3  v e r s u s  N K l . l  F A C S  p l o t  f o r  p e r m e a b i l i z e d  l i v e r  M N C .  H i s t o g r a m s  
d e m o n s t r a t e  T R A I L / i s o t y p e  c o n t r o l  a n t i b o d y  s t a i n i n g  o n  t h e  g a t e d  M N C  p o p u l a t i o n s  ( R l - R 4 ) ,  f o r  
p e r m e a b i l i z e d  c e l l s .  R e d  l i n e s  r e p r e s e n t  s t a i n i n g  w i t h  a n t i - m T R A I L  m A b ,  b l a c k  l i n e s  r e p r e s e n t  
s t a i n i n g  w i t h  i s o t y p e  m a t c h e d  c o n t r o l  m A b .  D a t a  a r e  r e p r e s e n t a t i v e  o f  t h e  a n a l y s i s  o f  5  m i c e  f o r  
( A )  a n d  2  m i c e  f o r  ( B ) .  
























Figure 2.21. Absence of TRAIL expression in the spleen of C57BL/6 TRAIL-deficient mice. 
Spleen MNC isolated from adult C57BL/6 TRAIL-/- mice were permeabilized or left 
unpermeabilized and stained with antibodies to CD3, NKl.l and TRAIL or isotype control mAb. 
(A) Representative CD3 versus NKl.l FACS plot for unpermeabilized spleen MNC. The Rl gate 
comprises NK1.1+CD3- cells, R2 comprises NKIXCD3+ cells, R3 comprises NKI.l+CD3+ cells 
and R4 comprises NKI.I"CD3- cells. Histograms demonstrate TRAIL/isotype control antibody 
staining on the gated MNC populations (Rl-R4), for unpermeabilized cells. (B) Representative 
CD3 versus NKI.l FACS plot for permeabilized spleen MNC. Histograms demonstrate 
TRAIL/isotype control antibody staining on the gated MNC populations (Rl-R4), for 
permeabilized cells. Red lines represent staining with anti-mTRAIL mAb, black lines represent 
staining with isotype matched control mAb. Data are representative of the analysis of 5 mice for 
(A) and 2 mice for (B). 
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F l u o r e s c e n c e  I n t e n s i t y  
F i g u r e  2 . 2 2 .  A b s e n c e  o f  T R A I L  e x p r e s s i o n  i n  t h e  l i v e r  a n d  s p l e e n  o f  B A L B / c  T R A I L -
d e f i c i e n t  m i c e .  L i v e r  a n d  s p l e e n  M N C  i s o l a t e d  f r o m  a d u l t  B A L B / c  T R A I L · / - m i c e  w e r e  s t a i n e d  
w i t h  a n t i b o d i e s  t o  C D 3 ,  IL-2R~, D X 5  a n d  T R A I L  o r  i s o t y p e  c o n t r o l  m A b .  H i s t o g r a m s  
d e m o n s t r a t e  T R A I L / i s o t y p e  c o n t r o l  a n t i b o d y  s t a i n i n g  o n  g a t e d  IL-2R~+Co3·, I L - 2 R W C D 3 \  I L -
2R~+CD3+ a n d  IL-2R~"CD3- l i v e r  a n d  s p l e e n  M N C .  R e d  l i n e s  r e p r e s e n t  s t a i n i n g  w i t h  a n t i -
m T R A I L  m A b ,  b l a c k  l i n e s  r e p r e s e n t  s t a i n i n g  w i t h  i s o t y p e  m a t c h e d  c o n t r o l  m A b .  D a t a  a r e  
r e p r e s e n t a t i v e  o f  t h e  a n a l y s i s  o f  4  m i c e .  
1 1 8  
2.4.10 TRAIL is not essential for NK cell development in vivo 
As we had shown that TRAIL is typically expressed on immature 
DX51°CD11b10Ly49-CD94hi NK cells (Figure 2.4), we then assessed whether 
proportions of immature NK cells were decreased in mice devoid of TRAIL 
expression. Proportions of immature DX51°CD11b10Ly49-CD94hi NK cells were 
equivalent in C57BL/6 TRAIL-/- compared to C57BL/6 WT mice (Figure 2.23), 
suggesting that TRAIL is not essential for NK cell development in vivo. 
2.4.11 TRAIL-mediated cytotoxicity in vitro 
To confirm that TRAIL-deficient mice lacked TRAIL function, the contribution 
of TRAIL to the cytotoxicity of hepatic and splenic NK cells was assessed 
against TRAIL-sensitive 4T1.2 and Renca tumor target cells. The cytotoxicity of 
liver MNC isolated from BALB/c WT mice, against 4T1.2 (Figure 2.24A) and 
Renca (Figure 2.25A) tumor targets was partially abrogated by the addition of 
neutralizing anti-mTRAIL mAb and completely inhibited by the addition of both 
anti-mTRAIL mAb and the pfP inhibitor CMA. This suggested that lysis of 4T1.2 
and Renca tumor targets by WT liver MNC is both TRAIL- and pfP-dependent. 
The cytotoxicity of liver MNC isolated from BALB/c IFN-y-1- and BALB/c 
TRAIL-/- mice, against 4T1.2 (Figure 2.24A) and Renca (Figure 2.25A) tumor 
targets was unaffected by the addition of anti-mTRAIL mAb, but completely 
inhibited by the addition of CMA, suggesting that liver MNC from these mice 
lacked TRAIL function but retained pfP function. In contrast, the cytotoxicity of 
liver MNC isolated from BALB/c ptp_1_ mice, against 4T1.2 (Figure 2.24A) and 
Renca (Figure 2.25A) tumor targets was unaffected by the addition of CMA, but 
completely inhibited by the addition of anti-mTRAIL mAb, suggesting that liver 
MNC from these mice lacked pfP function, but retained TRAIL function. The 
cytotoxicity of spleen MNC isolated from BALB/c WT mice against 4T1.2 
(Figure 2.24B) and Renca (Figure 2.25B) tumor targets was completely 
abrogated by CMA, indicating that pfP was the only effector mechanism used by 
freshly isolated spleen MNC to lyse these tumor targets. Consistent with this 
data, BALB/c ptp_1_ spleen MNC did not lyse 4Tl.2 (Figure 2.24B) or Renca 
(Figure 2.25B) targets. 
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F i g u r e  2 . 2 3 .  N K  c e l l  s u b p o p u l a t i o n s  i n  T R A I L - d e f i c i e n t  m i c e .  L i v e r  M N C  i s o l a t e d  f r o m  a d u l t  
C 5 7 B L / 6  W T  a n d  C 5 7 B L / 6  T R A I L - ; - m i c e  w e r e  s t a i n e d  w i t h  c o m b i n a t i o n s  o f  a n t i b o d i e s  t o  C D 3 ,  
N K ! . l ,  D X 5 ,  C D 9 4 ,  C D l l b ,  L y 4 9 s  ( A ,  C / I ,  G 2 ,  D )  a n d  T R A I L .  R e p r e s e n t a t i v e  C D 9 4  v e r s u s  
D X S .  L y 4 9 s  v e r s u s  C D l l b ,  L y 4 9 s  v e r s u s  D X 5  a n d  T R A I L  v e r s u s  D X S  a r e  s h o w n  f o r  g a t e d  
N K l . l " C D 3 - c e l l s .  N u m b e r s  r e p r e s e n t  t h e  p e r c e n t a g e s  o f  c e l l s  i n  e a c h  q u a d r a n t .  D a t a  a r e  
r e p r e s e n t a t i v e  o f  3  i n d e p e n d e n t  e x p e r i m e n t s .  




















































Figure 2.24. TRAIL contributes to NK cell-mediated cytotoxicity of 4T1.2 tumor cells in 
vitro. Liver and spleen MNC were isolated from adult BALB/c, BALB/c IFN-y1-, BALB/c pip_;_ 
and BALB/c TRAIL-/- mice and their cytotoxic activities tested against 4Tl.2 target cells by an 8 
h 51 Cr release assay. Assays were performed at various effector:target ratios, in the presence or 
absence of 50 nM CMA, 10 pg/ml anti-mTRAIL mAb, 50 nM CMA plus 10 11g/ml anti-mTRAIL 
mAb, or no inhibitor present (control). (A) Liver MNC lysis of 4Tl.2 targets cells is shown at 
50:1 effector:target ratio. (B) Spleen MNC lysis of 4Tl.2 target cells is shown at 100:1 
effector:target ratio. Data are representative of those across the effector:target ratio of 50 to 5:1 
(for liver) and 100 to 5:1 (for spleen). Data represent mean± SEM oftrip1icate samples. Asterisks 
indicate groups that are significantly different to control (* P < 0.05). Data are representative of2 
independent experiments. 
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F i g u r e  2 . 2 5 .  T R A I L  c o n t r i b u t e s  t o  N K  c e l l - m e d i a t e d  c y t o t o x i c i t y  o f  R e n c a  t u m o r  c e l l s  i n  
v i t r o .  L i v e r  a n d  s p l e e n  M N C  w e r e  i s o l a t e d  f r o m  a d u l t  B A L B / c ,  B A L B / c  I F N - y -
1
- ,  B A L B / c  p f p _ ; _  
a n d  B A L B / c  T R A I L _ ; _  m i c e  a n d  t h e i r  c y t o t o x i c  a c t i v i t i e s  t e s t e d  a g a i n s t  R e n c a  t a r g e t  c e l l s  b y  a n  8  
h  
5 1
C r  r e l e a s e  a s s a y .  A s s a y s  w e r e  p e r f o r m e d  a t  v a r i o u s  e f f e c t o r : t a r g e t  r a t i o s ,  i n  t h e  p r e s e n c e  o r  
a b s e n c e  o f  5 0  n M  C M A ,  1 0  1 1 g / m l  a n t i - m T R A I L  m A b ,  5 0  n M  C M A  p l u s  1 0  1 1 g / m l  a n t i - m T R A I L  
m A b ,  o r  n o  i n h i b i t o r  p r e s e n t  ( c o n t r o l ) .  ( A )  L i v e r  M N C  l y s i s  o f  R e n c a  t a r g e t s  c e l l s  i s  s h o w n  a t  
5 0 : 1  e f f e c t o r : t a r g e t  r a t i o .  ( B )  S p l e e n  M N C  l y s i s  o f  R e n c a  t a r g e t  c e l l s  i s  s h o w n  a t  1 0 0 : 1  
e f f e c t o r : t a r g e t  r a t i o .  D a t a  a r e  r e p r e s e n t a t i v e  o f  t h o s e  a c r o s s  t h e  e f f e c t o r : t a r g e t  r a t i o  o f  5 0  t o  5 : 1  
( f o r  l i v e r )  a n d  1 0 0  t o  5 : 1  ( f o r  s p l e e n ) .  D a t a  r e p r e s e n t  m e a n ±  S E M  o f  t r i p l i c a t e  s a m p l e s .  A s t e r i s k s  
i n d i c a t e  g r o u p s  t h a t  a r e  s i g n i f i c a n t l y  d i f f e r e n t  t o  c o n t r o l ( *  P  <  0 . 0 5 ) .  D a t a  a r e  r e p r e s e n t a t i v e  o f 2  
i n d e p e n d e n t  e x p e r i m e n t s .  
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2.5 Discussion 
Our study has significantly extended a previous report that identified constitutive 
TRAIL expression on a small subset of liver NK cells (Takeda et al., 2001 ), by 
demonstrating that TRAIL is expressed on DX51°CD11b10Ly49-CD94hi liver NK 
cells, a surface phenotype characteristic of "immature" NK cells (Kim et al., 
2002). Further, we identified that TRAIL-expressing NK cells predominate in the 
liver of fetal, neonatal and young mice, and showed that TRAIL is additionally 
expressed by fetal and neonatal spleen NK cells and by non-type I liver NKT 
cells in young mice. Moreover, fetal liver and spleen NK cells predominantly 
exerted TRAIL-dependent cytotoxicity, suggesting that TRAIL is the first 
cytotoxic molecule expressed on NK cells. Importantly, we also reported the first 
characterization of TRAIL-deficient mice generated by gene-targeting, and 
showed that these mice are devoid of TRAIL expression and function. 
A previous report suggested that adult IFN-y-deficient and IFN-y-receptor-
deficient mice lacked constitutive TRAIL expression on liver NK cells (Takeda et 
al., 2001), indicating a critical role for IFN-y in the regulation of TRAIL 
expression in vivo. Herein, we detected impaired TRAIL expression (5.5 ± 4.5%) 
on phenotypically immature liver NK cells in adult IFN -')'-deficient mice, 
compared to adult C57BL/6 WT mice (18.5 ± 4.5%). Relatively higher 
proportions of TRAIL-expressing liver NK cells were observed in IFN-y-
deficient mice at 2 and 4 weeks of age (45.4 ± 1.4% and 47.3 ± 2.4% 
respectively). Therefore, although endogenous host IFN-y contributes to TRAIL 
expression on liver NK cells, molecules other than IFN-y are additionally 
important, especially in the earlier stages of NK cell development. Our results 
indicated that IL-12, IL-18, TNF, IL-4, IFNa. and IFNf3 are not solely critical for 
TRAIL expression in vivo. Using germ-free mice, our collaborators have recently 
shown that TRAIL-expression by liver NK cells is normal and not dependent on 
endogenous bacterial flora (personal communication Dr. Kazuyoshi Takeda). 
T R A I L  i s  e x p r e s s e d  o n  l i v e r  N K  c e l l s  i s o l a t e d  f r o m  s c i d  a n d  R A G - 2 - d e f i c i e n t  
m i c e ,  s u g g e s t i n g  t h a t  t h e  I F N - ' ) '  r e q u i r e d  f o r  c o n s t i t u t i v e  T R A I L  e x p r e s s i o n  i n  t h e  
l i v e r  i s  n o t  p r o d u c e d  b y  c o n v e n t i o n a l  T  c e l l s  o r  N K T  c e l l s  ( T a k e d a  e t  a l . ,  2 0 0 1 ) .  
T h e  m a j o r i t y  o f  T R A I L - e x p r e s s i n g  l i v e r  N K  c e l l s  p r o d u c e  I F N - ' ) ' ,  s u g g e s t i n g  t h a t  
T R A I L  e x p r e s s i o n  o n  l i v e r  N K  c e l l s  m a y  b e  r e g u l a t e d  b y  I F N - ' ) '  s e c r e t e d  f r o m  
N K  c e l l s  i n  a n  a u t o c r i n e  m a n n e r  ( T a k e d a  e t  a l . ,  2 0 0 1 ) .  H o w e v e r ,  t h i s  d o e s  n o t  
e x p l a i n  T R A I L  e x p r e s s i o n  o n  t h e  s m a l l  p r o p o r t i o n  o f  l i v e r  N K  c e l l s  t h a t  d o  n o t  
p r o d u c e  I F N - y ,  a n d  s u g g e s t s  t h a t  a n  a d d i t i o n a l  s o u r c e  o f  I F N - ' ) '  i s  r e q u i r e d .  
A l t h o u g h  I L - 1 2  c a n  s t i m u l a t e  N K  c e l l s  a n d  m a c r o p h a g e s  t o  s e c r e t e  I F N - ' ) '  
( K o d a m a  e t  a l . ,  1 9 9 9 ;  P u d d u  e t  a l . ,  1 9 9 7 ;  T a k e d a  e t  a l . ,  2 0 0 0 ) ,  T R A I L  e x p r e s s i o n  
i n  I L - 1 2 - d e f i c i e n t  m i c e  w a s  e q u i v a l e n t  t o  W T  m i c e ,  s u g g e s t i n g  t h a t  I L - 1 2  d o e s  
n o t  r e g u l a t e  T R A I L  e x p r e s s i o n  i n  v i v o .  T h e  a l t e r n a t e  s o u r c e  o f  I F N - ' ) '  r e q u i r e d  f o r  
c o n s t i t u t i v e  T R A I L  e x p r e s s i o n  i n  v i v o  i s  y e t  t o  b e  d e t e r m i n e d .  
I n  t h e  p r e s e n t  s t u d y ,  w e  s h o w e d  t h a t  c o n s t i t u t i v e  T R A I L  e x p r e s s i o n  o n  I L -
2R~+CD3-liver N K  c e l l s  w a s  h i g h e r  i n  C 5 7 B U 6  W T  c o m p a r e d  t o  B A L B / c  W T  
m i c e .  I n  C h a p t e r  3 ,  w e  t e s t e d  a  p a n e l  o f  m o u s e  t u m o r  c e l l  l i n e s  f o r  s e n s i t i v i t y  t o  
T R A I L - m e d i a t e d  k i l l i n g .  W h i l s t  a  l a r g e  p r o p o r t i o n  o f  B A L B / c - d e r i v e d  t u m o r  c e l l  
l i n e s  w e r e  T R A I L - s e n s i t i v e ,  C 5 7 B U 6 - d e r i v e d  t u m o r  c e l l  l i n e s  w e r e  l a r g e l y  
r e s i s t a n t  t o  T R A I L - d e p e n d e n t  k i l l i n g .  O n  t h e  b a s i s  o f  i m m u n o e d i t i n g  ( D u n n  G P  
e t  a l . ,  2 0 0 2 ;  D u n n  G P  e t  a l . ,  2 0 0 4 ) ,  o n e  m i g h t  p o s t u l a t e  f r o m  t h e s e  f i n d i n g s  t h a t  
d e c r e a s e d  c o n s t i t u t i v e  T R A I L  e x p r e s s i o n  i n  B A L B / c  W T  m i c e  p r e d i s p o s e s  t h e m  
t o  d e v e l o p m e n t  o f  T R A I L - s e n s i t i v e  t u m o r s  t h a t  a r e  t y p i c a l l y  e l i m i n a t e d  i n  
C 5 7 B U 6  W T  m i c e .  C o n s i s t e n t  w i t h  t h i s  h y p o t h e s i s ,  T R A I L - s e n s i t i v e  t u m o r s  
p r e f e r e n t i a l l y  e m e r g e d  i n  a n t i - T R A I L  m A b - t r e a t e d  p 5 3 + / - m i c e  a n d  i n  a n t i -
m T R A I L  m A b - t r e a t e d  W T  m i c e  i n o c u l a t e d  w i t h  M C A  t o  d e v e l o p  f i b r o s a r c o m a s  
( T a k e d a  e t  a l . ,  2 0 0 2 ) .  M o r e o v e r ,  r e c e n t  s t u d i e s  i n  o u r  l a b o r a t o r y  h a v e  s h o w n  t h a t  
a p p r o x i m a t e l y  2 0 %  o f  C 5 7 B U 6  T R A I L - / - m i c e  d e v e l o p  l y m p h o m a  a n d  l e u k e m i a  
w i t h  a g e ,  s u g g e s t i n g  t h a t  T R A I L - d e f i c i e n c y  p r e d i s p o s e s  m i c e  t o  t u m o r  
d e v e l o p m e n t  i n  v i v o  ( p e r s o n a l  c o m m u n i c a t i o n ,  D r .  M a r k  J  S m y t h ) .  I t  m i g h t  n o w  
b e  o f  i n t e r e s t  t o  e x a m i n e  w h e t h e r  T R A I L  e x p r e s s i o n  o n  l i v e r  N K  c e l l s  v a r i e s  
s i g n i f i c a n t l y  b e t w e e n  a  n u m b e r  o f  m o u s e  s t r a i n s .  
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A linear differentiation model for human NK cell development has been proposed 
by Perussia and colleagues (Loza and Perussia, 2001) (Figure 1.1 ). Briefly, 
'Immature' (type 2) IL-13/IL-5-producing, TRAIL-expressing NK cells 
differentiate into 'Intermediate' (type 0) NK cells when cultured in the presence 
of IL-12. These 'Intermediate' (type 0) NK cells can produce both IL-13 and 
IFN-y and exert TRAIL-, FasL- and pfP-mediated cytotoxicity. IL-12 stimulated 
'Intermediate' (type 0) NK cells further differentiate into 'Mature' (type I) NK 
cells that produce IFN-y and mediate apoptosis in a FasL- and p:tp-dependent 
manner. Therefore, TRAIL+ mouse fetal liver and spleen NK cells that 
predominantly exerted TRAIL-dependent cytotoxicity, and do not secrete IFN-y 
or IL-13 (personal communication, Dr. Kazuyoshi Takeda), might correspond to 
'Immature' (type 2) human NK cells. TRAIL+ liver NK cells in adult mice that 
exerted TRAIL-, FasL- and pfP-mediated cytotoxicity might correspond to 
'Intermediate' (type 0) human NK cells. Importantly, phenotypic analysis ofNK 
cells isolated from TRAIL-deficient mice revealed normal proportions of 
immature and mature NK cells, suggesting that although TRAIL is expressed on 
phenotypically immature NK cells, TRAIL expression is not required for NK cell 
development. 
Cytotoxic molecules expressed on immature NK cells that lack the majority of 
Ly49 inhibitory receptors might be expected to cause non-specific apoptosis and 
tissue damage in young mice. CD94/NKG2 recognizes the non-classical MHC 
class I molecule Qa-1 b (Sivakumar et al., 1999; Vance et al., 1999; Vance et al., 
1998), is expressed at high levels by fetal splenic NK cells (Sivakumar et al., 
1999; Van Beneden et al., 2001), and has been suggested to play a role in the 
maintenance of self-tolerance during fetal life (Salcedo et al., 2000; Sivakumar et 
al., 1999; Van Beneden et al., 2001). Nonetheless, the selective ability of TRAIL 
to kill transformed and virus-infected cells, but not most normal self-cells, might 
render TRAIL a comparatively "safe" effector molecule to express on immature 
NK cells, compared to other less selective cytotoxic molecules such as FasL and 
p:tp. Although it is unknown why constitutive TRAIL expression is elevated in 
young mice and downregulated after birth, TRAIL may be required as a 
s u p p o r t i n g  e f f e c t o r  m o l e c u l e  d u r i n g  t h e  p e r i o d  t h a t  t h e  a d a p t i v e  i m m u n e  s y s t e m  
i s  b e i n g  m a t u r e d  i n  y o u n g  m i c e .  T h i s  w o u l d  b e  i m p o r t a n t  f o r  h o s t  r e s i s t a n c e  t o  
v i r u s  a n d  p a t h o g e n s  e n c o u n t e r e d  e a r l y  i n  l i f e ,  a s  d e p e n d e n c e  u p o n  m a t e r n a l  
i m m u n i t y  d i m i n i s h e s .  M o r e o v e r ,  t h e  c h a l l e n g e s  e n c o u n t e r e d  b y  t h e  n e o n a t e  
m i g h t  d i f f e r  f r o m  t h o s e  e n c o u n t e r e d  i n  t h e  a d u l t ,  a n d  m i g h t  r e q u i r e  d i f f e r e n t  
m e c h a n i s m s  o f  i m m u n e  d e f e n s e .  A l t e r n a t i v e l y ,  w h i l e  I F N s  c a n  s t i m u l a t e  T R A I L  
e x p r e s s i o n  o n  a  n u m b e r  o f  c e l l  t y p e s  i n  a d u l t  m i c e ,  y o u n g  m i c e  a r e  e x q u i s i t e l y  
s e n s i t i v e  t o  I F N - y  t o x i c i t y  ( G r e s s e r  e t  a l . ,  1 9 8 1 ) ,  a n d  m a y  r e q u i r e  a  h i g h e r  l e v e l  
o f  c o n s t i t u t i v e  T R A I L  e x p r e s s i o n  o n  N K  c e l l s  t o  a v o i d  t o x i c i t y  b y  I F N - y -
m e d i a t e d  s t i m u l a t i o n .  
W h i l s t  w e  h a v e  i d e n t i f i e d  c o n s t i t u t i v e  T R A I L  e x p r e s s i o n  o n  f e t a l  a n d  n e o n a t a l  
s p l e e n  N K  c e l l s ,  a n d  o n  n o n - t y p e  I  l i v e r  N K T  c e l l s  i n  y o u n g  m i c e ,  T R A I L  
e x p r e s s i o n  i s  n o t  r e t a i n e d  o n  t h e s e  c e l l s  l a t e r  i n  l i f e .  A d o p t i v e  t r a n s f e r  o f  T R A I L +  
N K  c e l l s  i s o l a t e d  f r o m  a d u l t  o r  n e o n a t a l  l i v e r ,  o r  n e o n a t a l  s p l e e n ,  r e s u l t e d  i n  t h e  
a p p e a r a n c e  o f  T R A I L - N K  c e l l s  i n  t h e  l i v e r  o r  s p l e e n  o f  r e c i p i e n t  m i c e  ( p e r s o n a l  
c o m m u n i c a t i o n ,  D r .  K a z u y o s h i  T a k e d a ) .  T h i s  s u g g e s t e d  t h a t  i m m a t u r e  T R A I L +  
N K  c e l l s  a r e  a b l e  t o  f u r t h e r  d i f f e r e n t i a t e  i n t o  m a t u r e  T R A I L - N K  c e l l s .  T h e  
r e a s o n  T R A I L  e x p r e s s i o n  i s  u n i q u e l y  r e t a i n e d  o n  a  s u b p o p u l a t i o n  o f  l i v e r  N K  
c e l l s  r e m a i n s  t o  b e  d e t e r m i n e d .  T h e  m i c r o - e n v i r o n m e n t  o f  t h e  l i v e r ,  a s  o p p o s e d  
t o  t h e  s p l e e n ,  m i g h t  f a c i l i t a t e  t h e  m a i n t e n a n c e  o f  T R A I L +  N K  c e l l s ,  s i n c e  s i g n a l s  
f r o m  s t r o m a l  c e l l s  a r e  k n o w n  t o  s u p p o r t  N K  c e l l  d i f f e r e n t i a t i o n  i n  v i v o  ( C o l u c c i  
e t  a l . ,  2 0 0 3 ;  I i z u k a  e t  a l . ,  1 9 9 9 ;  R o t h  e t  a l . ,  2 0 0 0 ;  W i l l i a m s  e t  a l . ,  1 9 9 9 ) .  
A l t e r n a t i v e l y ,  t h e  u n i q u e  p a t t e r n  o f  c y t o k i n e  a n d  c h e m o k i n e  r e c e p t o r ,  a n d / o r  
a d h e s i o n  m o l e c u l e  e x p r e s s i o n  o n  T R A I L +  N K  c e l l s  m i g h t  e n a b l e  t h e i r  r e t e n t i o n  
i n  t h e  l i v e r ,  s i n c e  c y t o k i n e s  a n d  c h e m o k i n e s  c r i t i c a l l y  c o n t r i b u t e  t o  N K  c e l l  
d e v e l o p m e n t  ( C o l u c c i  e t  a l . ,  2 0 0 3 ) .  
T h e  T R A I L - d e f i c i e n t  m i c e  g e n e r a t e d  i n  t h e  p r e s e n t  s t u d y  a r e  a  u n i q u e  t o o l  t h a t  
w i l l  b e  e x p l o i t e d  i n  t h e  r e m a i n i n g  c h a p t e r s  o f  t h i s  t h e s i s  t o  d e t e r m i n e  t h e  r o l e  o f  
T R A I L  i n  r e g u l a t i o n  o f  t u m o r  d e v e l o p m e n t ,  h o m e o s t a s i s  o f  t h e  i m m u n e  s y s t e m ,  
a n d  c o n t r o l  o f  a u t o i m m u n e  d i s e a s e  i n d u c t i o n .  
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CHAPTER THREE 
THE ROLE OF TRAIL IN NK CELL-MEDIATED 
TUMOR IMMUNITY 
1 ''\'7 
3 . 1  A b s t r a c t  
A l t h o u g h  r T R A I L  c a n  i n d u c e  s i g n i f i c a n t  t u m o r  r e g r e s s i o n  i n  v i v o  w i t h o u t  
s y s t e m i c  t o x i c i t y ,  l e s s  i s  k n o w n  a b o u t  t h e  r o l e  n a t u r a l  T R A I L  p l a y s  i n  t u m o r  
s u r v e i l l a n c e  i n  v i v o .  U s i n g  a  2 P K 3 - m T R A I L  t r a n s f e c t a n t  p r e v i o u s l y  s h o w n  t o  
i n d u c e  T R A I L - d e p e n d e n t  c y t o t o x i c i t y ,  w e  e x a m i n e d  t h e  s u s c e p t i b i l i t y  o f  1 6  
m u r i n e  t u m o r  c e l l  l i n e s  t o  T R A I L - m e d i a t e d  a p o p t o s i s  i n  v i t r o .  W e  i d e n t i f i e d  t h e  
B A L B / c - d e r i v e d  m a m m a r y  c a r c i n o m a s  4 T l . 2 ,  D A 3  a n d  E M T 6 . 5  t o  b e  
p a r t i c u l a r l y  T R A I L - s e n s i t i v e .  U s i n g  t h e  T R A I L  g e n e - t a r g e t e d  m i c e  c h a r a c t e r i z e d  
i n  C h a p t e r  2 ,  w e  n o w  d e m o n s t r a t e  t h a t  T R A I L  p l a y s  a n  i m p o r t a n t  r o l e  i n  t h e  
s u p p r e s s i o n  o f  4 T l . 2  a n d  D A 3  t u m o r  i n i t i a t i o n  a n d  m e t a s t a s i s ,  a n d  t h e  
t h e r a p e u t i c  e f f i c a c y  o f  a - G a l C e r .  P r e v i o u s  s t u d i e s  i n  o u r  l a b o r a t o r y  h a v e  s h o w n  
t h a t  N K G 2 D - m e d i a t e d  t u m o r  r e j e c t i o n  i s  p f p - d e p e n d e n t .  U s i n g  D A 3 - H 6 0  
r e t r o v i r a l  i n f e c t a n t s ,  w e  n o w  d e m o n s t r a t e  t h a t  T R A I L  p l a y s  a  m i n o r  r o l e  i n  
N K G 2 D - m e d i a t e d  t u m o r  r e j e c t i o n  i n  t h e  l u n g .  T h i s  s t u d y  i s  a m o n g s t  t h e  f i r s t  t o  
i n d i c a t e  a n  i m p o r t a n t  a n d  g e n e r a l  r o l e  f o r  T R A I L  i n  t h e  h o s t  d e f e n s e  a g a i n s t  
t r a n s f o r m e d  c e l l s .  O u r  d a t a  s u p p o r t  t h e  n o t i o n  t h a t  T R A I L ,  o r  s t i m u l a t i n g  t h e  
T R A I L  p a t h w a y ,  m a y  p r o v e  e f f e c t i v e  a s  a  c a n c e r  t h e r a p y  i n  v i v o .  
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3.2 Introduction 
The anti-tumor activity of rTRAIL has been clearly demonstrated in vivo against 
human colon carcinoma (Ashkenazi et al., 1999; LeBlanc et al., 2002), glioma 
(Fulda et al., 2002; Pollack et al., 2001 ), multiple myeloma (Mitsiades et al., 
2001) and breast carcinoma xenografts (Walczak et al., 1999). rTRAIL has also 
been reported to induce apoptosis in established xenografts (Ashkenazi et al., 
1999; Walczak et al., 1999), and to suppress the growth of xenografts of human 
tumor cells isolated from patients and grown only briefly in culture before 
transplantation into mice (Ashkenazi, 2002). Moreover, rTRAIL acts 
synergistically with ionizing radiation (Chinnaiyan et al., 2000) and certain 
chemotherapeutic drugs (Ashkenazi et al., 1999; Nagane et al., 2000) to cause 
regression and even remission of established tumor xenografts in vivo. Together 
these studies reveal the potential of rTRAIL as a cancer therapeutic, and highlight 
the importance of in depth studies to investigate the role of endogenous TRAIL in 
tumor surveillance. 
NK cells can mediate spontaneous killing of MHC class !-deficient tumor cells 
(Ljunggren and Karre, 1985; van den Broek et al., 1995), allowing them to kill 
cancerous host cells that have downregulated class I MHC expression in order to 
evade the adaptive immune response (Algarra et al., 2000). NK cells have also 
been established to play a role in control of tumor metastasis in vivo (Karre et al., 
1986; Smyth et al., 1999; Talmadge et al., 1980). TRAIL is constitutively 
expressed by a small proportion of liver NK cells in adult mice (Takeda et al., 
2001), and TRAIL expression can be induced on IL-2-, IL-15- and IFN-
stimulated NK cells (Kayagaki et al., 1999; Zamai et al., 1998). Recent studies in 
our laboratory have demonstrated that TRAIL blockade, using a neutralizing anti-
mTRAIL mAb, increased L929, LB27.4 and Renca experimental liver metastases 
in vivo (Takeda et al., 2001). Moreover, the anti-metastatic effect of TRAIL was 
not observed in mice depleted of NK cells, or in IFN-·y-!- mice that express low 
levels of TRAIL, suggesting that TRAIL contributes to NK cell-mediated tumor 
surveillance in the liver (Takeda et al., 2001). 
N K  c e l l  f u n c t i o n  i s  c o n t r o l l e d  b y  a  b a l a n c e  o f  N K  c e l l  i n h i b i t o r y  a n d  a c t i v a t i n g  
s i g n a l s  ( B i a s s o n i  e t  a l . ,  2 0 0 1 ;  C a m p b e l l  a n d  C o l o n n a ,  2 0 0 1 ;  D i e f e n b a c h  a n d  
R a u l e t ,  1 9 9 9 ;  D i e f e n b a c h  a n d  R a u l e t ,  2 0 0 1 ;  L a n i e r ,  2 0 0 0 ;  L a n i e r ,  2 0 0 1 ) .  N K c e l l  
i n h i b i t o r y  r e c e p t o r s  b i n d  t o  s e l f - M H C  c l a s s  I  m o l e c u l e s ,  w h e r e a s  N K  c e l l  
a c t i v a t i n g  r e c e p t o r s  b i n d  t o  l i g a n d s  e x p r e s s e d  o n  s t r e s s e d ,  t r a n s f o r m e d ,  a n d  v i r u s -
i n f e c t e d  c e l l s  ( B i a s s o n i  e t  a l . ,  2 0 0 3 ) .  T h e  N K G 2 D  r e c e p t o r  i s  a  t y p e  I I  
d i s u l p h i d e - l i n k e d  d i m e r  t h a t  c o n t a i n s  a  l e c t i n - l i k e  e x t r a c e l l u l a r  d o m a i n  ( D i n g  e t  
. a l . ,  1 9 9 9 ) .  I n  t h e  m o u s e ,  N K G 2 D  i s  e x p r e s s e d  o n  f r e s h l y  i s o l a t e d  N K  c e l l s ,  b u t  
a l s o  o n  L A K  c e l l s ,  a c t i v a t e d  C D S +  T  c e l l s  a n d  m a c r o p h a g e s  a s  w e l l  a s  s u b s e t s  o f  
N K T  a n d  y 8  T  c e l l s  ( J a m i e s o n  e t  a l . ,  2 0 0 2 ;  D i e f e n b a c h  e t  a l . ,  2 0 0 0 ) .  N K G 2 D  
r e c o g n i z e s  a n t i g e n s  e x p r e s s e d  o n  s t r e s s e d ,  v i r u s - a n d  b a c t e r i a - i n f e c t e d ,  a b n o r m a l  
o r  c a n c e r o u s  c e l l s  ( G r o h  e t  a l . ,  1 9 9 S ;  V e t t e r  e t  a l . ,  2 0 0 2 ) ,  a n d  p r o v i d e s  b o t h  
s t i m u l a t o r y  a n d  c o - s t i m u l a t o r y  s i g n a l s  t o  N K  c e l l s  ( D i e f e n b a c h  e t  a l . ,  2 0 0 0 ;  
D i e f e n b a c h  e t  a l . ,  2 0 0 2 ;  G i l f i l l a n  e t  a l . ,  2 0 0 2 ) .  M u r i n e  N K G 2 D  r e c o g n i z e s  t h e  
m i n o r  h i s t o c o m p a t i b i l i t y  m o l e c u l e  H 6 0 ,  m e m b e r s  o f  t h e  R a e - 1  f a m i l y  ( C e r w e n k a  
e t  a l . ,  2 0 0 0 ;  D i e f e n b a c h  e t  a l . ,  2 0 0 1 )  a n d  t h e  U L B P - l i k e  m o l e c u l e ,  M U L T - I  
( C a r a y a n n o p o u l o s  e t  a l . ,  2 0 0 2 ) .  R e j e c t i o n  o f  N K G 2 D  l i g a n d  e x p r e s s i n g  t u m o r  
c e l l s  i n  v i v o  i s  m e d i a t e d  b y  N K  a n d  C D S +  T  c e l l s  ( C e r w e n k a  e t  a l . ,  2 0 0 1 ;  
D i e f e n b a c h  e t  a l . ,  2 0 0 1 ) ,  a n d  i s  p f p - d e p e n d e n t  ( H a y a k a w a  e t  a l . ,  2 0 0 2 ) .  N K G 2 D -
m e d i a t e d  r e j e c t i o n  o f  H 6 0  e x p r e s s i n g  t u m o r s  i s  y e t  t o  b e  e x a m i n e d  i n  v i v o ,  a n d  
t h e  c o n t r i b u t i o n  o f  t h e  T N F - s u p e r f a m i l y  t o  N K G 2 D - s t i m u l a t e d  t u m o r  r e j e c t i o n  i s  
u n k n o w n .  
H e r e i n ,  w e  u s e  t h e  4  T l . 2  a n d  D A 3  m o u s e  m o d e l s  o f  b r e a s t  c a n c e r  m e t a s t a s i s ,  
a n d  t h e  T R A I L  g e n e - t a r g e t e d  m i c e  c h a r a c t e r i z e d  i n  C h a p t e r  2 ,  t o  s u b s t a n t i a t e  a  
r o l e  f o r  T R A I L  i n  a n t i - t u m o r  i m m u n i t y  i n  v i v o .  W e  a d d i t i o n a l l y  d e m o n s t r a t e  t h a t  
T R A I L  c o n t r i b u t e s  t o  t h e  t h e r a p e u t i c  e f f i c a c y  o f  a - G a l C e r  i n  t h e  m a m m a r y  g l a n d  
a n d  l i v e r ,  a n d  s h o w  t h a t  T R A I L  p l a y s  a  m i n o r  r o l e  i n  N K G 2 D - m e d i a t e d  t u m o r  
r e j e c t i o n  o f  l u n g  m e t a s t a s i s  i n  v i v o .  T o g e t h e r ,  o u r  f i n d i n g s  i n d i c a t e  t h a t  T R A I L  
p l a y s  a n  i m p o r t a n t  a n d  g e n e r a l  r o l e  i n  t u m o r  s u r v e i l l a n c e  i n  v i v o .  
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3.3 Materials and Methods 
Cell culture and reagents 
The BALB/c-derived renal adenocarcinoma cell line, Renca, the BALB/c-derived 
mammary carcinoma cell line, DA3, and 6-TG-resistant BALB/c-derived 
mammary carcinoma cell line, 4T1.2 were grown and maintained as detailed in 
Chapter 2, Section 2.1, Materials and Methods. The C57BL/6-derived T 
lymphoma cell line, EL4, the C57BL/6-derived prostate carcinoma cell line, RM-
1, the Lewis lung carcinoma cell line, 3LL (kindly provided by Dr. Robert 
Wiltrout, National Cancer Institute, Frederick Cancer Research and Development 
Center, Frederick, MD, USA), the BALB/c IFN-y1- MCA-induced tumors, IFN-y-
MCA2 and IFN-y-MCA3, the BALB/c MCA-induced tumors, BCMCA3 and 
BCMCA4, and the C57BL/6 pfP_1_ p53+/- PN53H1 tumor cell line (kindly 
provided by Shayna Street, Peter Mac) were maintained at 37°C, 10% C02 in 
DMEM supplemented with 10% (v/v) FCS and 2 mM L-glutamine. The 
BALB/c-derived mammary carcinoma cell line DA3 retrovirally infected with 
H60 (DA3-H60) or vector control (DA3-MSCV) (kindly provided by Janice 
Kelly, Peter Mac), the class !-deficient C57BL/6-derived lymphoma cell line, 
RMA-S, the B cell lymphoma cell line A20 (kindly provided by Dr. Thomas J. 
Sayers, Frederick, MD, USA), the p53_1_ T cell lymphoma cell lines K052-F11 
and K052-DA20 and the murine B lymphoma cell line 2PK3 and 2PK3 
transfected with mouse TRAIL (2PK3-mTRAIL) (kindly provided by Dr. Hideo 
Yagita, Juntendo University School of Medicine, Tokyo, Japan) were maintained 
at 37°C, 10% C02 in RPMI 1640 supplemented with 10% (v/v) FCS and 2 mM 
L-glutamine. The BALB/c derived breast carcinoma cell line EMT6.5 (kindly 
provided by Nicholas Clements, Peter Mac) was maintained at 37°C, 10% C02 in 
a-MEM supplemented with 10% (v/v) FCS and 2 mM L-glutamine. a-GalCer 
and control vehicle, and the anti-mTRAIL mAb (N2B2) were obtained and 
prepared as detailed in Chapter 2, Section 2.1, Materials and Methods . 
. Mice 
Inbred BALB/c WT mice were purchased from The WEHI. BALB/c TRAIL-1-, 
BALB/c pfP_;_ and BALB/c IFN-y1- mice were obtained and bred at Peter Mac as 
d e t a i l e d  i n  C h a p t e r  2 ,  S e c t i o n  2 . 1 ,  M a t e r i a l s  a n d  M e t h o d s .  B A L B / c  p : f p  a n d  
T R A I L - d e f i c i e n t  ( B A L B / c  p : f p _ ; _  T R A I L _
1
_ )  m i c e  w e r e  e s t a b l i s h e d  a t  P e t e r  M a c  b y  
c r o s s i n g  B A L B / c  p : f p _ ; _  a n d  B A L B / c  T R A I L _ ; _  m i c e  a n d  s u b s e q u e n t l y  
i n t e r b r e e d i n g  t h e  F
1  
g e n e r a t i o n .  A d u l t  m i c e  7 - 1 2  w e e k s  o f  a g e  w e r e  u s e d  i n  a l l  
e x p e r i m e n t s ,  u n d e r  s p e c i f i c  p a t h o g e n - f r e e  c o n d i t i o n s  a c c o r d i n g  t o  A n i m a l  
E x p e r i m e n t a l  E t h i c s  C o m m i t t e e  g u i d e l i n e s  a n d  a p p r o v a l .  
F l o w  c y t o m e t r i c  a n a l y s i s  
T h e  f o l l o w i n g  m A b  w e r e  u s e d  i n  m u l t i - p a r a m e t e r  f l o w  c y t o m e t r i c  a n a l y s i s :  a n t i -
m T R A I L - P E ,  r a t  I g G 2 a  i s o t y p e  c o n t r o l - P E ,  a n t i - H - 2 D d - b i o t i n  ( 3 4 - S - S S )  a n d  a n t i -
D R S - b i o t i n  ( M D S - 1 )  f o l l o w e d  b y  i n c u b a t i o n  w i t h  s t r e p t a v i d i n - P E .  T o  a v o i d  n o n -
s p e c i f i c  b i n d i n g  o f m A b s  t o  F c y R ,  a n t i - m o u s e  C D 1 6 / 3 2  ( 2 . 4 G 2 )  m A b  w a s  a d d e d  
t o  t h e  m A b  c o c k t a i l .  A n t i - m T R A I L - P E  ( N 2 B 2 )  w a s  o b t a i n e d  f r o m  e - B i o s c i e n c e ,  
a n t i - D R S - b i o t i n  w a s  k i n d l y  p r o v i d e d  b y  D r .  H i d e o  Y a g i t a  ( J u n t e n d o  U n i v e r s i t y  
S c h o o l  o f  M e d i c i n e ,  T o k y o ,  J a p a n )  a n d  t h e  r e m a i n i n g  r e a g e n t s  w e r e  s o u r c e d  
f r o m  B D  B i o s c i e n c e s  P h a r m i n g e n .  N K G 2 D  t e t r a m e r  a n d  T 2 2  c o n t r o l  t e t r a m e r  
w e r e  k i n d l y  p r o v i d e d  b y  D r .  D a v i d  R a u l e t  ( U n i v e r s i t y  o f  C a l i f o r n i a ,  B e r k e l e y ,  
C A ,  U S A ) .  A f t e r  w a s h i n g  t h e  c e l l s  w i t h  P B S / F C S / a z i d e ,  c e l l s  w e r e  a n a l y z e d  o n  a  
F A C S c a n ™  o r  F A C S D i v a ™  a n d  t h e  d a t a  p r o c e s s e d  b y  e i t h e r  C E L L Q u e s t ™  o r  
F C S - E x p r e s s  2  s o f t w a r e .  
M N C  p r e p a r a t i o n  
M i c e  w e r e  t r e a t e d  i . p .  w i t h  2  J . L g  a - G a l C e r  o n  d a y s  0  a n d  4 ,  p r i o r  t o  i s o l a t i o n  o f  
s p l e e n  a n d  h e p a t i c  M N C  o n  d a y  S .  L i v e r  a n d  s p l e e n  M N C  w e r e  i s o l a t e d  a n d  
p r e p a r e d  a s  d e t a i l e d  i n  C h a p t e r  2 ,  S e c t i o n  2 . 1 ,  M a t e r i a l s  a n d  M e t h o d s .  
C e l l u l a r  c y t o t o x i c i t y  a s s a y  
T h e  c y t o t o x i c  a c t i v i t i e s  o f  t h e  2 P K 3  p a r e n t a l  a n d  2 P K 3 - m T R A I L  t r a n s f e c t a n t s  
w e r e  d e t e r m i n e d  b y  
5 1
C r - r e l e a s e  a s s a y  a s  d e t a i l e d  i n  C h a p t e r  2 ,  S e c t i o n  2 . 1 ,  
M a t e r i a l s  a n d  M e t h o d s .  
5 1
C r - l a b e l l e d  t a r g e t s  w e r e  p l a c e d  i n  9 6 - w e l l  p l a t e s  ( 2  x  
1 0
4  
c e l l s / w e l l )  i n  2 0 0  J . L l  t o t a l  v o l u m e  a n d  i n c u b a t e d  i n  t h e  p r e s e n c e  o f  2 P K 3  
p a r e n t a l  o r  2 P K 3 - m T R A I L  t r a n s f e c t a n t s  a t  v a r i o u s  e f f e c t o r  t o  t a r g e t  c e l l  r a t i o s  
f o r  1 8  h  ( 3 7 ° C ,  S %  C 0 2 ) .  T h e  a s s a y  w a s  a l s o  p e r f o r m e d  i n  t h e  p r e s e n c e  o f  
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purified anti-mTRAIL (N2B2) mAb (1 J.lg/ml). Percent specific TRAIL-mediated 
lysis was determined by subtracting % specific lysis by 2PK3 parental cells from 
%specific lysis by 2PK3-mTRAIL transfected cells. 
The cytotoxic activity of spleen and liver MNC against Renca and 4T1.2 tumor 
targets was tested in an 8 h 51 Cr-release assay as detailed in Chapter 2, Section 
2.1, Materials and Methods. The assay was performed in the presence of purified 
control rat IgG2a (R35-95; 10 J.lg/ml), anti-mTRAIL mAb (N2B2; 10 J.lg/ml), 
and/or CMA (50 nM). 
4T1.2 mammary carcinoma growth and metastasis 
To examine 4T1.2 tumor growth within the peritoneum, female BALB/c WT, 
BALB/c TRAIC1-, BALB/c pfp-1-, BALB/c IFN-y-1- and BALB/c pfp_1_ TRAIC1-
mice were inoculated i.p. with between 1 to 10,000 4T1.2 cells and monitored for 
ascites development. Some mice were additionally injected with anti-mTRAIL 
mAb (N2B2; 500 J.lg i.p.) 3 times weekly. To examine primary tumor growth and 
spontaneous metastasis, female BALB/c WT or BALB/c TRAIC1- mice were 
inoculated s.c. in the abdominal mammary gland with 4T1.2 tumor cells at the 
doses indicated on day 0. Some groups of mice received either: anti-mTRAIL 
mAb (N2B2; 250 J.lg i.p.) on days 0, 1, 4, 7, 10, 14 and 21; anti-asialoGM1 
antibody (Wako Pure Chemicals, 200 J.lg i.p.) on days -1, 0, 7, and 14; and/or a-
GalCer (2 J.lg i.p.) on days 0,4, 8, 12 and 16. Primary tumors were measured 
every 4 days following tumor inoculation over the course of 30 days with a 
caliper square as the product of two perpendicular diameters ( cm2). Mice were 
sacrificed at 30 days and spontaneous metastasis in the liver and lung measured 
by colony assay. Liver samples were finely minced and digested in 5 ml enzyme 
cocktail (1 x PBS, 0.01% BSA, 1 mg/ml hyaluronidase and 1 mg/ml collagenase 
type 1, 20 min., 37°C). Lung samples were finely minced and digested in 5 ml 
enzyme cocktail (1 x PBS, 1 mg/ml collagenase type 4, 6 units/ml elastase, 1 h, 
. 4 °C). Digested samples were filtered through a 70 ~m nylon mesh and washed 3 
times with 1 x HBSS. Cells were then plated out neat or serially diluted in tissue 
culture dishes, in medium containing 60 ~ 6-TG for clonogenic growth. 6-TO-
resistant tumor cells formed foci within 10-14 days and were fixed with methanol 
a n d  s t a i n e d  w i t h  0 . 0 3 %  m e t h y l e n e  b l u e  f o r  c o u n t i n g .  C l o n o g e n i c  m e t a s t a s e s  w e r e  
c a l c u l a t e d  o n  a  p e r  o r g a n  b a s i s .  
D A 3  m a m m a r y  c a r c i n o m a  g r o w t h  a n d  m e t a s t a s i s  
T o  e x a m i n e  D A 3  p a r e n t a l  p r i m a r y  t u m o r  g r o w t h ,  f e m a l e  B A L B / c  W T  a n d  
B A L B / c  T R A I L - / - m i c e  w e r e  i n j e c t e d  s . c .  i n  t h e  h i n d  f l a n k  w i t h  5  x  1 0
5  
t o  3  x  1 0
6  
D A 3  c e l l s  a n d  t h e  t u m o r s  m e a s u r e d  e v e r y  o t h e r  d a y  w i t h  a  c a l i p e r  s q u a r e  f o r  a  
p e r i o d  o f  3 6  d a y s .  T o  e x a m i n e  D A 3 - M S C V  a n d  D A 3 - H 6 0  p r i m a r y  t u m o r  
g r o w t h ,  f e m a l e  B A L B / c  W T  m i c e  w e r e  i n j e c t e d  s . c .  w i t h  5  x  1 0
5  
D A 3  o r  D A 3 -
H 6 0  c e l l s  a n d  t h e  t u m o r s  m e a s u r e d  e v e r y  o t h e r  d a y  w i t h  a  c a l i p e r  s q u a r e  f o r  a  
p e r i o d  o f  4 5  d a y s .  A t  t h e  t e r m i n a t i o n  o f  t h e  e x p e r i m e n t ,  m i c e  w e r e  s a c r i f i c e d  a n d  
s p o n t a n e o u s  m e t a s t a s i s  m e a s u r e d  b y  h a r v e s t i n g  t h e  l u n g s ,  f i x i n g  t h e m  i n  B o u i n ' s  
s o l u t i o n  ( 7 5  m l  s a t u r a t e d  p i c r i c  a c i d ,  2 5  m l 4 0 %  f o m a l d e h y d e ,  5  m l  g l a c i a l  a c e t i c  
a c i d )  o v e r n i g h t  a n d  c o u n t i n g  t h e  n u m b e r  o f  m e t a s t a s e s  w i t h  t h e  a i d  o f  a  
d i s s e c t i n g  m i c r o s c o p e .  B A L B / c  W T ,  B A L B / c  T R A I L -
1
- ,  B A L B / c  p f p _
1
_  a n d  
B A L B / c  p f p _
1
_  T R A I L - / - m i c e  w e r e  a l s o  i n j e c t e d  i . v .  w i t h  b e t w e e n  5  x  1 0
4  
t o  5  x  
1 0
5  
D A 3  o r  D A 3 - H 6 0  c e l l s ,  s a c r i f i c e d  a f t e r  1 4  d a y s  a n d  t h e  n u m b e r  o f  l u n g  
m e t a s t a s e s  q u a n t i f i e d .  
R N A  i s o l a t i o n  a n d  R T  P C R  
T o  i s o l a t e  t o t a l  c e l l u l a r  R N A ,  1  x  1 0
7  
D A 3  o r  R e n c a  c e l l s  w e r e  l y s e d  i n  1  m l  
T R i z o l  ( I n v i t r o g e n  L i f e  T e c h n o l o g i e s ,  G a i t h e r s b u r g ,  M D ,  U S A )  a n d  i n c u b a t e d  a t  
R T  f o r  5  m i n .  A  f u r t h e r  1  m l  T R i z o l  a n d  0 . 2  m l  C H C b  w e r e  a d d e d ,  t h e  c e l l s  
s h a k e n  v i g o r o u s l y  f o r  1 5  s e c o n d s  a n d  i n c u b a t e d  a t  R  T  f o r  3  m i n .  A f t e r  
c e n t r i f u g a t i o n  ( 1 2 , 0 0 0  X  g ,  1 5  m i n . ,  4  ° C ) ,  t h e  a q u e O U S  p h a s e  w a s  t r a n s f e r r e d  t o  a  
c l e a n  t u b e  a n d  t h e  R N A  p r e c i p i t a t e d  w i t h  1  m l  i s o p r o p y l  a l c o h o l  ( 1 0  m i n . ,  R T ) .  
T h e  t u b e  w a s  t h e n  c e n t r i f u g e d  ( 1 2 , 0 0 0  x  g ,  1 5  m i n . ,  4 ° C ) ,  t h e  s u p e r n a t a n t  
r e m o v e d  a n d  t h e  R N A  w a s h e d  w i t h  1  m l  7 0 %  e t h a n o l .  T h e  R N A  p e l l e t  w a s  t h e n  
a i r - d r i e d  f o r  1 0  m i n . ,  a n d  r e s u s p e n d e d  i n  1 0 0  J ! l  R N a s e - f r e e  w a t e r  ( D E P C -
t r e a t e d ) .  R e v e r s e  t r a n s c r i p t i o n  w a s  p e r f o r m e d  u s i n g  2  J i g  o f  t o t a l  R N A  i n  a  f i r s t -
s t r a n d  e D N A  s y n t h e s i s  r e a c t i o n  w i t h  M u r i n e .  R e v e r s e  T r a n s c r i p t a s e  ( N e w  
E n g l a n d  B i o L a b s  I n c ,  B e v e r l y ,  M A ,  U S A ) .  P C R  w a s  t h e n  p e r f o r m e d  u s i n g  7  J . t l  
o f  t h e  R T  p r o d u c t .  T h e  f o l l o w i n g  o l i g o n u c l e o t i d e s  s p e c i f i c  f o r  H 6 0  s e q u e n c e s  
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were used in the PCR: 5' primer, 5'-CTCATGGCAAAGGGAGCCAC C-3'; and 
3' primer, 5'-CTATTTTTTTTCTTCAGCATACACCAAGCG-3'. The PCR (30 
cycles) was conducted in a Peltier thermal cycler PTC-200 (MJ Research Inc, 
Watertown, MA, USA). Each cycle included denaturation (95°C, 1 min), 
annealing (58°C, 1 min), and extension (72°C, 2 min). The initial denaturation 
period was 5 min. and the final extension was 7 min. As a negative control, the 
RT product was omitted from the PCR reaction. Amplified products were 
analyzed by DNA gel electrophoresis in 2% agarose, and visualized by ethidium 
bromide staining under UV illumination in an ImageMaster VDS (Pharrnacia 
Biotech). 
Statistical Analysis 
Data were analyzed using a two tailed, non-parametric, unpaired Mann Whitney 
test. P values< 0.05 were considered significant. 
3 . 4  R e s u l t s  
3 . 4 . 1  S e n s i t i v i t y  o f  m o u s e  t u m o r  c e l l  l i n e s  t o  T R A I L - m e d i a t e d  c y t o t o x i c i t y  
A l t h o u g h  a  n u m b e r  o f  T R A I L - s e n s i t i v e  h u m a n  t u m o r  c e l l s  l i n e s  h a v e  b e e n  
i d e n t i f i e d  ( P i t t i  e t  a l . ,  1 9 9 6 ;  W i l e y  e t  a l . ,  1 9 9 5 ) ,  l e s s  i s  k n o w n  a b o u t  t h e  
s e n s i t i v i t y  o f  m o u s e  t u m o r  c e l l  l i n e s  t o  T R A I L - m e d i a t e d  c y t o t o x i c i t y .  W e  
s c r e e n e d  a  p a n e l  o f  m o u s e  t u m o r  c e l l  l i n e s  f o r  t h e i r  s e n s i t i v i t y  t o  T R A I L -
m e d i a t e d  c y t o t o x i c i t y  i n  v i t r o ,  u s i n g  a  2 P K 3 - m T R A I L  t r a n s f e c t a n t  p r e v i o u s l y  
d e m o n s t r a t e d  t o  i n d u c e  T R A I L - d e p e n d e n t  a p o p t o s i s  ( K a y a g a k i  e t  a l . ,  1 9 9 9 ) .  
I n i t i a l l y ,  c e l l  s u r f a c e  e x p r e s s i o n  o f  m T R A I L  w a s  v e r i f i e d  o n  t h e  2 P K 3 - m T R A I L  
t r a n s f e c t a n t  c e l l s  a n d  s h o w n  t o  b e  a b s e n t  o n  2 P K 3  p a r e n t a l  c e l l s  ( F i g u r e  3 . 1  A ) .  
T o  c o n f i r m  t h a t  2 P K 3 - m T R A I L  c e l l s  i n d u c e d  T R A I L - d e p e n d e n t  c y t o t o x i c i t y  i n  
v i t r o ,  t r a n s f e c t a n t  c e l l s  w e r e  t e s t e d  f o r  t h e i r  a b i l i t y  t o  l y s e  T R A I L - s e n s i t i v e  
R e n c a  t u m o r  t a r g e t  c e l l s  i n  a n  1 8  h  
5 1
C r  r e l e a s e  a s s a y .  A s  e x p e c t e d ,  2 P K 3 -
m T R A I L  c e l l s  s i g n i f i c a n t l y  l y s e d  R e n c a  t a r g e t s ,  e v e n  a t  l o w  e f f e c t o r  t o  t a r g e t  
r a t i o s  ( F i g u r e  3 . 1 B ) ,  a n d  a d d i t i o n  o f  n e u t r a l i z i n g  a n t i - m T R A I L  m A b  c o m p l e t e l y  
a b r o g a t e d  c y t o t o x i c i t y  ( F i g u r e  3 . 1  C ) .  I n  c o n t r a s t ,  n o  s i g n i f i c a n t  c y t o t o x i c i t y  w a s  
o b s e r v e d  w i t h  2 P K 3  p a r e n t a l  c e l l s  ( F i g u r e  3 . 1  B ) .  T h e  s e n s i t i v i t y  o f  a  n u m b e r  o f  
m o u s e  t u m o r  c e l l  l i n e s  t o  T R A I L - m e d i a t e d  c y t o t o x i c i t y  w a s  t h e n  c o m p a r e d  
r e l a t i v e  t o  R e n c a  a t  a n  e f f e c t o r  t o  t a r g e t  r a t i o  o f  5 0 : 1 .  T h e  B A L B / c - d e r i v e d  
m o u s e  m a m m a r y  c a r c i n o m a s  4 T l . 2 ,  D A 3  a n d  E M T 6 . 5  w e r e  f o u n d  t o  b e  
p a r t i c u l a r l y  T R A I L - s e n s i t i v e ,  w h i l s t  a  n u m b e r  o f  t u m o r  c e l l  l i n e s  i n c l u d i n g  t h e  
C 5 7 B L / 6 - d e r i v e d  R M A - S  l y m p h o m a ,  a n d  L e w i s  l u n g  c a r c i n o m a  3 L L  w e r e  
T R A I L - r e s i s t a n t  ( F i g u r e  3 . 2 )  ( A p p e n d i x  I I ) .  I n t e r e s t i n g l y ,  t h e  m a j o r i t y  o f  
B A L B / c - d e r i v e d  t u m o r  c e l l  l i n e s  w e r e  T R A I L - s e n s i t i v e ,  w h i l s t  t h e  m a j o r i t y  o f  
C 5 7 B L / 6 - d e r i v e d  t u m o r  c e l l  l i n e s  w e r e  r e l a t i v e l y  T R A I L - r e s i s t a n t .  T o  v e r i f y  t h i s  
t r e n d ,  g r e a t e r  n u m b e r s  o f  B A L B / c - a n d  C 5 7 B L / 6 - d e r i v e d  m o u s e  t u m o r  c e l l  l i n e s  
n e e d  t o  b e  t e s t e d  f o r  t h e i r  s e n s i t i v i t y  t o  T R A I L - m e d i a t e d  k i l l i n g .  
3 . 4 . 2  T R A I L - m e d i a t e d  s u p p r e s s i o n  o f  4 T 1 . 2  t u m o r  g r o w t h  
T h e  4 T l . 2  m o u s e  m a m m a r y  c a r c i n o m a  i s  h i g h l y  t u m o r i g e n i c  a n d  s p o n t a n e o u s l y  
m e t a s t a t i c  i n  s y n g e n e i c  B A L B / c  m i c e  ( A s l a k s o n  a n d  M i l l e r ,  1 9 9 2 ;  M i l l e r  e t  a l . ,  
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Figure 3.1. Characterization of mouse TRAIL transfectants. (A) Cell surface staining of2PK3 
and 2PK3-mTRAIL transfectant cells with anti-mTRAIL or isotype control mAb. Red histograms 
represent staining with anti-mTRAIL mAb, black histograms represent staining with isotype 
matched control mAb. Data are representative of over 10 independent experiments. (B) The 
cytotoxic activity of2PK3 and 2PK3-mTRAIL cells against Renca tumor targets was tested in an 
18 h 51Cr release assay. Data represent mean± SEM of triplicate samples. Data are representative 
of over 20 independent experiments. (C) Cytotoxic activity of 2PK3-mTRAIL cells was tested in 
the presence or absence of I j.lg/ml anti-mTRAIL mAb in an 18 h 51 Cr release assay at an 
effector:target ratio of 50:1. Data represent mean ± SEM of triplicate samples. Asterisks in (B) 
indicate that lysis by 2PK3-mTRAIL transfectants is significantly different to lysis by 2PK3 cells, 
and (C) indicate that lysis in the presence and absence of anti-mTRAIL mAb is significantly 
different (* P < 0.03). Data are representative of 8 independent experiments. 
3  
Q )  
: G  2 . 5  
r o  
a > - -
. _  . . -
> . I I  2  
. . . . .  _ . .  
· : ; :  r o  
: ; : : : ;  ( . . )  
· - c  
~ Q )  1 . 5  
Q ) o : : :  
e n  o  
_ _ .  . . . . .  1  
~ 
1 - 0 . 5  
0  
N  
( ' i )  
1 . 0  
0  
c t l  
< (  
c O  
N  
( . )  




< (  
c :  
Q )  
" < t  
2  
0 : : :  
w  
. . . . .  
( ' i )  
( ' i )  
" < t  
0  
. . . . .  _ J  
( / )  I  
~ 
~ 
. . . . .  
< (  < (  
_ J  
~ 
I  
_ J  
< (  
( ' i )  
L L .  w  
2  
( ' i )  
( )  ( )  
2  
1 . 0  
( )  
( )  
I  
0 : : :  
N  
2  2  
0  




1 . 0  
I  





( )  >  
~ 
z  
[ ( l  
1 . 0  
[ ( l  
z  
L L .  
0  
L L .  
~ 
M o u s e  t u m o r  c e l l  l i n e  
F i g u r e  3 . 2 .  S e n s i t i v i t y  o f  m o u s e  t u m o r  c e l l  l i n e s  t o  T R A I L - m e d i a t e d  c y t o t o x i c i t y .  T h e  
c y t o t o x i c  a c t i v i t y  o f 2 P K 3 - m T R A I L  t r a n s f e c t a n t  c e l l s  a g a i n s t  v a r i o u s  m o u s e  t u m o r  c e l l  l i n e s  w a s  
t e s t e d  i n  a n  1 8  h  
5 1
C r  r e l e a s e  a s s a y .  P e r c e n t  s p e c i f i c  T R A I L - m e d i a t e d  l y s i s  w a s  d e t e r m i n e d  b y  
s u b t r a c t i n g  p e r c e n t  s p e c i f i c  l y s i s  b y  2 P K 3  p a r e n t a l  c e l l s  f r o m  %  s p e c i f i c  l y s i s  b y  2 P K 3 - m T R A I L  
t r a n s f e c t a n t  c e l l s .  P e r c e n t  s p e c i f i c  T R A I L - m e d i a t e d  l y s i s  f o r  e a c h  c e l l  l i n e  i s  s h o w n  r e l a t i v e  t o  
l y s i s  o f  R e n c a  ( = 1 )  a t  a n  e f f e c t o r : t a r g e t  r a t i o  o f  5 0 : 1 ,  a n d  a r e  r e p r e s e n t a t i v e  o f  t h o s e  a c r o s s  t h e  
e f f e c t o r : t a r g e t  r a t i o  o f  1 0 0  t o  1 : 1 .  D a t a  r e p r e s e n t  m e a n  ±  S E M  o f  3 - 2 0  i n d e p e n d e n t  e x p e r i m e n t s  
f o r  t h e  5  m o s t  s e n s i t i v e  c e l l  l i n e s ,  a n d  1 - 2  i n d e p e n d e n t  e x p e r i m e n t s  f o r  a l l  r e m a i n i n g  c e l l  l i n e s .  
1 3 8  
1983). Following injection into the mammary fat pad, the 4Tl.2 tumor 
spontaneously metastasizes to the lung, liver, LNs, bone, brain and peripheral 
blood. The 4T1.2 model is one of the best available models of breast cancer 
metastatic disease and has proven useful for testing various immunotherapies in 
vivo (Lin et al., 1998; Pulaski et al., 2000a; Pulaski and Ostrand-Rosenberg, 
1998; Pulaski et al., 2000b; Rakhmilevich et al., 2000). Given that 4 T1.2 cells 
were found to be particularly TRAIL-sensitive, we chose to investigate the role of 
TRAIL in tumor surveillance using this model. 
We first examined the growth of 4T1.2 tumor cells injected into the peritoneum 
of BALB/c WT, BALB/c TRAIL_;_ and BALB/c WT mice treated with a 
neutralizing anti-mTRAIL mAb. The 4T1.2 tumor was observed to grow as 
ascites within the peritoneal cavity. At the higher doses of 4 T1.2 cells inoculated 
(1,000 and 10,000 cells i.p.), all mice developed tumor and were sacrificed 15-36 
days post-inoculation (Figure 3.3). At lower doses of 4Tl.2 cells inoculated (10 
and 100 cells i.p.), mice lacking TRAIL were more susceptible to tumor growth 
(Figure 3.3). Whilst 4/4 BALB/c TRAIC1- mice and 4/4 BALB/c WT mice 
treated with anti-mTRAIL mAb succumbed to tumor when inoculated with 100 
4Tl.2 cells i.p., only 1/4 BALB/c WT mice developed tumor at this dose. 
Moreover, 1/4 BALB/c TRAIL_;_ and 2/4 BALB/c WT mice treated with anti-
mTRAIL mAb developed tumor when inoculated with 10 cells i.p., whereas all 
BALB/c WT mice were tumor free. These results suggested that TRAIL inhibited 
4T1.2 tumor growth within the peritoneum. 
To ascertain whether TRAIL-mediated inhibition of 4Tl.2 i.p. tumor growth was 
dependent upon p:tp or IFN-')', we assessed tumor growth in BALB/c p:tp-l- or 
BALB/c IFN-y1- mice treated with a neutralizing anti-mTRAIL mAb or PBS. At 
the higher doses of 4T1.2 cells inoculated (100 and 1000 cells i.p.), all mice 
developed tumor, except 2/4 BALB/c p:tp_1_ mice inoculated with 100 4Tl.2 cells 
i.p. that remained tumor free (Figure 3.4). This suggested that mice deficient in 
p:tp are less susceptible to 4T1.2 i.p. tumor growth than mice deficient in IFN-')'. 
When 10 4T1.2 cells were inoculated i.p., tumor development was equivalent in 
BALB/c IFN-y1- mice with or without treatment with a neutralizing anti-
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N u m b e r  o f  4 T 1 . 2  t u m o r  c e l l s  a d m i n i s t e r e d  i . p .  
F i g u r e  3 . 3 .  T R A I L  s u p p r e s s e s  4 T 1 . 2  i n t r a p e r i t o n e a l  ( i . p . )  t u m o r  g r o w t h .  G r o u p s  o f  f e m a l e  
B A L B / c  o r  B A L B / c  T R A I C
1
- m i c e  w e r e  i n o c u l a t e d  o n  d a y  0  w i t h  1 0 ,  1 0 0 ,  1 0 0 0  o r  1 0 , 0 0 0  4 T l . 2  
m a m m a r y  c a r c i n o m a  c e l l s  i . p .  S o m e  B A L B / c  m i c e  w e r e  a d d i t i o n a l l y  t r e a t e d  w i t h  5 0 0  1 1 g  a n t i -
m T R A I L  m A b  i . p .  o n  d a y s  0 ,  1 ,  7  a n d  1 4 .  M i c e  w e r e  m o n i t o r e d  f o r  a s c i t e s  d e v e l o p m e n t  a n d  
s a c r i f i c e d  w h e n  m o r i b u n d .  F o u r  m i c e  a r e  s h o w n  f o r  e a c h  g r o u p  f o r  e a c h  t u m o r  d o s a g e ,  w i t h  e a c h  
m o u s e  r e p r e s e n t e d  b y  a n  i n d i v i d u a l  s y m b o l .  M i c e  t h a t  s u r v i v e d  p a s t  1 0 0  d a y s  w e r e  d e e m e d  t u m o r  
f r e e .  D a t a  a r e  r e p r e s e n t a t i v e  o f 3  i n d e p e n d e n t  e x p e r i m e n t s .  
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Figure 3.4. TRAIL-mediated clearance of 4T1.2 i.p. tumor is IFN-y-dependent. Groups of 
female BALB/c ptp·l- or BALB/c IFN-y·l- mice were inoculated on day 0 with 1, 10, 100 or 1000 
4Tl.2 mammary carcinoma cells i.p. Some BALB/c ptp·l- and BALB/c IFN-y1- mice were 
additionally treated with 500 ~g anti-mTRAIL mAb i.p. on days 0, 1, 7 and 14. Mice were 
monitored for ascites development and sacrificed when moribund. Four mice are shown for each 
group for each tumor dosage, with each mouse represented by an individual symbol. Mice that 
survived past 120 days were deemed tumor free. 
m T R A I L  m A b ,  s u g g e s t i n g  t h a t  T R A I L - m e d i a t e d  r e j e c t i o n  o f  4 T l . 2  i . p .  t u m o r  i s  
I F N - ' ) ' - d e p e n d e n t  ( F i g u r e  3 . 4 ) .  I n  c o n t r a s t ,  3 / 4  B A L B / c  p f p _
1
_  m i c e  i n o c u l a t e d  
w i t h  t e n  4 T l . 2  c e l l s  i . p .  r e m a i n e d  t u m o r  f r e e ,  w h i l s t  a l l  B A L B / c  p f p _
1
_  m i c e  
t r e a t e d  w i t h  a  n e u t r a l i z i n g  a n t i - m T R A I L  m A b  s u c c u m b e d  t o  t u m o r  ( F i g u r e  3 . 4 ) .  
T h i s  s u g g e s t e d  t h a t  T R A I L - m e d i a t e d  r e j e c t i o n  o f  4  T 1 . 2  t u m o r  i n  t h e  p e r i t o n e u m  
i s  p f p - i n d e p e n d e n t .  
3 . 4 . 3  T R A I L - m e d i a t e d  s u p p r e s s i o n  o f  4 T 1 . 2  s u b c u t a n e o u s  ( s . c . )  t u m o r  
g r o w t h  
W e  n e x t  a s s e s s e d  p r i m a r y  t u m o r  g r o w t h  o f  4 T l . 2  t u m o r  c e l l s  i n j e c t e d  i n t o  t h e  
m a m m a r y  g l a n d  o f  B A L B / c  W T ,  B A L B / c  T R A I C
1
- a n d  B A L B / c  W T  m i c e  
t r e a t e d  w i t h  a  n e u t r a l i z i n g  a n t i - m T R A I L  m A b .  A t  t h e  l o w e r  d o s e s  o f  4 T l . 2  
t u m o r  c e l l s  i n j e c t e d  ( 5  x  1 0
3  
a n d  1  x  1 0
4
) ,  t u m o r  g r o w t h  w a s  e n h a n c e d  i n  
B A L B / c  T R A I L _ ; _  a n d  B A L B / c  W T  m i c e  t r e a t e d  w i t h  a  n e u t r a l i z i n g  a n t i -
m T R A I L  m A b ,  c o m p a r e d  t o  B A L B / c  W T  m i c e  ( F i g u r e  3 . 5 A  a n d  B ) .  T u m o r  
g r o w t h  w a s  a c c e l e r a t e d  e v e n  f u r t h e r  i n  m i c e  d e p l e t e d  o f  N K  c e l l s  u s i n g  a n t i -
a s i a l o G M 1  A b  ( F i g u r e  3 . 5 A  a n d  B ) .  A t  t h e  h i g h e s t  d o s e  o f  t u m o r  c e l l s  i n o c u l a t e d  
( 2 . 5  x  1 0
4
) ,  t h e  i m m u n e  s y s t e m  o f  t h e  m i c e  w a s  o v e r c o m e  a n d  m a x i m u m  t u m o r  
g r o w t h  w a s  o b s e r v e d  f o r  a l l  g r o u p s  ( F i g u r e  3 . 5 C ) .  T o g e t h e r ,  t h e s e  d a t a  
d e m o n s t r a t e d  t h a t  T R A I L  n a t u r a l l y  s u p p r e s s e d  4  T 1 . 2  t u m o r  g r o w t h  i n  v i v o ,  a n d  
i m p o r t a n t l y ,  i n  t h e  m a m m a r y  g l a n d  i t s e l f ,  a  s i t e  n o t  p r e v i o u s l y  e x a m i n e d  f o r  
T R A I L  f u n c t i o n .  O u r  d a t a  a d d i t i o n a l l y  i n d i c a t e d  t h a t  N K  c e l l s  p l a y  a n  i m p o r t a n t  
r o l e  i n  s u p p r e s s i o n  o n  4 T l . 2  t u m o r  g r o w t h  i n  t h e  m a m m a r y  g l a n d .  
3 . 4 . 4  a - G a l C e r  s t i m u l a t e s  T R A I L - m e d i a t e d  c y t o t o x i c i t y  
A d m i n i s t r a t i o n  o f  I F N - ' ) '  h a s  p r e v i o u s l y  b e e n  s h o w n  t o  r a p i d l y  i n d u c e  T R A I L  
e x p r e s s i o n  i n  t h e  l i v e r  a n d  s p l e e n  o f C 5 7 B U 6  I F N - y
1
- m i c e  ( T a k e d a  e t  a l . ,  2 0 0 1 ) .  
A s  a - G a l C e r  h a s  p r e v i o u s l y  b e e n  s h o w n  t o  p o t e n t l y  s t i m u l a t e  V a 1 4  i n v a r i a n t -
N K T  c e l l s  t o  p r o d u c e  h i g h  l e v e l s  o f  I F N - ' ) '  ( K a w a n o  e t  a l . ,  1 9 9 7 ) ,  w e  n e x t  
e x a m i n e d  t h e  e f f e c t  o f  a - G a l C e r  t r e a t m e n t  o n  T R A I L  f u n c t i o n .  L i v e r  M N C  
i s o l a t e d  f r o m  B A L B / c  W T  m i c e  t r e a t e d  w i t h  a - G a l C e r  d i s p l a y e d  a u g m e n t e d  
c y t o t o x i c i t y  a g a i n s t  4 T 1 . 2  a n d  R e n c a  t a r g e t s  ( F i g u r e  3 . 6 A ) ,  t h a t  w a s  p a r t i a l l y  
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Figure 3.5. TRAIL contributes to the suppression of 4Tl.2 primary tumor growth in the 
mammary fat pad. Groups of female BALB/c or BALB/c TRAIL-/- mice were inoculated on day 
0 into the abdominal mammary fat pad with (A) 5 x 103, (B) I x 104 or (C) 2.5 x 104 4Tl.2 
mammary carcinoma cells. Some BALB/c mice were additionally treated with 200 !lg anti-
asialoGM1 Ab on days -1, 0, 7 and 14, or 250 !lg anti-mTRAIL mAb i.p. on days 0, 1, 4, 7, 10, 14 
and 2 I. Tumor size was measured over the course of 30 days. Data represent mean ± SEM of 5 
mice in each group. (D) Groups of female BALB/c or BALB/c TRAIL-/- mice were inoculated on 
day 0 into the abdominal mammary fat pad with 2.5 x 104 4Tl.2 mammary carcinoma cells and 
were i.p. administered with 2 !lg of a-GalCer on days 0, 4, 8, 12 and 16. Some groups of mice 
were additionally treated with 200 11g anti-asialoGM1 Ab on days -1, 0, 7 and 14, or 250 11g anti-
mTRAIL mAb i.p. on days 0, 1, 4, 7, 10, 14 and 21. Tumor size was measured over the course of 
30 days. Data represent mean± SEM of 5 mice in each group. 
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s p l e e n ) .  D a t a  r e p r e s e n t  m e a n  ±  S E M  o f  t r i p l i c a t e  s a m p l e s .  A s t e r i s k s  i n d i c a t e  g r o u p s  t h a t  a r e  
s i g n i f i c a n t l y  d i f f e r e n t  t o  c o n t r o l  ( *  P  <  0 . 0 5 ) .  D a t a  a r e  r e p r e s e n t a t i v e  o f  2  i n d e p e n d e n t  
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1 4 4  
abrogated by the addition of neutralizing anti-mTRAIL mAb and completely 
inhibited by the addition ofboth anti-mTRAIL mAb and CMA. Liver MNC from 
BALB/c TRAIL-/- mice treated with a-GalCer displayed increased p:tp-mediated 
cytotoxicity against 4Tl.2 and Renca targets, but did not display TRAIL-
mediated cytotoxicity (Figure 3.6A). Together, these data indicated that a-GalCer 
treatment can augment both TRAIL- and p:tp-dependent cytotoxicity. 
Spleen MNC isolated from BALB/c WT miCe treated with a-GalCer also 
displayed augmented cytotoxicity against 4T1.2 and Renca targets (Figure 3.6B), 
that was partially abrogated by the addition of neutralizing anti-mTRAIL mAb 
and completely inhibited by the addition of both anti-mTRAIL mAb and CMA. 
In contrast, spleen MNC from BALB/c TRAIC1- mice treated with a-GalCer 
displayed increased p:tp-mediated cytotoxicity against 4T1.2 and Renca targets 
but did not display TRAIL-mediated cytotoxicity (Figure 3.6B). These data 
indicated that a-GalCer can stimulate both TRAIL- and p:tp-dependent 
cytotoxicity in spleen MNC. 
3.4.5 Therapeutic efficacy of a-GalCer on 4T1.2 tumor growth and 
metastasis 
a-GalCer has previously been shown to enhance NK cell killing of tumor cells 
when administered to mice (Kitamura et al., 1999). As we had shown that a-
GalCer treatment stimulated TRAIL-mediated killing by liver and spleen MNCs, 
and NK cells and TRAIL suppress 4Tl.2 tumor growth in the mammary gland, 
we next investigated whether TRAIL plays a role in the therapeutic efficacy of a-
GalCer in vivo. The a-GalCer treatment regime (2 J..lg i.p. on days 0, 4, 8, 12 and 
16) was chosen based on previous efficacy studies in the Renca tumor model 
(Smyth et al., 2001). Whilst a-GalCer treatment significantly inhibited the 
growth of 4Tl.2 cells in the mammary gland (Figure 3.5D), a-GalCer had no 
effect in mice depleted of NK cells, and was only partially effective in BALB/c 
TRAIL-/- mice and BALB/c WT mice treated with a neutralizing anti-mTRAIL 
mAb (Figure 3.5D). These findings indicated that TRAIL played a significant 
r o l e  i n  t h e  N K  c e l l - m e d i a t e d  t h e r a p e u t i c  e f f i c a c y  o f  a - G a l C e r  a g a i n s t  4 T 1 . 2  
t u m o r  g r o w t h  i n  t h e  m a m m a r y  g l a n d .  
F o l l o w i n g  i n j e c t i o n  i n t o  t h e  m a m m a r y  g l a n d ,  t h e  4 T l . 2  t u m o r  s p o n t a n e o u s l y  
m e t a s t a s i z e s  t o  a  n u m b e r  o f  s i t e s ,  i n c l u d i n g  t h e  l u n g  a n d  l i v e r .  G i v e n  t h a t  a -
G a l C e r  s i g n i f i c a n t l y  i n h i b i t e d  4 T l . 2  p r i m a r y  t u m o r  g r o w t h  i n  t h e  m a m m a r y  
g l a n d ,  w e  e x a m i n e d  t h e  e f f e c t  o f  a - G a l C e r  o n  4  T 1 . 2  l u n g  a n d  l i v e r  m e t a s t a s i s .  a -
G a l C e r  s i g n i f i c a n t l y  r e d u c e d  b o t h  l u n g  a n d  l i v e r  m e t a s t a s i s  i n  B A L B / c  W T  m i c e  
( P  <  0 . 0 1 )  ( F i g u r e  3 . 7 ) .  M o r e o v e r ,  t h e  a n t i - m e t a s t a t i c  e f f e c t  o f  a - G a l C e r  w a s  
c o m p l e t e d  a b r o g a t e d  i n  m i c e  d e p l e t e d  o f  N K  c e l l s ,  i n d i c a t i n g  a  c r i t i c a l  
c o n t r i b u t i o n  b y  N K  c e l l s  ( F i g u r e  3 . 7 ) .  I n  t h e  l u n g ,  t h e  a n t i - m e t a s t a t i c  e f f e c t  o f  a -
G a l C e r  w a s  T R A I L - i n d e p e n d e n t  ( F i g u r e  3 . 7 ) .  I n  c o n t r a s t ,  a - G a l C e r  w a s  o n l y  
p a r t i a l l y  e f f e c t i v e  i n  t h e  l i v e r  o f  B A L B / c  T R A I L - / - m i c e  a n d  B A L B / c  W T  m i c e  
t r e a t e d  w i t h  a  n e u t r a l i z i n g  a n t i - m T R A I L  m A b  ( F i g u r e  3 .  7 ) ,  s u g g e s t i n g  t h a t  
T R A I L  c o n t r i b u t e s  t o  t h e  a n t i - m e t a s t a t i c  e f f e c t  o f  a - G a l C e r  i n  t h e  l i v e r .  
3 . 4 . 6  T R A I L - m e d i a t e d  s u p p r e s s i o n  o f  D A 3  s . c .  t u m o r  g r o w t h  
A s  D A 3  t u m o r  c e l l s  w e r e  f o u n d  t o  b e  p a r t i c u l a r l y  T R A I L - s e n s i t i v e  i n  v i t r o ,  w e  
i n v e s t i g a t e d  t h e  r o l e  o f  T R A I L  i n  t u m o r  s u r v e i l l a n c e  u s i n g  t h e  D A 3  m o d e l  o f  
b r e a s t  c a n c e r  m e t a s t a s i s .  W e  f i r s t  a s s e s s e d  s . c .  g r o w t h  o f  D A 3  t u m o r  c e l l s  
i n j e c t e d  i n t o  B A L B / c  W T  a n d  B A L B / c  T R A I L - / - m i c e .  D A 3  t u m o r  g r o w t h  w a s  
a c c e l e r a t e d  i n  B A L B / c  T R A I L - / - c o m p a r e d  t o  B A L B / c  W T  m i c e  a t  a l l  d o s e s  
t e s t e d  ( F i g u r e  3 . 8 ) .  T h i s  i n d i c a t e d  t h e  p o t e n c y  o f  T R A I L  i n  e r a d i c a t i o n  o f  a  b o l u s  
o f  t u m o r  c e l l s  t r a n s p l a n t e d  a t  a  p e r i p h e r a l  s i t e .  
3 . 4 .  7  G e n e r a t i o n  o f  D A 3 - H 6 0  i n f e c t a n t s  
P r e v i o u s l y ,  N K  a n d  C D S +  T  c e l l s  h a v e  b e e n  i d e n t i f i e d  t o  r e j e c t  N K G 2 D  l i g a n d  
e x p r e s s i n g  t u m o r  c e l l s  i n  v i v o  ( C e r w e n k a  e t  a l . ,  2 0 0 1 ;  D i e f e n b a c h  e t  a l . ,  2 0 0 1 ) .  
R e c e n t  s t u d i e s  i n  o u r  l a b o r a t o r y  h a v e  d e m o n s t r a t e d  t h a t  N K G 2 D  c a n  s t i m u l a t e  
p f p - m e d i a t e d  r e j e c t i o n  o f  N K G 2 D  l i g a n d  e x p r e s s i n g  t u m o r  c e l l s  i n  v i v o  
( H a y a k a w a  e t  a l . ,  2 0 0 2 ) .  A s  t h e  c o n t r i b u t i o n  o f  t h e  T N F - s u p e r f a m i l y  t o  N K G 2 D -
s t i m u l a t e d  t u m o r  r e j e c t i o n  i s  u n k n o w n ,  w e  c h o s e  t o  i n v e s t i g a t e  t h e  r o l e  o f  T R A I L  
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Figure 3.7. TRAIL contributes to the suppression of 4T1.2 spontaneous metastasis. Groups 
of female BALB/c or BALB/c TRAIC1- mice were inoculated on day 0 into the abdominal 
mammary fat pad with 2.5 x 104 4Tl.2 mammary carcinoma cells. Some mice were additionally 
administered i.p. with 2 ~g of a-GalCer on days 0, 4, 8, 12 and 16, and/or 200 ~g anti-asialoGM 1 
Ab on days -1, 0, 7 and 14, or 250 ~g anti-mTRAIL mAb i.p. on days 0, 1, 4, 7, 10, 14 and 21. 
Mice were sacrificed at 30 days, their lungs and livers harvested and metastases counted by 
colony assay. Data represent mean ± SEM of 5 mice in each group, with the significance 
compared with a-GalCer-treated BALB/c WT mice(* P < 0.01). a-GalCer was also statistically 
effective alone compared with no treatment in the livers and lungs of BALB/c WT mice (* P < 
0.01). 
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S E M  o f  5  m i c e  i n  e a c h  g r o u p .  D a t a  a r e  r e p r e s e n t a t i v e  o f  4  i n d e p e n d e n t  e x p e r i m e n t s  f o r  e a c h  d o s e  
i n o c u l a t e d .  
1 4 8  
m the pnmary immunity generated by the DA3 tumor cells expressing the 
NKG2D ligand H60. Initially, DA3-MSCV (vector alone control) and DA3-H60 
infectants were produced by retroviral transduction. H60 expression was 
examined on these cells using a NKG2D tetramer that specifically binds to cells 
that express NKG2D ligand (Figure 3.9). A high level of NKG2D ligand 
expression was detected on DA3-H60 infectant cells and a low level on DA3-
MSCV control cells (Figure 3.9). To verify the low level of NKG2D ligand 
expression detected in DA3 parental cells, mRNA from DA3 parental cells was 
analyzed by RT-PCR. A low intensity H60 amplification product 740bp in size 
was detected in DA3 cells (Figure 3.10), confirming a low level of H60 
expression in these cells. MHC class I (H-2Dd) and TRAIL receptor (DR5) 
expression were additionally examined on DA3-MSCV and DA3-H60 cells and 
found to be equivalent (Figure 3.1 0). This ensured that any detectable differences 
in tumor rejection of DA3-MSCV and DA3-H60 cells in vivo were due to H60 
expression rather than the ability of these cells to evade detection by NK cells or 
their susceptibility to TRAIL-mediated killing. 
3.4.8 H60-mediated inhibition of DA3 s.c. tumor growth and metastasis 
To investigate whether H60 expressed on DA3 cells could induce tumor 
rejection, BALB/c WT mice were injected s.c. with either DA3-H60 or DA3-
MSCV control cells. The DA3 mouse mammary carcinoma spontaneously 
metastasizes to the lung when injected s.c. in mice. DA3-H60 cells were rejected 
more avidly than DA3-MSCV control cells, confirming that H60 expression 
induced primary tumor rejection (Figure 3.11 A). Spontaneous metastasis to the 
lung (Figure 3.11B) was also decreased in mice injected with DA3-H60 
compared to DA3-MSCV control cells, illustrating that H60 can potently 
stimulate NK cell-mediated tumor rejection in vivo. 
3.4.9 H60-mediated inhibition of spontaneous DA3 lung metastasis 
. DA3 tumor cells injected i.v. into mice spontaneously metastasize to the lung. 
We next investigated the relative contribution ofptp and TRAIL in the rejection 
of spontaneous DA3-H60 lung metastasis in vivo. BALB/c WT, BALB/c ptp-1-, 
N K G 2 D  
t e t r a m e r  
H - 2 D d  
D R 5  
1 . . -
Q )  
. . 0  
E  
: : l  
z  
Q )  
0  
Q )  
>  
: O J  
r o  
Q )  
0 : : :  
D A 3 - M S C V  
D A 3 - H 6 0  
F l u o r e s c e n c e  I n t e n s i t y  ~ 
F i g u r e  3 . 9 .  C h a r a c t e r i z a t i o n  o f  D A 3 - H 6 0  r e t r o v i r a l  i n f e c t a n t s .  C e l l  s u r f a c e  s t a i n i n g  o f  D A 3 -
M S C V  a n d  D A 3 - M S C V - H 6 0  i n f e c t a n t s  w i t h  N K G 2 D  t e t r a m e r  o r  c o n t r o l  T 2 2 - t e t r a m e r ,  a n t i - H -
2 D d  m A b ,  a n t i - D R S  m A b  o r  i s o t y p e  c o n t r o l  m A b .  R e d  h i s t o g r a m s  r e p r e s e n t  s t a i n i n g  w i t h  
N K G 2 D  t e t r a m e r ,  a n t i - H - 2 D d  m A b  o r  a n t i - D R S  m A b  a s  i n d i c a t e d .  B l a c k  h i s t o g r a m s  r e p r e s e n t  
s t a i n i n g  c o n t r o l  T 2 2 - t e t r a m e r ,  o r  w i t h  i s o t y p e  m a t c h e d  c o n t r o l  m A b .  D a t a  a r e  r e p r e s e n t a t i v e  o f  S  
i n d e p e n d e n t  e x p e r i m e n t s .  














........ Q) en 





















Figure 3.10. Detection of H60 transcript in DA3 cells. RNA was isolated from DA3 cells (or 
Renca as a positive control), and first-strand eDNA synthesis was performed, followed by PCR 
amplification using specific primers to H60. As a negative control, the RT product was omitted 
from the PCR reaction. Samples were separated on a 2% agarose gel, and DNA visualized by 
ethidium bromide staining under UV illumination. An H60 amplification product of 740bp is 
shown for Renca and DA3 cells. 
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1 5 2  
BALB/c TRAIL_;_ and BALB/c pfp_1_ TRAIL_;_ mice were injected with DA3-
MSCV or DA3-H60 cells i.v. and lung metastases quantified after 14 days. At all 
doses of tumor tested, H60 expression significantly reduced the number of lung 
metastasis in BALB/c WT mice, and completely suppressed metastasis at the 
lowest dose oftumor cells inoculated (5 x 104) (Figure 3.12). H60 expression also 
reduced numbers of lung metastasis in BALB/c pfp_1_ and BALB TRAIL-/- mice, 
but had no effect on the number of lung metastasis in BALB/c pfp_1_ TRAIL_1_ 
mice (Figure 3.12). These data suggested that NKG2D stimulated pfp- and 
TRAIL-mediated rejection of DA3-H60 lung metastasis, and pfp played a 
dominant role in this process. 
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B o u i n ' s  s o l u t i o n  a n d  m e t a s t a s e s  c o u n t e d .  D a t a  r e p r e s e n t  m e a n ±  S E M  ( n =  5 / g r o u p ) .  A s t e r i s k s  a n d  
p a r e n t h e s e s  i n d i c a t e  g r o u p s  t h a t  a r e  s i g n i f i c a n t l y  d i f f e r e n t ( *  P  <  0 . 0 0 8 ) .  
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3.5 Discussion 
Despite the breadth of knowledge regarding rTRAIL, less is known about the role 
TRAIL plays in natural tumor immunity. This knowledge is fundamental if the 
TRAIL pathway is to be used safely and with efficacy in the clinic. In the present 
study, we identified a number of TRAIL-sensitive mouse tumor models that were 
useful to dissect the role of TRAIL in tumor surveillance. In particular, the 
TRAIL-sensitive 4 T1.2 and DA3 mouse mammary carcinomas that closely 
approximate human breast cancer metastatic disease will be useful in the future to 
assess TRAIL function in a number of sites including the brain, bone, LN, 
peripheral blood, lung and liver. Interestingly, we observed that a large 
proportion of BALB/c-derived tumor cells lines were TRAIL-sensitive, whilst the 
majority of C57BL/6-derived tumor cell lines were resistant to TRAIL-mediated 
apoptosis. Whilst the differences in sensitivities are quite striking, these tumor 
cell lines have undergone extensive in vitro passage in tissue culture, and the 
differences may just be random. In Chapter 2 we reported decreased constitutive 
TRAIL expression on NK cells in BALB/c compared to C57BL/6 mice. 
Moreover, TRAIL-sensitive tumors have been reported to preferentially emerge 
in anti-mTRAIL mAb-treated mice (Takeda et al., 2002). From these findings, we 
speculate that decreased TRAIL expression in BALB/c mice might predispose 
them to the development of TRAIL-sensitive tumors, that are typically eliminated 
in C57BL/6 mice. 
During this candidature, our laboratory reported that endogenous TRAIL 
expressed on liver NK cells was at least partially responsible for the suppression 
of TRAIL-sensitive L929, LB27.4 and Renca experimental liver metastasis in 
vivo (Smyth et al., 2001; Takeda et al., 2001 ). Our study is the first to 
demonstrate TRAIL-mediated suppression of tumor growth in a number of 
unique sites including the peritoneum, mammary gland and lung. Whether 
TRAIL is constitutively expressed on cells within these unique sites is of great 
interest, particularly in the mammary gland, a common site of human neoplasia. 
In addition, it would be interesting to examine whether TRAIL+ NK cells migrate 
into these sites, or whether NK cells become activated and express TRAIL within 
t h e s e  s i t e s  i n  r e s p o n s e  t o  t u m o r  g r o w t h .  F u t u r e  e x p e r i m e n t s  u s i n g  t h e  4 T l . 2  
b r e a s t  c a n c e r  m e t a s t a s i s  m o d e l  t h a t  m e t a s t a s i z e s  t o  s i t e s  i n c l u d i n g  p e r i p h e r a l  
b l o o d ,  b o n e  a n d  b r a i n ,  a n d  t h e  T R A I L  g e n e - t a r g e t e d  m i c e  d e s c r i b e d  i n  t h i s  t h e s i s  
w i l l  b e  u s e f u l  t o  a s s e s s  T R A I L  f u n c t i o n  i n  n o v e l  s i t e s .  
A l t h o u g h  a  n u m b e r  o f  s t u d i e s  h a v e  e v a l u a t e d  t h e  t h e r a p e u t i c  e f f i c a c y  o f  a -
G a l C e r  i n  t h e  s u p p r e s s i o n  o f  t u m o r  m e t a s t a s e s ,  f e w  s t u d i e s  h a v e  a s s e s s e d  t h e  
a b i l i t y  o f  a - G a l C e r  t o  c o n t r o l  p r i m a r y  t u m o r  g r o w t h .  S u p p r e s s i o n  o f  t u m o r  
g r o w t h  a t  t h e  p r i m a r y  s i t e  m i g h t  b e  u s e f u l  t o  e l i m i n a t e  r e s i d u a l  c a n c e r  c e l l s  t h a t  
h a v e  f a i l e d  t o  b e  c l e a r e d  f r o m  t h e  p r i m a r y  t u m o r  s i t e  p o s t - s u r g e r y .  O u r  s t u d y  h a s  
i n d i c a t e d  t h a t  a - G a l C e r  c a n  s t i m u l a t e  N K  c e l l s  a n d  T R A I L  t o  c o n t r o l  p r i m a r y  
t u m o r  g r o w t h  i n  t h e  m a m m a r y  g l a n d ,  s u g g e s t i n g  t h a t  a - G a l C e r - t r e a t r n e n t  m i g h t  
b e  b e n e f i c i a l  f o r  t h e  t r e a t m e n t  o f  p a t i e n t s  w i t h  b r e a s t  c a n c e r .  U s i n g  t h e  4 T 1 . 2  
m o d e l ,  w e  a d d i t i o n a l l y  s h o w e d  t h a t  T R A I L  c o n t r i b u t e d  t o  t h e  a n t i - m e t a s t a t i c  
e f f e c t  o f  a - G a l C e r  i n  t h e  l i v e r ,  b u t  n o t  i n  t h e  l u n g .  F u r t h e r  s t u d i e s  i n  o u r  
l a b o r a t o r y  u s i n g  t h e  R e n c a  r e n a l  c a r c i n o m a  t u m o r  m o d e l  s i m i l a r l y  i d e n t i f i e d  a  
c o n t r i b u t i o n  b y  T R A I L  t o  t h e  a n t i - m e t a s t a t i c  e f f e c t  o f  a - G a l C e r  i n  t h e  l i v e r ,  b u t  
n o t  i n  t h e  l u n g  ( S m y t h  e t  a l . ,  2 0 0 1 ) .  I n  a g r e e m e n t  w i t h  o u r  f i n d i n g s ,  
a d m i n i s t r a t i o n  o f  a - G a l C e r  i n  v i v o  s t i m u l a t e d  T R A I L  e x p r e s s i o n  a n d  c y t o t o x i c  
a c t i v i t y  i n  t h e  l i v e r  N K  c e l l s ,  b u t  n o t  i n  l u n g  N K  c e l l s  ( S m y t h  e t  a l . ,  2 0 0 1 ) .  
I m p o r t a n t l y ,  a l t h o u g h  o u r  s t u d i e s  h a v e  i n d i c a t e d  t h a t  u - G a l C e r  c a n  l i m i t  t h e  
g r o w t h  a n d  e s t a b l i s h m e n t  o f  t u m o r s  i n  v i v o ,  f u t u r e  s t u d i e s  a r e  r e q u i r e d  t o  
d e t e r m i n e  w h e t h e r  u - G a l C e r  t r e a t m e n t  c a n  s u p p r e s s  t h e  g r o w t h  o f  e s t a b l i s h e d  
t u r n  o r s  i n  v i v o .  
D u r i n g  t h i s  c a n d i d a t u r e ,  a  n u m b e r  o f  a d d i t i o n a l  s t u d i e s  u n d e r t a k e n  i n  o u r  
l a b o r a t o r y  a n d  o t h e r s  h a v e  g r e a t l y  c o n t r i b u t e d  t o  o u r  k n o w l e d g e  o f  t h e  r o l e  
T R A I L  p l a y s  i n  a n t i - t u m o r  i m m u n i t y .  I m p o r t a n t l y ,  t h e  T R A I L  g e n e - t a r g e t e d  
m i c e  c h a r a c t e r i z e d  i n  t h e  c u r r e n t  s t u d y  w e r e  u s e d  t o  i d e n t i f y  a  r o l e  f o r  T R A I L  i n  
n a t u r a l  h o s t  p r o t e c t i o n  f r o m  M C A - i n d u c e d  f i b r o s a r c o m a  d e v e l o p m e n t  ( C r e t n e y  
e t  a l . ,  2 0 0 2 ) .  M o r e o v e r ,  T R A I L - s e n s i t i v e  M C A - i n d u c e d  t u m o r s  w e r e  i d e n t i f i e d  
t o  p r e f e r e n t i a l l y  e m e r g e  i n  a n t i - r n T R A I L  r n A b - t r e a t e d ,  N K  c e l l - d e p l e t e d ,  a n d  
I F N - y
1
- m i c e ,  i n d i c a t i n g  t h a t  T R A I L  p l a y s  a n  i m p o r t a n t  r o l e  i n  N K  c e l l - a n d  I F N -
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y-mediated immune surveillance (Takeda et al., 2002). A role for TRAIL in 
natural protection from spontaneous tumor development in C57BL/6 p53+/- mice 
was also identified (Takeda et al., 2002). In a separate study, transfection of 
TRAIL-sensitive R331 renal carcinoma cells with cFLIP increased the number of 
liver metastasis in mice inoculated with this tumor, illustrating the importance of 
TRAIL-mediated apoptosis in control of tumor growth in vivo (Seki et al., 2003). 
TRAIL-mediated necrosis and apoptosis of tumor cells were also described, in 
studies using rTRAIL adenovirus (Griffith et al., 2000; Kemp et al., 2003b). The 
same group of researchers also reported that specific CpG-containing 
oligodeoxynucleotides can induce TRAIL expression and anti-tumor activity in 
human B cells and macrophages, implicating these cells in the suppression of 
tumor growth (Kemp et al., 2003a; Kemp et al., 2004). IL-12 administration was 
additionally reported to induce TRAIL expression and cytotoxic activity on lung 
and liver NK cells, and the anti-metastatic activity of IL-12 in these organs was 
partially mediated by TRAIL (Smyth et al., 2001). Together these studies, 
combined with those reported herein, reveal an important and general role for 
TRAIL in tumor surveillance. 
NKG2D ligand-expressing tumor cells are rejected by NK and CDS+ T cells in 
vivo (Cerwenka et al., 2001; Diefenbach et al., 2001). Recent studies in our 
laboratory have demonstrated the importance of p:tp-mediated cytotoxicity in 
NKG2D-mediated tumor rejection in vivo (Hayakawa et al., 2002). Given that we 
had identified TRAIL to be important in NK cell-mediated tumor surveillance in 
vivo, we hypothesized that TRAIL might play a role in NKG2D-mediated tumor 
rejection by NK cells. The previous study that identified p:tp to be important in 
NKG2D-mediated tumor rejection in vivo utilized TRAIL-resistant RMA-S 
lymphoma cells. In our study, we used TRAIL-sensitive DA3-H60 infectant cells 
to demonstrate that TRAIL plays a minor role in NKG2D-mediated rejection of 
lung metastasis. Given that the anti-tumor activity of endogenous TRAIL is 
greater in the liver compared to the lung, it would be interesting to evaluate the 
contribution of TRAIL to NKG2D-mediated rejection of liver metastases. 
T o g e t h e r  o u r  s t u d i e s  u s i n g  a n t i - m T R A I L  m A b  a n d  T R A I L  g e n e - t a r g e t e d  m i c e  
h a v e  s u p p o r t e d  a  d i r e c t  r o l e  f o r  T R A I L  i n  s u p p r e s s i o n  o f  4 T l . 2  a n d  D A 3  t u m o r  
i n i t i a t i o n  a n d  m e t a s t a s i s ,  a n d  t h e  t h e r a p e u t i c  e f f i c a c y  o f  a - G a l C e r  i n  t h e  l i v e r  a n d  
m a m m a r y  g l a n d .  O u r  r e s u l t s  a d d i t i o n a l l y  i n d i c a t e d  t h a t  T R A I L  p l a y e d  a  m i n o r  
r o l e  i n  N K G 2 D - m e d i a t e d  r e j e c t i o n  o f  H 6 0  e x p r e s s i n g  t u m o r  c e l l s  i n  v i v o .  
I n c r e a s i n g  o u r  k n o w l e d g e  o f  t h e  r o l e  o f  T R A I L  i n  n a t u r a l  t u m o r  i m m u n i t y  w i l l  
a l l o w  m o r e  e f f e c t i v e  d e s i g n  o f  f u t u r e  c l i n i c a l  t r i a l s  u s i n g  r T R A I L  t o  t r e a t  c a n c e r .  
M a n i p u l a t i n g  T R A I L  a c t i v i t y  u s i n g  n o v e l  c o m p o u n d s  s u c h  a s  a - G a l C e r  m i g h t  
a l s o  p r o v e  e f f e c t i v e  i n  t h e  s u p p r e s s i o n  o f  t u m o r  i n i t i a t i o n  a n d  m e t a s t a s i s  i n  v i v o .  
I m p o r t a n t l y ,  o u r  s t u d i e s  m i g h t  a l l o w  f o r  a d v a n c e  p r e d i c t i o n s  t o  b e  m a d e  o n  t h e  
r e l a t i v e  e f f e c t i v e n e s s  o f  v a r i o u s  T R A I L  t h e r a p i e s  (  e g .  a d j u v a n t s  a n d  c y t o k i n e  
t h e r a p i e s )  b a s e d  o n  t h e  s i t e  o f  t h e  p r i m a r y  t u m o r ,  t h e  s i t e  o f  t i s s u e  m e t a s t a s e s  a n d  
t h e  i n h e r e n t  s e n s i t i v i t y  o f  t h e  t u m o r  t o  T R A I L - m e d i a t e d  a p o p t o s i s .  
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CHAPTER FOUR 
THE ROLE OF TRAIL AND TNF IN 
IMMUNOREGULATION 
4 . 1  A b s t r a c t  
I n  C h a p t e r  3 ,  T R A I L  w a s  d e m o n s t r a t e d  t o  s u p p r e s s  t u m o r  i n i t i a t i o n ,  g r o w t h  a n d  
m e t a s t a s i s .  I n  a d d i t i o n  t o  a n  a n t i - t u m o r  f u n c t i o n ,  s o m e  m e m b e r s  o f  t h e  T N F  
s u p e r f a m i l y ,  s u c h  a s  F a s L ,  p l a y  a  m a j o r  r o l e  i n  h o m e o s t a s i s  o f  t h e  p e r i p h e r a l  
i m m u n e  s y s t e m .  G l d  m i c e  t h a t  c a r r y  a  l o s s  o f  f u n c t i o n  m u t a t i o n  i n  t h e  F a s L  g e n e ,  
d e v e l o p  s p l e n o m e g a l y ,  l y m p h a d e n o p a t h y ,  h y p e r g a m m a g l o b u l i n e m i a ,  s t r a i n -
d e p e n d e n t  a u t o i m m u n e  d i s e a s e  a n d  s u c c u m b  t o  p r e m a t u r e  d e a t h  a s  a  
c o n s e q u e n c e  o f  i m p a i r e d  p e r i p h e r a l  d e l e t i o n  o f  a c t i v a t e d  l y m p h o c y t e s .  G l d  m i c e  
h a v e  a l s o  b e e n  r e p o r t e d  t o  d e v e l o p  p l a s m a c y t o m a s  w i t h  a g e ,  s u g g e s t i n g  a  r o l e  f o r  
t h e  F a s / F a s L  p a t h w a y  i n  t h e  i n h i b i t i o n  o f  t u m o r  d e v e l o p m e n t .  P r e v i o u s l y ,  w e  
h a v e  s h o w n  t h a t  m i c e  d e f i c i e n t  f o r  b o t h  F a s L  a n d  T N F  h a v e  a  s u b s t a n t i a l l y  
m i l d e r  g l d  p h e n o t y p e  w i t h  r e g a r d  t o  m o r t a l i t y ,  l y m p h o a c c u m u l a t i o n ,  
h y p e r g a m m a g l o b u l i n e m i a  a n d  G C  f o r m a t i o n .  H e r e i n ,  w e  i n v e s t i g a t e  f u r t h e r  t h e  
e f f e c t  o f  T R A I L  d e f i c i e n c y  o n  t h e  g l d  p h e n o t y p e  b y  g e n e r a t i n g  m i c e  d e f i c i e n t  f o r  
b o t h  F a s L  a n d  T R A I L .  P l a s m a c y t o m a  d e v e l o p m e n t  i n  a g e d  C 5 7 B L / 6  g l d  T N F
1
;  
m i c e  w a s  a l s o  e x a m i n e d .  W e  r e p o r t  t h a t  a b s e n c e  o f  T R A I L  h a s  n o  d i s c e m a b l e  
e f f e c t  o n  t h e  g l d  p h e n o t y p e  a n d  t h a t  T N F  i s  n o t  r e q u i r e d  f o r  p l a s m a c y t o m a  
d e v e l o p m e n t  i n  a g e d  C 5 7 B L / 6  g l d  m i c e .  
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4.2 Introduction 
Homeostasis of the immune system is controlled at several stages of lymphocyte 
development and involves both activation/proliferation and cell death. The 
importance of the Fas/FasL pathway in lymphocyte homeostasis is clearly 
demonstrated in mice carrying loss of function mutations in the Fas (lpr, 
lymphoproliferation) or FasL (gld, generalized lymphoproliferative disease) 
genes (Adachi et al., 1993; Takahashi et al., 1994; Watanabe-Fukunaga et al., 
1992; Watson et al., 1992) or human ALPS patients who harbor Fas/FasL 
deficiencies (Fisher et al., 1995; Rieux-Laucat et al., 1995; Drappa et al., 1996). 
Gld and lpr mice develop lymphadenopathy, splenomegaly, hypergammaglobuli-
nemia, strain-dependent autoimmune disease and succumb to premature death 
(Cohen and Eisenberg, 1991; Izui et al., 1984; Roths et al., 1984; Theofilopoulos 
and Dixon, 1981 ). Lymphoproliferative disease in ALPS patients, and lpr and gld 
mice, is characterized by an accumulation of B220+TCRa~+CD4-CD8- double 
negative (B220+ DN) T cells in LNs and spleen (Cohen and Eisenberg, 1991; 
Rieux-Laucat et al., 1999; Sneller et al., 1997) that are typically eliminated by 
Fas/FasL interactions. 
Previously we examined the effect of TNF deficiency on the gld phenotype by 
generating mice doubly deficient in FasL and TNF (Korner et al., 2000). 
Lymphoaccumulation was markedly reduced in C57BL/6 gld TNF1- compared to 
C57BL/6 gld mice (Figure 4.1). From the age of 16 weeks, the weight of 
secondary lymphoid organs [mesenteric LN (mLN), pLN and spleen] 
dramatically increased in C57BL/6 gld mice, but only slightly increased in 
C57BL/6 gld TNF1- mice compared to C57BL/6 and C57BL/6 TNF1- controls 
(Figure 4.1 ). As hypergammaglobulinemia and circulating autoantibodies are 
hallmark features of the gld phenotype (Cohen and Eisenberg, 1991), the 
concentration of serum IgG, anti-IgG autoantibody and anti-dsDNA autoantibody 
were also compared. From 16 weeks of age, the concentration of serum IgG was 
20-65% lower in C57BL/6 gld TNF1- compared to C57BL/6 gld mice (Figure 
4.2). However, serum IgG levels in C57BL/6 gld TNF1- mice were still elevated 
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F i g u r e  4 . 1 .  R e d u c e d  l y r n p h o a c c u r n u l a t i o n  i n  m i c e  d o u b l y  d e f i c i e n t  f o r  F a s L  a n d  T N F .  ( A )  
m L N  ( 2  r a n d o m l y  c h o s e n ) ,  ( B )  p L N  ( t w o  a x i l l a r y ,  t w o  c e r v i c a l  a n d  t w o  i n g u i n a l )  a n d  ( C )  s p l e e n  
w e i g h t s  a r e  s h o w n  i n  m i l l i g r a m s  ( m g )  f o r  C 5 7 B L / 6 ,  C 5 7 B L / 6  T N F
1
- ,  C 5 7 B L / 6  g l d  a n d  C 5 7 B L / 6  
g l d  T N F
1
- m i c e  a t  4 ,  8 ,  1 2 ,  1 6 ,  2 0 ,  2 4  a n d  2 8  w e e k s  o f  a g e .  D a t a  r e p r e s e n t  m e a n ±  S E M  o f  s i x  
m i c e  a t  e a c h  t i m e  p o i n t ,  f o r  e a c h  g e n o t y p e .  A s t e r i s k s  i n d i c a t e  t h e  g r o u p s  o f  C 5 7 B L / 6  g l d  m i c e  
t h a t  a r e  s i g n i f i c a n t l y  d i f f e r e n t  f r o m  C 5 7 B L / 6  g l d T N F "
1
- m i c e ( *  P  <  0 . 0 4 ) .  
P l e a s e  n o t e :  D a t a  s h o w n  i n  F i g u r e  4 . 1  w a s  g e n e r a t e d  b y  E r i k a  C r e t n e y  p r i o r  t o  u n d e r t a k i n g  
P h D  c a n d i d a t u r e  ( K o r n e r  e t  a l . ,  2 0 0 0 ) .  
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Figure 4.2. Reduced serum lgG but equivalent autoantibody production in mice doubly 
deficient for FasL and TNF. Serum was isolated from C57BL/6 (•), C57BL/6 TNF1-(o), 
C57BL/6 gld (..._)and C57BL/6 gld TNF1- (~)mice at 4, 8, 12, 16, 20, 24 and 28 weeks of age 
and tested by ELISA for (A) total concentration of IgG, (B) anti-IgG autoantibody (IgM, B). The 
concentration of anti-IgG autoantibodies are shown relative to that observed for 28 week 
C57BL/6 gld mice (1 Unit was defined as the mean of absorbance at 405nm for 28 week 
C57BL/6 g/dmice). Mean± SEM for (A) were calculated from the analysis of four to six mice at 
each time point, for each genotype. In (B), four to nine mice are shown at each time point, for 
each genotype, with each mouse represented by an individual symbol. Asterisks indicate groups 
ofC57BL/6 g/dmice that are significantly different from C57BL/6 gldTNF1- mice(* P < 0.05). 
Please note: Data shown in Figure 4.2 was generated by Erika Cretney prior to undertaking 
PhD candidature (Korner et al., 2000). 
1 0 - 2 0 - f o l d  c o m p a r e d  w i t h  c o n t r o l  C 5 7 B L / 6  a n d  C 5 7 B L / 6  T N F
1
- m i c e ,  
s u g g e s t i n g  t h a t  T N F  o n l y  p l a y s  a  m i n o r  r o l e  i n  h y p e r g a m m a g l o b u l i n e m i a  
a s s o c i a t e d  w i t h  g l d  ( F i g u r e  4 . 2 A ) .  A n a l y s i s  o f  s e r u m  a n t i - d s D N A  ( d a t a  n o t  
s h o w n ) ,  a n d  a n t i - I g G  ( F i g u r e  4 . 2 B )  a u t o a n t i b o d y  l e v e l s  i n  C 5 7 B L / 6  g l d  a n d  
C 5 7 B L / 6  g l d  T N F
1
- m i c e  f a i l e d  t o  r e v e a l  a  r o l e  f o r  T N F  i n  a u t o a n t i b o d y  
p r o d u c t i o n ,  a l t h o u g h  t h e  q u a l i t a t i v e  e f f e c t  o f  t h e s e  a n t i b o d i e s  w a s  n o t  e x a m i n e d .  
T o  f u r t h e r  c h a r a c t e r i z e  t h e  r o l e  o f  T N F  i n  c o n t r i b u t i n g  t o  t h e  g l d  p h e n o t y p e ,  
B 2 2 0 +  D N  T  c e l l  a c c u m u l a t i o n  w a s  e x a m i n e d .  A l t h o u g h  p r o p o r t i o n s  o f  B 2 2 0 +  
D N  T  c e l l s  w e r e  e q u i v a l e n t  i n  C 5 7 B L / 6  g l d  a n d  C 5 7 B L / 6  g l d  T N F
1
- s p l e e n ,  t o t a l  
n u m b e r s  o f  t h e s e  c e l l s  w e r e  i n c r e a s e d  i n  C 5 7 B L / 6  g l d  m i c e ,  d u e  t o  i n c r e a s e d  
s p l e e n  s i z e  i n  t h e s e  m i c e .  I n  c o n t r a s t ,  p r o p o r t i o n s  o f  B 2 2 0 +  D N  T  c e l l s  w e r e  
d e c r e a s e d  i n  t h e  b l o o d  o f  C 5 7 B L / 6  g l d  T N F
1
- c o m p a r e d  t o  C 5 7 B L / 6  g l d  m i c e ,  
s u g g e s t i n g  t h a t  p e r i p h e r a l  a c c u m u l a t i o n  o f  t h e s e  a b n o r m a l  c e l l s  i s  r e t a r d e d  i n  
m i c e  l a c k i n g  T N F .  I m p o r t a n t l y ,  o u r  p r e v i o u s  s t u d y  s h o w e d  t h a t  T N F  a l s o  
c o n t r i b u t e d  t o  t h e  m o r t a l i t y  a s s o c i a t e d  w i t h  g l d ,  a s  o n l y  4 . 1 %  o f  C 5 7 B L / 6  g l d  
T N F
1
- m i c e  d i e d  b y  4 2 0  d a y s ,  c o m p a r e d  w i t h  3 1 . 9 %  o f  C 5 7 B L / 6  g l d  m i c e .  
A l t h o u g h  T N F  c l e a r l y  c o n t r i b u t e s  t o  t h e  l y m p h o a c c u m u l a t i o n  a n d  p r e m a t u r e  
d e a t h  a s s o c i a t e d  w i t h  t h e  g l d  p h e n o t y p e ,  t h e  m e c h a n i s m  u s e d  b y  T N F  t o  
e x a c e r b a t e  d i s e a s e  h a s  n o t  b e e n  d e t e r m i n e d .  T N F  i s  k n o w n  t o  p r o m o t e  
l y m p h o c y t e  t r a f f i c k i n g  t o ,  a n d  w i t h i n ,  l y m p h o i d  o r g a n s  b y  i n d u c i n g  c h e m o k i n e  
p r o d u c t i o n  ( N g o  e t  a l . ,  1 9 9 9 ;  S e d g w i c k  e t  a l . ,  2 0 0 0 ) ,  a n d  i n  s o  d o i n g  m i g h t  
p e r m i t  t h e  h o m i n g  a n d  a c c u m u l a t i o n  o f  B 2 2 0 +  D N  T  c e l l s  i n  g l d  m i c e .  
A l t e r n a t i v e l y ,  T N F  h a s  b e e n  s h o w n  t o  i n h i b i t  T  c e l l  a p o p t o s i s  ( S a l m o n  e t  a l . ,  
1 9 9 7 ;  V e l l a  e t  a l . ,  1 9 9 5 )  a n d  m i g h t  a c t  a n t a g o n i s t i c a l l y  b y  i n h i b i t i n g  a p o p t o s i s  o f  
B 2 2 0 +  D N  T  c e l l s ,  a l l o w i n g  a n  a c c u m u l a t i o n  o f  t h e s e  c e l l s .  C 3 H  g l d  a n d  B A L B / c  
g l d  m i c e  h a v e  b e e n  r e p o r t e d  t o  d e v e l o p  p l a s m a c y t o m a s  w i t h  a g e  ( D a v i d s o n  e t  a l . ,  
1 9 9 8 ) ,  a n d  T N F  c a n  s t i m u l a t e  t h e  g r o w t h  o f  B  c e l l  t u m o r s  i n  v i v o  b y  i n d u c i n g  I L -
6  p r o d u c t i o n  ( C a r t e r  e t  a l . ,  1 9 9 0 ) .  H e r e  w e  s h o w  t h a t  T N F  c o n t r i b u t e s  t o  t h e  
p r e m a t u r e  d e a t h  i n  g l d  m i c e  b y  p r o m o t i n g  p l a s m a c y t o m a  d e v e l o p m e n t .  
H e r e i n ,  w e  i n v e s t i g a t e  T R A I L  a s  a  c a n d i d a t e  m o l e c u l e  f o r  r e g u l a t i o n  o f  t h e  g l d  
d i s e a s e .  T R A I L  p r e f e r e n t i a l l y  i n d u c e s  a p o p t o s i s  i n  t r a n s f o r m e d ,  b u t  n o t  n o r m a l  
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cells (Nagata, 1997; Pitti et al., 1996; Wiley et al., 1995), although activated 
lymphocytes (Marsters et al., 1996; Ursini-Siegel et al., 2002; Wang et al., 2000) 
and APCs such as monocytes and DCs (Griffith et al., 1999; Hayakawa et al., 
2004; Wang et al., 1999) may also be susceptible to TRAIL-mediated killing. 
Although lymphocyte homeostasis is normal in TRAIL-deficient mice, we 
hypothesized that TRAIL might contribute to the gld phenotype by inducing 
apoptosis in T or B lymphocytes and/or APCs to negatively regulate immune 
responses in gld mice. We report that in contrast to TNF, TRAIL has no effect on 
lymphoaccumulation, development of B220+ DN T cells, production of 
autoantibodies, or hypergammaglobulinemia associated with the gld phenotype. 
4 . 3  M a t e r i a l s  a n d  M e t h o d s  
M i c e  
I n b r e d  C 5 7 B U 6  W T  m i c e  w e r e  p u r c h a s e d  f r o m  T h e  W E H I  a n d  C 5 7 B U 6  
T R A I L · / - m i c e  w e r e  o b t a i n e d  a n d  b r e d  a t  P e t e r  M a c  a s  d e t a i l e d  i n  C h a p t e r  2 ,  
S e c t i o n  2 . 3 ,  M a t e r i a l s  a n d  M e t h o d s .  C 5 7 B U 6  g l d  ( F a s L  m u t a n t )  ( C o h e n  a n d  
E i s e n b e r g ,  1 9 9 1 ;  D a v i d s o n  e t  a l . ,  1 9 8 6 ) ,  C 5 7 B U 6  T N F - d e f i c i e n t  ( C 5 7 B U 6  
T N F
1
" )  m i c e  ( K o r n e r  e t  a l . ,  1 9 9 7 )  a n d  C 5 7 B U 6  g l d  T N F
1
- m i c e  ( K o r n e r  e t  a l . ,  
2 0 0 0 )  w e r e  o b t a i n e d  f r o m  D r .  H e i n r i c h  K o r n e r ,  t h e  C e n t e n a r y  I n s t i t u t e  o f  C a n c e r  
M e d i c i n e  a n d  C e l l  B i o l o g y ,  S y d n e y ,  A u s t r a l i a  a n d  b r e d  a t  P e t e r  M a c .  C 5 7 B U 6  
T R A I L + ; +  g l d ,  C 5 7 B / 6  T R A I L + ! - g l d  a n d  C 5 7 B U 6  T R A I L · ! - g l d  m i c e  w e r e  
e s t a b l i s h e d  b y  t h e  a u t h o r  a t  P e t e r  M a c  b y  c r o s s i n g  C 5 7 B U 6  g l d  ( n = 1 0  
b a c k c r o s s e d  t o  C 5 7 B U 6 )  a n d  C 5 7 B U 6  T R A I L · / - m i c e  ( n = 5  b a c k c r o s s e d  t o  
C 5 7 B U 6 )  a n d  s u b s e q u e n t l y  i n t e r b r e e d i n g  t h e  F
1  
g e n e r a t i o n .  T h i s  i n t e r b r e e d i n g  
e n a b l e d  t h e  g e n e r a t i o n  o f  C 5 7 B U 6  T R A I L + ! +  g l d ,  C 5 7 B U 6  T R A I L + ! - g l d  
a n d  C 5 7 B U 6  T R A I L · / - g l d  m i c e  o n  g e n e t i c a l l y  v e r y  c l o s e l y  m a t c h e d  
b a c k g r o u n d s .  T h i s  w a s  a n  i m p o r t a n t  c o n s i d e r a t i o n ,  a s  t h e  b a c k g r o u n d  s t r a i n  o f  
g l d  m i c e  c a n  a f f e c t  s e v e r i t y  o f  d i s e a s e  ( l z u i  e t  a l . ,  1 9 8 4 ) .  M i c e  4 - 2 8  w e e k s  o f  a g e  
w e r e  u s e d  i n  a l l  e x p e r i m e n t s ,  e x c l u d i n g  a g i n g  e x p e r i m e n t s  w h e r e  m i c e  w e r e  a g e d  
u n t i l  m o r i b u n d  a n d  t h e n  c u l l e d .  E x p e r i m e n t s  w e r e  c o m p l e t e d  a c c o r d i n g  t o  
A n i m a l  E x p e r i m e n t a l  E t h i c s  C o m m i t t e e  g u i d e l i n e s  a n d  a p p r o v a l  a n d  u n d e r t a k e n  
i n  s p e c i f i c  p a t h o g e n - f r e e  c o n d i t i o n s .  
O r g a n  w e i g h t s / h i s t o l o g y  
M i c e  w e r e  w e i g h e d  a n d  t h e n  s a c r i f i c e d  a t  t h e  a g e s  i n d i c a t e d .  S p l e e n ,  m L N s  a n d  
a x i l l a r y  ( a )  L N s  w e r e  e x c i s e d  a n d  w e i g h e d  w e t .  O r g a n  w e i g h t s  o f 6  m i c e  ( 3  m a l e ,  
3  f e m a l e )  w e r e  u s e d  f o r  e a c h  t i m e  p o i n t .  F o r  a g i n g  e x p e r i m e n t s ,  m i c e  w e r e  
s a c r i f i c e d  a n d  s p l e e n  a n d  a L N s  w e r e  w e i g h e d  w e t .  A  f u l l  a u t o p s y  w a s  p e r f o r m e d  
a t  s a c r i f i c e  a n d  r o u t i n e l y  L N s ,  s p l e e n  a n d  l i v e r  w e r e  e x a m i n e d  b y  h i s t o l o g y  
( h e m a t o x y l i n  a n d  e o s i n  ( H & E )  s t a i n i n g )  a f t e r  f i x i n g  t h e s e  t i s s u e s  i n  f o r m a l i n .  
T h e  p r e p a r a t i o n  a n d  s t a i n i n g  o f  s e c t i o n s  f o r  h i s t o l o g y  a n d  d i a g n o s i s  o f  
p l a s m a c y t o m a  d e v e l o p m e n t  i n  a g e d  m i c e  w e r e  c a r r i e d  o u t  b y  D r .  D u n c a n  
M a c G r e g o r  ( D e p a r t m e n t  o f  A n a t o m i c a l  P a t h o l o g y ,  A u s t i n  H o s p i t a l ,  H e i d e l b e r g ,  
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Victoria, Australia). A total of 52 C57BL6 gld and 46 C57BL/6 gld TNF1- mice 
were aged. 
Serum enzyme-linked immunosorbent assays (ELISAs) 
Mice were culled at various time points. Six mice (3 male, 3 female) were used 
for each time point. Sera were tested by ELISA for total IgG, total anti-dsDNA 
antibodies and IgG1-specific anti-dsDNA antibodies. (a) IgG: ELISA plates 
(Costar, Cambridge, MA, USA) were pre-coated with 10 Jlg/ml goat anti-mouse 
IgG (Sigma Chemical Co.) in PBS for 1 hat RT. Plates were then washed 7 times 
in 0.05% Tween-20/PBS (TPBS) and blocked with 2% BSA/PBS for 1 h at room 
temperature. Subsequent steps with intervening washes included adding sera for 1 
hat RT, horseradish peroxidase (HRP)-conjugated polyclonal goat anti-mouse Ig 
(multiply adsorbed) (BD Biosciences Pharmingen) for 1 h at RT and 
development with 2,2' -azino-bis(3-ethylbenz-thiazoline-6-sulfonic acid) (ABTS) 
for 10-20 min. (read at OD 405 nm). (b) Total anti-dsDNA: Maxi-Sorp ELISA 
plates (Nalge Nunc International, Roskilde, Denmark) were pre-coated with 10 
Jlg/ml methylated BSA (Sigma Chemical Co.) in 0.2 M carbonate buffer 
overnight at 4°C. After 4 washes in TPBS, 10 Jlg/ml herring sperm DNA was 
added in carbonate buffer overnight at 4 °C. Plates were washed and blocked with 
2% polyethylene glycol 8,00011% gelatine/1% BSA in TPBS for 30 min. at 37°C. 
Subsequent steps with intervening washes included adding sera for 2 h at 37°C, 
HRP-conjugated polyclonal goat anti-mouse Ig (multiply adsorbed) for 1 h at 
37°C and development with ABTS for 10-20 min. (read at OD 405 nm). (c) IgG1 
anti-dsDNA: ELISAs were performed the same as for total anti-dsDNA, except 
HRP-conjugated rat anti-mouse IgG I (Zymed Laboratories, South San Francisco, 
CA, USA) was used in place of HRP-conjugated goat anti-mouse Ig (multiply 
adsorbed). The mean level of serum anti-dsDNA antibodies of 28 week C57BL/6 
TRAIL+!+ gld mice was set at 1 00% and the results of other genotypes were 
recorded in relation to this level. 
Flow cytometric analysis 
The following mAb were used in multi-parameter flow cytometric analysis: anti-
mTRAIL-PE (N2B2), rat IgG2a isotype control-PE, anti-mouse DRS-biotin 
( M D S - 1 ) ,  a n t i - m o u s e  C D 3 - P E  o r  - C y - C h r o m e  ( 1 7 A 2 ) ,  a n t i - m o u s e  T C R P - F I T C  
( H 5 7 - 5 9 7 ) ,  a n t i - m o u s e  B 2 2 0 - A P C  ( R A 3 - 6 B 2 ) ,  a n t i - m o u s e  C D 4 - P E  o r  - F I T C  
( R M - 4 . 5 ) ,  a n t i - m o u s e  C D 8 a - P E - C y 5 . 5 ,  - P E  o r  - F I T C  ( 5 3 - 6 . 7 )  f o l l o w e d  b y  
i n c u b a t i o n  w i t h  s t r e p t a v i d i n - P E  o r  s t r e p t a v i d i n - A P C - C y 7 .  T o  a v o i d  t h e  n o n -
s p e c i f i c  b i n d i n g  o f m A b s  t o  F c y R ,  a n t i - m o u s e  C D 1 6 / 3 2  ( 2 . 4 0 2 )  m A b  w a s  a d d e d  
t o  t h e  m A b  c o c k t a i l .  A n t i - m T R A I L - P E  w a s  o b t a i n e d  f r o m  e - B i o s c i e n c e ,  a n t i -
D R S - b i o t i n  w a s  k i n d l y  p r o v i d e d  b y  D r .  H i d e o  Y a g i t a  ( J u n t e n d o  U n i v e r s i t y  
S c h o o l  o f  M e d i c i n e ,  T o k y o ,  J a p a n ) ,  a n t i - C D 8 a - P E - C y 5 . 5  w a s  s o u r c e d  f r o m  
C a l t a g  a n d  t h e  r e m a i n i n g  r e a g e n t s  f r o m  B D  B i o s c i e n c e s  P h a r m i n g e n .  A f t e r  
w a s h i n g  t h e  c e l l s  w i t h  P B S / F C S / a z i d e ,  c e l l s  w e r e  a n a l y z e d  o n  a  F A C S c a n ™  o r  
F  A C S D i v a  a n d  t h e  d a t a  p r o c e s s e d  b y  e i t h e r  C E L L Q u e s t ™  o r  F C S - E x p r e s s  2  
s o f t w a r e .  
S t a t i s t i c a l  a n a l y s i s  
D a t a  w e r e  a n a l y z e d  u s i n g  a  t w o  t a i l e d ,  n o n - p a r a m e t r i c ,  u n p a i r e d  M a n n  W h i t n e y  
t e s t .  P  v a l u e s <  0 . 0 5  w e r e  c o n s i d e r e d  s i g n i f i c a n t .  
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4.4 Results 
4.4.1 Expression of TRAIL and TRAIL receptor (DRS) in the spleen of gld 
mice. 
To explore the possibility that TRAIL might contribute to the gld phenotype by 
inducing apoptosis in T or B lymphocytes, expression of TRAIL and TRAIL 
receptor (DR5) was examined on various cell types within the spleen of C57BL/6 
gld mice. If TRAIL-mediated apoptosis is important for lymphocyte homeostasis 
in gld mice, DR5 expression might be expected on target lymphocyte populations 
and TRAIL expression might be predicted on effector cell populations within the 
spleen. However, TRAIL and DR5 expression were not observed on B220+ DN T 
cells, T cells, B cells or on B220-TCRjf cells in the spleen (Figure 4.3). 
4.4.2 TRAIL has no effect on the lymphoaccumulation associated with gld 
To evaluate whether TRAIL contributes to the lymphoaccumulation associated 
with the gld phenotype, spleen, aLN and mLN weight were compared in 
C57BL/6 gld, C57BL/6 TRAIL +I- gld and C57BL/6 TRAIC1- gld mice. Spleen 
and mLN weight gradually increased in C57BL/6 gld mice from 4 weeks of age, 
whereas aLN weight increased from 12 weeks of age (Figure 4.4). 
Lymphoaccumulation was equivalent in C57BL/6 gld, C57BL/6 TRAIL+/- gld 
and C57BL/6 TRAIC1- gld mice (Figure 4.4), whereas C57BL/6 mice did not 
show obvious signs of lymphoproliferation, as expected (Figure 4.4). Total body 
weight increased over the period of observation, but was equivalent in all strains 
tested (Figure 4.4). Together, these data suggest that unlike TNF, TRAIL has no 
effect on the generalized lymphoproliferation associated with the gld phenotype. 
4.4.3 Accumulation of B220+TCRafi+CD4-CD8- double negative (DN) T 
cells in TRAIL_,_ gld spleen and peripheral blood lymphocytes (PBL) 
Lymphoproliferative disease in gld mice is characterized by an accumulation of 
. B220+ DN T cells in LNs, spleen and PBL (Cohen and Eisenberg, 1991) that are 
typically eliminated by Fas/FasL interactions. To investigate whether TRAIL 
plays a role in the accumulation or localization of these cells in gld mice, flow 
cytometric analysis was performed to compare proportions of these cells in the 
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F i g u r e  4 . 3 .  L a c k  o f  T R A I L  a n d  T R A I L  r e c e p t o r  ( D R S )  e x p r e s s i o n  i n  t h e  s p l e e n  o f  g l d  m i c e .  
S p l e n o c y t e s  i s o l a t e d  f r o m  a d u l t  ( >  8  w e e k s )  C S 7 B L / 6  g l d  m i c e  w e r e  a n a l y z e d  b y  f l o w  c y t o m e t r y  
f o r  T R A I L  a n d  T R A I L  r e c e p t o r  ( D R S )  e x p r e s s i o n .  B l a c k  h i s t o g r a m s  r e p r e s e n t  i s o t y p e  c o n t r o l  
s t a i n i n g  a n d  r e d  h i s t o g r a m s  r e p r e s e n t  T R A I L  o r  D R S  s t a i n i n g  a s  i n d i c a t e d .  R e s u l t s  s h o w n  a r e  
r e p r e s e n t a t i v e  o f t w o  i n d e p e n d e n t  e x p e r i m e n t s ,  e a c h  c o n t a i n i n g  o n e  C S 7 B L / 6  g / d m o u s e .  
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Figure 4.4. Lymphoid organ and body weights for C57BL/6, C57BL/6 gld, C57BL/6 
TRAIL +J-gld and C57BL/6 TRAIL-/- gld mice. Spleen, aLN, mLN and total body weight are 
shown in grams (g) for C57BL/6, C57BL/6 gld, C57BL/6 TRAie1·gtd and C57BL/6 TRAIL_;_ gld 
.mice at 4, 8, 12, 16, 20, 24 and 28 weeks of age. Data represent mean± SEM of six mice (3 
female, 3 male) at each time point, for each genotype. Asterisks indicate groups of gld mice that 
are significantly different(* P < 0.02). 
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- ,  C 5 7 B L / 6  g l d  a n d  
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g l d  a n d  C 5 7 B L / 6  T R A I L - / - g l d  m i c e .  B 2 2 0 +  D N  T  c e l l s  d i d  n o t  a c c u m u l a t e  i n  
C 5 7 B L / 6  W T  o r  C 5 7 B L / 6  T R A I L _ ; _  m i c e .  C o m p a r a b l e  p r o p o r t i o n s  o f  B 2 2 0 +  D N  
T  c e l l s  i n  t h e  b l o o d  a n d  s p l e e n  o f  T R A I L  s u f f i c i e n t  a n d  T R A I L  d e f i c i e n t  g l d  
m i c e  s u g g e s t s  a  n e g l i g i b l e  r o l e  f o r  T R A I L  i n  t h e  a c c u m u l a t i o n  a n d  l o c a l i z a t i o n  o f  
t h e s e  a b n o r m a l  l y m p h o c y t e s .  
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g l d  a n d  C 5 7 B L / 6  T R A I C
1
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a l t h o u g h  5  w e e k  o l d  C 5 7 B L / 6  T R A I C
1
- g l d  m i c e  a p p e a r e d  t o  h a v e  e l e v a t e d  
p r o p o r t i o n s  o f T  c e l l s  a n d  d e c r e a s e d  p r o p o r t i o n s  o f  B  c e l l s  c o m p a r e d  t o  t h e  o t h e r  
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d e t e r m i n e  w h e t h e r  t h i s  f i n d i n g  i s  r e p r o d u c i b l e .  











Figure 4.5. TCR(3 versus B220 expression on PBLs. C57BLI6, C57BL/6 TRAIL·1·, C57BL/6 
gld and C57BL/6 TRAIL·/- gld mice were sacrificed at 5, I2 and 20 weeks of age, PBLs isolated 
and stained with antibodies to B220 and TCR~. Numbers represent percentage B220+TCR~+ cells 
for each profile. Data are representative from the analysis of3 C57BL/6 gld, 3 C57BL/6 TRAIL·I-
gld, 3 C57BL/6 and 3 C57BL/6 TRAIL·/- mice for each age group, except at 5 weeks where I 
C57BL/6 and I C57BL/6 TRAIL·/- mouse were analyzed. 
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s p l e n o c y t e s  i s o l a t e d  a n d  s t a i n e d  w i t h  a n t i b o d i e s  t o  B 2 2 0  a n d  TCR~. D a t a  a r e  r e p r e s e n t a t i v e  f r o m  
t h e  a n a l y s i s  o f  3  C 5 7 B L / 6  g l d ,  3  C 5 7 B L / 6  T R A I L · ! - g l d ,  3  C 5 7 B L / 6  a n d  3  C 5 7 B L / 6  T R A I L · i -
m i c e  f o r  e a c h  a g e  g r o u p ,  e x c e p t  a t  5  w e e k s  w h e r e  1  C 5 7 B L / 6  a n d  1  C 5 7 B L / 6  T R A I L · / - m o u s e  
w e r e  a n a l y z e d .  
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Figure 4.7. Age-related accumulation of B220+TCRa.f3+CD4-CD8- DN T cells in PBL and 
spleen. C57BL/6, C57BL/6 TRAIL-1-, C57BL/6 gld and C57BL/6 TRAIL_;_ gld mice were 
sacrificed at 5, 12 and 20 weeks of age, their splenocytes and PBLs isolated and stained with 
antibodies to B220, TCR~, CD4 and CDS. Percentage B220~CRa.~+CD4-CD8- T cells is shown 
for PBL (A) and spleen (B). Data represent mean± SEM for 3 C57BL/6 gld, 3 C57BL/6 TRAIL_1_ 
gld, 3 C57BL/6 and 3 C57BL/6 TRAIL-/- mice for each age group, except at 5 weeks when 1 
C57BL/6 and 1 C57BL/6 TRAIL-/- mouse were analyzed. Proportions of B220~CRa.~+CD4-
CD8- DN T cells in C57BL/6 gld and C57BL/6 TRAIL_;_ gld spleen or PBL are not significantly 








5 weeks 12 weeks 20 weeks 
T cells CO/oL B cells(%) T cells(%) B cells(%) T cells(%) B cells(%) 
45.28 37.82 27.71±1.46 59.18±1.93 27.46±2.20 46.27±6.40 
51.84 38.27 24.46±0.64 61.53±0.93 35.51±6.96 28.79±2.87 
44.88±3.45 34.54±1.83 33.37±2.68 40.88±0.44 21.85±2.71 37.53±5.28 
63.77±1.64 17.61±3.42 36.62±1.13 42.17±2.15 23.38±2.93 36.86±4.29 
Spleen 
5 weeks 12 weeks 20 weeks 
T cells(%) B cells(%) T cells(%) B cells(%) T cells(%) B cells(%) 
C57BL/6 20.43 70.66 22.86±0.76 65.45.±2.40 28.05±2.67 56.52.±3.79 
C57BL/6 TRAIL_,_ 20.42 66.78 23.35±0.82 67.25.±0.60 27.75±3.66 51.81±3.89 
C57BL/6 gld 21.46±0.45 64.19.±2.20 21.76±2.20 53.19.±2.74 22.41±2.10 44.22±2.19 
C57BL/6 TRAIL·1-g/d 25.17+1.03 60.84+4.51 24.90+0.71 51.35±1.89 20.32±1.42 35.77+5.26 
Table 4.1. Proportional changes in T and B cells in the blood and spleen. PBL and spleen were isolated from C57BL/6, 
C57BL/6 TRAIL·'·, C57BL/6 gld and C57BL/6 TRAIL_,_ gld mice and stained with antibodies to B220, TCRp, CD4 and CD8. 
Percentage T and B cells was calculated by subtracting the percentage of B220+TCRa.~+CD4"CD8- DN T cells present from 
the percentage of total TCRp+ and total B220+ cells. Data represent mean ± SEM for 3 C57BL/6 gld, 3 C57BL/6 TRAIL_,_ 
gld, 3 C57BL/6 and 3 C57BL/6 TRAIL_,_ mice for each age group, except at 5 weeks when only 1 C57BL/6 and 1 C57BL/6 
TRAIL_,_ mouse were analyzed. 
4.4.5 Levels of serum IgG and anti-double stranded (ds) DNA Abs in 
TRAIL_,_ gld mice 
Hypergammaglobulinemia and circulating autoantibodies are features of the gld 
phenotype (Cohen and Eisenberg, 1991). Given that TRAIL has previously been 
shown to induce apoptosis in B lymphocytes (Ursini-Siegel et al., 2002; Wang et 
al., 2000), we were interested in the effect that TRAIL might have on antibody 
production in gld mice. Concentration of serum IgG and anti-ds DNA 
autoantibody were compared in C57BL/6 gld, C57BLI6 TRAIL+/- gld and 
C57BL/6 TRAIL-/- gld mice. The concentration of IgG in the serum increased 
dramatically until 12-16 weeks of age, regardless of the genotype (Figure 4.8A). 
Serum anti-dsDNA autoantibody levels also increased with age, regardless ofthe 
genotype (Figure 4.8B). Interestingly, although serum IgG concentrations peaked 
after 12-16 weeks of age, anti-dsDNA antibody levels continued to increase, even 
at 28 weeks of age (Figure 4.8B). Given that serum autoantibody levels of the 
IgG 1 subclass were reported to be elevated in gld mice administered with a 
neutralizing anti-mTRAIL mAb (Kayagaki et al., 2002), we examined the effect 
of TRAIL deficiency on anti-dsDNA IgG1 autoantibody levels. Serum IgG1 anti-
dsDNA antibody levels increased with age, regardless of phenotype (Figure 
4.8C). However, considerable variability in IgGl autoantibody production was 
observed between mice, suggesting that larger group sizes may need to be 
analyzed to obtain statistically significant differences between genotypes. 
Analysis of circulating autoantibodies with different specificities may also be 
required to ascertain whether IgG 1 subclass autoantibodies are elevated in 
C57BL/6 TRAIC1- gld mice. 
4.4.5 Phenotype of aged TNF_,_ gld and TNF+t+ gld mice 
Previous studies undertaken in our laboratory have identified a critical 
contribution for TNF in the lymphoaccumulation and mortality associated with 
the gld phenotype (Komer et al., 2000). To investigate the mechanism used by 
TNF to promote premature death, C57BL/6 gld and C57BL/6 gld TNF1- mice 
were aged and lymphoaccumulation was compared in these mice (Appendix III 
and IV). C57BL/6 gld TNF1- mice had an increased life expectancy (63.9 ± 2.4 
weeks, n=46) compared with C57BL/6 gld mice ( 48.4 ± 1.6 weeks, n=52) 
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F i g u r e  4 . 8 .  E f f e c t  o f  T R A I L  d e f i c i e n c y  o n  s e r u m  I g G  a n d  a u t o a n t i b o d y  c o n c e n t r a t i o n  i n  g l d  
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m i c e  a t  4 ,  8 ,  1 2 ,  1 6 ,  2 0 ,  2 4  a n d  2 8  w e e k s  o f  a g e  a n d  t e s t e d  b y  E L I S A  f o r  ( A )  t o t a l  c o n c e n t r a t i o n  
o f  I g G ,  ( B )  t o t a l  a n t i - d s D N A  a u t o a n t i b o d i e s  a n d  ( C )  I g G l  a n t i - d s D N A  a u t o a n t i b o d i e s .  T h e  
c o n c e n t r a t i o n  o f  a n t i - d s D N A  a u t o a n t i b o d i e s  a r e  s h o w n  r e l a t i v e  t o  t h a t  o b s e r v e d  f o r  2 8  w e e k  
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m i c e  t h a t  a r e  s i g n i f i c a n t l y  d i f f e r e n t  t o  C 5 7 B L / 6  g l d  o r  C 5 7 B L / 6  T R A I L + / - g l d  m i c e  o f  t h e  s a m e  
a g e ( *  P  <  0 . 0 5 ) .  
1 7 8  
(P < 0.01, Figure 4.9 and 4.10). Moreover, secondary lymphoid organ (aLN and 
spleen) weight was significantly reduced in C57BU6 gld TNF1: compared with 
C57BU6 gld mice at death (P < 0.01, Figure 4.10), although total body weights 
were equivalent. This suggested that the cause of death, at least in C57BU6 gld 
TNF1- mice, was not a direct consequence of lymphoaccumulation. 
4.4.6 TNF is not required for plasmacytoma development in aged gld mice 
C3H gld and BALB/c gld mice have been reported to develop plasmacytomas 
with age (Davidson et al., 1998), and TNF is known to stimulate the growth of 
some B cell tumors in vivo by inducing IL-6 production (Carter et al., 1990). To 
investigate whether TNF contributes to premature death in gld mice by promoting 
plasmacytoma development, LN, spleen and liver sections from C57BU6 gld and 
C57BU6 gld TNF1- mice were examined by histology (H&E staining) after 
fixing these tissues in formalin. Histological analysis revealed the presence of 
malignant lymphoma in all C57BU6 gld and C57BU6 gld TNF1- mice evaluated 
at death. Moreover, lymphoid cells with plasmacytoid nuclear (medium to large 
size nuclei, coarse chromatin and irregular nuclear outlines) and cytoplasmic 
features were identified in these mice (Figure 4.11). Plasmacytoma was 
diagnosed in a minimum of one organ per mouse, and often in multiple organs of 
C57BU6 gld and C57BU6 gld TNF1- mice diagnosed with malignant lymphoma. 
Plasmacytoma was identified in a variety of LN s, spleen and the liver. 
Representative H&E stained spleen, liver and LN are shown from a single 
C57BU6 gld and C57BU6 gld TNF1- mouse, illustrating that plasmacytoid 
features often presented in more than one organ per mouse (Figure 4.12). 
Together these data suggest that gld mice deficient in TNF are capable of 
developing plasmacytomas. 
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C57BL/6 gld C57BL/6 
gldTNF-t-
Figure 4.10. Increased life expectancy and decreased lymphoaccumulation in aged C57BL/6 
gld TNF_,_ mice. C57BL/6 gld mice and C57BL/6 gld TNF1- mice were aged until death and a full 
autopsy performed. (A) Age, (B) body weight, (C) spleen weight and (D) mean aLN weight at 
· death are shown. Mean± SEM were calculated from analysis of 52 C57BL/6 gld and 46 C57BL/6 
gld TNF_1_ mice (for age at death), and from analysis of 38 C57BL/6 gld and 27 C57BL/6 gld 
TNF1- mice (for body and organ weights). Asterisks indicate groups that are significantly different 
(* p < 0.01). 
1 Q 1 
F i g u r e  4 . 1 1 .  C o m p a r i s o n  o f  t h e  p h e n o t y p i c  c h a r a c t e r i s t i c s  o f  m a t u r e  p l a s m a  c e l l s  a n d  
a t y p i c a l  p l a s m a c y t o i d  c e l l s .  R e p r e s e n t a t i v e  H & E  s t a i n i n g  o n  m L N  i s o l a t e d  f r o m  a n  a g e d  
C 5 7 B L / 6  g l d  m o u s e .  Y e l l o w  a r r o w s  i n d i c a t e  m a t u r e  p l a s m a  c e l l s ,  t h a t  a r e  c h a r a c t e r i z e d  b y  a  
p r o m i n e n t  n u c l e o l u s ,  p e r i p h e r a l  c h r o m a t i n  c l u m p i n g  a n d  a  p a r a n u c l e a r  c l e a r i n g  ( o r  " h o f ' ) ,  a s  w e l l  
a s  e c c e n t r i c  c y t o p l a s m .  W h i t e  a r r o w s  i n d i c a t e  a t y p i c a l  p l a s m a  c e l l s  ( p l a s m a c y t o i d  c e l l s )  
c h a r a c t e r i z e d  b y  m e d i u m  t o  l a r g e  s i z e  n u c l e i ,  c o a r s e  c h r o m a t i n  a n d  i r r e g u l a r  n u c l e a r  o u t l i n e s .  
( O r i g i n a l  m a g n i f i c a t i o n  x  4 0 ) .  





C57BL/6 gld C57BL/6 gld TN F_,_ 
Figure 4.12. Malignant lymphoid infiltrates in the tissues of aged C57BL/6 gld and C57BL/6 
gld TNF_,_ mice. Representative H&E staining on spleen, liver and LN isolated from aged 
C57BU6 gld (A, C, E) and C57BU6 g/d TNF-I- (B, D, F) mice at death. Histological analysis 
reveals the presence of malignant lymphoma in spleen, liver and LN of C57BU6 gld and 
C57BU6 g/d TNF-I- mice. The presence of lymphoid cells with plasmacytoid nuclei and 
cytoplasmic features suggests a diagnosis of plasmacytoma in these mice. Yellow arrows indicate 
mature plasma cells, whereas white arrows indicate atypical plasma cells (plasmacytoid cells). 
Histology depicted is of organs isolated from one C57BU6 gld and one C57BU6 g/d TNF_,_ 
mouse and are representative from the analysis of 5 aged C57BU6 gld and 5 aged C57BU6 g/d 
TNF-I- mice. Original magnification x 10. 
4 . 5  D i s c u s s i o n  
T N F  w a s  t h e  f i r s t  s p e c i f i c  m o l e c u l e  r e p o r t e d  t o  c o n t r i b u t e  t o  t h e  
l y m p h o a c c u m u l a t i o n  a n d  p r e m a t u r e  d e a t h  a s s o c i a t e d  w i t h  t h e  g l d  p h e n o t y p e  
( K o m e r  e t  a l . ,  2 0 0 0 ) .  T h i s  f i n d i n g  h a s  i m p o r t a n t  t h e r a p e u t i c  a p p l i c a t i o n s ,  a s  
s t r a t e g i e s  t o  b l o c k  T N F  f u n c t i o n  m a y  s u p p r e s s  l y m p h o a c c u m u l a t i o n  a n d  i n c r e a s e  
[  
t h e  l i f e  e x p e c t a n c y  o f  p a t i e n t s  w i t h  l y m p h o p r o l i f e r a t i v e  d i s o r d e r s  s u c h  a s  A L P S .  
T h e  c h e m o k i n e  m o n o c y t e  c h e m o a t t r a c t a n t  p r o t e i n  ( M C P ) - 1  h a s  b e e n  r e p o r t e d  t o  
c o n t r i b u t e  t o  s o m e  f e a t u r e s  o f  t h e  l p r  p h e n o t y p e ,  s u c h  a s  a u t o i m m u n e  d i s e a s e  a n d  
l y m p h a d e n o p a t h y ,  b u t  n o t  o t h e r s  s u c h  a s  s p l e n o m e g a l y  o r  h y p e r g a m m a -
g l o b u l i n e m i a  ( T e s c h  e t  a l . ,  1 9 9 9 ) .  T N F  i s  k n o w n  t o  i n d u c e  t h e  p r o d u c t i o n  o f  
c h e m o k i n e s  ( N g o  e t  a l . ,  1 9 9 9 ;  S e d g w i c k  e t  a l . ,  2 0 0 0 )  a n d  m a y  a c t  u p s t r e a m  o f  
M C P - 1  o r  o t h e r  c h e m o k i n e s  t o  r e g u l a t e  d i s e a s e  i n  g l d  o r  l p r  m i c e .  
I n  t h e  p r e s e n t  s t u d y ,  t h e  p o t e n t i a l  o f  T R A I L  t o  r e g u l a t e  t h e  g l d  p h e n o t y p e  w a s  
i n v e s t i g a t e d .  W h e n  T R A I L  w a s  d e l e t e d  i n  C 5 7 B L / 6  g l d  m i c e  b y  g e n e - t a r g e t i n g ,  
l y m p h o a c c u m u l a t i o n  i n  s e c o n d a r y  l y m p h o i d  o r g a n s ,  a n d  a c c u m u l a t i o n  o f  B 2 2 0 +  
D N  T  c e l l s  i n  t h e  b l o o d  a n d  s p l e e n  w e r e  u n a f f e c t e d .  M o r e o v e r ,  h y p e r -
g a m m a g l o b u l i n e m i a  a n d  c i r c u l a t i n g  a u t o a n t i b o d i e s  w e r e  u n c h a n g e d  i n  t h e s e  
m i c e .  T h u s ,  a l t h o u g h  T R A I L  h a s  b e e n  r e p o r t e d  t o  i n d u c e  a p o p t o s i s  i n  a c t i v a t e d  B  
a n d  T  l y m p h o c y t e s  ( M a r s t e r s  e t  a l . ,  1 9 9 6 ;  U r s i n i - S i e g e l  e t  a l . ,  2 0 0 2 ;  W a n g  e t  a l . ,  
2 0 0 0 ) ,  s u r p r i s i n g l y  T R A I L  d o e s  n o t  a p p e a r  t o  p l a y  a  m a j o r  r o l e  i n  r e g u l a t i o n  o f  
t h e  g l d  d i s e a s e .  
D u r i n g  t h e  c o u r s e  o f  o u r  s t u d y ,  i t  w a s  r e p o r t e d  b y  K a y a g a k i  a n d  c o l l e a g u e s  t h a t  
a d m i n i s t r a t i o n  o f  n e u t r a l i z i n g  a n t i - m T R A I L  m A b  h a d  n o  e f f e c t  o n  
l y m p h o a c c u m u l a t i o n  o r  t h e  d e v e l o p m e n t  o f  B 2 2 0 +  D N  T  c e l l s  i n  C 3 H / H e J  g l d  
m i c e  ( K a y a g a k i  e t  a l . ,  2 0 0 2 ) .  W h i l s t  a d m i n i s t r a t i o n  o f  n e u t r a l i z i n g  a n t i - m T R A I L  
m A b  i s  a n  e f f e c t i v e  m e a n s  o f  b l o c k i n g  T R A I L  a c t i v i t y  i n  v i v o ,  T R A I L  
n e u t r a l i z a t i o n  i n  t h e  K a y a g a k i  e t  a l .  s t u d y  w a s  o n l y  c o m m e n c e d  a t  3  w e e k s  o f  
a g e .  I f  T R A I L  i n f l u e n c e s  t h e  g l d  p h e n o t y p e  p r i o r  t o  3  w e e k s  o f  a g e ,  t h e  f u l l  
e x t e n t  o f  t h e  c o n t r i b u t i o n  b y  T R A I L  t o  t h e  g l d  p h e n o t y p e  w o u l d  n o t  b e  
r e c o g n i z e d  i n  t h e  K a y a g a k i  e t  a l .  s t u d y .  N o n e t h e l e s s ,  o u r  c h a r a c t e r i z a t i o n  o f  
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C57BL/6 TRAIL_;_ gld mice also failed to reveal a contribution by TRAIL to the 
gld phenotype. In contrast to our findings, TRAIL neutralization was shown to 
increase serum autoantibody levels of the IgG 1 subclass in C3H/HeJ gld mice 
(Kayagaki et al., 2002). This difference may be due to the comparative sensitivity 
of C57BL/6 gld and C3H/HeJ gld mice to development of autoimmune disease, 
although this is yet to be tested. Interestingly, antibody production was reported 
to be decreased in mice immunized with TRAIL expressing antigen-bearing 
APCs, suggesting that APCs can suppress antibody production in vivo in a 
TRAIL-dependent manner (Kayagaki et al., 2002). 
The severity of the gld phenotype is greater in highly susceptible C3H/HeJ gld 
mice (Izui et al., 1984), compared to less susceptible C57BL/6 gld mice. Whilst 
highly susceptible C3H/HeJ gld mice were analyzed by Kayagaki et al., our study 
' demonstrated that TRAIL does not contribute to the lymphoaccumulation 
associated with a less severe form of gld disease in C57BL/6 gld mice. 
Examining disease development in both highly permissive and less permissive 
strains of gld mice is critical to gain a full understanding of the mechanisms 
regulating disease development. Considerable variation in severity of disease is 
evident between individual ALPS patients and between ALPS patients of 
different classifications (ALPS 0, ALPS Ia, ALPS Ib, ALPS II and ALPS III) 
(Rieux-Laucat et al., 2003). Accordingly, the molecular mechanisms involved in 
regulation of the disease might vary depending on the severity of symptoms in 
these patients. 
In Chapter 5, we use TRAIL-deficient mice and a neutralizing anti-mTRAIL 
mAb to identify a role for TRAIL in suppression of EAE. In that model, we 
demonstrate that TRAIL suppressed T cell proliferation, but had no effect on 
antibody production associated with disease. Other researchers have used soluble 
TRAIL receptor (DR5) to block TRAIL function and to similarly identify a role 
for TRAIL in suppression of EAE. However, in that study, TRAIL had a 
negligible effect on lymphocyte proliferation (Hilliard et al., 2001). TRAIL has 
also been identified to suppress collagen-induced arthritis (Song et al., 2000) as 
well as cyclophosphamide and streptozotocin-induced diabetes (Lamhamedi-
1Q<::: 
C h e r r a d i  e t  a l . ,  2 0 0 3 ) .  I n  t h o s e  e x p e r i m e n t a l  m o d e l s ,  T R A I L  w a s  p r o p o s e d  t o  
s u p p r e s s  b o t h  l y m p h o c y t e  p r o l i f e r a t i o n ,  a n d  a n t i b o d y  p r o d u c t i o n  a s s o c i a t e d  w i t h  
d i s e a s e  ( L a m h a m e d i - C h e r r a d i  e t  a l . ,  2 0 0 3 ;  S o n g  e t  a l . ,  2 0 0 0 ) .  I n  c o n t r a s t ,  w e  
o b s e r v e d  n o  s i g n i f i c a n t  e f f e c t  o f  T R A I L  o n  l y m p h o c y t e  p r o l i f e r a t i o n  o r  a n t i b o d y  
p r o d u c t i o n  a s s o c i a t e d  w i t h  t h e  g l d  p h e n o t y p e ,  s u g g e s t i n g  t h a t  t h e  r o l e  o f  T R A I L  
i n  d i s e a s e  i s  d e p e n d e n t  o n  t h e  p a t h o l o g i c a l  c o n d i t i o n .  
A l t h o u g h  a  p r e v i o u s  s t u d y  i n  o u r  l a b o r a t o r y  r e v e a l e d  t h a t  T N F  c o n t r i b u t e s  t o  t h e  
p r e m a t u r e  d e a t h  a s s o c i a t e d  w i t h  t h e  g l d  d i s e a s e ,  t h e  s t u d y  w a s  l i m i t e d  a s  m i c e  
w e r e  o n l y  a g e d  f o r  a  p e r i o d  o f  4 2 0  d a y s  ( K o m e r  e t  a l . ,  2 0 0 0 ) .  I n  t h e  c u r r e n t  
s t u d y ,  C 5 7 B L / 6  g l d  a n d  C 5 7 B L / 6  g l d  T N F
1
- m i c e  w e r e  a g e d  u n t i l  m o r i b u n d  ( u p  
t o  6 6 7  d a y s )  t o  o b s e r v e  t h e  f u l l  m a n i f e s t a t i o n  o f  l y m p h o p r o l i f e r a t i v e  d i s e a s e  i n  
t h e s e  m i c e .  A s  e x p e c t e d ,  T N F - d e f i c i e n c y  i n c r e a s e d  t h e  l i f e s p a n  o f  C 5 7 B L / 6  g l d  
m i c e .  M o r e o v e r ,  l y m p h o a c c u m u l a t i o n  w a s  d e c r e a s e d  i n  C 5 7 B L / 6  g l d  T N F
1
-
c o m p a r e d  t o  C 5 7 B L / 6  g l d  m i c e  a t  d e a t h .  A  n u m b e r  o f  t r e a t m e n t s  h a v e  b e e n  
r e p o r t e d  t o  d e c r e a s e  l y m p h o p r o l i f e r a t i v e  d i s e a s e  a n d  a c c u m u l a t i o n  o f  B 2 2 0 +  D N  
T  c e l l s  i n  l p r  m i c e ,  i n c l u d i n g  c h r o n i c  t r e a t m e n t  w i t h  m A b  s p e c i f i c  f o r  B 2 2 0 ,  
C D 4 ,  C D S  o r  T C R  V f 3 ,  c h r o n i c  a d m i n i s t r a t i o n  o f  S E B  o r  c y c l o s p o r i n e  A  a n d  
n e o n a t a l  t h y m e c t o m y  ( A s e n s i  e t  a l . ,  1 9 8 9 ;  d e  A l b o r a n  e t  a l . ,  1 9 9 2 ;  M o u n t z  e t  a l . ,  
1 9 8 7 ;  S a n t o r o  e t  a l . ,  1 9 8 8 ;  S t e i n b e r g  e t  a l . ,  1 9 8 0 ) .  O u r  f i n d i n g s  s u g g e s t  t h a t  T N F  
b l o c k a d e  o r  s u p p r e s s i o n  o f  d o w n s t r e a m  c h e m o t a c t i c  p a t h w a y s  m i g h t  d e c r e a s e  t h e  
l y m p h o a c c u m u l a t i o n  a n d  i n c r e a s e  t h e  l i f e  e x p e c t a n c y  o f  A L P S  p a t i e n t s .  
A  n u m b e r  o f  s t u d i e s  h a v e  i m p l i c a t e d  t h e  F a s / F a s L  p a t h w a y  i n  c o n t r o l  o f  B  c e l l  
t u m o r  g r o w t h .  G r o w t h  o f  P a s - s e n s i t i v e  A 2 0  B  c e l l  t u m o r  c e l l s  i s  a c c e l e r a t e d  
w h e n  t h e s e  c e l l s  a r e  t r a n s f e c t e d  w i t h  F L I P ,  s u g g e s t i n g  t h a t  F a s  c a n  c o n t r o l  
m a l i g n a n t  B  c e l l  t u m o r  g r o w t h  i n  v i v o  ( D j e r b i  e t  a l . ,  1 9 9 9 ) .  I n  a d d i t i o n ,  t u m o r  
c e l l s  i s o l a t e d  f r o m  a  n u m b e r  o f  B  c e l l  m a l i g n a n c i e s  a r e  r e s i s t a n t  t o  P a s - i n d u c e d  
d e a t h  e v e n  t h o u g h  t h e y  e x p r e s s  a d e q u a t e  c e l l  s u r f a c e  F a s  r e c e p t o r  ( O w e n - S c h a u b  
e t  a l . ,  1 9 9 3 ;  P l u m a s  e t  a l . ,  1 9 9 8 ;  W e s t e n d o r f  e t  a l . ,  1 9 9 5 ;  X e r r i  e t  a l . ,  1 9 9 8 ) .  I n  
c o n t r a s t ,  T N F  i s  t h o u g h t  t o  c o n t r i b u t e  t o  t h e  d e v e l o p m e n t  o f  t h e  B - c e l l  
m a l i g n a n c y  m u l t i p l e  m y e l o m a ,  b y  i n d u c i n g  I L - 6  w h i c h  a c t s  a s  a  m a j o r  g r o w t h  
f a c t o r  f o r  m u l t i p l e  m y e l o m a  c e l l s  i n  v i t r o  a n d  i n  v i v o  ( C a r t e r  e t  a l . ,  1 9 9 0 ) .  
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Previous studies have shown that gld mice develop plasmacytomas with age 
(Davidson et al., 1998) and ALPS patients with Fas/FasL mutations are 
frequently diagnosed with non-Hodgkin's and Hodgkin's B cell malignancies 
(Lin, 1995). In the present study, we demonstrated that although C57BL/6 gld 
TNF_1_ mice have an increased life expectancy compared to C57BL/6 gld mice, 
both strains develop plasmacytomas. This suggests that TNF is not absolutely 
critical for the development of plasmacytomas in gld mice, but might promote 
plasmacytoma development, causing premature death. Histological analysis of 
tissue sections from C57BL/6 gld TNF1- and C57BL/6 gld mice at various time 
points prior to death will allow assessment of this hypothesis. In addition to 
plasmacytoma development, premature death in a proportion of gld mice might 
be direct consequence ofthe effects oflymphoaccumulation on the functioning of 
essential organs. 
Although TRAIL can suppress tumor initiation, growth and metastasis, we were 
unable to identify a major role for TRAIL in regulation of the gld phenotype. We 
also revealed that TNF is not critical for plasmacytoma development in gld mice, 
but may promote the development of these tumors. The mechanism used by TNF 
to sustain the gld phenotype is yet to be discovered. 
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T R A I L  S U P P R E S S E S  E X P E R I M E N T A L  
A U T O I M M U N E  E N C E P H A L O M Y E L I T I S  ( E A E )  
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5.1 Abstract 
TRAIL can selectively induce apoptosis in transformed and virus-infected cells, 
and suppress tumor initiation, growth and metastasis in vivo. In contrast, the role 
of TRAIL in non-transformed tissues is largely unknown. In Chapter 4, we failed 
to identify a role for TRAIL in regulation of the gld phenotype, but here we 
investigate TRAIL function in the regulation of autoimmune disease. A previous 
study suggested that TRAIL may suppress collagen-induced arthritis in mice. 
Herein, we show that TRAIL suppresses autoimmune damage in both relapsing-
remitting and chronic non-remitting models of EAE. TRAIL-deficient mice and 
WT mice treated with neutralizing anti-mTRAIL antibody displayed increased 
clinical score, increased T cell proliferation responses to MOG, and increased 
numbers of inflammatory lesions in the CNS. Importantly, therapeutic 
intervention with recombinant soluble TRAIL/ Apo2L or anti-TRAIL receptor 
(DRS) antibody reduced the severity of MOO-induced EAE. Together, these data 
illustrate the potential therapeutic value of rTRAILI Apo2L and anti-DR5 
antibody in suppressing EAE/MS and suggest that TRAIL may play a general 
role in suppression ofT cell-mediated autoimmune diseases. 
5 . 2  I n t r o d u c t i o n  
M S  i s  a n  a u t o i m m u n e  d i s e a s e  t h a t  i n v o l v e s  b o t h  c e l l u l a r  a n d  h u m o r a l  r e s p o n s e s  
d i r e c t e d  a g a i n s t  p r o t e i n s  o f  t h e  m y e l i n  s h e a t h ,  s u c h  a s  M O G ,  M B P  a n d  P L P  ( A b o  
e t  a l . ,  1 9 9 3 ;  M o k h t a r i a n  e t  a l . ,  1 9 8 4 ;  S c h l u e s e n e r  e t  a l . ,  1 9 8 7 ;  S t e i n m a n ,  1 9 9 6 ) .  
T h e  d i s e a s e  i s  c h a r a c t e r i z e d  b y  a n  i n f i l t r a t i o n  o f  i n f l a m m a t o r y  c e l l s  i n t o  t h e  C N S ,  
a c c o m p a n i e d  b y  l o c a l i z e d  d e s t r u c t i o n  o f  t h e  m y e l i n  s h e a t h  a n d  l o s s  o f  
o l i g o d e n d r o c y t e s  ( E w i n g  a n d  B e r n a r d ,  1 9 9 8 ) .  M S  l e s i o n s  c o n s i s t  p r e d o m i n a n t l y  
o f  a c t i v a t e d  C D 4 +  T  c e l l s  t h a t  s e c r e t e  a  v a r i e t y  o f  c y t o k i n e s  s u c h  a s  I F N - y  a n d  
T N F - a ,  B  c e l l s  a n d  m a c r o p h a g e s  a n d  m o s t  p a t i e n t s  h a v e  o l i g o c l o n a l  l g G  b a n d s  
w i t h  a  s p e c i f i c i t y  f o r  m y e l i n  p r o t e i n s  i n  t h e i r  c e r e b r o s p i n a l  f l u i d  ( E w i n g  a n d  
B e r n a r d ,  1 9 9 8 ;  R a i n e ,  1 9 9 1 ) .  M o s t  t h e r a p i e s  f o r M S  h a v e  f o c u s e d  o n  t h e  u s e  o f  
s t e r o i d s  t o  s u p p r e s s  t h e  i n f l a m m a t o r y  r e s p o n s e  a s s o c i a t e d  w i t h  d i s e a s e  ( G r i f f i t h s  
a n d  N e w m a n ,  1 9 9 4 ) .  C l i n i c a l  t r i a l s  u s i n g  IFN-~ h a v e  a l s o  y i e l d e d  p r o m i s i n g  
r e s u l t s ,  w i t h  IFN-~ t r e a t m e n t  d e c r e a s i n g  t h e  r a t e  o f  r e l a p s e  a n d  d e l a y i n g  
d i s a b i l i t y  i n  p a t i e n t s  ( P e n d e r  a n d  W o l f e ,  2 0 0 2 ;  R u u l s  a n d  S e d g w i c k ,  1 9 9 8 ) .  
E A E  i s  a n  a n i m a l  m o d e l  w i t h  m a n y  c l i n i c a l  a n d  h i s t o p a t h o l o g i c a l  s i m i l a r i t i e s  t o  
M S .  L i k e  M S ,  E A E  i s  c h a r a c t e r i z e d  b y  a n  e a r l y  b r e a c h  o f  t h e  b l o o d - b r a i n  b a r r i e r ,  
i n f i l t r a t i o n  o f  i n f l a m m a t o r y  c e l l s  i n t o  t h e  C N S  a n d  d e m y e l i n a t i o n  t h a t  u l t i m a t e l y  
l e a d s  t o  p a r a l y s i s  o f  t h e  a n i m a l  ( B e r n a r d  e t  a l . ,  1 9 9 2 ;  R a i n e ,  1 9 9 0 a ) .  I n  m i c e ,  
E A E  c a n  b e  i n d u c e d  b y  i m m u n i z a t i o n  w i t h  m y e l i n  o r  m y e l i n  c o m p o n e n t s ,  
i n c l u d i n g  M B P ,  P L P  o r  m y e l i n  p e p t i d e s  s u c h  a s  M O G .  E A E  i s  a l s o  i n d u c e d  b y  
a d o p t i v e  t r a n s f e r  o f  M B P - ,  P L P - ,  o r  M O O - s p e c i f i c  C D 4 +  T h 1  T  c e l l s  i n t o  n a i v e  
r e c i p i e n t s .  T C R  t r a n s g e n i c  m i c e  t h a t  a r e  s p e c i f i c  f o r  M B P ,  P L P  a n d  M O G  h a v e  
a l s o  b e e n  g e n e r a t e d  ( L a f a i l l e  e t  a l . ,  1 9 9 4 ;  M e n d e l  e t  a l . ,  2 0 0 4 ;  W a l d n e r  e t  a l . ,  
2 0 0 0 ) ,  a l t h o u g h  i m m u n i z a t i o n  i s  r e q u i r e d  t o  i n d u c e  d i s e a s e  i n  s o m e  o f  t h e s e  
m i c e .  M O G
3
s - s s  p e p t i d e  i n d u c e s  a  r e l a p s i n g - r e m i t t i n g  f o r m  o f  E A E  i n  N O D / L t  
m i c e  a n d  a  c h r o n i c  n o n - r e m i t t i n g  p a r a l y t i c  d i s e a s e  i n  C 5 7 B L / 6  m i c e ,  w h i c h  i s  
c h a r a c t e r i z e d  b y  M N C  i n f i l t r a t i o n  i n t o  t h e  C N S  a n d  m u l t i f o c a l  d e m y e l i n a t i o n  i n  
t h e  b r a i n  a n d  s p i n a l  c o r d  ( B e r n a r d  e t  a l . ,  1 9 9 7 ;  S l a v i n  e t  a l . ,  1 9 9 8 ) .  T h e  r e l a p s i n g -
r e m i t t i n g  c o u r s e  o f  E A E  t h a t  d e v e l o p s  i n  N O D / L t  m i c e  i s  t h o u g h t  t o  b e s t  
a p p r o x i m a t e  t h e  M S  d i s e a s e  p r o f i l e  i n  h u m a n s  ( R a i n e ,  1 9 9 0 b  ) .  
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TNF superfamily members play an important role in the regulation of a multitude 
of autoimmune diseases in humans and in animal models of autoimmune disease. 
Abnormal regulation of apoptosis, inflammation of the CNS and production of 
regulatory cytokines have been implicated in EAE. Members of the TNF 
superfamily play an important role in apoptosis, and many possess inflammatory 
activity that might influence the severity of MS/EAE. Moreover, cytokines 
produced during the course of disease (Ruuls and Sedgwick, 1998) may regulate 
the expression and function of TNF superfamily members. Within this family, 
TNF, FasL and LT-a have been examined in models ofEAE, and each has been 
demonstrated to regulate disease (Dittel et al., 1999; Gommerman et al., 2003; 
Kassiotis and Kollias, 2001; Komer et al., 1997; Sabelko et al., 1997; Sabelko-
Downes et al., 1999; Sean Riminton et al., 1998; Waldner et al., 1997). Recently, 
TRAIL was reported to suppress collagen-induced arthritis in DBA/1 mice (Song 
et al., 2000). TRAIL blockade using soluble TRAIL receptor (DRS) exacerbated 
disease score, increased lymphocyte proliferation within LNs, and increased both 
cytokine production and collagen-specific antibodies in mice immunized to 
develop disease (Song et al., 2000). Moreover, TRAIL gene transfer using a 
replication-defective adenovirus inhibited disease (Song et al., 2000). 
As TRAIL was previously reported to inhibit collagen-induced arthritis (Song et 
al., 2000), we chose to investigate whether TRAIL plays a general role in 
suppression of T cell-mediated autoimmune diseases. In this study, we used 
TRAIL-deficient mice, a potent neutralizing anti-mTRAIL mAb, recombinant 
soluble TRAIL/ Apo2L and an anti-TRAIL receptor (DRS) antibody to 
demonstrate that TRAIL suppresses autoimmune damage in chronic non-remitting 
and relapsing-remitting models of EAE. We also show that TRAIL suppresses 
MOO-specific T cell proliferation responses and infiltration of inflammatory cells 
into the CNS in mice immunized to develop disease. As knowledge of the 
immunoregulatory processes involved in EAE increases, more specific 
intervention of disease in MS patients will become possible. 
5 . 3  M a t e r i a l s  a n d  M e t h o d s  
M i c e  
I n b r e d  C 5 7 B U 6 ,  B A L B / c  a n d  N O D / L t  m i c e  w e r e  p u r c h a s e d  f r o m  T h e  W E H I .  
C 5 7 B U 6  T R A I L _ ; _  a n d  B A L B / c  T R A I L _ ; _  m i c e  w e r e  o b t a i n e d  a n d  b r e d  a t  P e t e r  
M a c  a s  d e t a i l e d  i n  C h a p t e r  2 ,  S e c t i o n  2 . 1 ,  M a t e r i a l s  a n d  M e t h o d s .  A g e  m a t c h e d  
8 - 2 0  w e e k  o l d  f e m a l e  m i c e  w e r e  u s e d  i n  a l l  e x p e r i m e n t s  u n d e r  s p e c i f i c  p a t h o g e n -
f r e e  c o n d i t i o n s  a c c o r d i n g  t o  A n i m a l  E x p e r i m e n t a l  E t h i c s  C o m m i t t e e  G u i d e l i n e s  
a n d  a p p r o v a l .  
R e a g e n t s  
M o u s e  M O G 3 s - s s  p e p t i d e  ( M E V G W Y R S P F S R V V H L  Y R N G K )  w a s  p u r c h a s e d  
f r o m  A u s p e p  ( P a r k v i l l e ,  V i c t o r i a ,  A u s t r a l i a )  a n d  d e t e r m i n e d  t o  b e  o v e r  9 4 %  p u r e  
b y  r e v e r s e d - p h a s e  H P L C .  C h i c k e n  O V  A z s 7 - 2 6 4  p e p t i d e  ( S I I N F E K L )  w a s  k i n d l y  
p r o v i d e d  b y  D r .  F r a n k  C a r b o n e  ( U n i v e r s i t y  o f  M e l b o u r n e ,  P a r k v i l l e ,  V i c t o r i a ,  
A u s t r a l i a ) .  C o m p l e t e  F r e u n d ' s  a d j u v a n t  ( C F A )  w a s  p u r c h a s e d  f r o m  G I B C O  B R L  
( R o c k v i l l e ,  M D ,  U S A ) ,  M y c o b a c t e r i u m  t u b e r c u l o s i s  f r o m  D i f c o  ( D e t r o i t ,  M I ,  
U S A ) ,  s a l t - f r e e  p e r t u s s i s  t o x i n  f r o m  L i s t  B i o l o g i c a l  L a b o r a t o r i e s  ( C a m p b e l l ,  C A ,  
U S A )  a n d  w h o l e  r a t  l g G  f r o m  S i g m a  C h e m i c a l  C o .  T h e  n e u t r a l i z i n g  a n t i - m  
T R A I L  m A b  ( N 2 B 2 )  w a s  p r e p a r e d  a s  d e t a i l e d  i n  C h a p t e r  2 ,  S e c t i o n  2 . 1 ,  
M a t e r i a l s  a n d  M e t h o d s  a n d  c o n t r o l  r a t  I g G 2 a  ( R 3 5 - 9 5 )  p u r c h a s e d  f r o m  B D  
B i o s c i e n c e s  P h a r m i n g e n .  A n t i - D R S  m A b  ( M D 5 - : 1 )  w a s  k i n d l y  p r o v i d e d  b y  D r .  
H i d e o  Y a g i t a  ( J u n t e n d o  U n i v e r s i t y  S c h o o l  o f  M e d i c i n e ,  T o k y o ,  J a p a n )  a n d  
r e c o m b i n a n t  u n t a g g e d  s o l u b l e  h u m a n  A p o 2 U T R A I L ,  c u r r e n t l y  b e i n g  u s e d  i n  
c l i n i c a l  t r i a l s ,  w a s  p r o v i d e d  b y  D r .  A  v i  A s h k e n a z i  (  G e n e n t e c h  I n c ,  S o u t h  S a n  
F r a n c i s c o ,  C A ,  U S A )  ( A s h k e n a z i  e t  a l . ,  1 9 9 9 ) .  C o n c a n a v a l i n  A  ( C o n  A )  w a s  
p u r c h a s e d  f r o m  S i g m a  C h e m i c a l  C o .  
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p e p t i d e  ( 1  0 0  } l g ) ,  e m u l s i f i e d  i n  C F  A  a n d  s u p p l e m e n t e d  w i t h  
M y c o b a c t e r i u m  t u b e r c u l o s i s  (  4  m g / m l ) ,  w a s  i n j e c t e d  s . c .  i n t o  e a c h  h i n d  f l a n k  
( t o t a l  o f  2 0 0  ) l g  p e p t i d e  p e r  m o u s e ) .  S h o r t l y  a f t e r ,  m i c e  w e r e  i n j e c t e d  i . p .  w i t h  
3 5 0  n g  p e r t u s s i s  t o x i n / P B S  w i t h  a  r e p e a t  d o s e  4 8  h o u r s  l a t e r  ( B e r n a r d  e t  a l . ,  
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1997). Mice were weighed three times weekly and monitored daily for clinical 
signs of disease. Neurological impairment was scored as follows: 0, no 
detectable impairment; 1, flaccid tail and/or abnormal gait; 2, hind limb 
weakness; 3, complete paralysis of one/both hind limbs; 4, complete hind limb 
paralysis and ascending paralysis; 5, moribund or deceased. In accordance with 
Animal Experimental Ethics Committee Guidelines, mice with a score of 4 or 
greater for more than 12 h were sacrificed. Mice that died due to severe EAE 
were scored as 5 for the remainder of the study. 
Treatment with anti-mTRAIL mAb, anti-DRS mAb and recombinant 
soluble TRAIL/Apo2L 
To neutralize mouse TRAIL in vivo, mice were injected with between 250-500 
Jlg anti-mTRAIL mAb (N2B2) three times weekly, commencing immediately 
prior to immunization, or on the days as indicated. Negative control mice were 
injected with either PBS or isotype control rat IgG. Administration of control IgG 
had no effect on disease course. To examine therapeutic activity, 50 Jlg 
recombinant soluble TRAIL in saline, or 50 J..Lg anti-DRS mAb was administered 
i.p. on the days as indicated. Anti-mTRAIL mAb (N2B2) does not neutralize 
human rTRAIL activity (data not shown). 
CNS Histology 
Brain and spinal cord were carefully dissected and immersion fixed or perfused 
with 4% paraformaldehyde in PBS. Fixed tissues were embedded in paraffin wax 
and 10 J..Lm sections were cut from various locations of the brain and spinal cord. 
The preparation and staining of sections for histology was undertaken by 
technical staff at The WEHI. Sections were stained with H&E for evidence of 
inflammation (Johns et al., 1995). 
3H-Thymidine cell proliferation assay 
Splenocytes (1.5 to 4.5 x 105/well) isolated from MOG35_55 immunized mice 
were incubated in 96-well flat-bottomed plates with either 20 Jlg/ml MOG3s-ss 
peptide, 20 Jlg/ml OV A2s1-264 peptide, or 3 Jlg/ml Con A (or the concentrations of 
peptide and Con A stated). Seventy-two hours later, 3H-thymidine (0.5 JlCi) was 
a d d e d  a n d  t h e  c e l l s  w e r e  i n c u b a t e d  f o r  a  f u r t h e r  1 8  h .  C e l l s  w e r e  h a r v e s t e d  o n  
g l a s s  f i b r e  f i l t e r  m a t s  ( P a c k a r d ,  M e r i d e n ,  C T ,  U S A ) ,  a d d e d  t o  l i q u i d  s c i n t i l l a n t  
( P e r k i n  E l m e r  L i f e  S c i e n c e s ,  B o s t o n ,  M A ,  U S A )  a n d  c o u n t e d  o n  a  l i q u i d  
s c i n t i l l a t i o n  a n a l y z e r  ( T r i - C a r b 2 1  O O T R ,  P a c k a r d ) .  
C y t o k i n e  s e c r e t i o n  E L I S A  
S p l e n o c y t e s  ( 0 . 5 - 4 . 5  x  1 0
5
/ w e l l )  i s o l a t e d  f r o m  M O G 3 s - s s  i m m u n i z e d  m i c e  w e r e  
h a r v e s t e d  a t  t h e  e n d  o f  t h e  d i s e a s e  c o u r s e  a n d  i n c u b a t e d  i n  9 6 - w e l l  f l a t -
b o t t o m e d  p l a t e s  i n  2 0  J . l g / m l  M O G  p e p t i d e ,  3  J . l g / m l  C o n  A  o r  m e d i a  a l o n e .  
S e v e n t y - t w o  h o u r s  l a t e r ,  s u p e r n a t a n t s  w e r e  h a r v e s t e d  a n d  t e s t e d  f o r  c y t o k i n e  
c o n c e n t r a t i o n  u s i n g  t h e  O p t E I A  I F N  - y  E L I S A  k i t  a c c o r d i n g  t o  t h e  
m a n u f a c t u r e r s '  i n s t r u c t i o n s  ( B D  B i o s c i e n c e s  P h a r m i n g e n ) .  
M O G - s p e c i f i c  a n t i b o d y  E L I S A  
S e r a  f r o m  M O G - i m m u n i z e d  m i c e  w e r e  t e s t e d  f o r  M O G - r e a c t i v e  a n t i b o d i e s  b y  
E L I S A .  N i n e t y - s i x - w e l l  p l a t e s  w e r e  p r e - c o a t e d  w i t h  5  J . l g / m l  M O G  p e p t i d e  i n  
c a r b o n a t e  b u f f e r  p H  9 . 6 ,  o v e r n i g h t  a t  4 ° C .  P l a t e s  w e r e  t h e n  w a s h e d  3 - 5  t i m e s  
w i t h  0 . 0 5 %  T w e e n - 2 0 / P B S  a n d  b l o c k e d  f o r  1 . 5  h  a t  R T  w i t h  2 %  B S A / P B S .  
S u b s e q u e n t  s t e p s  w i t h  i n t e r v e n i n g  w a s h e s  i n c l u d e d  a d d i n g  s e r a  f o r  2  h  a t  R T ,  
H R P - c o n j u g a t e d  g o a t  a n t i - m o u s e  l g G  ( S i g m a  C h e m i c a l  C o . )  f o r  2  h  a t  R T  a n d  
d e v e l o p m e n t  w i t h  a - p h e n y l e n e d i a m i n e  d i h y d r o c h l o r i d e  ( S i g m a  C h e m i c a l  C o . )  i n  
p h o s p h a t e  c i t r a t e  b u f f e r  ( p H  5 . 0 )  f o r  3 0  m i n .  R e a c t i o n s  w e r e  s t o p p e d  u s i n g  3  M  
H C l  a n d  r e a d  a t  O D  4 9 2  n m .  
S t a t i s t i c a l  a n a l y s i s .  
D a t a  w e r e  a n a l y z e d  u s i n g  a  t w o  t a i l e d ,  n o n - p a r a m e t r i c ,  u n p a i r e d  M a n n  W h i t n e y  
t e s t .  P  v a l u e s  <  0 . 0 5  w e r e  c o n s i d e r e d  s i g n i f i c a n t .  
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5.4 Results 
5.4.1 TRAIL neutralization exacerbates relapsing-remitting and chronic 
non-remitting EAE 
The relapsing-remitting course of EAE that develops in MOG35_55 peptide 
immunized NOD/Lt mice is thought to best approximate the MS disease profile 
in humans (Raine, 1990b ). To investigate the role of endogenous TRAIL in 
autoimmune-mediated demyelination, NOD/Lt mice were immunized with 
MOG3s-ss peptide to induce EAE. Mice were injected 3 times weekly, beginning 
immediately prior to immunization, with an anti-mTRAIL mAb previously 
demonstrated to effectively block TRAIL function in vivo (Smyth et al., 2001; 
Takeda et al., 2001; Takeda et al., 2002). Mean clinical score was greater for 
mice treated with anti-mTRAIL mAb, and these mice developed a severe 
progressive disease, compared with control treated mice that developed the usual 
relapsing-remitting disease that is characterized by 'peaks' and 'troughs' in 
disease score (Figure 5.1A). In addition, mean cumulative score was significantly 
higher, and mean day of disease onset significantly earlier for anti-mTRAIL 
mAb-treated mice compared to control-treated NOD/Lt mice (P < 0.05, Table 
5.1 ). Moreover, 60% of anti-mTRAIL mAb-treated NOD/Lt mice died during the 
course the study, compared to 20% of control-treated mice (Table 5.1 ). 
To investigate whether endogenous TRAIL also suppresses chronic non-remitting 
EAE, C57BL/6 mice were immunized with MOG35_5s peptide to induce EAE and 
injected 3 times weekly, beginning immediately prior to immunization, with anti-
mTRAIL mAb. Clinical symptoms were exacerbated in mice treated with anti-
mTRAIL mAb compared to isotype control-treated mice, particularly at the later 
stages of disease (25 days post immunization onward) (Figure 5.1B). Moreover, 
mean maximum score was significantly higher for anti-mTRAIL mAb-, 
compared to isotype control-treated C57BL/6 mice (P < 0.05), and 100% of anti-
mTRAIL mAb-treated C57BL/6 mice died during the course of the study, 
compared to 0% of control-treated mice (Table 5.1 ). Together, these data 
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D a y s  p o s t  i m m u n i z a t i o n  
F i g u r e  5 . 1 .  H o s t  T R A I L  s u p p r e s s e s  r e l a p s i n g - r e m i t t i n g  a n d  n o n - r e m i t t i n g  E A E .  ( A )  
R e l a p s i n g - r e m i t t i n g  E A E :  f e m a l e  N O D / L t  m i c e  w e r e  i m m u n i z e d  w i t h  M O G
3
s - s s  p e p t i d e  a n d  
i n j e c t e d  t h r e e  t i m e s  w e e k l y  f o r  t h e  d u r a t i o n  o f  t h e  e x p e r i m e n t  w i t h  e i t h e r  P B S  ( o p e n  s q u a r e s ,  
n = 5 )  o r  2 5 0  J . l g  a n t i - m T R A I L  m A b  i . p .  ( c l o s e d  s q u a r e s ,  n = 5 )  t o  d e v e l o p  E A E .  ( B )  C h r o n i c  n o n -
r e m i t t i n g  E A E :  f e m a l e  C 5 7 B L / 6  m i c e  w e r e  i m m u n i z e d  w i t h  M O G 3 5 _
5 5  
p e p t i d e  a n d  i n j e c t e d  t h r e e  
t i m e s  w e e k l y  f o r  t h e  d u r a t i o n  o f t h e  e x p e r i m e n t  w i t h  e i t h e r  5 0 0  J . l g  r a t  I g G  ( o p e n  s q u a r e s ,  n = 5 )  o r  
5 0 0  J . l g  a n t i - m T R A I L  m A b  i . p .  ( c l o s e d  s q u a r e s ,  n = 5 )  t o  d e v e l o p  E A E .  M e a n ±  S E M  a r e  s h o w n  
f o r  e a c h  t i m e  p o i n t .  R e s u l t s  a r e  r e p r e s e n t a t i v e  o f  4  i n d e p e n d e n t  e x p e r i m e n t s  i n  ( A )  a n d  I  i n  ( B ) .  
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.9 , I ;1\'leanday · .•. 
~ ', ofonset± 
.:~ .. ·· ·SEM ·'·•· 
1/5 13.6 + 0.2 
3/5 11.8 ± 0.4* 
0/5 14.4 + 0.7 
5/5 16.0 + 2.3 
0/7 16.6 + 1.4 
1/7 13.7±2.2 
0/6 13.3 ± 1.2 
0/6 27.0 ± 2.7* 
1/6 13.6 ±0.7 
0/6 23.7 ±2.9* 
1/6 15.7 + 1.4 
0/6 23.6 + 4.0' 




2.80 + 0.58 
4.20 ± 0.49 
2.80 + 0.20 
5.00 + 0.00* 
2.14 + 0.26 
3.43 ± 0.43* 
2.50 ± 0.34 
1.17 ± 0.17* 
3.67 ± 0.33 
1.67 ± 0.21 * 
3.17 + 0.48 
1.33 + 0.43* 




.... (days ~ored) 
43.7 + 5.8 (36) 
77.2 ± 10.2 (36)* 
43.4 + 0.8 (37) 
69.0 + 13.6 (37) 
29.3 + 5.7 (40) 
71.4 ± 12.4 (40)* 
45.3 ± 5.3 (40) 
13.3 ± 3.0 (40)* 
62.5 ± 5.3 (40) 
17.8 ± 3.4 (40)* 
56.0 + 9.0 (40) 
15.2 + 5.1 (40)* 
22.2 + 4.2 (40)* 
Table 5.1. Effect of TRAIL on clinical parameters following MOG immunization. 1Mean 
maximum (max) score was calculated from the highest score achieved for each individual mouse 
in a group over the course of disease. 2Mean cumulative score was calculated from the sum of the 
scores for each day from day 0 for the period of days indicated in parentheses. 3 Mean day of 
onset was calculated from the day of onset of the 5 mice in this group that succumbed to disease. 
Disease was completely suppressed in one mouse. * P < 0.05 compared to group above, except 
last row which is compared to control IgG group 2 rows above. 
s u g g e s t e d  t h a t  e n d o g e n o u s  T R A I L  s u p p r e s s e d  b o t h  r e l a p s i n g - r e m i t t i n g  a n d  
c h r o n i c  n o n - r e m i t t i n g  f o r m s  o f  E A E .  
5 . 4 . 2  T R A I L - d e f i c i e n t  C 5 7 B L / 6  m i c e  d e v e l o p  e x a c e r b a t e d  E A E  
T o  e x a m i n e  t h e  e f f e c t  o f  T R A I L - d e f i c i e n c y  o n  d e v e l o p m e n t  o f  c h r o n i c  n o n -
r e m i t t i n g  E A E ,  C 5 7 B L / 6  W T  a n d  C 5 7 B L / 6  T R A I L - / - m i c e  w e r e  i m m u n i z e d  w i t h  
M O G 3 s - s s  p e p t i d e  t o  i n d u c e  E A E .  S i m i l a r  t o  a n t i - m T R A I L  m A b - t r e a t e d  C 5 7 B L / 6  
m i c e ,  C 5 7 B L / 6  T R A I L - / - m i c e  d e v e l o p e d  e x a c e r b a t e d  E A E  c o m p a r e d  t o  
C 5 7 B L / 6  W T  c o n t r o l  m i c e ,  p a r t i c u l a r l y  a t  t h e  l a t e r  s t a g e s  o f  d i s e a s e  ( 2 4  d a y s  
p o s t  i m m u n i z a t i o n  o n w a r d )  ( F i g u r e  5 . 2 ) .  M e a n  m a x i m u m  s c o r e  a n d  m e a n  
c u m u l a t i v e  s c o r e  w e r e  a l s o  s i g n i f i c a n t l y  h i g h e r  f o r  C 5 7 B L / 6  T R A I C
1
- c o m p a r e d  
t o  C 5 7 B L / 6  W T  m i c e  ( T a b l e  5 . 1 ,  P  <  0 . 0 5 ) .  F o u r t e e n  p e r c e n t  o f  C 5 7 B L / 6  
T R A I L _ ; _  m i c e  d i e d  d u r i n g  t h e  c o u r s e  o f  t h e  s t u d y ,  c o m p a r e d  t o  0 %  o f  C 5 7 B L / 6  
W T  m i c e  ( T a b l e  5 . 1 ) .  T h e s e  d a t a  f u r t h e r  c o n f i r m e d  t h a t  e n d o g e n o u s  T R A I L  
s u p p r e s s e d  c h r o n i c  n o n - r e m i t t i n g  E A E .  
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Figure 5.2. C57BL/6 TRAIL_,_ mice develop exacerbated EAE. Female C57BL/6 (open 
squares, n=7) and C57BL/6 TRAIL_,_ mice (closed squares, n=7) were immunized with MOG35_55 
peptide to develop EAE. Mean ± SEM are shown for each time point. Results are representative 
of 4 independent experiments. 
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with M0035-55 peptide were largely resistant to disease induction, although 115 
mice developed a limp tail (clinical score of 1) for a period of24 h (Figure 5.4A). 
In contrast, resistance was overcome in 3/6 BALB/c TRAIC1- mice, with one of 
these mice developing a severe form of EAE and achieving a clinical score of 3 
(Figure 5.4B). These data further supported the contention that TRAIL 
contributed to the resistance ofBALB/c WT mice to EAE. 
5.4.5 TRAIL suppresses T cell infiltration and inflammation in the central 
nervous system (CNS) 
Like MS, EAE is typically characterized by an infiltration of inflammatory cells 
into the CNS (Bernard et al., 1992; Raine, 1990a). To evaluate whether TRAIL 
regulated inflammation associated with EAE, NOD/Lt mice were immunized 
with M0035-55 peptide to develop EAE and injected 3 times weekly with anti-
mTRAIL mAb or PBS. At the termination of the experiment (day 36), CNS 
sections from these mice were analyzed. Far more extensive inflammation and 
greater numbers of lesions were revealed in the CNS parenchyma (Figure 5.5), 
cerebellum (Figure 5.6) and spinal cord (Figure 5.7) of anti-mTRAIL mAb-
treated, compared with PBS-treated mice. Moreover, extensive oedema was 
observed in the spinal cord of anti-mTRAIL mAb-treated, compared to control-
treated mice (Figure 5.7). These data demonstrated that TRAIL suppressed EAE 
by inhibiting the infiltration of inflammatory cells into the CNS and by inhibiting 
oedema associated with disease. 
5.4.6 TRAIL suppresses T cell proliferation but has no effect on MOG-
specific antibody or cytokine production 
To determine whether TRAIL influences the autoreactive phase of EAE, we 
examined the immune response generated against MOO. At the termination of 
the experiment (day 36), splenocytes isolated from M0035_55 peptide-immunized 
NOD/Lt mice were restimulated with M0035_55 peptide in vitro and MOO-
specific proliferation was determined by 3H-thymidine incorporation assay. 
MOO-specific proliferative responses were almost 3-fold higher for splenocytes 
isolated from anti-mTRAIL mAb-treated, compared with control-treated NOD/Lt 
mice (Figure 5 .8A), suggesting that TRAIL inhibited lymphocyte proliferation 
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3 5
.
5 5  
p e p t i d e  t o  
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r e p r e s e n t a t i v e  o f 3  i n d e p e n d e n t  e x p e r i m e n t s .  
2 0 2  
Figure 5.5. TRAIL suppresses leukocyte cell infiltration in the CNS parenchyma. Female 
NOD/Lt mice were immunized with MOG35•55 peptide to develop EAE. Mice were injected i.p. 
three times weekly from the day of immunization, for the duration of the experiment, with 500 
Jlg anti-mTRAIL mAb (A) or PBS (B). Thirty-six days after immunization, mice were sacrificed 
and H&E staining performed on CNS parenchyma (original magnification x 10). White arrows 
indicate inflammatory lesions. Histology is representative of 5 NOD/Lt mice for each group. 
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Figure 5.7. TRAIL suppresses leukocyte cell infiltration and oedema in the spinal cord. 
Female NOD/Lt mice were immunized with MOG35•55 peptide to develop EAE. Mice were 
injected i.p. three times weekly from the day of immunization, for the duration of the 
experiment, with 500 J.lg anti-mTRAIL mAb (A) or PBS (B). Thirty-six days after 
immunization, mice were sacrificed and H&E staining performed on spinal cord (original 
magnification x 10). White arrows indicate inflammatory lesions, black arrows indicate the 
presence of oedema. Histology is representative of 5 NOD/Lt mice for each group. 
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p r o l i f e r a t i o n .  ( B )  S e r u m  i s o l a t e d  f r o m  t h e  s a m e  m i c e  w a s  t e s t e d  f o r  M O G - s p e c i f i c  a n t i b o d y  
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p r o l i f e r a t i o n )  I  ( C o n  A  p r o l i f e r a t i o n  - m e d i a  p r o l i f e r a t i o n )  x  1 0 0 % .  M e a n  ±  S E M  w e r e  
c a l c u l a t e d  f r o m  t h e  a n a l y s i s  o f  4  N O D / L t  m i c e  t r e a t e d  w i t h  P B S  a n d  4  N O D / L t  m i c e  t r e a t e d  
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i n d e p e n d e n t  e x p e r i m e n t s  f o r  ( B ) .  A s t e r i s k  i n d i c a t e s  t h a t  p r o l i f e r a t i o n  i s  s i g n i f i c a n t l y  d i f f e r e n t  
b e t w e e n  N O D / L t  m i c e  i n j e c t e d  w i t h  P B S  a n d  N O D ! L t  m i c e  i n j e c t e d  w i t h  a n t i - m T R A I L  m A b  ( *  
p  <  0 . 0 3 ) .  
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associated with relapsing-remitting EAE. In contrast, TRAIL had no discernable 
affect on the levels of total MOG-reactive antibody in the serum of these mice 
(Figure 5.8B). 
We then examined MOG-specific proliferative responses in C57BL/6 WT and 
C57BL/6 TRAIL-/- mice. At the termination of the experiment (day 35), 
splenocytes isolated from MOG35_5s peptide immunized mice were restimulated 
with peptide in vitro, and the MOG-specific proliferation response determined by 
3H-thymidine assay. MOG-specific proliferative responses were at least 3-fold 
higher for splenocytes isolated from C57BL/6 TRAIC1- mice compared with 
C57BL/6 WT mice (Figure 5.9A), suggesting that TRAIL inhibited lymphocyte 
proliferation associated with chronic non-remitting EAE. Restimulated 
splenocytes from C57BL/6 WT and C57BL/6 TRAIL-/- mice were also examined 
for MOG-specific production of IFN-y in vitro (Figure 5.9B), although TRAIL-
deficiency appeared to have no affect on cytokine production in vitro. 
5.4.7 rTRAIL/Apo2L suppresses EAE in non-obese diabetic (NOD)/Lt mice 
In murine models, recombinant soluble human TRAIL/Apo2L (rTRAIL/Apo2L) 
has demonstrated remarkable anti-tumor activity against human colon carcinoma 
(Ashkenazi et al., 1999; LeBlanc et al., 2002), glioma (Fulda et al., 2002; Pollack 
et al., 2001), multiple myeloma (Mitsiades et al., 2001) and breast carcinoma 
xenografts (Walczak et al., 1999). As we had demonstrated a role for endogenous 
TRAIL in suppression of EAE in mice of three different genetic backgrounds, we 
assessed whether continuous treatment with human rTRAIL/ Apo2L could 
suppress relapsing-remitting EAE in MOG35"55 peptide-immunized NOD/Lt mice. 
Whilst NOD/Lt mice immunized to develop EAE and treated with control Ig 
developed the usual relapsing-remitting disease, treatment with rTRAIL/ Apo2L 
dramatically decreased clinical signs of disease (Figure 5.10A). Mean maximum 
score and mean cumulative score were significantly decreased and mean day of 
disease onset was significantly later in rTRAIL/Apo2L-treated mice (P < 0.05, 
Table 5.1). The therapeutic efficacy of rTRAIL/Apo2L was also tested in 
NOD/Lt mice stimulated with anti-mTRAIL mAb to develop an exacerbated 
form of EAE. Treatment with rTRAIL/ Apo2L also dramatically decreased the 
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Figure 5.10. rTRAIL/Apo2L suppresses EAE. (A) Female NOD/Lt WT mice were 
immunized with MOG3s-s5 peptide to develop EAE. Mice were injected on days 0, 2, 4, 7, 9, II, 
I4, 16, 20, 22, 24, 28, 30 and 36 with either 50 Jlg control Ig (open symbols, n = 6) or 50 Jlg 
recombinant human TRAIL/Apo2L (closed symbols, n = 6). (B) Female NOD/Lt WT mice were 
immunized with MOG3s-ss peptide to develop EAE. All mice were injected on days 0, 2, 4, 7, 9, 
II, I4, I6, 20, 22, 24, 28, 30 and 36 with 250 Jlg anti-mTRAIL mAb to develop exacerbated 
EAE. Mice were concurrently injected on days 0, 2, 4, 7, 9, II, I4, 16, 20, 22, 24, 28, 30 and 36 
with either 50 Jlg control Ig (open symbols, n = 6) or 50 Jlg rTRAIL/Apo2L (closed symbols, n 
= 6). Mean ± SEM are shown for each time point. Results are representative of 2 independent 
experiments. 
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c e l l  p r o l i f e r a t i o n .  
5 . 4 . 8  A n t i - D R S  m o n o c l o n a l  a n t i b o d y  ( m A b )  s u p p r e s s e s  E A E  i n  N O D / L t  
m i c e  
I n  m i c e ,  a n t i - m o u s e  T R A I L  r e c e p t o r  ( D R S )  m A b  h a s  b e e n  r e p o r t e d  t o  i n d u c e  
p o t e n t  a n t i - t u m o r  e f f e c t s  a g a i n s t  T R A I L - s e n s i t i v e  t u m o r  c e l l s  b y  r e c r u i t i n g  F c -
r e c e p t o r - e x p r e s s i n g  i n n a t e  i m m u n e  c e l l s  s u c h  a s  N K  c e l l s  a n d  m a c r o p h a g e s  
( T a k e d a  e t  a l . ,  2 0 0 4 ) .  G i v e n  t h a t  r T R A I L / A p o 2 L  p o t e n t l y  s u p p r e s s e d  E A E ,  w e  
t h e n  a s s e s s e d  w h e t h e r  c o n t i n u o u s  t r e a t m e n t  w i t h  a n t i - D R S  m A b  c o u l d  s u p p r e s s  
E A E .  N O D / L t  m i c e  w e r e  i m m u n i z e d  w i t h  M O G
3
s - s s  p e p t i d e  t o  i n d u c e  E A E  a n d  
i n j e c t e d  t h r e e  t i m e s  w e e k l y  w i t h  a n t i - D R S  m A b ,  c o m m e n c i n g  i m m e d i a t e l y  p r i o r  
t o  i m m u n i z a t i o n .  C l i n i c a l  s i g n s  o f  d i s e a s e  w e r e  d r a m a t i c a l l y  d e c r e a s e d  i n  a n t i -
D R S  m A b - t r e a t e d  m i c e ,  c o m p a r e d  w i t h  c o n t r o l - t r e a t e d  m i c e  ( F i g u r e  S . 1 2 ) .  M e a n  
m a x i m u m  s c o r e  a n d  m e a n  c u m u l a t i v e  s c o r e  w e r e  a l s o  s i g n i f i c a n t l y  d e c r e a s e d  i n  
a n t i - D R S - t r e a t e d  N O D / L t  m i c e ,  c o m p a r e d  t o  c o n t r o l - t r e a t e d  m i c e  ( P  <  O . O S ,  
T a b l e  S  . 1  ) .  T h e  e x t e n t  o f  d i s e a s e  i n h i b i t i o n  a f f o r d e d  b y  a n t i - D R S  m A b  t h e r a p y  
w a s  e q u i v a l e n t  t o  t h a t  a c h i e v e d  b y  t r e a t m e n t  w i t h  r T R A I L / A p o 2 L  ( F i g u r e  S . 1 2 ) .  
T h e s e  d a t a  c o l l e c t i v e l y  d e m o n s t r a t e d  t h e  t h e r a p e u t i c  e f f i c a c y  o f  r T R A I L /  A p o 2 L  
a n d  a n t i - D R S  m A b  i n  s u p p r e s s i o n  o f  E A E .  
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Figure 5.11. rTRAIL!Apo2L suppresses MOG-specific T cell proliferation. Female NOD/Lt 
WT mice were immunized with MOG35_55 peptide to develop EAE. Mice were injected on days 
0, 2, 4, 7, 9, 11, 14, 16, 20, 22, 24, 28, 30 and 36 with either 50 11g control Ig (n = 6) or 50 11g 
rTRAIL!Apo2L (n = 6). Some mice were additionally injected i.p. on days 0, 2, 4, 7, 9, 11, 14, 
16, 20, 22, 24, 28, 30 and 36 with 250 11g anti-mTRAIL mAb (n=6) to develop exacerbated 
EAE. Fourty days after immunization, mice were sacrificed, their splenocytes pooled and tested 
for MOG35_55 peptide-specific proliferation. Proliferation in the presence of Con A or OV A257_264 
peptide was tested as a positive and negative control. Proliferation of naive splenocytes is 
additionally shown as a negative control. Results are expressed as the mean ± SEM of cpm 
calculated from the analysis of triplicate samples. 
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D a y s  p o s t  i m m u n i z a t i o n  
F i g u r e  5 . 1 2 .  A n t i - D R S  m A b  t r e a t m e n t  s u p p r e s s e s  E A E .  F e m a l e  N O D / L t  m i c e  w e r e  
i m m u n i z e d  w i t h  M O G
3 5
_
5 5  
p e p t i d e  t o  d e v e l o p  E A E .  M i c e  w e r e  i n j e c t e d  e v e r y  s e c o n d  d a y  w i t h  
e i t h e r  5 0  j l g  c o n t r o l  I g  ( o p e n  s q u a r e s ) ,  5 0  j l g  r T R A I L ! A p o 2 L  ( g r e y  s q u a r e s )  o r  2 5 0  ! l g  a n t i - D R S  
m A b  ( b l a c k  s q u a r e s ) .  M e a n  ±  S E M  w e r e  c a l c u l a t e d  f r o m  c l i n i c a l  s c o r e s  d e t e r m i n e d  f o r  n = 6  
m i c e  f o r  e a c h  g r o u p .  
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5.5 Discussion 
A number of studies have demonstrated the selective ability of rTRAIL to induce 
apoptosis in transformed and virus-infected cells, but not in most normal cells 
(Ashkenazi et al., 1999; Walczak et al., 1999). Moreover, in Chapter 3, we 
reported that TRAIL suppressed tumor initiation, growth and metastases in vivo. 
Whilst a role for TRAIL in transformed and virus-infected tissues has been 
clearly established, the function of TRAIL in non-transformed tissues was largely 
unknown. We have now demonstrated a role for endogenous TRAIL in the 
suppression of both relapsing-remitting and chronic non-remitting EAE. In 
addition, we have shown that TRAIL contributes to the resistance of BALB/c 
mice to induction of EAE. Recall of T cell proliferation responses to MOG 
autoantigen was greater in TRAIL-deficient mice or WT mice treated with 
neutralizing anti-mTRAIL mAb, compared with WT mice. Mice lacking TRAIL 
also exhibited increased leukocyte infiltration into the CNS compared to WT 
mice. Importantly, this is the first report to demonstrate the therapeutic efficacy 
of exogenously administered rTRAILI Apo2L or anti-DRS mAb in suppression of 
EAE. Together, our findings suggested that recombinant human TRAIL/ Apo2L 
or humanized anti-DRS mAb administration may be effective in suppressing 
disease episodes in MS patients. 
During the course of our studies, TRAIL was demonstrated by others to suppress 
both cyclophosphamide- and streptozatocin-induced diabetes m miCe 
(Lamhamedi-Cherradi et al., 2003a; Lamhamedi-Cherradi et al., 2003b; Mi et al., 
2003). Furthermore, TRAIL-deficient mice were reported to be hypersensitive to 
collagen-induced arthritis (Lamhamedi-Cherradi et al., 2003b) and TRAIL 
blockade using soluble TRAIL receptor (DRS) exacerbated MOG-induced EAE 
in CS7BL/6 WT mice (Hilliard et al., 2001). Whilst the role ofmany of the TNF 
superfamily members in autoimmune disease has been controversial, TRAIL has 
consistently been shown to inhibit autoimmune disease induction. These recent 
findings, combined with our results, suggest an important and general role for 
TRAIL in suppression ofT -cell mediated autoimmune disease. 
A l t h o u g h  t h e  p r e c i s e  m e c h a n i s m ( s )  w h e r e b y  T R A I L  i n h i b i t s  E A E  w e r e  n o t  c l e a r ,  
o u r  d a t a  s u g g e s t e d  t h a t  T R A I L  i n h i b i t e d  T  c e l l  p r o l i f e r a t i o n  a n d  i n f i l t r a t i o n  o f  
l e u k o c y t e s  i n t o  t h e  C N S .  O u r  d a t a  a l s o  s u g g e s t e d  t h a t  T R A I L  h a s  n o  e f f e c t  o n  
M O O - s p e c i f i c  c y t o k i n e  o r  a n t i b o d y  p r o d u c t i o n  i n  E A E .  H i l l i a r d  a n d  c o l l e a g u e s  
s i m i l a r l y  r e p o r t e d  t h a t  T R A I L  s u p p r e s s e d  l e u k o c y t e  i n f i l t r a t i o n  i n t o  t h e  C N S ,  b u t  
i n  c o n t r a s t  t o  o u r  f i n d i n g s ,  t h e y  r e p o r t e d  t h a t  T R A I L  a d d i t i o n a l l y  i n h i b i t s  
c y t o k i n e  p r o d u c t i o n  a s s o c i a t e d  w i t h  d i s e a s e  ( H i l l i a r d  e t  a l . ,  2 0 0 1 ) .  I m p o r t a n t l y ,  
M O O - s p e c i f i c  c y t o k i n e  p r o d u c t i o n  w a s  t e s t e d  a t  a n  e a r l i e r  s t a g e  o f  d i s e a s e  ( d a y  
2 6  c o m p a r e d  t o  d a y  3 5  i n  o u r  s t u d y ) ,  a n d  T R A I L  a c t i v i t y  w a s  o n l y  b l o c k e d  f o r  
t h e  f i r s t  1 6  d a y s  o f  t h e  e x p e r i m e n t  i n  t h e  H i l l i a r d  e t  a l .  s t u d y ,  w h i l s t  w e  u s e d  
T R A I L - d e f i c i e n t  m i c e .  P e r h a p s  t h e s e  d i f f e r e n c e s  a c c o u n t  f o r  t h e  d i s c r e p a n c i e s  i n  
o u r  f i n d i n g s .  F u r t h e r  s t u d i e s  a r e  c l e a r l y  r e q u i r e d  t o  d e t e r m i n e  t h e  e x a c t  
m e c h a n i s m ( s )  b y  w h i c h  T R A I L  s u p p r e s s e s  E A E ,  a n d  t h e  k e y  T R A I L - e x p r e s s i n g  
e f f e c t o r  c e l l s  t h a t  a r e  i n v o l v e d .  
T R A I L  i s  c o n s t i t u t i v e l y  e x p r e s s e d  o n  a  p r o p o r t i o n  o f  m o u s e  l i v e r  N K  c e l l s  
( T a k e d a  e t  a l . ,  2 0 0 1 ) ,  a n d  T R A I L  e x p r e s s i o n  c a n  b e  i n d u c e d  o n  N K  c e l l s ,  T  c e l l s ,  
m o n o c y t e s  a n d  D C s  u p o n  s t i m u l a t i o n  w i t h  i n t e r f e r o n s  o r  c y t o k i n e s  s u c h  a s  I L - 2  
a n d  I L - 1 5  ( F a n g e r  e t  a l . ,  1 9 9 9 ;  G r i f f i t h  e t  a l . ,  1 9 9 9 ;  K a y a g a k i  e t  a l . ,  1 9 9 9 a ;  
K a y a g a k i  e t  a l . ,  1 9 9 9 b ;  Z a m a i  e t  a l . ,  1 9 9 8 ) .  I F N - I 3  h a s  r e c e n t l y  b e e n  s h o w n  t o  b e  
e f f e c t i v e  i n  t h e  t r e a t m e n t  o f  M S  a n d  E A E  ( P e n d e r  a n d  W o l f e ,  2 0 0 2 ;  R u u l s  a n d  
S e d g w i c k ,  1 9 9 8 ;  T e i g e  e t  a l . ,  2 0 0 3 ;  v a n  d e r  M e i d e  e t  a l . ,  1 9 9 8 ;  W e n d e r  e t  a l . ,  
2 0 0 1 ;  Y a s u d a  e t  a l . ,  1 9 9 9 ;  Y u  e t  a l . ,  1 9 9 6 ) ,  w i t h  s e v e r a l  s t u d i e s  s u g g e s t i n g  t h a t  
I F N - I 3  i n h i b i t s  p r o - i n f l a m m a t o r y  c y t o k i n e s  a n d  s t i m u l a t e s  a n t i - i n f l a m m a t o r y  
c y t o k i n e s  t o  r e g u l a t e  d i s e a s e  ( T e i g e  e t  a l . ,  2 0 0 3 ;  W e n d e r  e t  a l . ,  2 0 0 1 ;  Y a s u d a  e t  
a l . ,  1 9 9 9 ) .  A s  I F N - I 3  i s  o n e  o f  t h e  b e s t  s t i m u l i  o f N K  c e l l  T R A I L  e x p r e s s i o n  ( S a t o  
e t  a l . ,  2 0 0 1 ) ,  a n d  N K  c e l l s  c a n  i n h i b i t  E A E  ( Z h a n g  e t  a l . ,  1 9 9 7 ) ,  I F N - I 3  m i g h t  
s u p p r e s s  M S / E A E  b y  s t i m u l a t i n g  a  p o p u l a t i o n  o f  e f f e c t o r  N K  c e l l s  t o  e x p r e s s  
T R A I L .  T R A I L - e x p r e s s i n g  N K  c e l l s  m a y  b e  h y p o t h e s i z e d  t o  i n h i b i t  E A E  b y  
i n d u c i n g  a p o p t o s i s  i n  a u t o r e a c t i v e  T  c e l l s  o r  D C s ,  t h u s  p r e v e n t i n g  a u t o i m m u n e  
d a m a g e  a n d  t h e  f u r t h e r  p r i m i n g  o f  a u t o r e a c t i v e  T  c e l l s .  I F N  - I 3  i s  a l s o  k n o w n  t o  
u p r e g u l a t e  T R A I L  e x p r e s s i o n  o n  D C s  ( L i u  e t  a l . ,  2 0 0 1 )  a n d  t h e s e  D C s  m a y  b e  
h y p o t h e s i z e d  t o  s u p p r e s s  d i s e a s e  b y  d e l e t i n g  a u t o r e a c t i v e  T  c e l l s .  I n d e e d ,  
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recently, DCs have been reported to inhibit the proliferation of autoreactive T 
cells in EAE in a TRAIL-dependent manner, suggesting an alternative role for 
DCs in regulation of EAE (Suter et al., 2003). 
Recently, a critical role for TRAIL in negative selection was proposed by 
Lamhamedi-Cherradi and colleagues (Lamhamedi-Cherradi et al., 2003b ). These 
authors postulated, but did not directly demonstrate, that impaired negative 
selection ofT cells in TRAIL-deficient mice may lead to enhanced susceptibility 
to autoimmune disease. This report clearly contrasted with a previous study that 
used soluble blocking TRAIL-R2-Fc to demonstrate that negative selection of 
mouse and human thymocytes was TRAIL-independent (Simonet al., 2001), and 
studies that excluded a role for the FADD-caspase 8 pathway (Newton et al., 
1998; Smith et al., 1996). In Chapter 6, we show that TRAIL does not play a role 
in thymocyte negative selection, suggesting that TRAIL regulates EAE induction 
by a different mechanism. TRAIL is known to contribute to AICD of PBLs, in 
vitro activated human CD4+ T cell clones, and the human leukemia line Jurkat 
(Martinez-Lorenzo et al., 1998; Zhang et al., 2003). It remains to be determined 
whether potentially-autoreactive T cells in the periphery undergo AICD by a 
TRAIL-dependent mechanism. Understanding how TRAIL suppresses EAE will 
be of great importance prior to any future planning of clinical trials in MS 
patients using rTRAILI Apo2L. 
While TRAIL-deficient mice and mice in which TRAIL activity was blocked 
were more susceptible to disease induction in several models of experimental 
autoimmune disease, it remained unclear by which mechanism TRAIL 
suppressed the induction of autoimmunity. Disease induction in these 
experimental models is complex and often involves adjuvants that stimulate DCs 
and innate immune cell networks that may affect TRAIL function, or activation-
induced T cell death in the periphery. Thus, it is important not to over-interpret 
findings in experimental models of autoimmune disease. Moreover, many 
therapies that are effective in EAE, are ineffective in MS patients (Pender and 
Wolfe, 2002). Furthermore, in Chapter 6, we demonstrate that aged C57BL/6 
TRAIC1- mice do not develop spontaneous autoimmune disease, suggesting that 
T R A I L  f u n c t i o n  i s  n o t  c r i t i c a l  f o r  t h e  s u p p r e s s i o n  o f  s p o n t a n e o u s  a u t o i m m u n i t y  
i n  t h e s e  m i c e .  
R e c e n t l y ,  T R A I L  h a s  b e e n  i d e n t i f i e d  a s  a  p o t e n t i a l  r e s p o n s e  m a r k e r  f o r  IFN-~ 
t h e r a p y  i n  M S  p a t i e n t s  ( W a n d i n g e r  e t  a l . ,  2 0 0 3 ) .  P a t i e n t s  w i t h  r a i s e d  l e v e l s  o f  
s o l u b l e  T R A I L  i n  t h e i r  s e r a  p r i o r  t o  IFN-~ t h e r a p y  a n d  t h o s e  w h o  s h o w e d  e a r l y  
a n d  s u s t a i n e d  T R A I L  i n d u c t i o n  a f t e r  t h e r a p y  w e r e  m o s t  l i k e l y  t o  r e s p o n d  t o  
t r e a t m e n t  ( W a n d i n g e r  e t  a l . ,  2 0 0 3 ) .  P B L s  i s o l a t e d  f r o m  M S  p a t i e n t s  h a v e  a l s o  
b e e n  r e p o r t e d  t o  e x p r e s s  h i g h e r  l e v e l s  o f  T R A I L  t h a n  h e a l t h y  c o n t r o l  s u b j e c t s  
( H u a n g  e t  a l . ,  2 0 0 0 ) ,  b u t  i t  h a s  y e t  t o  b e  i n v e s t i g a t e d  w h e t h e r  l e v e l s  o f  P B L  
T R A I L  e x p r e s s i o n  c o r r e l a t e  w i t h  r e s p o n s e  t o  IFN-~ t h e r a p y .  A l t h o u g h  i t  i s  n o t  
y e t  d e t e r m i n e d  w h e t h e r  T R A I L  c a n  r e g u l a t e  M S ,  o u r  s t u d y  h a s  s u g g e s t e d  t h a t  
a d m i n i s t r a t i o n  o f  r T R A I L I  A p o 2 L  o r  a n t i - D R S  m A b  m a y  p r o v e  t o  b e  a n  e f f e c t i v e  
s t r a t e g y  f o r  d a m p e n i n g  t h e  a u t o i m m u n e  r e s p o n s e .  
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CHAPTER SIX 
NORMAL THYMOCYTE NEGATIVE SELECTION 
IN TRAIL-DEFICIENT MICE 
6 . 1  A b s t r a c t  
N e g a t i v e  s e l e c t i o n  i s  e s s e n t i a l  f o r  d e l e t i o n  o f  p o t e n t i a l l y  s e l f - r e a c t i v e  t h y m o c y t e s  
a n d  t h e  g e n e r a t i o n  o f  a  l a r g e l y  s e l f - t o l e r a n t  p e r i p h e r a l  T  c e l l  r e p e r t o i r e .  A l t h o u g h  
a  n u m b e r  o f  f a c t o r s  h a v e  b e e n  i d e n t i f i e d  t o  p l a y  a  r o l e  i n  n e g a t i v e  s e l e c t i o n ,  t h e  
s i g n a l i n g  p a t h w a y ( s )  i n v o l v e d  a r e  n o t  f u l l y  u n d e r s t o o d .  I n  p a r t i c u l a r ,  t h e  
i n v o l v e m e n t  o f  t h e  D R  s u b g r o u p  o f  t h e  T N F  s u p e r f a m i l y  h a s  b e e n  t h e  s u b j e c t  o f  
m a n y  i n v e s t i g a t i o n s ,  w i t h  e q u i v o c a l  r e s u l t s .  A  r e c e n t  r e p o r t  s u g g e s t e d  t h a t  
T R A I L - d e f i c i e n t  m i c e  h a v e  d e f e c t i v e  n e g a t i v e  s e l e c t i o n  o f  t h y m o c y t e s .  B y  
c o n t r a s t ,  p r e v i o u s  s t u d i e s  h a d  i n d i c a t e d  t h a t  i n h i b i t i o n  o f  t h e  F  A D D - c a s p a s e  8  
p a t h w a y  n e c e s s a r y  f o r  T R A I L  s i g n a l i n g ,  o r  d i r e c t  i n h i b i t i o n  o f  T R A I L  u s i n g  
i n h i b i t o r s ,  e a c h  f a i l e d  t o  p r e v e n t  n e g a t i v e  s e l e c t i o n  o f  T  c e l l s .  I n  C h a p t e r  5 ,  
T R A I L  w a s  d e m o n s t r a t e d  t o  s u p p r e s s  a u t o i m m u n e  d a m a g e  i n  t h r e e  d i f f e r e n t  
m o d e l s  o f  E A E .  S i n c e  i m p a i r e d  n e g a t i v e  s e l e c t i o n  o f  T  c e l l s  m i g h t  e x p l a i n  a  
p r e d i s p o s i t i o n  o f  T R A I L - d e f i c i e n t  m i c e  t o  d e v e l o p m e n t  o f  a u t o i m m u n e  d i s e a s e ,  
w e  s o u g h t  t o  i n v e s t i g a t e  i n t r a t h y m i c  n e g a t i v e  s e l e c t i o n  i n  t h e s e  m i c e .  U s i n g  
s e v e r a l  w e l l - e s t a b l i s h e d  m o d e l s  i n c l u d i n g :  a n t i b o d y - m e d i a t e d  T C R / C D 3  l i g a t i o n  
i n  v i t r o  a n d  i n  v i v o ;  s t i m u l a t i o n  w i t h  e n d o g e n o u s  s u p e r a n t i g e n  i n  v i t r o  a n d  i n  
v i v o ;  s t i m u l a t i o n  o f  T C R  t r a n s g e n i c  t h y m o c y t e s  w i t h  a g o n i s t  p e p t i d e  i n  v i t r o ;  a n d  
t r e a t m e n t  w i t h  e x o g e n o u s  s u p e r a n t i g e n  i n  v i t r o ,  w e  w e r e  u n a b l e  t o  d e m o n s t r a t e  a  
c r i t i c a l  r o l e  f o r  T R A I L  s i g n a l i n g  i n  n e g a t i v e  s e l e c t i o n  o f  t h y m o c y t e s .  M o r e o v e r ,  
w e  f a i l e d  t o  r e v e a l  a n y  s i g n s  o f  s p o n t a n e o u s  a u t o i m m u n i t y  i n  a g e d  C 5 7 B L / 6  
T R A I L _ ; _  o r  B A L B / c  T R A I L - / - m i c e ,  s u g g e s t i n g  a  m a i n t e n a n c e  o f  i m m u n o l o g i c a l  
t o l e r a n c e  i n  m i c e  d e f i c i e n t  i n  T R A I L .  
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6.2 Introduction 
Within the thymus, BM-derived stem cells undergo a series of maturation events 
and prior to export, undergo thymic selection to ensure that the majority of 
thymocytes entering the periphery are capable of interacting with self-MHC with 
low affinity. DP thymocytes that express TCRs with a low affinity for peptide-
MHC undergo positive selection (Anderson et al., 1993) and can exit to the 
periphery where they circulate throughout the secondary lymphoid organs 
awaiting encounter with antigen (Goldrath and Bevan, 1999). By contrast, DP 
thymocytes that express TCRs that recognize self peptide-MHC with a high 
affinity and are potentially self-reactive, undergo negative selection leading to 
apoptosis (Palmer, 2003). Negative selection is essential for the generation of a 
self-tolerant peripheral T cell repertoire and recent studies have reiterated the 
importance of negative selection in the prevention of autoimmune disease 
(Anderson et al., 2002; Bouillet et al., 1999; Bouillet et al., 2002; Liston et al., 
2003). Depending on the model system used, negative selection appears to occur 
at the immature DP stage of thymocyte differentiation in the thymic cortex and 
possibly later at the SP HSA hi semi-mature stage when thymocytes transit 
through the CMJ (Stockinger, 1999). 
The molecular mechanisms which underly the death of autoreactive thymocytes 
in negative selection are yet to be fully understood, although a number of factors 
have been identified to play a role in the process. A number of intracellular 
signaling factors have been shown to be important for negative selection, 
including the Nur-77/Nurr1/Norl transcription factor family (Calnan et al., 1995; 
Cheng et al., 1997; Lee et al., 1995) and the pro-apoptotic Bcl-2 family members 
Bim (Bouillet et al., 2002), Bax and Bak (Rathmell et al., 2002). More 
controversial is the contribution made by the DRs; members of the tumor 
necrosis factor receptor family containing an intra-cellular DD (eg. Fas, TNF-R1 
and TRAIL receptors) (DeYoung et al., 2000; Page et al., 1998; Sprent and 
Kishimoto, 2002; Wang et al., 2001a; Wang et al., 2001b). 
S e v e r a l  m e m b e r s  o f  t h e  T N F  s u p e r f a m i l y  h a v e  b e e n  i n v e s t i g a t e d  f o r  t h e i r  r o l e  i n  
n e g a t i v e  s e l e c t i o n ,  i n c l u d i n g :  T R A I L ,  F a s ,  T N F ,  D R 3 ,  L T ,  L I G H T  a n d  C D 3 0  
( A m a k a w a  e t  a l . ,  1 9 9 6 ;  C h i a r l e  e t  a l . ,  1 9 9 9 ;  D e  Y o u n g  e t  a l . ,  2 0 0 0 ;  G r e c h  e t  a l . ,  
2 0 0 0 ;  K i s h i m o t o  a n d  S p r e n t ,  1 9 9 9 ;  K i s h i m o t o  e t  a l . ,  1 9 9 8 ;  L a m h a m e d i - C h e r r a d i  
e t  a l . ,  2 0 0 3 ;  P a g e ,  1 9 9 9 ;  P a g e  e t  a l . ,  1 9 9 8 ;  S i m o n  e t  a l . ,  2 0 0 1 ;  S p r e n t  a n d  
K i s h i m o t o ,  2 0 0 2 ;  W a n g  e t  a l . ,  2 0 0 1 a ;  W a n g  e t  a l . ,  2 0 0 1 b ) .  T h e s e  s t u d i e s  h a v e  
y i e l d e d  c o n f l i c t i n g  r e s u l t s ,  m a k i n g  i t  u n c l e a r  w h e t h e r  t h e  T N F  s u p e r f a m i l y  p l a y s  
a  r o l e  i n  t h e  p r o c e s s .  F o r  e x a m p l e ,  K i s h i m o t o  a n d  c o l l e a g u e s  s u g g e s t  a  r o l e  f o r  
\  
F a s  a t  h i g h ,  b u t  n o t  l o w  i n t e n s i t y  T C R  s t i m u l a t i o n  ( K i s h i m o t o  e t  a l . ,  1 9 9 8 ) ,  
w h e r e a s  o t h e r  i n v e s t i g a t o r s  p r o p o s e  t h a t  F a s  s i g n a l i n g  i s  d i s p e n s a b l e  f o r  n e g a t i v e  
s e l e c t i o n  ( S i d m a n  e t  a l . ,  1 9 9 2 ;  V i l l u n g e r  e t  a l . ,  2 0 0 4 ) .  I m p o r t a n t l y ,  n e g a t i v e  
s e l e c t i o n  o c c u r s  n o r m a l l y  i n  F A D D  d o m i n a n t - n e g a t i v e  m i c e  ( N e w t o n  e t  a l . ,  
1 9 9 8 )  a n d  i n  t r a n s g e n i c  m i c e  l a c k i n g  c a s p a s e - 8  f u n c t i o n  ( S m i t h  e t  a l . ,  1 9 9 6 ) ,  
q u e s t i o n i n g  t h e  i n v o l v e m e n t  o f  t h e  D R s  ( t h a t  u t i l i z e  t h i s  p a t h w a y  t o  i n d u c e  
a p o p t o s i s )  i n  n e g a t i v e  s e l e c t i o n .  
R e c e n t l y ,  a  c r i t i c a l  r o l e  f o r  T R A I L  i n  n e g a t i v e  s e l e c t i o n  w a s  p r o p o s e d  b y  
L a m h a m e d i - C h e r r a d i  a n d  c o l l e a g u e s  ( L a m h a m e d i - C h e r r a d i  e t  a l . ,  2 0 0 3 ) .  
N e g a t i v e  s e l e c t i o n  w a s  d e m o n s t r a t e d  t o  b e  a t  l e a s t  p a r t i a l l y  i m p a i r e d  i n  T R A I L -
d e f i c i e n t  m i c e  o r  i n  t h e  p r e s e n c e  o f  b l o c k i n g  s o l u b l e  T R A I L  r e c e p t o r  ( D R 5 ) ,  
u s i n g  s e v e r a l  i n  v i t r o  a n d  i n  v i v o  m o d e l s ,  i n c l u d i n g :  a n t i b o d y - m e d i a t e d  
T C R / C D 3  l i g a t i o n  i n  v i t r o  a n d  i n  v i v o ,  s t i m u l a t i o n  w i t h  e n d o g e n o u s  s u p e r a n t i g e n  
i n  v i v o ,  a n d  s t i m u l a t i o n  w i t h  a n t i g e n i c  p e p t i d e  i n  v i v o .  T h i s  r e p o r t  c l e a r l y  
c o n t r a s t e d  w i t h  a  p r e v i o u s  s t u d y  t h a t  u s e d  s o l u b l e  b l o c k i n g  T R A I L - R 2 - F c  t o  
d e m o n s t r a t e  t h a t  n e g a t i v e  s e l e c t i o n  o f  m o u s e  a n d  h u m a n  t h y m o c y t e s  w a s  
T R A I L - i n d e p e n d e n t  ( S i m o n e t  a l . ,  2 0 0 1 ) ,  a n d  s t u d i e s  t h a t  e x c l u d e d  a  r o l e  f o r  t h e  
F A D D - c a s p a s e  8  p a t h w a y  ( N e w t o n  e t  a l . ,  1 9 9 8 ;  S m i t h  e t  a l . ,  1 9 9 6 ) .  T o  e x p l a i n  
t h e s e  d i s c r e p a n c i e s ,  i t  h a s  b e e n  p r o p o s e d  t h a t  T R A I L  m i g h t  u t i l i z e  a n  a l t e r n a t i v e  
( a s  y e t  u n d e f i n e d )  a p o p t o s i s  s i g n a l i n g  p a t h w a y  t h a t  d o e s  n o t  i n v o l v e  F A D D -
c a s p a s e  8 ,  b u t  m a y  a c t i v a t e  B i m  a n d  B a x / B a k  ( G r e e n ,  2 0 0 3 ) .  
I n  t h i s  s t u d y ,  w e  s o u g h t  t o  i n v e s t i g a t e  t h e  r o l e  o f  T R A I L  i n  t h y m o c y t e  n e g a t i v e  
s e l e c t i o n  u s i n g  T R A I L - d e f i c i e n t  m i c e  a n d  a  p o w e r f u l  n e u t r a l i z i n g  a n t i - m T R A I L  
mAb. We demonstrate that TRAIL does not play a role in thymocyte negative 
selection using several well-established models. These include: antibody-
mediated TCR/CD3 ligation in vitro and in vivo; deletion of endogenous 
superantigen reactive T cells in vivo and in vitro; stimulation with the 
superantigen SEB in vitro; and in vitro stimulation of TCR transgenic thymocytes 
with agonist peptide. Development of spontaneous autoimmune disease in aged 
C57BL/6 TRAIC1- mice was also monitored. 
6 . 3  M a t e r i a l s  a n d  M e t h o d s  
M i c e  
I n b r e d  B A L B / c  W T ,  C 5 7 B L / 6  W T  a n d  C 5 7 B L / 6  O T  - I  T C R  t r a n s g e n i c  m i c e  
w e r e  p u r c h a s e d  f r o m  T h e  W E H I .  B A L B / c  T R A I L -
1
- ,  C 5 7 B L / 6  T R A I L -
1
- ,  
C 5 7 B L / 6  g l d  a n d  C 5 7 B L / 6  T R A I L - / - g l d  m i c e  w e r e  o b t a i n e d  a n d  b r e d  a t  P e t e r  
M a c  a s  d e t a i l e d  i n  C h a p t e r  2 ,  S e c t i o n  2 . 3  a n d  C h a p t e r  4 ,  S e c t i o n  4 . 3 ,  M a t e r i a l s  
a n d  M e t h o d s .  T o  o b t a i n  t i m e d  p r e g n a n c i e s ,  m i c e  w e r e  m a t e d  f o r  1 5  h  a n d  t h e  
e m b r y o s  r e m o v e d  a t  f e t a l  d a y  ( F D )  1 5  o r  1 8  ( p l u g  d a t e  =  d a y  0 ) .  A g e  a n d  s e x  
m a t c h e d  m i c e ,  5 - 1 8  w e e k s  o f  a g e  w e r e  u s e d  i n  a l l  e x p e r i m e n t s  ( u n l e s s  o t h e r w i s e  
s t a t e d ) ,  u n d e r  s p e c i f i c  p a t h o g e n - f r e e  c o n d i t i o n s  a c c o r d i n g  t o  A n i m a l  
E x p e r i m e n t a l  E t h i c s  C o m m i t t e e  g u i d e l i n e s  a n d  a p p r o v a l .  
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F e t a l  t h y m i c  l o b e s  w e r e  i s o l a t e d  f r o m  d a y  1 5  B A L B / c  W T  a n d  B A L B / c  T R A I L _ ; _  
e m b r y o s  a n d  c u l t u r e d  f o r  1 2  d a y s  i n  R P M I - 1 6 4 0  m e d i u m  s u p p l e m e n t e d  w i t h  
1 0 %  F C S ,  2  m M  G l u t a M A X ,  1 0 0  I U / m l  p e n i c i l l i n ,  1 0 0  ) l g / m l  s t r e p t o m y c i n ,  1 5  
m M  H E P E S  b u f f e r  ( I n v i t r o g e n  L i f e  T e c h n o l o g i e s  C o r p ) ,  a n d  1  m M  s o d i u m  
p y r u v a t e  ( I n v i t r o g e n  L i f e  T e c h n o l o g i e s  C o r p )  w i t h  o r  w i t h o u t  2 0  ) l g / m l  a n t i -
m T R A I L  m A b  ( N 2 B 2 )  ( p r e p a r e d  a s  d e t a i l e d  i n  C h a p t e r  2 ,  S e c t i o n  2 . 1 ,  M a t e r i a l s  
a n d  M e t h o d s )  a n d  1 0  ) l g / m l  S E B  ( T o x i n  T e c h n o l o g y  C o . ,  S a r a s o t a ,  F L ,  U S A ) .  
L o b e s  w e r e  c u l t u r e d  i n  g r o u p s  o f  2  p e r  w e l l  o f  a  6 - w e l l  p l a t e  a n d  m e d i u m  w a s  
c h a n g e d  a f t e r  6  d a y s .  A t  t h e  e n d  o f  c u l t u r e ,  t h y m o c y t e s  w e r e  h a r v e s t e d  f r o m  
l o b e s ,  c o u n t e d  a n d  a n a l y z e d  b y  f l o w  c y t o m e t r y .  
F e t a l  t h y m i c  l o b e s  w e r e  a l s o  i s o l a t e d  f r o m  d a y  1 5  C 5 7 B L / 6  O T - I  T C R  t r a n s g e n i c  
e m b r y o s  a n d  c u l t u r e d  f o r  7  d a y s  i n  s u p p l e m e n t e d  m e d i a  w i t h  o r  w i t h o u t  2 0 0  
) l g / m l  a n t i - m T R A I L  m A b  a n d  1 - 1 0 , 0 0 0  n M  O V  A z s ? - 2 6 4  p e p t i d e  ( S I I N F E K L ) .  I n  
o t h e r  e x p e r i m e n t s ,  f e t a l  t h y m i c  l o b e s  w e r e  i s o l a t e d  f r o m  d a y  1 5  C 5 7 B L / 6  O T - 1  
T C R  t r a n s g e n i c  e m b r y o s ,  c u l t u r e d  f o r  3  d a y s  i n  s u p p l e m e n t e d  m e d i a  a n d  t h e n  
c u l t u r e d  f o r  3 0  m i n .  i n  t h e  p r e s e n c e  o r  a b s e n c e  o f  2 0 0  ) l g / m l  a n t i - m T R A I L  m A b .  
O V  A z s 7 - 2 6 4  p e p t i d e  ( 2 0  ] J M )  w a s  t h e n  a d d e d  t o  s e l e c t  w e l l s  a n d  t h e  c u l t u r e s  
i n c u b a t e d  a  f u r t h e r  2 4  h  t o  i n d u c e  d e l e t i o n .  L o b e s  w e r e  c u l t u r e d  i n  g r o u p s  o f  2  
2 2 2  
per well of a 6-well plate. At the end of culture, thymocytes were harvested from 
lobes, counted and analyzed by flow cytometry. 
Anti-CD3 ligation in vitro 
For in vitro analysis, thymocyte suspensions were produced from thymic lobes 
isolated from day 18 BALB/c WT and BALB/c TRAIL_;_ embryos or from thymi 
isolated from adult BALB/c WT, BALB/c TRAIL-1-, C57BL/6 WT, C57BL/6 
TRAIC1-, C57BL/6 gld or C57BL/6 TRAIL-/- gld mice. Cells were cultured at a 
density of 1 x 106 cells/ml, in DMEM medium supplemented with 10% FCS in 
wells of a 96-well plate that had been coated overnight or at 37°C for 1 h with 
hamster anti-mouse CD3E (145-2C11), anti-CD28 (37.51) mAb (both sourced 
from BD Biosciences Pharmingen) and/or PBS. Twenty hours later, proportions 
of live and apoptotic cells were identified by staining with propidium iodide (PI) 
(Sigma Chemical Co) and annexin V-FITC (Roche, IN, USA). Live cells were 
considered to be PI" and annexin V- FITC. 
Anti-CD3 antibody treatment in vivo 
Eight week old BALB/c and BALB/c TRAIL-/- mice were injected i.p. with either 
20 J..lg anti-CD3 mAb (145-2Cll), or vehicle control, PBS. Fourty hours after 
injection, mice were sacrificed, their thymi and spleens isolated, cells counted 
and analyzed by flow cytometry. 
Thymic stromal cell isolation 
This procedure was adapted by Dr. Daniel Gray (Monash Medical School, 
Prahran, Victoria, Australia) (Gray et al., 2002) from (Shortman et al., 1989). 
Thymi were dissected from 5-7 week old C57BL/6 WT mice and trimmed of fat 
and connective tissue. Small cuts into the capsules were made with a pair of fine 
scissors and the lobes were gently agitated in 50 ml of RPMI-1640 with a 
magnetic stirrer at 4°C for 30 min. to remove the majority of thymocytes. The 
resulting thymic fragments were transferred into 10 ml of fresh RPMI-1640 and 
dispersed further with a wide bore glass pipette to free more thymocytes. The 
thymic fragments were then incubated in 5 ml of 0.125% (w/v) collagenase D 
and 0.1% (w/v) DNAse I (both obtained from Boehringer Mannheim, Penzberg, 
G e r m a n y )  i n  R P M I - 1 6 4 0  a t  3 7 ° C  f o r  1 S  m i n . ,  w i t h  g e n t l e  a g i t a t i o n  u s i n g  a  
P a s t e u r  p i p e t t e  e v e r y  S  m i n .  E n z y m e  m i x t u r e s  w i t h  i s o l a t e d  c e l l s  w e r e  r e m o v e d  
a f t e r  f r a g m e n t s  h a d  s e t t l e d ,  t h e n  r e p l a c e d  w i t h  f r e s h  m i x t u r e  f o r  f u r t h e r  
i n c u b a t i o n .  G e n t l e  m e c h a n i c a l  a g i t a t i o n  w a s  p e r f o r m e d  w i t h  a  2 0 0  ~1 p i p e t t e  t i p  
t o  b r e a k  u p  a g g r e g a t e s  r e m a i n i n g  i n  f i n a l  d i g e s t i o n s .  A f t e r  4 - S  d i g e s t i o n s ,  c e l l s  
f r o m  t h e  f i n a l  1 - 2  d i g e s t s  w e r e  p o o l e d  a n d  c e n t r i f u g e d  a t  4 S O  x  g  f o r  S  m i n . ,  a n d  
r e s u s p e n d e d  i n  S  m M  E D T A  i n  F  A C S  b u f f e r .  T h y m i c  s t r o m a l  c e l l s  w e r e  t h e n  
p a s s e d  t h r o u g h  1 0 0  J . l m  m e s h  t o  r e m o v e  d e b r i s  p r i o r  t o  c e l l  c o u n t s .  T h y m i c  
e p i t h e l i a l  c e l l s  w e r e  i d e n t i f i e d  b y  f l o w  c y t o m e t r y  a s  C D 4 Y E p C A M +  a n d  t h y m i c  
D C s  a s  C D 1 1 c + M H C - I l h i _  
A n n e x i n - V  I  P I  s t a i n i n g  
C e l l s  w e r e  w a s h e d  t h r e e  t i m e s  i n  a n n e x i n - V  b i n d i n g  b u f f e r  ( 0 . 0 1  M  H e p e s ,  0 . 1 4  
M  N a C l ,  2 . S  m M  C a C h ) ,  b e f o r e  l a b e l l i n g  w i t h  F I T C - c o n j u g a t e d  A n n e x i n - V  f o r  
2 S  m i n .  a t  R T ,  p r o t e c t e d  f r o m  l i g h t .  C e l l s  w e r e  w a s h e d  o n c e  a n d  r e s u s p e n d e d  i n  
a n n e x i n - V  b u f f e r .  P I  w a s  a d d e d  t o  a  f i n a l  c o n c e n t r a t i o n  o f  O . S  J . l g / m l  a n d  t h e  c e l l s  
i m m e d i a t e l y  a n a l y z e d  b y  f l o w  c y t o m e t r y .  
F l o w  c y t o m e t r i c  a n a l y s i s  
T h y m o c y t e s ,  s p l e n o c y t e s ,  L N ,  · e p i t h e l i a l  a n d  D C s  w e r e  s t a i n e d  w i t h  s u r f a c e  
m a r k e r - s p e c i f i c  m A b s  i n c l u d i n g :  a n t i - T C R J 3 - A P C  ( H S 7 - S 9 7 ) ,  a n t i - C D 3 - F I T C  
( 1 7 A 2 ) ,  a n t i - C D 4 - P e r C P - C y S . S ,  - F I T C  a n d  - A P C  ( R M 4 - S ) ,  a n t i - C D 8 a - P E ,  
- A P C ,  - P e r C P  a n d  - F I T C  ( S 3 - 6 . 7 ) ,  a n t i - C D 2 S - P E  ( P C 6 1 ) ,  a n t i - C D 6 9 - P E  
( H 1 . 2 F 3 ) ,  a n t i - H S A  ( C D 2 4 ) - P E  ( M 1 / 6 9 ) ,  a n t i - I A / I E - F I T C  a n d  - P E  
( M S / 1 1 4 . 1 S . 2 ) ,  a n t i - E p C a m  ( G 8 . 8 ) ,  a n t i - m T R A I L - P E  ( N 2 B 2 ) ,  a n t i - C D 4 S - A P C  
( 3 0 - F 1 1 ) ,  a n t i - C D l l b - A P C  ( M 1 / 7 0 ) ,  a n t i - D R S - b i o t i n  ( M D S - 1 ) ,  a n t i - C D l l c -
F I T C  a n d  - b i o t i n  ( H L 3 ) ,  a n t i - V a 2 - P E  ( B 2 0 . 1 ) ,  a n t i - T C R V J 3 3 - b i o t i n  ( K J 2 S ) ,  a n t i -
T C R V J 3 S . l / S . 2 - b i o t i n  ( M R 9 - 4 ) ,  a n t i - T C R V J 3 6 - b i o t i n  ( R R 4 - 7 ) ,  a n t i - T C R V J 3 8 . 1 -
8 . 2 - b i o t i n  ( M R S - 2 )  a n d  a n t i - V J 3 1 1 - b i o t i n  ( R R 3 - 1 S )  i n  t h e  p r e s e n c e  o f  a n t i - F c : y  
r e c e p t o r  b l o c k  C D 1 6 / 3 2  ( 2 . 4 G 2 ) .  B i o t i n y l a t e d  a n t i b o d i e s  w e r e  d e t e c t e d  w i t h  
s t r e p t a v i d i n - A P C  o r  s t r e p t a v i d i n - C y C h r o m e  ( B D  B i o s c i e n c e s  P h a r m i n g e n )  a n d  
a n t i - E p C a m  w a s  d e t e c t e d  w i t h  p o l y c l o n a l  a n t i - r a t - F I T C  ( S i l e n u s  L a b o r a t o r i e s ,  
H a w t h o r n ,  V i c t o r i a ,  A u s t r a l i a ) .  A n t i  D R S - b i o t i n  w a s  k i n d l y  p r o v i d e d  b y  D r .  
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Hideo Yagita (Juntendo University School of Medicine, Tokyo, Japan), anti-
EpCam was kindly provided by Dr. Andy Farr (Department of Biological 
Structure, University of Washington, Seattle, WA, USA), anti-mTRAIL-PE was 
obtained from e-Bioscience and all remaining antibodies from BD Biosciences 
Pharmingen. Analysis was performed on a F ACSCalibur™ and analyzed using 
the CELLQuest™ software. 
Histology 
For aging experiments, C57BL/6 and C57BL/6 TRAIC1- mice were sacrificed at 
> 555 days and a full autopsy performed. Kidney, spleen and pancreas were 
examined for signs of autoimmune disease (inflammation and tissue destruction) 
by histology (H&E staining) after fixing these tissues in formalin. The 
preparation and staining of sections for histology was carried out by Brenda 
Aisbett (Histology Laboratory, Peter Mac). 
Serum ELISAs 
Sera from aged C57BL/6 WT and C57BL/6 TRAIL-/- mice and from 28 week 
C57BL/6 gld mice (as a positive control) was tested by ELISA for total IgG and 
anti-dsDNA antibodies as detailed in Chapter 4, Section 4.3, Materials and 
Methods. 
Statistical analysis 
Data were analyzed using a two tailed, non-parametric, unpaired Mann Whitney 
test. P values < 0.05 were considered significant. 
6 . 4  R e s u l t s  
6 . 4 . 1  A n t i - C D 3 / a n t i - C D 2 8  m A b - i n d u c e d  a p o p t o s i s  i n  v i t r o  
O n e  w i d e l y  u s e d  m o d e l  o f  n e g a t i v e  s e l e c t i o n  i s  i n  v i t r o  e x p o s u r e  o f  t h y m o c y t e s  
t o  a n t i - C D 3  m A b ,  w h i c h  a g g r e g a t e s  t h e  T C R - C D 3  c o m p l e x  a n d  i n d u c e s  
a p o p t o s i s .  T h y m i c  l o b e s  i s o l a t e d  f r o m  E 1 8  m i c e  a r e  a  r i c h  s o u r c e  o f  D P  
i m m a t u r e  t h y m o c y t e s  ( 9 0 - 9 5 % )  a n d  i m p o r t a n t l y  l a c k  m a t u r e  T  c e l l s  t h a t  u p o n  
T C R / C D 3  l i g a t i o n  m i g h t  r e l e a s e  s o l u b l e  f a c t o r s  t h a t  k i l l  D P  t h y m o c y t e s  
i n d i r e c t l y .  I n  v i t r o  s t i m u l a t i o n  w i t h  a n t i - C D 3  m A b  i n d u c e d  a p o p t o s i s  o f  E 1 8  
B A L B / c  W T  t h y m o c y t e s  i n  a  d o s e - d e p e n d e n t  m a n n e r  a s  d e t e r m i n e d  b y  s t a i n i n g  
w i t h  F I T C - c o u p l e d  a n n e x i n  V ,  w h i c h  d e t e c t s  e x t e r n a l i z e d  p h o s p h a t i d y l - s e r i n e ,  a  
h a l l m a r k  o f  a p o p t o t i c  c e l l s  ( F i g u r e  6 . 1  ) .  S t i m u l a t i o n  w i t h  a n t i - C D 3  p l u s  a n t i -
C D 2 8  m A b  i n d u c e d  h i g h e r  l e v e l s  o f  t h y m o c y t e  a p o p t o s i s  c o m p a r e d  t o  
s t i m u l a t i o n  w i t h  a n t i - C D 3  m A b  a l o n e  ( F i g u r e  6 . 1  ) .  E q u i v a l e n t  l e v e l s  o f  a p o p t o s i s  
w e r e  i n d u c e d  i n  B A L B / c  W T ,  B A L B / c  T R A I L - I - a n d  B A L B / c  W T  t h y m o c y t e s  
i n c u b a t e d  w i t h  a  n e u t r a l i z i n g  a n t i - m T R A I L  m A b  a t  a l l  c o n c e n t r a t i o n s  o f  a n t i -
C D 3  a n d  a n t i - C D 2 8  m A b  t e s t e d  ( F i g u r e  6 . 1  ) .  T h e  s p o n t a n e o u s  d e a t h  o f  B A L B / c  
W T ,  B A L B / c  T R A I L - / - a n d  B A L B / c  W T  t h y m o c y t e s  i n c u b a t e d  w i t h  a n t i -
m T R A I L  m A b  i n  c u l t u r e  w a s  a l s o  e q u i v a l e n t  ( F i g u r e  6 . 1 ) .  
W e  t h e n  e x a m i n e d  i n  v i t r o  t h e  a n t i - C D 3  p l u s  a n t i - C D 2 8  m A b - i n d u c e d  a p o p t o s i s  
o f  t h y m o c y t e s  i s o l a t e d  f r o m  a d u l t  m i c e .  A p o p t o s i s  o f  t o t a l  ( F i g u r e  6 . 2 A )  a n d  D P  
( F i g u r e  6 . 2 B )  t h y m o c y t e s  w a s  e x a m i n e d  b y  s t a i n i n g  w i t h  F I T C - c o u p l e d  a n n e x i n  
V .  S i m i l a r  r e s u l t s  w e r e  o b t a i n e d  f o r  t o t a l  t h y m o c y t e s  a n d  D P  t h y m o c y t e s  t h a t  a r e  
k n o w n  t o  b e  s u s c e p t i b l e  t o  n e g a t i v e  s e l e c t i o n .  S t i m u l a t i o n  w i t h  a n t i - C D 3  m A b ,  
w i t h  o r  w i t h o u t  a n t i - C D 2 8  m A b  i n d u c e d  e q u i v a l e n t  a p o p t o s i s  i n  B A L B / c  W T  
a n d  B A L B / c  T R A I L _ ; _  t h y m o c y t e s  a n d  i n  C 5 7 B L I 6  W T  a n d  C 5 7 B L / 6  T R A I L _
1
_  
t h y m o c y t e s  ( F i g u r e  6 . 2 A  a n d  B ) .  S t i m u l a t i o n  w i t h  a n t i - C D 3  p l u s  a n t i - C D 2 8  m A b  
i n d u c e d  h i g h e r  l e v e l s  o f  t o t a l  t h y m o c y t e  a p o p t o s i s  c o m p a r e d  t o  s t i m u l a t i o n  w i t h  
a n t i - C D 3  m A b  a l o n e  ( F i g u r e  6 . 2 A  a n d  B ) .  T h e  s p o n t a n e o u s  d e a t h  o f  B A L B / c  
W T  a n d  B A L B / c  T R A I L _ ; _  t h y m o c y t e s  a n d  o f  C 5 7 B L I 6  W T  a n d  C 5 7 B L / 6  
T R A I L - / - t h y m o c y t e s  i n  c u l t u r e  w a s  a l s o  e q u i v a l e n t  ( F i g u r e  6 . 2 A  a n d  B ) .  
I n t e r e s t i n g l y ,  t h e  s p o n t a n e o u s  d e a t h  o f  t h y m o c y t e s  i s o l a t e d  f r o m  m i c e  o f  
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Figure 6.1. Anti-CD3 plus anti-CD28 mAb-induced apoptosis of day 18 embryo (El8) 
thymocytes in vitro. Thymocytes from BALB/c WT and BALB/c TRAIL·/- El8 mice were 
cultured in plates coated with anti-CD3£ (145-2Cll) plus anti-CD28 (37.51) mAbs and/or PBS. 
Neutralizing anti-mTRAIL mAb was added to some of the cultures. After 20 h, live and apoptotic 
cells were discriminated by staining with annexin V-FITC and flow cytometric analysis. Data 
represent mean ± SEM, for thymocytes isolated from 6 BALB/c mice with or without the addition 
of anti-mTRAIL mAb, or 4 BALB/c TRAIL·/- mice. Asterisk indicates groups that are 
significantly different (* P < 0.05). 
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F i g u r e  6 . 2 .  A n t i - C D 3  p l u s  a n t i - C D 2 8  m A b - i n d u c e d  a p o p t o s i s  o f  a d u l t  t h y m o c y t e s  i n  v i t r o .  
T h y m o c y t e s  i s o l a t e d  f r o m  a d u l t  B A L B / c ,  B A L B / c  T R A I L - ' · ,  C 5 7 B L / 6  a n d  C 5 7 B L / 6  T R A I L · ' ·  
m i c e  w e r e  c u l t u r e d  i n  p l a t e s  c o a t e d  w i t h  a n t i - C D 3 E  ( 1 4 5 - 2 C l l )  p l u s  a n t i - C D 2 8  ( 3 7 . 5 1 )  m A b s  
a n d / o r  P B S .  A f t e r  2 0  h ,  l i v e  a n d  a p o p t o t i c  c e l l s  w e r e  d i s c r i m i n a t e d  b y  s t a i n i n g  w i t h  a n n e x i n  V -
F I T C  a n d  f l o w  c y t o m e t r i c  a n a l y s i s .  P e r c e n t a g e  a n n e x i n  y +  t h y m o c y t e s  i s  i l l u s t r a t e d  f o r  ( A )  t o t a l  
t h y m o c y t e s  a n d  ( B )  C D 4 + C D 8 +  D P  t h y m o c y t e s .  D a t a  r e p r e s e n t  m e a n  ±  S E M  f o r  3  B A L B / c ,  
B A L B / c  T R A I L - ' · ,  C 5 7 B L I 6  a n d  C 5 7 B L / 6  T R A I L _ , _  m i c e .  P e r c e n t a g e  a n n e x i n  y +  i s  n o t  
s i g n i f i c a n t l y  d i f f e r e n t  f o r  C 5 7 B L / 6  a n d  C 5 7 B L / 6  T R A I L · ' - ( P  >  0 . 0 5 )  o r  B A L B / c  a n d  B A L B / c  
T R A I L _ , _  m i c e  ( P  >  0 . 0 5 )  f o r  a n y  o f  t h e  s t i m u l i  s h o w n .  
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C57BL/6 background was significantly higher than that observed for thymocytes 
isolated from mice of BALB/c background (Figure 6.2A and B), suggesting that 
C57BL/6 WT thymocytes were more sensitive to the overnight culture conditions 
than BALB/c WT thymocytes. 
A role for Fas in negative selection remains controversial. Although one report 
suggests that Fas plays a role in negative selection against high, but not low 
affinity ligands (Kishimoto et al., 1998) other reports suggest that Fas signaling is 
dispensable for negative selection (Sidman et al., 1992; Villunger et al., 2004). 
To evaluate the potential contribution ofFasL and determine whether redundancy 
operated between the FasL and TRAIL signaling pathways, negative selection 
was compared in adult C57BL/6 gld (FasL mutant) and C57BL/6 TRAIL-1-gld 
thymocytes. Apoptosis of total (Figure 6.3A) and DP (Figure 6.3B) thymocytes 
was examined by staining with FITC-coupled annexin V. Similar results were 
obtained for total thymocytes and DP thymocytes. Stimulation with anti-CD3 
mAb, with or without anti-CD28 mAb induced equivalent apoptosis in C57BL/6 
WT, C57BL/6 gld, C57BLI6 TRAIL_;_ and C57BL/6 TRAIL-1-gld thymocytes 
(Figure 6.3A and B). Stimulation with anti-CD3 plus anti-CD28 mAb induced 
higher levels of thymocyte apoptosis compared to stimulation with anti-CD3 
mAb alone (Figure 6.3A and B). The spontaneous death of C57BL/6 WT, 
C57BL/6 gld, C57BLI6 TRAIL_;_ and C57BL/6 TRAIL-1-gld thymocytes in 
culture was also equivalent (Figure 6.3A and B). Together, these data suggest that 
neither TRAIL, nor FasL plays a role in negative selection of thymocytes. 
Furthermore, TRAIL and FasL do not function cooperatively to induce negative 
selection in vitro. 
6.4.2 SIINFEKL-induced depletion of OT-1 thymocytes developing in fetal 
thymic organ culture (FTOC) 
Our next study examined intrathymic deletion of C57BL/6 OT-I TCR transgenic 
thymocytes induced by agonist peptide in FTOC. Acute deletion of DP 
thymocytes was measured by culturing E15 C57BL/6 OT-I thymic lobes for 3 
days to allow the development ofDP thymocytes and then stimulating for 24 h in 
the presence or absence of SIINFEKL peptide (OV Ap) and neutralizing anti-
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mTRAIL mAb. OVAp induced complete deletion of OT-I DP thymocytes, and 
the addition of neutralizing anti-mTRAIL mAb afforded no protection against 
negative selection (Figure 6.4A). A proportion of SP thymocytes were also 
deleted in a TRAIL-independent manner upon addition of OV Ap (Figure 6.4A). 
Deletion ofDP and SP thymocytes in cultures incubated with agonist peptide was 
reflected by a decrease in total cell numbers per thymus lobe (Figure 6.4B) and 
an increase in the percentage of cells undergoing apoptosis as determined by 
staining with FITC-coupled annexin-V (Figure 6.4C). 
Although TRAIL was not required for acute deletion of C57BL/6 OT-1 
thymocytes stimulated with agonist peptide, the question remained whether 
TRAIL might play a role in negative selection at lower levels of TCR signaling. 
To help answer this question, a long-term culture of E15 C57BL/6 OT-1 thymic 
lobes was performed [as in (Hogquist et al., 1994)] in 0 to 10-5M OVAp in the 
presence or absence of anti-mTRAIL mAb for a period of 7 days. Stimulation 
with OV Ap deleted both DP and SP thymocytes in a dose-dependent manner and 
addition of neutralizing anti-mTRAIL mAb had no effect on deletion (Figure 
6.5). These results suggest that TRAIL does not play a critical role in thymocyte 
negative selection induced by agonist peptide in vitro. 
6.4.3 Stapphylococcus enterotoxin B (SEB)-induced deletion of Vf38+ T cells 
developing in FTOC 
Stimulation with the superantigen SEB activates and deletes the majority of T 
cells that express a variable region (V)f38 TCR, whereas T cells that express TCR 
Vf36 do not respond to SEB and remain unaffected (Jenkinson et al., 1990). The 
effect of TRAIL-deficiency on SEB-induced deletion of TCRVf38 cells was 
examined in FTOC. Equivalent SEB-induced deletion of TCRVf38+ T cells was 
observed in BALB/c WT, BALB/c TRAIC1- and BALB/c WT fetal thymus lobes 
incubated with a neutralizing anti-mTRAIL mAb (Figure 6.6). SEB promoted 
deletion of both CD3+CD4+CD8- and CD3+CD4-CD8+ subsets of TCRVf38+ T 
- cells, whilst TCRVf36+ T cells that do not respond to SEB were unaffected 
(Figure 6.6). These data further substantiated the argument that that TRAIL is not 
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F i g u r e  6 . 4 .  S I I N F E K L - i n d u c e d  d e p l e t i o n  o f  O T - 1  t h y m o c y t e s  d e v e l o p i n g  i n  F T O C .  T h y m i c  
l o b e s  i s o l a t e d  f r o m  E l 5  O T  - 1  T C R  t r a n s g e n i c  m i c e  w e r e  c u l t u r e d  f o r  3  d a y s  t o  a l l o w  
d e v e l o p m e n t  o f  D P  t h y m o c y t e s .  A c u t e  d e l e t i o n  w a s  i n d u c e d  b y  t h e  a d d i t i o n  o f  2 0  J l M  a g o n i s t  
p e p t i d e  ( O V  A p ,  a m i n o  a c i d  s e q u e n c e  S I I N F E K L )  o r  a n  e q u i v a l e n t  v o l u m e  o f  P B S  a s  n e g a t i v e  
c o n t r o l ,  i n  t h e  p r e s e n c e  o r  a b s e n c e  o f 2 0 0  J l g / m L  a n t i - m T R A I L  m A b .  T w e n t y - f o u r  h o u r s  a f t e r  t h e  
a d d i t i o n  o f  O V  A p ,  t h y m o c y t e s  w e r e  h a r v e s t e d ,  c e l l s  c o u n t e d  a n d  s t a i n e d  w i t h  a n t i b o d i e s  t o  C D 4 ,  
C D 8 ,  C D 3  o r  V a 2 .  ( A )  R e p r e s e n t a t i v e  C D 4  v e r s u s  C D 8  F A C S  p r o f i l e s  ( B )  t o t a l  c e l l s  p e r  l o b e  
a n d  ( C )  %  a n n e x i n  v +  a r e  s h o w n .  M e a n  ±  S E M  w e r e  c a l c u l a t e d  f r o m  a n a l y s i s  o f  2  s a m p l e s  p e r  
g r o u p ,  e a c h  c o n t a i n i n g  2  t h y m i c  l o b e s .  T o t a l  c e l l s  p e r  l o b e  a n d  p e r c e n t a g e  a n n e x i n  v +  a r e  n o t  
s i g n i f i c a n t l y  d i f f e r e n t  f o r  l o b e s  i n c u b a t e d  w i t h  o r  w i t h o u t  a n t i - m T R A I L  m A b .  
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Figure 6.5. SIINFEKL-induced depletion of OT-1 thymocytes at lower TCR avidities. 
Thymic lobes isolated from El5 OT-1 TCR transgenic mice were cultured for 7 days with 0 to 10 
1-tM OVAp in the presence or absence of200 ~-tg/ml anti-mTRAIL mAb or the equivalent volume 
of PBS. Percentage CD8-SP and DP thymocytes, in the presence or absence of anti-mTRAIL 
mAb, is shown at various peptide concentrations. Mean± SEM were calculated from analysis of 
3-4 samples per group, each containing 2 thymic lobes. Percentage CD8-SP and DP thymocytes 
are not significantly different for lobes incubated with or without anti-mTRAIL mAb. 
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F i g u r e  6 . 6 .  S E B - i n d u c e d  d e l e t i o n  o f  T C R  V~S+ T  c e l l s  d e v e l o p i n g  i n  F T O C .  T h y m i c  l o b e s  
i s o l a t e d  f r o m  E l 5  B A L B / c  W T  a n d  B A L B / c  T R A I L _ ; _  m i c e  w e r e  c u l t u r e d  f o r  1 2  d a y s  i n  t h e  
p r e s e n c e  o r  a b s e n c e  o f  1 0  J l g / m l  S E B  p l u s  o r  m i n u s  2 0  J l g / m l  a n t i - m T R A I L  m A b  o r  a n  
e q u i v a l e n t  v o l u m e  o f  P B S .  T h y m o c y t e  s u s p e n s i o n s  w e r e  i s o l a t e d ,  c o u n t e d  a n d  s t a i n e d  w i t h  
a n t i b o d i e s  t o  C D 4 ,  C D S ,  C D 3  a n d  T C R  V~S, V~6 o r  V ( 3 5 .  ( A )  H i s t o g r a m s  d e m o n s t r a t e  
e x p r e s s i o n  o f  T C R  V~S, V~6 o r  V~5 o n  C D 3 h i g h  t h y m o c y t e s  ( C D 4 +  o r  C D S )  a f t e r  i n c u b a t i o n  
w i t h  S E B  o r  P B S .  ( B )  T o t a l  c e l l s  p e r  t h y m i c  l o b e .  ( C )  T C R  V~S+, T C R  V~6+ o r  T C R  V~5 c e l l s  
a s  a  p e r c e n t a g e  o f  C D 3 + C D 4 + C D S - a n d  C D 3 + C D 4 - C D S +  t h y m o c y t e  s u b s e t s .  M e a n  ±  S E M  w e r e  
c a l c u l a t e d  f r o m  a n a l y s i s  o f  6  B A L B / c  T R A I L · / - a n d  S  B A L B / c  W T  t h y m i c  l o b e s  f o r  b o t h  P B S  
a n d  S E B  t r e a t m e n t .  
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6.4.4 Mouse mammary tumor virus (MMTV)6 and MMTV9 deletion of VJ33+ 
and Vf35+ T ceHs 
To determine whether TRAIL plays a role in negative selection induced by 
endogenous antigens, MMTV6 and MMTV9-induced negative selection was 
investigated in vitro and in vivo. MMTV6 and MMTV9 encode endogenous 
superantigens that selectively delete TCRVps+ and TCRVP3+ T cells in mice that 
express the class II MHC antigen (I-E) (Tomonari et al., 1993; Woodland et al., 
1991 ). To investigate the effect of endogenous superantigen in vitro, BALB/c (I-
E+) TCRVps+ T cells developing in FTOC were examined for deletion by 
MMTV6 and 9. TRAIL deficiency, or addition of neutralizing anti-mTRAIL 
mAb did not protect developing TCRVP5+ T cells from deletion (Figure 6.6A 
and B). Intrathymic deletion ofTCRVP5+ and TCRVP3+ T cells by MMTV6 and 
9 were also assessed in adult BALB/c WT mice in vivo. The frequencies of 
TCRVps+ and TCRVP3+ cells amongst CD4+ and CD8+ subsets were examined 
in thymus, spleen and pLNs isolated from BALB/c WT, BALB/c TRAIC1- and 
C57BL/6 WT mice (Figure 6.7A and B). Similar deletion of CD4+ and CD8+ 
subsets of TCRVps+ and TCRVP3+ T cells was observed in BALB/c WT and 
BALB/c TRAIL-/- mice, whereas cells with these specificities were not 
deleted in C57BL/6 WT mice (I-E) (Figure 6.7A and B). As a negative control, 
frequencies of TCRVp6+ and TCRVP8+ T cells that are not deleted by MMTV6 
and 9 are shown (Figure 6. 7 A and B). These data indicate that TRAIL is not 
required for intrathymic deletion induced by endogenous antigen in vitro and in 
vivo. 
6.4.5 Anti-CD3 mAb mediated apoptosis in vivo 
The final model of negative selection tested was in vivo exposure of thymocytes 
to anti-CD3 mAb. Although this model is frequently used to investigate negative 
selection, apoptosis induced in this manner is known to be largely TCR-
independent, and is typically mediated by inflammatory cytokines and steroid 
hormones produced by peripheral T cells (Brewer et al., 2002; Martin and Bevan, 
1997). Nevertheless, given that previous researchers had utilized this model and 
demonstrated a role for TRAIL in negative selection (Lamhamedi-Cherradi et al., 
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F i g u r e  6 . 7 .  M M T V - 6  a n d  M M T V - 9  i n d u c e d  d e l e t i o n  o f  T C R  V~3 a n d  T C R  V~S T  c e l l s  i n  
v i v o .  T h y m o c y t e s ,  s p l e n o c y t e s  a n d  p L N  c e l l s  w e r e  i s o l a t e d  f r o m  8  w e e k - o l d  m a l e  C 5 7 B L / 6 ,  
B A L B / c  a n d  B A L B / c  T R A I L - / - m i c e .  C e l l  s u s p e n s i o n s  w e r e  s t a i n e d  w i t h  a n t i b o d i e s  t o  C D 4 ,  
C D 8 ,  C D 3  a n d  T C R  V~3, V~5, V~6, o r  V~8. ( A )  H i s t o g r a m s  d e m o n s t r a t e  e x p r e s s i o n  o f T C R  
V~3, T C R  V~5, T C R  V~6, o r  T C R  V~8 o n  C D 4 +  C D 3 h i g h  o r  C D 8 +  C D 3 h i g h  t h y m o c y t e s .  ( B )  T C R  
V~3, T C R  V~5, T C R  V~6, o r  T C R  V~8 c e l l s  a s  a  p e r c e n t a g e  o f C D 3 + C D 4 + C D 8 - a n d  C D 3 + C D 4 -
C D 8 +  s u b s e t s  o f  t h y m o c y t e s ,  s p l e n o c y t e s  a n d  p L N  c e l l s .  M e a n  ±  S E M  w e r e  c a l c u l a t e d  f r o m  
a n a l y s i s  o f  c e l l s  i s o l a t e d  f r o m  3  C 5 7 B L / 6 ,  1 2  B A L B / c  a n d  I I  B A L B / c  T R A I L - / - m i c e .  D a t a  
s h o w n  i s  p o o l e d  f r o m  4  i n d e p e n d e n t  e x p e r i m e n t s .  
2 3 6  
2003), we also chose to perform such experiments. J.p. injection of anti-CD3 
mAb into BALB/c WT mice depleted approximately 70-80% of DP thymocytes 
and equivalent deletion was observed in BALB/c TRAIL_;_ mice (Figure 6.8A). 
Depletion of DP thymocytes in mice injected with anti-CD3 mAb was reflected 
by a decrease in total numbers of cells per thymus and total numbers of DP cells 
per thymus (Figure 6.8B). Anti-CD3 mAb treatment also induced depletion of 
CD4+HSAhi and CD8+HSAhi semi-mature thymocytes, but not mature 
CD4+HSA10 or CD8+HSA10 thymocytes that have previously been shown to be 
resistant to negative selection (Figure 6.8C) (Kishimoto and Sprent, 1997). 
As a large component of the anti-CD3 mAb-induced thymocyte death observed in 
vivo is due to inflammatory cytokines and steroid hormones produced by 
activated peripheral T cells, we investigated peripheral T cell activation in the 
spleen of mice injected with PBS or anti-CD3 mAb. Differences in peripheral 
activation between BALB/c WT and BALB/c TRAIC1- mice would preclude 
comparison of anti-CD3 mAb-induced thymocyte death in these experiments. 
Nonetheless, equivalent peripheral T cell activation, indicated by staining with 
the early activation marker CD69, was observed in BALB/c WT and BALB/c 
TRAIL-/- mice injected with PBS or anti-CD3 mAb (Figure 6.9). 
Consistent with an earlier report (Lamhamedi-Cherradi et al., 2003), the thymus 
of adult BALB/c TRAIL_;_ mice injected with PBS (1.40 ± 0.15 x 108 cells), was 
slightly enlarged compared with PBS injected BALB/c WT mice (0.95 ± 0.17 x 
1 08) (P < 0.05, Figure 6.8B). There was no significant difference in spleen or LN 
cellularity between the strains. The basis for this subtle difference in thymus size 
is unclear, but does not appear to be due to impaired negative selection. 
6.4.6 Expression of TRAIL and TRAIL receptor (DRS) 
Given that the most potent inducers of negative selection in the thymus are 
thymic DCs and epithelial cells (Hoffmann et al., 1995; Sprent and Webb, 1995; 
Tanaka et al., 1993), and that target cell expression of TRAIL receptor (DR5) is 
required for sensitivity to TRAIL-mediated apoptosis, we next examined TRAIL 
and DRS expression on various cell types within the thymus. If TRAIL was 
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F i g u r e  6 . 8 .  A n t i - C D 3  m A b  m e d i a t e d  t h y m o c y t e  a p o p t o s i s  i n  v i v o .  B A L B / c  a n d  B A L B / c  
T R A I L . ; .  m i c e  w e r e  i n j e c t e d  i . p .  w i t h  e i t h e r  2 0  1 1 g  a n t i - C D 3  m A b  ( 1 4 5 - 2 C l l )  o r  P B S  v e h i c l e  
c o n t r o l .  F o u r t y  h o u r s  a f t e r  i n j e c t i o n ,  m i c e  w e r e  s a c r i f i c e d ,  t h e i r  t h y m o c y t e s  a n d  s p l e n o c y t e s  
i s o l a t e d ,  c o u n t e d  a n d  s t a i n e d  w i t h  a n t i b o d i e s  t o  C D 4 ,  C D S ,  TCRa~ a n d  H S A  ( C D 2 4 ) .  ( A )  
R e p r e s e n t a t i v e  C D 4  v e r s u s  C D S  F A C S  p r o f i l e s ,  ( B )  n u m b e r s  o f t o t a l  a n d  D P  t h y m o c y t e s  a n d  ( C )  
t o t a l  n u m b e r s  o f  C D S +  a n d  C D 4 +  H S A  h i  a n d  H S A
1 0  
c e l l s  p e r  t h y m u s  i s  s h o w n .  M e a n ±  S E M  w e r e  
c a l c u l a t e d  f r o m  a n a l y s i s  o f  c e l l s  i s o l a t e d  f r o m  3  B A L B / c  a n d  3  B A L B / c  T R A I L . ; .  m i c e .  R e s u l t s  
a r e  r e p r e s e n t a t i v e  o f  t h r e e  i n d e p e n d e n t  e x p e r i m e n t s .  
2 3 8  
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Figure 6.9. Equivalent peripheral activation in anti-CD3 treated BALB/c and BALB/c 
TRAIL-deficient mice. BALB/c and BALB/c TRAIL-/- mice were injected i.p. with either 20 Jlg 
anti-CD3 mAb (145-2Cll) or PBS vehicle control. Fourty hours after injection, mice were 
sacrificed, their splenocytes isolated and stained with antibodies to CD4, CD8 and CD69. CD69 
staining on CD4+ and CD8+ splenocytes isolated from PBS or anti-CD3 mAb treated mice is 
shown. Mean ± SEM are shown for results pooled from two experiments, each containing 3 or 4 
BALB/c and 3 or 4 BALB/c TRAIL-/- mice injected i.p. with PBS or anti-CD3 mAb. Percentage 
CD69+ cells was not significantly different for BALB/c and BALB/c TRAIL-/- mice (P > 0.05). 
c r i t i c a l  f o r  n e g a t i v e  s e l e c t i o n ,  T R A I L  e x p r e s s i o n  m i g h t  b e  p r e d i c t e d  o n  e p i t h e l i a l  
c e l l s  a n d / o r  D C s ,  a n d  D R S  e x p r e s s i o n  m i g h t  b e  e x p e c t e d  o n  t a r g e t  t h y m o c y t e  
p o p u l a t i o n s .  T h y m i c  e p i t h e l i a l  c e l l s  a n d  D C s  w e r e  i s o l a t e d  a s  d e s c r i b e d  i n  
M a t e r i a l s  a n d  M e t h o d s ,  C h a p t e r  6 ,  S e c t i o n  6 . 3  a n d  i d e n t i f i e d  b y  f l o w  c y t o m e t r y  
a s  C D 4 Y E p C A M +  a n d  C D 1 1 c + M H C - I l h i  r e s p e c t i v e l y .  T R A I L  e x p r e s s i o n  w a s  n o t  
o b s e r v e d  o n  t h y m i c  e p i t h e l i a l  c e l l s ,  D C s  o r  t h y m o c y t e  p o p u l a t i o n s ,  a l t h o u g h  
T R A I L  w a s  c l e a r l y  e x p r e s s e d  o n  l i v e r  N K  c e l l s  a s  a  p o s i t i v e  c o n t r o l  ( d a t a  n o t  
s h o w n )  ( F i g u r e  6 . 1 0 ) .  L i k e  p e r i p h e r a l  D C s ,  t h y m i c  D C s  e x p r e s s e d  D R S  a n d  
s o m e  l o w  l e v e l  D R S  s t a i n i n g  w a s  o b s e r v e d  o n  t h y m o c y t e s ,  a l t h o u g h  t h e  
f u n c t i o n a l  s i g n i f i c a n c e  o f  t h i s  l o w  l e v e l  s t a i n i n g  i s  y e t  t o  b e  d e t e r m i n e d  ( F i g u r e  
6 . 1  0 ) .  L e v e l s  o f  T R A I L  a n d  D R S  s t a i n i n g  w e r e  u n c h a n g e d  i n  t h y m o c y t e s  
a c t i v a t e d  w i t h  a n t i - C D 3  a n d  a n t i - C D 2 8  m A b  ( F i g u r e  6 . 1 1  ) .  T h e r e f o r e ,  u n l e s s  
s p e c i a l  i n  v i v o  c o n d i t i o n s  p e r m i t  t h e  e x p r e s s i o n  o f  D R S  o n  t h y m o c y t e s ,  a n d  
T R A I L  o n  c e l l s  t h a t  c a n  i n d u c e  n e g a t i v e  s e l e c t i o n ,  i t  i s  u n l i k e l y  t h a t  T R A I L  c a n  
i n d u c e  a p o p t o s i s  w i t h i n  t h e  t h y m u s .  
6 . 4 . 7  A g e d  C 5 7 B L / 6  T R A I L - d e f i c i e n t  m i c e  d o  n o t  d e v e l o p  s p o n t a n e o u s  
a u t o i m m u n e  d i s e a s e  
D e f e c t s  i n  n e g a t i v e  s e l e c t i o n  h a v e  b e e n  a s s o c i a t e d  w i t h  t h e  d e v e l o p m e n t  o f  
s p o n t a n e o u s  a u t o i m m u n e  d i s e a s e  ( A n d e r s o n  e t  a l . ,  2 0 0 2 ;  B o u i l l e t  e t  a l . ,  1 9 9 9 ;  
B o u i l l e t  e t  a l . ,  2 0 0 2 ;  L i s t o n  e t  a l . ,  2 0 0 3 ) .  A s  n e g a t i v e  s e l e c t i o n  i s  r e s p o n s i b l e  f o r  
t h e  r e m o v a l  o f  p o t e n t i a l l y  a u t o r e a c t i v e  t h y m o c y t e s ,  d e f e c t s  i n  n e g a t i v e  s e l e c t i o n  
m i g h t  a l l o w  t h e  r e l e a s e  o f  s e l f - r e a c t i v e  T  c e l l s  i n t o  t h e  p e r i p h e r a l  p o o l ,  
p r e d i s p o s i n g  a n  i n d i v i d u a l  t o  a u t o i m m u n e  d i s e a s e .  
A s  T R A I L - d e f i c i e n t  m i c e  w e r e  r e p o r t e d  t o  e x h i b i t  d e f e c t i v e  n e g a t i v e  s e l e c t i o n  
( L a m h a m e d i - C h e r r a d i  e t  a l . ,  2 0 0 3 ) ,  w e  a g e d  C S 7 B L / 6  W T  a n d  C S 7 B L / 6  
T R A I L - / - m i c e >  5 S 5  d a y s  t o  i n v e s t i g a t e  w h e t h e r  T R A I L  s u p p r e s s e d  s p o n t a n e o u s  
a u t o i m m u n e  d i s e a s e .  S e r u m  i s o l a t e d  f r o m  a g e d  m i c e  w a s  a n a l y z e d  f o r  l e v e l s  o f  
t o t a l  I g G  ( F i g u r e  6 . 1 2 A )  a n d  a n t i - d s D N A  a u t o a n t i b o d i e s  ( F i g u r e  6 . 1 2 B . ) .  S e r u m  
i s o l a t e d  f r o m  2 8  w e e k  o l d  C 5 7 B L / 6  g l d  m i c e  w a s  u s e d  a s  a  p o s i t i v e  c o n t r o l ,  a s  
t h e s e  m i c e  e x h i b i t  e l e v a t e d  l e v e l s  o f  s e r u m  I g G  a n d  c i r c u l a t i n g  a u t o a n t i b o d i e s  
( K o m e r  e t  a l . ,  2 0 0 0 ) .  N e i t h e r  t o t a l  I g G  n o r  a n t i - d s D N A  a u t o a n t i b o d i e s  



















--Fluorescence Intensity • 
Figure 6.10. TRAIL and TRAIL receptor (DRS) expression within the thymus. Thymic 
epithelial cells, thymic DCs and thymocytes were isolated from BALB/c thymi (n=5) by 
enzymatic digestion with DNase and collagenase. Cells were analyzed by flow cytometry for 
TRAIL and TRAIL receptor (DR5) expression. Thymic epithelial cells were identified as CD4Y 
EpCAM+, thymic DCs as CDllc+MHC-IIhi and thymocyte subsets were identified by staining 
with antibodies to CD4 and CDS. Dotted histograms represent isotype control staining and black 
histograms represent TRAIL or DRS staining as indicated. Results are representative of three 
independent experiments (thymocytes) or one experiment (epithelial and DCs). 
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F i g u r e  6 . 1 1 .  E x p r e s s i o n  o f  T R A I L  a n d  T R A I L  r e c e p t o r  ( D R S )  b y  a c t i v a t e d  t h y m o c y t e s .  
T h y m o c y t e s  i s o l a t e d  f r o m  a d u l t  B A L B / c  a n d  B A L B / c  T R A I C
1
- m i c e  w e r e  c u l t u r e d  f o r  2 0  h  i n  
p l a t e s  c o a t e d  w i t h  2 0  J l g / m l  a n t i - C D 3 £  ( 1 4 S - 2 C l l )  p l u s  1 0  J l g / m l  a n t i - C D 2 8  ( 3 7 . S l )  m A b  o r  
P B S .  A c t i v a t e d  t h y m o c y t e s  w e r e  t h e n  s t a i n e d  w i t h  a n t i b o d i e s  t o  C D 4 ,  C D S ,  D R S  a n d  m T R A I L .  
D o t t e d  h i s t o g r a m s  r e p r e s e n t  i s o t y p e  c o n t r o l  s t a i n i n g  a n d  b l a c k  h i s t o g r a m s  r e p r e s e n t  T R A I L  o r  
D R S  s t a i n i n g  a s  i n d i c a t e d .  R e s u l t s  a r e  r e p r e s e n t a t i v e  o f  t h r e e  i n d e p e n d e n t  e x p e r i m e n t s ,  e a c h  
c o n t a i n i n g  2  - 3  m i c e .  
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c Aged C57/BL6 Aged C57BU6 TRAIL4-
(mean+ SEM) (mean+ SEM) 
aLN 
CD4SP% 19.24 .! 5.46 23.21 .! 4.23 
CD8SP% 15.42.! 1.53 15.63.! 2.39 
co4·co8•% 0.34.! 0.02 0.38.! 0.06 
TCR-13 SP% 52.37.! 6.98 44.37 +4.73 
8220 SP% 39.22.! 8.47 43.32±4.28 
Spleen 
CD4SP% 13.76.! 5.00 13.69.! 2.45 
CD8SP% 11.25.! 2.62 9.90 .:!;2.29 
co4•co8·% 0.25.! 0.29 0.2:!:. 0.03 
TCR-13 SP% 37.28.! 11.7 41.33 + 8.63 
8220 SP% 46.71 + 11.63 44.31 + 8.42 
Thymus 
CD4SP% 5.38.! 0.87 6.87:!:. 1.83 
CD8SP% 3.87:!:.1.12 5.45:!:. 2.11 
co4•co8•% 84.59.! 0.65 78.73:!:. 6.15 
TCR-13 SP% 8.39.! 2.76 9.88.:!: 3.08 
8220 SP% 4.80 + 3.94 9.00 + 4.45 
Figure 6.12. Serum antibody concentration and lymphoid organ composition in aged 
C57BL/6 and C57BL/6 TRAIL-deficient mice. Serum was isolated from aged (> 555 days) 
C57BL/6 and C57BL/6 TRAIL-/- or 28 week old C57BL/6 gld mice (as a positive control) and 
tested by ELISA for (A) total concentration of IgG and (B) anti-dsDNA autoantibodies. The 
concentration of anti-dsDNA autoantibodies is shown relative to that observed for 28 week old 
C57BL/6 gld mice (I 00 Units was defined as the mean ± SEM of absorbance at 405 nm for 28 
week C57BL/6 gld mice). Mean± SEM were calculated from the sera of 3 C57BL/6, 3 C57BL/6 
TRAIL-/- and 4 C57BL/6 gld mice. (C) The lymphocyte composition observed in the aLN, spleen 
and thymus of aged C57BL/6 and C57BL/6 TRAIL-/- mice is also shown. SP, single positive. 
Mean ± SEM were calculated from analysis of cells isolated from 4 C57BL/6 and 6 C57BL/6 
TRAIL-/- mice. Results are pooled from two independent experiments. Serum IgG, anti-dsDNA 
and lymphocyte composition are not significantly different for aged C57BL/6 and C57BL/6 
TRAIL-I- mice (P > 0.05). 
w e r e  e l e v a t e d  i n  a g e d  C 5 7 B L / 6  W T  o r  C 5 7 B L / 6  T R A I L - / - m i c e  ( F i g u r e  6 . 1 2  A  
a n d  B ) .  M o r e o v e r ,  t h e  o v e r a l l  l y m p h o c y t e  c o m p o s i t i o n  w a s  c o m p a r a b l e  i n  L N ,  
s p l e e n  a n d  t h y m u s  o f  a g e d  C 5 7 B L / 6  W T  a n d  C 5 7 B L / 6  T R A I L - / - m i c e  ( F i g u r e  
6 . 1 2 C )  a n d  h i s t o l o g i c a l  a n a l y s i s  o f  a  n u m b e r  o f  o r g a n s  f a i l e d  t o  r e v e a l  a n y  
o b v i o u s  s i g n s  ( s u c h  a s  l y m p h o c y t i c  i n f i l t r a t i o n  o r  t i s s u e  d e s t r u c t i o n )  o f  
s p o n t a n e o u s  a u t o i m m u n e  d i s e a s e  i n  t h e s e  m i c e  ( F i g u r e  6 . 1 3 ) .  C o l l e c t i v e l y  t h e s e  
f i n d i n g s  s u g g e s t  t h a t  T R A I L  d o e s  n o t  s u p p r e s s  s p o n t a n e o u s  a u t o i m m u n e  d i s e a s e .  




Figure 6.13. Aged C57BL/6 TRAIL-deficient mice do not develop spontaneous autoimmune 
disease. Representative H&E staining on spleen, kidney and pancreas sections isolated from 
C57BU6 (A, C, E) and C57BU6 TRAIL_,_ (B, D, F) mice aged 555-700 days. Normal spleen, 
kidney and pancreatic architecture with a lack of obvious signs of spontaneous autoimmune 
disease are observed in aged C57BU6 and C57BU6 TRAIL_,_ mice. Original magnification xlO 
for spleen and kidney and x 20 for pancreas. 
6 . 5  D i s c u s s i o n  
T h e  r o l e  o f  T R A I L  s i g n a l i n g  i n  i n t r a t h y m i c  n e g a t i v e  s e l e c t i o n  i s  c o n t r o v e r s i a l .  A  
r e c e n t  r e p o r t  b y  L a m h a m e d i - C h e r r a d i  a n d  c o l l e a g u e s  ( L a m h a m e d i - C h e r r a d i  e t  
a l . ,  2 0 0 3 )  s u g g e s t e d  t h a t  T R A I L  w a s  c r i t i c a l  f o r  n e g a t i v e  s e l e c t i o n  o f  
a u t o r e a c t i v e  t h y m o c y t e s .  O u r  d a t a ,  u s i n g  f i v e  s e p a r a t e  m o d e l s  o f  t h y m o c y t e  
n e g a t i v e  s e l e c t i o n ,  s u g g e s t e d  t h a t  T R A I L  w a s  n o t  r e q u i r e d  f o r  t h i s  p r o c e s s .  T h u s ,  
o u r  d a t a  c o n c u r s  w i t h  a n  e a r l i e r  s t u d y  u s i n g  s o l u b l e  b l o c k i n g  T R A I L - R 2 - F c  t o  
d e m o n s t r a t e  t h a t  n e g a t i v e  s e l e c t i o n  o f  m o u s e  a n d  h u m a n  t h y m o c y t e s  w a s  
T R A I L - i n d e p e n d e n t  ( S i m o n  e t  a l . ,  2 0 0 1 ) .  M o r e o v e r ,  o u r  d a t a  i s  i n  a g r e e m e n t  
w i t h  r e s u l t s  f r o m  S m i t h  e t  a l .  ( S m i t h  e t  a l . ,  1 9 9 6 )  a n d  N e w t o n  e t  a l .  ( N e w t o n  e t  
a l . ,  1 9 9 8 )  t h a t  c l e a r l y  e x c l u d e  a  r o l e  f o r  t h e  F  A D D - c a s p a s e  8  p a t h w a y  ( w h i c h  i s  
e s s e n t i a l  f o r  T R A I L - R  a n d  D R - i n d u c e d  a p o p t o s i s  i n  g e n e r a l )  i n  n e g a t i v e  
s e l e c t i o n  o f T  c e l l s .  
I t  i s  d i f f i c u l t  t o  e x p l a i n  t h e  d i s c r e p a n c i e s  b e t w e e n  o u r  r e s u l t s  a n d  t h o s e  r e c e n t l y  
p u b l i s h e d  ( L a m h a m e d i - C h e r r a d i  e t  a l . ,  2 0 0 3 ) ,  w h i c h  u s e  T R A I L - / - m i c e  f r o m  t h e  
s a m e  s o u r c e  a n d  s i m i l a r  m o d e l s  t o  i n v e s t i g a t e  n e g a t i v e  s e l e c t i o n .  H o w e v e r ,  
c a r e f u l  a n a l y s i s  o f  a t  l e a s t  s o m e  o f  t h e  d a t a  i n  t h e  L a m h a m e d i - C h e r r a d i  e t  a l .  
s t u d y  r e v e a l s  s o m e  u n c e r t a i n t i e s .  P r o p o r t i o n s  o f  TCRV~5+ a n d  TCRV~ 1 1  +  T  
c e l l s  i n  p e r i p h e r a l  l y m p h o i d  o r g a n s  i n  T R A I L - / - m i c e  a r e  o n l y  s l i g h t l y  ( a l b e i t  
s i g n i f i c a n t l y )  i n c r e a s e d  ( L a m h a m e d i - C h e r r a d i  e t  a l . ,  2 0 0 3 ) .  C e l l s  w i t h  t h e s e  
s p e c i f i c i t i e s  a r e  d e l e t e d  b y  t h e  e n d o g e n o u s  s u p e r a n t i g e n  M M T V 9  p r e s e n t e d  b y  I -
E +  c l a s s  I I  M H C  a s  o c c u r s  i n  B A L B / c  m i c e .  H o w e v e r ,  p r o p o r t i o n s  o f  t h e s e  c e l l s  
i n  1 - K  m i c e  s u c h  a s  C 5 7 B L / 6  W T ,  a r e  a t  l e a s t  1 0  t i m e s  t h a t  d e t e c t e d  i n  B A L B / c  
W T  m i c e .  G i v e n  t h a t  t h e  p e r c e n t a g e  o f  TCRV~5+ a n d  TCRV~11+ T  c e l l s  i n  
B A L B / c  T R A I L _ ; _  w a s  o n l y  s l i g h t l y  h i g h e r  t h a n  t h a t  o b s e r v e d  i n  c o n t r o l  B A L B / c  
W T  m i c e ,  t h e  i m p a c t  o f  T R A I L  i n  t h i s  m o d e l  o f  n e g a t i v e  s e l e c t i o n  a p p e a r s  t o  b e  
m i n i m a l  a t  b e s t .  M o r e o v e r ,  D P  r a t h e r  t h a n  S P  t h y m o c y t e s  w e r e  a n a l y z e d  f o r  
M M T V  - m e d i a t e d  n e g a t i v e  s e l e c t i o n  ( L a m h a m e d i - C h e r r a d i  e t  a l . ,  2 0 0 3 ) .  A n a l y s i s  
o f  D P  t h y m o c y t e s  i s  c o m p l i c a t e d ,  a s  m o s t  o f  t h e s e  c e l l s  e x p r e s s  l o w  l e v e l s  o f  
TCRa~ a n d  o n l y  t h e  v e r y  l a t e s t  s t a g e s  o f  D P  t h y m o c y t e  d e v e l o p m e n t  a r e  
s u s c e p t i b l e  t o  M M T V - m e d i a t e d  n e g a t i v e  s e l e c t i o n  ( G u i d o s  e t  a l . ,  1 9 9 0 ;  H u g o  e t  
2 4 6  
al., 1991). Thus, changes in TCRVf3 representation are far easier and more 
reliable to detect in SP thymocytes. In fact, our own data and that of others (Hugo 
et al., 1991), suggests that whilst TCRVf35+ T cells are clearly deficient at the SP 
stage, these cells are not dramatically under-represented in the DP thymocyte 
population. Further uncertainties were revealed in the analysis of C57BL/6 
TRAIC1- mice. MMTV9 can mediate significant deletion of TCRVf35+ cells in 
C57BL/6 WT mice (I-A+, I-E) and the proportion of these cells is increased in 
Bim-deficient mice that are known to have defective negative selection. 
However, no difference in the proportions of these cells were reported in 
C57BL/6 TRAIC1- mice, again raising some concern over the extent to which 
TRAIL regulates negative selection (Lamhamedi-Cherradi et al., 2003). 
An important finding in this study was that thymic DCs and thymic epithelial 
cells which are the two most important cellular mediators of negative selection in 
the thymus (Hoffmann et al., 1995; Sprent and Webb, 1995; Tanaka et al., 1993), 
do not constitutively express TRAIL. Thymocyte populations also lacked TRAIL 
expression. If TRAIL was critical for negative selection, TRAIL expression 
might be predicted on these cells. Although TRAIL RNA has previously been 
detected in whole thymus (Wiley et al., 1995), this would likely reflect the 
presence of thymocyte rather than stromal cell TRAIL RNA given that 
thymocytes comprise 99% of thymus cellularity. Nonetheless, if TRAIL 
expressing cells capable of mediating negative selection are present in the 
thymus, TRAIL receptor (DR5) expression would be required for induction of an 
apoptotic signal in thymocytes. Our extensive flow cytometric analysis revealed 
extremely low levels of DR5 expression on thymocytes. DR5 expression was 
unchanged when thymocytes were cultured in vitro with anti-CD3 and anti-CD28 
mAb. The level ofDR5 expression detected on thymocytes was approximately 10 
to I 00-fold lower than typical DR5 expression detected on TRAIL-sensitive 
tumor cell lines or on primary cells such as DCs. To clarify whether the low level 
DR5 expression on thymocytes is physiologically relevant, functional assays are 
required to determine the sensitivity of mouse thymocytes to TRAIL killing. 
Human thymocytes have previously been shown to express low levels of TRAIL-
Rl and R2 and to become sensitized to TRAIL-induced apoptosis upon 
s t i m u l a t i o n  w i t h  a n t i - C D 3  m A b  ( S i m o n  e t  a l . ,  2 0 0 1 ) ,  a l t h o u g h  t h i s  i s  y e t  t o  b e  
e x a m i n e d  f o r  m o u s e  t h y m o c y t e s .  T h u s ,  t h e  p h y s i o l o g i c a l  r e l e v a n c e  o f  D R S  
e x p r e s s i o n  i n  t h e  t h y m u s  i n  t h e  a b s e n c e  o f  T R A I L  e x p r e s s i n g  e f f e c t o r  c e l l s  i s  
q u e s t i o n a b l e .  I t  w i l l  b e  i n t e r e s t i n g  t o  f u r t h e r  a s s e s s  n e g a t i v e  s e l e c t i o n  i n  m i c e  
l a c k i n g  D R S .  
A s  n e g a t i v e  s e l e c t i o n  i s  r e s p o n s i b l e  f o r  t h e  r e m o v a l  o f  p o t e n t i a l l y  a u t o r e a c t i v e  
t h y m o c y t e s ,  d e f e c t s  i n  n e g a t i v e  s e l e c t i o n  m i g h t  a l l o w  t h e  r e l e a s e  o f  s e l f - r e a c t i v e  
T  c e l l s  i n t o  t h e  p e r i p h e r a l  p o o l ,  p r e d i s p o s i n g  a n  i n d i v i d u a l  t o  a u t o i m m u n e  
d i s e a s e .  D e f i c i e n c y  o f  t h e  p r o - a p o p t o t i c  B c l - 2  f a m i l y  m e m b e r  B i m ,  t h a t  i s  c r i t i c a l  
f o r  n e g a t i v e  s e l e c t i o n ,  l e a d s  t o  s p o n t a n e o u s  d e v e l o p m e n t  o f  a u t o i m m u n e  
g l o m e r u l o n e p h r i t i s  ( B o u i l l e t  e t  a l . ,  1 9 9 9 ) .  M u t a t i o n  o f  A I R E  i n h i b i t s  t h e  
e x p r e s s i o n  o f  p e r i p h e r a l  a n t i g e n s  i n  t h e  t h y m u s ,  p r e v e n t i n g  t h e  d e l e t i o n  o f  s e l f -
r e a c t i v e  T  c e l l s ,  a n d  p r e d i s p o s e s  m i c e  ( A n d e r s o n  e t  a l . ,  2 0 0 2 ;  L i s t o n  e t  a l . ,  2 0 0 3 )  
a n d  h u m a n s  ( N a g a m i n e  e t  a l . ,  1 9 9 7 )  t o  a  m u l t i t u d e  o f  o r g a n - s p e c i f i c  a u t o i m m u n e  
d i s e a s e s .  W e  f a i l e d  t o  r e v e a l  a n y  s i g n s  o f  s p o n t a n e o u s  a u t o i m m u n i t y  i n  a g e d  
C S 7 B L / 6  T R A I L - / - m i c e  ( >  S S S  d a y s ) ,  c o m p a r e d  w i t h  a g e d  s y n g e n e i c  C S 7 B L / 6  
W T  m i c e .  P e r h a p s  t h i s  i s  t h e  s t r o n g e s t  a r g u m e n t  t h a t  T R A I L  i s  n o t  c r i t i c a l  f o r  
m a i n t a i n i n g  s e l f - t o l e r a n c e ,  a n d  i s  d i s p e n s a b l e  f o r  i n t r a t h y m i c  n e g a t i v e  s e l e c t i o n .  
I n  C h a p t e r S ,  T R A I L  w a s  c l e a r l y  d e m o n s t r a t e d  t o  s u p p r e s s  a u t o i m m u n e  d a m a g e  
i n  t h r e e  d i f f e r e n t  m o d e l s  o f  E A E .  O t h e r s  s t u d i e s  h a v e  a l s o  d e m o n s t r a t e d  t h a t  
T R A I L - d e f i c i e n t  m i c e  a r e  m o r e  s u s c e p t i b l e  t o  t h e  i n d u c t i o n  o f  a u t o i m m u n i t y  i n  
c e r t a i n  e x p e r i m e n t a l  m o d e l s  ( H i l l i a r d  e t  a l . ,  2 0 0 1 ;  L a m h a m e d i - C h e r r a d i  e t  a l . ,  
2 0 0 3 ;  S o n g  e t  a l . ,  2 0 0 0 ) ,  h o w e v e r ,  i t  r e m a i n s  u n c l e a r  b y  w h a t  m e c h a n i s m  T R A I L  
s u p p r e s s e s  t h e  i n d u c t i o n  o f  a u t o i m m u n i t y .  C l e a r l y ,  d i s e a s e  i n d u c t i o n  i n  t h e s e  
e x p e r i m e n t a l  m o d e l s  i s  c o m p l e x  a n d  o f t e n  i n v o l v e s  a d j u v a n t s  t h a t  s t i m u l a t e  D C s ,  
i n n a t e  i m m u n e  c e l l  n e t w o r k s  t h a t  m a y  i n v o l v e  T R A I L  f u n c t i o n ,  o r  A I C D  i n  t h e  
p e r i p h e r y .  I n d e e d ,  s e v e r a l  s t u d i e s  h a v e  i m p l i c a t e d  T R A I L  i n  A I C D  ( M a r t i n e z -
L o r e n z o  e t  a l . ,  1 9 9 8 ;  Z h a n g  e t  a l . ,  2 0 0 3 ) ,  a l t h o u g h  i t  r e m a i n s  t o  b e  d e t e r m i n e d  
w h e t h e r  T R A I L  c o n t r i b u t e s  t o  t h e  m a i n t e n a n c e  o f  s e l f - t o l e r a n c e  i n  t h i s  m a n n e r .  
W h i l s t  T R A I L  m a y  b e  f u n c t i o n a l  o n  a c t i v a t e d  m a t u r e  T  c e l l s  a n d  N K  c e l l s  a n d  
m a y  b e  c a p a b l e  o f  s u p p r e s s i n g  i n d u c t i o n  o f  e x p e r i m e n t a l  a u t o i m m u n e  d i s e a s e  ( a s  
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illustrated in Chapter 5), we have shown in five different models that TRAIL is 
not critical for intrathymic negative selection. We are unable to easily explain the 
basis of the discrepancies between our results and those recently published 
(Lamhamedi-Cherradi et al., 2003), but in light of our data and other supportive 
studies (Simon et al., 2001) we suggest that the importance of TRAIL in 
intrathymic negative selection is, at best, unclear and requires further 
investigation. Rigorous testing is now required to determine whether TRAIL can 




Important research completed prior to this thesis had focused on investigating the 
potential of rTRAIL as a cancer therapeutic since it demonstrated a unique ability 
to induce apoptosis in transformed cells, but not in most normal cells (Ashkenazi, 
2002; Ashkenazi et al., 1999; Walczak et al., 1999). Despite great interest in 
TRAIL as a single agent or . in combination with chemotherapeutic drugs 
(Ashkenazi et al., 1999; Nagane et al., 2000) or ionizing radiation (Chinnaiyan et 
al., 2000) for cancer therapy, little was known about TRAIL protein expression, 
or the function of TRAIL in immune responses and tumor immunosurveillance. 
This thesis provides the first detailed evidence of the leukocyte expression and 
function of mouse TRAIL. Importantly, we have demonstrated that TRAIL 
suppresses the initiation, growth and metastasis of tumors in mice, and that 
TRAIL inhibits EAE induction, but does not play a role in thymic negative 
selection of T cells or regulation of lymphoproliferation in Fas ligand mutant 
mice. Collectively, this data suggested that appropriate targeted manipulation of 
the TRAIL pathway might prove to be a useful strategy to suppress tumor growth 
and T cell-mediated autoimmune disease. 
7.1 Constitutive TRAIL expression in the mouse 
Previously, our laboratory had shown that TRAIL was constitutively expressed 
on a small subset of liver NK cells in adult mice (Takeda et al., 2001). Herein, we 
have extended the earlier study to demonstrate that TRAIL is expressed on a 
unique population of phenotypically immature NK cells in the adult liver. 
Moreover, phenotypically similar TRAIL-expressing NK cells predominate in the 
liver and spleen of fetal and neonatal mice, but decrease in proportion with age 
and are uniquely retained in decreased numbers in the adult liver. Several 
possibilities exist as to why TRAIL+ NK cells are retained in the adult liver and 
not in other lymphoid organs. TRAIL might play a role in lymphocyte cell death 
that is reported to occur in the liver (Eberl and MacDonald, 1998; Mehal et al., 
1999), or the surveillance of stressed cells in this site (Rabinovich et al., 2000), 
however there was no abnormal accumulation of lymphocytes observed in 
TRAIL-deficient mice. TRAIL might also play a role in tolerance responses to 
antigens derived from food or endogenous commensural pathogens that may first 
t r a f f i c  f r o m  t h e  g u t  v i a  t h e  p o r t a l  v e i n .  I n t e r e s t i n g l y ,  T a k e d a  a n d  c o l l e a g u e s  h a v e  
r e c e n t l y  s h o w n  t h a t  g e r m - f r e e  m i c e  a l s o  c o n t a i n  t h e  s a m e  T R A I L +  p o p u l a t i o n  o f  
a d u l t  l i v e r  N K  c e l l s  ( p e r s o n a l  c o m m u n i c a t i o n ,  D r .  K a z u y o s h i  T a k e d a ) .  
A l t e r n a t i v e l y ,  T R A I L  m i g h t  p l a y  a  r o l e  i n  N K  c e l l - m e d i a t e d  c l e a r a n c e  o f  
p a t h o g e n s  w i t h i n  t h e  l i v e r .  I F N - y  p r o d u c e d  b y  l i v e r  N K  c e l l s  p l a y s  a n  i m p o r t a n t  
r o l e  i n  t h e  r e g u l a t i o n  o f  M C M V  i n f e c t i o n  ( T a y  a n d  W e l s h ,  1 9 9 7 ) ,  a n d  h u m a n  
f o r e s k i n  f i b r o b l a s t s  i n f e c t e d  w i t h  H C M V  u p r e g u l a t e  e x p r e s s i o n  o f  D D -
c o n t a i n i n g  T R A I L  r e c e p t o r s  a n d  b e c o m e  s e n s i t i v e  t o  T R A I L - m e d i a t e d  a p o p t o s i s  
( S e d g e r  e t  a l . ,  1 9 9 9 ) .  T h e r e f o r e ,  i t  m i g h t  n o w  b e  i n t e r e s t i n g  t o  e x a m i n e  w h e t h e r  
T R A I L  e x p r e s s e d  o n  l i v e r  N K  c e l l s  c a n  r e g u l a t e  C M V  i n f e c t i o n  i n  t h e  l i v e r .  
F u t u r e  s t u d i e s  t o  i n v e s t i g a t e  t h e  r o l e  o f  T R A I L  i n  t h e  r e g u l a t i o n  o f  m a l a r i a  
i n f e c t i o n  m i g h t  a l s o  b e  w a r r a n t e d ,  g i v e n  t h a t  I F N - y  p r o d u c t i o n  b y  N K  c e l l s  i s  
i m p o r t a n t  i n  t h e  r e g u l a t i o n  o f  t h e  s p o r o z o i t e  s t a g e  o f  m a l a r i a  i n f e c t i o n  i n  t h e  l i v e r  
( M o h a n  e t  a l . ,  1 9 9 7 ;  O j o - A m a i z e  e t  a l . ,  1 9 8 4 ) .  
I m p o r t a n t l y ,  w e  h a v e  s h o w n  t h a t  T R A I L  i s  t h e  f i r s t  e f f e c t o r  m o l e c u l e  e x p r e s s e d  
o n  f e t a l  N K  c e l l s .  M o r e  r e c e n t l y ,  o u r  c o l l a b o r a t o r s  h a v e  s h o w n  t h a t  a d o p t i v e  
t r a n s f e r  o f  i m m a t u r e  T R A I L +  N K  c e l l s  i s o l a t e d  f r o m  n e o n a t a l  m i c e  o r  a d u l t  l i v e r  
r e s u l t e d  i n  t h e  a p p e a r a n c e  o f  T R A I C  N K  c e l l s  w i t h  a  m a t u r e  p h e n o t y p e  
( p e r s o n a l  c o m m u n i c a t i o n ,  D r .  K a z u y o s h i  T a k e d a ) .  T h i s  s u g g e s t e d  t h a t  T R A I L +  
N K  c e l l s  a r e  t h e  p r e c u r s o r s  o f  T R A I C  N K  c e l l s .  O u r  d a t a  s u g g e s t s  t h a t  T R A I L  i s  
a  d i s t i n c t i v e  f u n c t i o n a l  m a r k e r  t o  d e f i n e  a  u n i q u e  s t a g e  o f N K  c e l l  d i f f e r e n t i a t i o n .  
E x p r e s s i o n  o f  h i g h  l e v e l s  o f  C D 9 4  b y  f e t a l  N K  c e l l s  h a s  b e e n  s u g g e s t e d  t o  p l a y  
a n  i m p o r t a n t  r o l e  i n  t h e  m a i n t e n a n c e  o f  s e l f - t o l e r a n c e  d u r i n g  f e t a l  l i f e  ( S a l c e d o  e t  
a l . ,  2 0 0 0 ;  S i v a k u m a r  e t  a l . ,  1 9 9 9 ;  V a n  B e n e d e n  e t  a l . ,  2 0 0 1 ) .  T h u s ,  t h e  h i g h  l e v e l  
o f  C D 9 4  e x p r e s s i o n  o b s e r v e d  o n  T R A I L +  l i v e r  N K  c e l l s  m i g h t  a c t  t o  n e g a t i v e l y  
r e g u l a t e  t h e s e  c e l l s ,  p r e v e n t i n g  c y t o t o x i c i t y  a g a i n s t  s e l f - t i s s u e  i n  v i v o .  O u r  s t u d y  
s u g g e s t s  t h a t  t h e  l i m i t e d  a v a i l a b i l i t y  o f  N K  c e l l  e f f e c t o r  p a t h w a y s  e a r l y  i n  l i f e  
m i g h t  c o m p r i s e  a n o t h e r  l e v e l  o f  r e g u l a t i o n .  T R A I L  m i g h t  b e  t h e  p r e f e r r e d  
e f f e c t o r  m o l e c u l e  p a t h w a y  f o r  p o t e n t i a l l y  s e l f - r e a c t i v e  N K  c e l l s  w h e n  t h e y  l a c k  
t h e  m a j o r i t y  o f M H C  c l a s s  I  b i n d i n g  i n h i b i t o r y  r e c e p t o r s  ( e g .  L y 4 9 s ) .  
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Understanding the specific cytokines that regulate constitutive TRAIL expression 
in vivo might ultimately enable therapeutic manipulation of TRAIL function in 
vivo. Indeed, our finding that IFN-y regulated constitutive TRAIL expression in 
vivo prompted further studies in our laboratory which revealed that TRAIL 
induction on NK cells played a critical role in the IFN-y-mediated anti-metastatic 
effects of a-GalCer and IL-12 (Smyth et al., 2001). Our laboratory is now 
investigating the effects of other biological response modifiers such as IL-18 and 
IL-21, that induce NK cell IFN -y production, on TRAIL function. 
7.2 TRAIL and T cell homeostasis 
Several years ago, our laboratory reported a critical role for TNF in the 
lymphoaccumulation and premature death associated with the gld phenotype 
(Komer et al., 2000). Given that TRAIL can induce apoptosis in activated T and 
B cells (Marsters et al., 1996; Ursini-Siegel et al., 2002; Wang et al., 2000), we 
hypothesized that TRAIL, like TNF, might regulate lymphoproliferation in gld 
mice. Surprisingly, TRAIL had no effect on the gld phenotype. The role of 
TRAIL in T cell homeostasis was additionally investigated using several models 
of thymocyte negative selection. Although TRAIL had previously been reported 
to be critical for intrathymic negative selection (Lamhamedi-Cherradi et al., 
2003b ), we clearly showed that negative selection is normal in TRAIL-deficient 
mice. We additionally showed that negative selection is normal in mice deficient 
in both TRAIL and FasL, suggesting that TRAIL and FasL do not function co-
operatively to induce negative selection. It might now be of interest to delete 
multiple TNF-superfamily members, to determine whether negative selection is 
completely independent of DRs. Although we can not rule out a specific role for 
TRAIL in T cell regulation, together our data suggested that TRAIL does not 
globally affect T cell homeostasis. 
7.3 TRAIL and autoimmune disease 
TRAIL has been shown to inhibit autoimmune disease in a variety of mouse 
models including autoimmune arthritis (Lamhamedi-Cherradi et al., 2003b; Song 
e t  a l . ,  2 0 0 0 )  a n d  a u t o i m m u n e  d i a b e t e s  ( L a m h a m e d i - C h e r r a d i  e t  a l . ,  2 0 0 3 b )  
( L a m h a m e d i - C h e r r a d i  e t  a l . ,  2 0 0 3 a ) .  I n  t h e s e  s t u d i e s ,  T R A I L  w a s  s u g g e s t e d  t o  
p l a y  a  v a r i e t y  o f  r o l e s  r a n g i n g  f r o m  i n h i b i t i n g  c y t o k i n e  a n d  a n t i b o d y  p r o d u c t i o n  
t o  i n h i b i t i n g  i n f l a m m a t i o n  a n d  c e l l  c y c l e  p r o g r e s s i o n .  T h e  d a t a  p r e s e n t e d  i n  t h i s  
t h e s i s  h a v e  c l e a r l y  d e m o n s t r a t e d  t h a t  T R A I L  s u p p r e s s e s  a u t o i m m u n e  d a m a g e  i n  
r e l a p s i n g - r e m i t t i n g  a n d  c h r o n i c  n o n - r e m i t t i n g  m o d e l s  o f  E A E .  O u r  d a t a  
s u g g e s t e d  t h a t  T R A I L  s u p p r e s s e d  E A E  b y  i n h i b i t i n g  T  c e l l  p r o l i f e r a t i o n  a n d  
i n f i l t r a t i o n  o f  l e u k o c y t e s  i n t o  t h e  C N S .  T h e s e  f i n d i n g s  s u b s t a n t i a t e d  a n  i m p o r t a n t  
a n d  g e n e r a l  r o l e  f o r  T R A I L  i n  t h e  i n h i b i t i o n  o f  t h e  i n d u c t i o n  o f T  c e l l - m e d i a t e d  
a u t o i m m u n e  d i s e a s e .  
D i s e a s e  i n d u c t i o n  i n  e x p e r i m e n t a l  m o d e l s  o f  a u t o i m m u n e  d i s e a s e  i s  e x t r e m e l y  
c o m p l e x  a n d  o f t e n  i n v o l v e s  a d j u v a n t s  t h a t  s t i m u l a t e  D C s  a n d  o t h e r  i n n a t e  
i m m u n e  c e l l s  a n d  a c t i v a t i o n - i n d u c e d  T  c e l l  d e a t h  i n  t h e  p e r i p h e r y .  G i v e n  t h a t  
T R A I L  e x p r e s s i o n  c a n  b e  i n d u c e d  o n  a c t i v a t e d  N K  c e l l s  ( K a y a g a k i  e t  a l . ,  1 9 9 9 )  
a n d  D C s  ( F a n g e r  e t  a l . ,  1 9 9 9 ) ,  t h e  i n v o l v e m e n t  o f  T R A I L  i n  E A E  m i g h t  b e  
a t t r i b u t e d  t o  t h e  e f f e c t s  o f  a d j u v a n t  a d m i n i s t e r e d  t o  i n d u c e  d i s e a s e .  I n d e e d ,  C F  A  
a d m i n i s t r a t i o n  i s  k n o w n  t o  s t i m u l a t e  N K  c e l l  I F N - y  p r o d u c t i o n  ( L e e  e t  a l . ,  2 0 0 4 ;  
S h i  e t  a l . ,  2 0 0 0 ) ,  a n d  t o  s u p p r e s s  a u t o i m m u n e  d i a b e t e s  ( L e e  e t  a l . ,  2 0 0 4 )  a n d  
p r i s t a n e - i n d u c e d  a r t h r i t i s  i n  m i c e  ( Z h e n g  e t  a l . ,  2 0 0 2 ;  Z h e n g  e t  a l . ,  2 0 0 3 ) .  
M o r e o v e r ,  s t u d i e s  i n  o u r  l a b o r a t o r y  h a v e  i m p l i c a t e d  a u t o c r i n e  I F N - y p r o d u c e d  b y  
N K  c e l l s  i n  t h e  r e g u l a t i o n  o f  T R A I L  e x p r e s s i o n  ( T a k e d a  e t  a l . ,  2 0 0 1 ) .  
C o l l e c t i v e l y ,  t h e s e  f i n d i n g s  e n t e r t a i n  t h e  p o s s i b i l i t y  t h a t  T R A I L - m e d i a t e d  
s u p p r e s s i o n  o f  E A E  m i g h t  b e  a d j u v a n t - d e p e n d e n t .  
T h e  p r e c i s e  m e c h a n i s m ( s )  w h e r e b y  T R A I L  s u p p r e s s e s  E A E ,  a n d  t h e  k e y  T R A I L -
e x p r e s s i n g  e f f e c t o r  c e l l s  i n v o l v e d  a r e  u n k n o w n .  A l t h o u g h  . T R A I L  c a n  s u p p r e s s  
E A E ,  o u r  s t u d y  r e v e a l e d  t h a t  a g e d  C 5 7 B L / 6  T R A I L - / - m i c e  d o  n o t  d e v e l o p  
s p o n t a n e o u s  a u t o i m m u n e  d i s e a s e ,  s u g g e s t i n g  a  m i n o r  r o l e  a t  b e s t  f o r  T R A I L  i n  
s u p p r e s s i o n  o f  a u t o i m m u n e  d i s e a s e .  I m p o r t a n t l y ,  w e  d i s p r o v e d  t h e  p o s t u l a t e  t h a t  
T R A I L  p l a y s  a  k e y  r o l e  i n  n e g a t i v e  s e l e c t i o n  o f  t h y m o c y t e s ,  s u g g e s t i n g  t h a t  
T R A I L  i n h i b i t s  E A E  i n d u c t i o n  b y  a  d i f f e r e n t  m e c h a n i s m .  I m m u n o f l u o r e s c e n c e  
s t u d i e s  u s i n g  t h e  a n t i - m T R A I L  m A b  m i g h t  h e l p  e l u c i d a t e  t h e  k e y  T R A I L -
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expressing effector cells that infiltrate the CNS in EAE. NK cells are a good 
effector cell candidate to express TRAIL, and have been established to suppress 
EAE in mice (Zhang et al., 1997). Future NK cell depletion studies in TRAIL-
deficient mice are required to determine whether TRAIL-mediated suppression of 
EAE is NK cell-dependent. Our laboratory have recently shown that TRAIL-
expressing NK cells can eliminate DCs in vivo (Hayakawa et al., 2004), leading 
us to speculate that TRAIL-expressing NK cells might suppress EAE by inducing 
apoptosis in DCs that prime autoreactive T cells. Alternatively, TRAIL-
expressing NK cells might induce apoptosis in autoreactive T cells to suppress 
disease. 
DCs or autoreactive T cells might also potentially express TRAIL and suppress 
EAE. Indeed, recent studies have suggested that TRAIL-expressing DCs can 
inhibit proliferation of autoreactive T cells in EAE to suppress disease (Suter et 
al., 2003). Alternatively, TRAIL-expressing DCs might be hypothesized to 
directly induce apoptosis in autoreactive T cells. EAE can be induced in naive 
mice by transfer of BM-derived DCs pulsed with MOG peptide in vitro (Weir et 
al., 2002). If DCs suppress EAE in a TRAIL-dependent manner, transfer of DCs 
isolated from TRAIL-/- mice might be expected to induce a more severe form of 
EAE. If autoreactive T cells can suppress EAE in a TRAIL-dependent manner, 
adoptive transfer of autoreactive T cells isolated from TRAIL-deficient TCR 
transgenic mice (specific for MBP, PLP or MOG) may induce a more severe 
form of EAE compared to transfer of TRAIL-sufficient autoreactive T cells. 
Clearly, understanding how TRAIL suppresses EAE will be of great importance 
before any future planning of clinical trials in MS patients using rTRAILI Apo2L. 
In this thesis, we have illustrated the therapeutic value of rTRAIL and anti-DRS 
antibody in suppressing the animal model EAE. Recent studies in our laboratory 
have shown that although rTRAIL or anti-DRS antibody administration from the 
time of disease induction could suppress MOO-induced EAE in NOD/Lt mice, 
treatment during the disease course had no effect on the severity of EAE. 
Importantly, these data suggested that early treatment with rTRAIL. or anti-DRS 
antibody is required to maximally exploit the TRAIL-TRAIL-R pathway to 
t h e r a p e u t i c  a d v a n t a g e .  T h i s  h i g h l i g h t s  t h e  i m p o r t a n c e  o f  e a r l y  d e t e c t i o n  o f  
d i s e a s e  i f  r T R A I L  o r  h u m a n i z e d  a n t i - D R 5  a n t i b o d y  i s  t o  b e  u s e d  e f f e c t i v e l y  t o  
t r e a t  M S  p a t i e n t s .  I n  a  r e c e n t  s t u d y ,  T R A I L  w a s  i d e n t i f i e d  a s  a  r e s p o n s e  m a r k e r  
f o r  IFN-~ t h e r a p y  i n  M S  p a t i e n t s  ( W a n d i n g e r  e t  a l . ,  2 0 0 3 ) .  P a t i e n t s  w i t h  r a i s e d  
l e v e l s  o f  T R A I L  i n  t h e i r  s e r a  p r i o r  t o  IFN-~ t h e r a p y  a n d  t h o s e  s h o w i n g  s u s t a i n e d  
T R A I L  i n d u c t i o n  p o s t - t h e r a p y  r e s p o n d e d  b e s t  t o  t r e a t m e n t  ( W a n d i n g e r  e t  a l . ,  
2 0 0 3 ) .  A l t h o u g h  t h i s  r e p o r t  s u g g e s t e d  t h a t  T R A I L  m i g h t  b e  e f f e c t i v e  i n  M S  
p a t i e n t s ,  a  n u m b e r  o f  t h e r a p i e s  t h a t  a r e  e f f e c t i v e  i n  s u p p r e s s i o n  o f  E A E  a r e  
i n e f f e c t i v e  i n  M S  p a t i e n t s  ( P e n d e r  a n d  W o l f e ,  2 0 0 2 ) ,  a n d  t h e  T R A I L  r e c e p t o r  
s y s t e m  i n  h u m a n s  d i f f e r s  f r o m  m i c e .  O n c e  T R A I L  i s  s h o w n  t o  b e  s a f e  i n  P h a s e  I  
t r i a l s  i n  c a n c e r  p a t i e n t s ,  c l i n i c a l  t r i a l s  m a y  b e  c o n s i d e r e d  t o  d e t e r m i n e  t h e  
t h e r a p e u t i c  e f f i c a c y  o f  t a r g e t i n g  t h e  T R A I L  p a t h w a y  i n  M S  p a t i e n t s .  
7 . 4  T R A I L  a n d  t u m o r  i m m u n e  s u r v e i l l a n c e  
P r e v i o u s l y ,  a  n u m b e r  o f  s t u d i e s  h a d  d e m o n s t r a t e d  t h e  a b i l i t y  o f  r T R A I L  t o  i n d u c e  
r e g r e s s i o n  o f  t u m o r  x e n o g r a f t s  i n  m i c e  w i t h o u t  s y s t e m i c  t o x i c i t y  ( A s h k e n a z i  e t  
a l . ,  1 9 9 9 ;  W a l c z a k  e t  a l . ,  1 9 9 9 ) ,  a l t h o u g h  l e s s  w a s  k n o w n  a b o u t  t h e  r o l e  T R A I L  
p l a y e d  i n  n a t u r a l  t u m o r  i m m u n i t y .  T h e  s t u d i e s  i n  t h i s  t h e s i s  h a v e  s u p p o r t e d  a  
d i r e c t  r o l e  f o r  T R A I L  i n  s u p p r e s s i o n  o f  t u m o r  i n i t i a t i o n  a n d  m e t a s t a s i s .  
I m p o r t a n t l y ,  w e  h a v e  r e p o r t e d  t h e  i n i t i a l  c h a r a c t e r i z a t i o n  o f  T R A I L  g e n e - t a r g e t e d  
m i c e ,  a n d  i d e n t i f i e d  a  n u m b e r  o f  T R A I L - s e n s i t i v e  m o u s e  t u m o r  m o d e l s  t h a t  w i l l  
f a c i l i t a t e  i n  d e p t h  s t u d i e s  i n v e s t i g a t i n g  t h e  r o l e  o f  T R A I L  i n  t u m o r  i m m u n i t y .  
T h e  m a m m a r y  g l a n d  i s  a  c o m m o n  s i t e  o f  h u m a n  n e o p l a s i a .  I n  t h i s  s t u d y  w e  
u n i q u e l y  d e m o n s t r a t e d  t h a t  T R A I L  s u p p r e s s e d  t u m o r  g r o w t h  i n  t h e  m a m m a r y  
g l a n d  a n d  m e t a s t a s e s  f r o m  t h i s  s i t e .  T h i s  f i n d i n g  s u g g e s t e d  t h a t  T R A I L  m i g h t  b e  
c o n s t i t u t i v e l y  e x p r e s s e d  o n  N K  c e l l s  w i t h i n  t h e  m a m m a r y  g l a n d ,  o r  t h a t  a  
p r e s e n c e  o f  t r a n s f o r m e d  c e l l s  i n  t h i s  s i t e  m i g h t  s t i m u l a t e  a n  i n f i l t r a t i o n  o f  
T R A I L - e x p r e s s i n g  N K  c e l l s .  W e  a r e  n o w  e s t a b l i s h i n g  T R A I L - d e f i c i e n t  H e r 2 / n e u  
t r a n s g e n i c  m i c e  t o  i n v e s t i g a t e  w h e t h e r  T R A I L  p l a y s  a  g e n e r a l  r o l e  i n  s u p p r e s s i o n  
o f  t u m o r  g r o w t h  i n  t h e  m a m m a r y  g l a n d .  G i v e n  t h a t  I F N - y  m i g h t  p l a y  a  r o l e  i n  
c o n t r o l  o f  t u m o r  d e v e l o p m e n t  i n  H e r 2 / n e u  t r a n s g e n i c  m i c e  ( B o g g i o  e t  a l . ,  1 9 9 8 ) ,  
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and IFN-y is important in the regulation of TRAIL expression in vivo, these 
studies are of particular interest. 
In addition to the studies described in this thesis, a number of recent studies in 
our laboratory and others have greatly contributed to our knowledge of the role 
TRAIL plays in tumor surveillance. TRAIL was shown to play a role in natural 
protection from spontaneous tumor development in CS7BL/6 pS3+/- mice (Takeda 
et al., 2002). Importantly, TRAIL was also demonstrated to suppress the initiation 
of MCA-induced fibrosarcomas (Cretney et al., 2002). The majority of 
fibrosarcoma cell lines established from MCA-inoculated TRAIC1- or anti-
mTRAIL mAb-treated mice were susceptible to TRAIL-mediated cytotoxicity, 
whereas the majority of fibrosarcomas isolated from control-Ig-treated mice were 
TRAIL-resistant (Takeda et al., 2002). This suggested that TRAIL might 
naturally select TRAIL-resistant tumor variants. Future studies in our laboratory 
will investigate the mechanisms by which tumors escape TRAIL-mediated tumor 
surveillance. TRAIL-resistant MCA-induced fibrosarcoma cell lines will be 
assessed for DRS and TRAIL decoy receptor expression, and key points in the 
cell death cascade normally triggered by TRAIL will be analyzed. By 
understanding the mechanism tumors use to escape TRAIL-mediated 
surveillance, we hope to design more effective therapies to suppress tumor 
initiation and metastasis in vivo. 
A number of recent studies have helped elucidate the mechanisms whereby tumor 
cells become resistant to TRAIL-mediated apoptosis. TRAIL-sensitive tumor 
cells transfected with cFLIP were recently demonstrated to escape TRAIL-
mediated surveillance in vivo (Seki et al., 2003), and inhibition of cFLIP with 
small interfering RNAs sensitized tumor cells to TRAIL-mediated apoptosis in 
vitro (Siegmund et al., 2002). Proteosome inhibitors such as PS-341 and N-
acetyl-L-leucinyl-L-leucinyl-L-norleucinal (LLnL) have been reported to 
sensitize tumor cells to TRAIL-mediated apoptosis by reducing the levels of 
cFLIP (Sayers et al., 2003), blocking NFKB activation (Franco et al., 2001; 
Jeremias et al., 1998) and elevating the levels of TRAIL receptors DR4 and DRS 
(Johnson et al., 2003). Recently, a small molecule Smac mimic has been 
d e v e l o p e d  t h a t  f u n c t i o n s  b y  r e l i e v i n g  l A P - m e d i a t e d  s u p p r e s s i o n  o f  c a s p a s e  
a c t i v i t y ,  a n d  a c t s  s y n e r g i s t i c a l l y  w i t h  T R A I L  t o  i n d u c e  t u m o r  c e l l  a p o p t o s i s  ( L i  e t  
a l . ,  2 0 0 4 ) .  I n  a n o t h e r  r e p o r t ,  o v e r e x p r e s s i o n  o f  t h e  M Y C  o n c o g e n e  w a s  r e p o r t e d  
t o  s e n s i t i z e  c e l l s  t o  T R A I L - o r  D R 5  a g o n i s t - i n d u c e d  a p o p t o s i s ,  b y  u p r e g u l a t i n g  
c e l l  s u r f a c e  e x p r e s s i o n  o f  D R 5  ( W a n g  e t  a l . ,  2 0 0 4 ) .  T h e s e  s t u d i e s  i l l u s t r a t e  t h a t  
s e n s i t i z i n g  t u m o r  c e l l s  t o  T R A I L - m e d i a t e d  a p o p t o s i s  v i a  m o d u l a t i o n  o f  v a r i o u s  
m o l e c u l a r  t a r g e t s ,  a n d  s p e c i f i c a l l y  s t i m u l a t i n g  a p o p t o s i s  u s i n g  r T R A I L ,  m a y  b e  
a n  e f f e c t i v e  t h e r a p e u t i c  a p p r o a c h .  
T h e  m a j o r i t y  o f  t h e  m o d e l s  u s e d  t o  i n v e s t i g a t e  t h e  r o l e  o f  T R A I L  i n  t u m o r  
s u r v e i l l a n c e  h a v e  b e e n  m o d e l s  o f  N K  c e l l  s u p p r e s s i o n .  R e c e n t l y ,  a  s i g n i f i c a n t  
r o l e  f o r  T R A I L  i n  T  c e l l - m e d i a t e d  t u m o r  i m m u n i t y  w a s  r e p o r t e d  ( S c h m a l t z  e t  a l . ,  
2 0 0 2 ) .  T R A I L  w a s  r e q u i r e d  f o r  o p t i m a l  g r a f t - v e r s u s - t u m o r  a c t i v i t y  b y  d o n o r  T  
c e l l s  i n  a l l o g e n e i c  h e m a t o p o i e t i c - c e l l  t r a n s p l a n t a t i o n  s t u d i e s  i n  m i c e  ( S c h m a l t z  e t  
a l . ,  2 0 0 2 ) .  I m p o r t a n t l y ,  t h i s  s t u d y  s u g g e s t e d  t h a t  s t r a t e g i e s  t o  s t i m u l a t e  T R A I L  
e x p r e s s i o n  a n d  f u n c t i o n  o n  d o n o r  T  c e l l s  m i g h t  d e c r e a s e  r e l a p s e  i n  l e u k e m i a  
p a t i e n t s .  R e c e n t l y ,  T R A I L  e x p r e s s i o n  a n d  a n t i - t u m o r  a c t i v i t y  w e r e  r e p o r t e d  t o  b e  
i n d u c e d  i n  h u m a n  B  c e l l s  a n d  m a c r o p h a g e s  b y  s p e c i f i c  C p G - c o n t a i n i n g  
o l i g o d e o x y n u c l e o t i d e s  ( K e m p  e t  a l . ,  2 0 0 3 ;  K e m p  e t  a l . ,  2 0 0 4 ) .  G i v e n  t h a t  
M y c o b a c t e r i a l  D N A  c o n t a i n s  h i g h  l e v e l s  o f  C p G  m o t i f s ,  t h e s e  s t u d i e s  p r o m p t e d  
t h e  i n v e s t i g a t i o n  o f  t h e  a n t i - t u m o r  p r o p e r t i e s  o f  M y c o b a c t e r i u m  b o v i s  B a c i l l u s  
C a l m e t t e - G u e r i n  ( B C G ) .  B C G  i s  a  p o t e n t  i m m u n o s t i m u l a n t  t h a t  i n d u c e s  a  T h l  
c y t o k i n e  r e s p o n s e  a n d  i s  a n  o f t e n  p r e s c r i b e d  t r e a t m e n t  f o r  p a t i e n t s  w i t h  b l a d d e r  
c a n c e r .  P a t i e n t s  r e s p o n d i n g  t o  B C G  t h e r a p y  e x h i b i t e d  h i g h e r  l e v e l s  o f  T R A I L  i n  
t h e i r  u r i n e  c o m p a r e d  t o  n o n - r e s p o n d e r s  ( L u d w i g  e t  a l . ,  2 0 0 4 ) .  M o r e o v e r ,  s o l u b l e  
u r i n a r y  T R A I L  c o u l d  i n d u c e  a p o p t o s i s  i n  b l a d d e r  c a r c i n o m a  c e l l s  i n  v i t r o  
( L u d w i g  e t  a l . ,  2 0 0 4 ) .  I n t e r e s t i n g l y ,  w h i l e  t h e  r o l e  o f  N K  c e l l s  w a s  n o t  
s p e c i f i c a l l y  e x a m i n e d ,  T R A I L  w a s  s h o w n  t o  b e  e x p r e s s e d  o n  v o i d e d  n e u t r o p h i l s ,  
s u g g e s t i n g  a n  a n t i - t u m o r  r o l e  f o r  n e u t r o p h i l s  i n  v i v o  ( L u d w i g  e t  a l . ,  2 0 0 4 ) .  
T o g e t h e r  t h e s e  s t u d i e s  i n d i c a t e d  t h a t  a  w i d e  v a r i e t y  o f  e f f e c t o r  c e l l s  m i g h t  
e x p r e s s  T R A I L  a n d  m e d i a t e  T R A I L - d e p e n d e n t  a n t i - t u m o r  a c t i v i t y  i n  v i v o .  
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TRAIL is primarily expressed as a type II transmembrane protein, but also exists 
as a soluble form that is enzymatically cleaved from the cell surface (Mariani and 
Krammer, 1998), or secreted in microvesicles (Monleon et al., 2001 ). The 
therapeutic efficacy of BCG correlates with an increased production of soluble 
TRAIL in patients with bladder cancer (Ludwig et al., 2004). Moreover, 
neutrophils and PBMCs isolated from CML patients and stimulated with IFN-a 
in vitro secrete high levels of soluble TRAIL, that induces apoptosis in TRAIL-
sensitive leukemia cells in vitro (Tecchio et al., 2004). Collectively, these studies 
suggest that both soluble and membrane-bound TRAIL might be capable of 
exerting tumoricidal activity. It might now be interesting to produce mice 
deficient in membrane-bound, or soluble TRAIL, to help elucidate the 
importance of these forms of TRAIL in immunosurveillance. Indeed, mice 
deficient in soluble TNF have been used to differentiate the specific roles of 
membrane versus soluble TNF in mice (Ruuls et al., 2001). 
7.5 Cancer therapeutic potential of TRAIL 
Administration of rTRAIL in mice and primates induced tumor regression 
without systemic toxicity (Ashkenazi et al., 1999; Walczak et al., 1999) and 
TRAIL has been shown to act synergistically with ionizing radiation (Chinnaiyan 
et al., 2000) and chemotherapeutic drugs (Ashkenazi et al., 1999; Nagane et al., 
2000). Radiation and most DNA-damaging chemotherapeutic drugs induce tumor 
cell apoptosis via p53-mediated activation of the intrinsic mitochondrial death 
pathway (Levine, 1997). In contrast, TRAIL induces apoptosis in a p53-
independent manner via 'cell-extrinsic' or 'cell-intrinsic' death pathways 
(Ashkenazi et al., 1999). Treatment with rTRAIL might therefore be expected to 
circumvent resistance to conventional chemotherapy and radiotherapy in cancer 
patients. Genentech Incorporated is currently planning a Phase I clinical trial 
(PR01762) of recombinant soluble TRAIL/Apo2L in cancer patients. The data in 
this thesis have confirmed that natural TRAIL plays an important role in tumor 
surveillance, providing hope that synthetic TRAIL will prove effective in the 
eradication of tumor in cancer patients. 
A  n u m b e r  o f  t u m o r  x e n o g r a f t  s t u d i e s  h a v e  d e m o n s t r a t e d  t h e  c a p a b i l i t y  o f  
a g o n i s t i c  m A b s  t h a t  e n g a g e  h u m a n  D R 4  o r  D R S  t o  e x e r t  a n t i - t u m o r  a c t i v i t y  i n  
v i v o  ( C h u n t h a r a p a i  e t  a l . ,  2 0 0 1 ;  I c h i k a w a  e t  a l . ,  2 0 0 1 ;  W a n g  e t  a l . ,  2 0 0 4 ) .  H u m a n  
G e n o m e  S c i e n c e s  a n d  C a m b r i d g e  A n t i b o d y  T e c h n o l o g y  a r e ·  c u r r e n t l y  p l a n n i n g  a  
P h a s e  I  c l i n i c a l  t r i a l  o f  a n  a g o n i s t i c  h u m a n i z e d  a n t i - D R S  m A b  i n  c a n c e r  p a t i e n t s .  
S p e c i f i c  t a r g e t i n g  o f  d e a t h - i n d u c i n g  D R S  o r  D R 4  r e c e p t o r s  b y  a g o n i s t i c  
a n t i b o d i e s  m i g h t  b e  a d v a n t a g e o u s  o v e r  r T R A I L  a d m i n i s t r a t i o n  i f  t u m o r  c e l l s  a r e  
p r o t e c t e d  f r o m  r T R A I L - i n d u c e d  a p o p t o s i s  b y  t h e  e x p r e s s i o n  o f  c e l l  s u r f a c e  d e c o y  
r e c e p t o r s .  H o w e v e r ,  i f  n o r m a l  c e l l s  o v e r  e x p r e s s  d e c o y  r e c e p t o r s  a s  a  p r o t e c t i v e  
m e c h a n i s m  a g a i n s t  T R A I L - m e d i a t e d  k i l l i n g ,  a d m i n i s t r a t i o n  o f  a g o n i s t i c  
a n t i b o d i e s  t o  D R 4  o r  D R S  m i g h t  p o t e n t i a l l y  p r o v e  m o r e  t o x i c  t h a n  a d m i n i s t r a t i o n  
o f r T R A I L .  
T h e  f i n d i n g s  i n  t h i s  t h e s i s  h a v e  e s t a b l i s h e d  a n  i m p o r t a n t  r o l e  f o r  T R A I L  i n  t u m o r  
s u r v e i l l a n c e  i n  v i v o  a n d  h a v e  p r o v i d e d  s u p p o r t i n g  r a t i o n a l e  f o r  t h e  t e s t i n g  o f  
s o l u b l e  r T R A I L  a s  a  c a n c e r  t h e r a p e u t i c .  I m m u n o t h e r a p i e s  t h a t  m o b i l i z e  T R A I L +  
e f f e c t o r  c e l l s  ( i n c l u d i n g  N K ,  T ,  m y e l o i d  c e l l s  a n d  n e u t r o p h i l s )  m i g h t  p r o v e  
e f f e c t i v e  i n  c a n c e r  p a t i e n t s .  G i v e n  t h a t  r T R A I L  a c t s  s y n e r g i s t i c a l l y  w i t h  
c h e m o t h e r a p y  a n d  r a d i o t h e r a p y ,  c o m b i n a t i o n s  o f  t h e s e  t h e r a p i e s  w i t h  T R A I L -
i n d u c i n g  a g e n t s  s u c h  a s  a - G a l C e r ,  I L - 1 2  a n d  I F N s  m i g h t  a l s o  p r o v e  e f f e c t i v e .  
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Appendix I. Constitutive TRAIL expression in gene-targeted mice. Liver MNC isolated from 
adult C57BL/6 mice were stained with antibodies to CD3, NKI.l and TRAIL or isotype control 
mAb. Histograms demonstrate TRAIL/isotype control control antibody staining on gated 
NK1.1+CD3" cells. Red lines represent staining with anti-mTRAIL mAb, black lines represent 
staining with isotype matched control mAb. Data are representative of the analysis of 20 
C57BL/6, 4 C57BL/6 TNF1·, 10 C57BL/6 IL-12·1·, 8 C57BL/6 IL-18·1·, 10 C57BL/6 IL-12·1· IL-
18"1·, 7 C57BL/6 IL-4·1·, 4 C57BL/6 IFNaR1·1·, and 4 C57BL/6 IFNaR2_1_ mice. Liver NK cell 
TRAIL expression was not statistically different between the strains of mice shown (P > 0.05). 
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E f f e c t o r : T a r g e t  
A p p e n d i x  I I .  S e n s i t i v i t y  o f  m o u s e  t u m o r  c e l l  l i n e s  t o  T R A I L - m e d i a t e d  c y t o t o x i c i t y .  T h e  
c y t o t o x i c  a c t i v i t y  o f 2 P K 3 - m T R A I L  t r a n s f e c t a n t  c e l l s  a g a i n s t  v a r i o u s  m o u s e  t u m o r  c e l l  l i n e s  w a s  
t e s t e d  i n  a n  1 8  h  
5 1
C r  r e l e a s e  a s s a y .  P e r c e n t  s p e c i f i c  T R A I L - m e d i a t e d  l y s i s  w a s  d e t e r m i n e d  b y  
s u b t r a c t i n g  p e r c e n t  s p e c i f i c  l y s i s  b y  2 P K 3  p a r e n t a l  c e l l s  f r o m  %  s p e c i f i c  l y s i s  b y  2 P K 3 - m T R A I L  
t r a n s f e c t a n t  c e l l s .  D a t a  r e p r e s e n t  m e a n ±  S E M  o f  6  4 T 1 . 2 ,  3  D A 3 ,  8  E M T 6 . 5 ,  3  A 2 0 ,  2 0  R e n c a ,  2  
K 0 5 2 - F 1 1 ,  1  I F N y M C A 3 ,  1  B C M C A 3 ,  1  E L 4 ,  2  K 0 5 2 - D A 2 0 ,  1  R M - 1 ,  1  3 L L ,  1  R M A S ,  I  
P N 5 3 H ,  1  B C M C A 4  a n d  1  I F N y M C A 2  e x p e r i m e n t .  
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Appendix II. Continued. 
M o u s e  ( s e x )  
A g e  ( w e e k s )  B o d y  w e i g h t  ( g )  S p l e e n  w e i g h t  { g )  
S p l e e n %  B W  a l . N  w e i g h t s  ( g  
a l . N %  B W  
6  ( M )  4 7 . 1 0  
2 3 . 3 3  
0 . 3 6 1  1 . 5 4  
0 . 1 4 4 ,  0 . 1 8 3  0 . 6 1 7 ,  0 . 7 8 4  
7  ( M )  4 4 . 1 0  3 0 . 8 0  
0 . 3 8 0  1 . 2 3  0 . 0 1 ,  0 . 0 1  
0 . 0 3 2 ,  0 . 0 3 2  
3 6  ( M )  
5 0 . 9 0  2 9 . 2 0  
0 . 6 3 9  2 . 1 8 8  0 . 0 4 9 ,  0 . 0 1 9  
0 . 1 6 8 ,  0 . 0 6 5  
6 8  ( M )  4 6 . 6 0  3 4 . 4 6  0 . 8 0 0  2 . 3 2 2  
1 . 9 4 2 ,  0 . 0 2 3  5 . 6 3 6 ,  0 . 0 6 7  
6 2  ( F )  4 6 . 3 0  3 5 . 8 2  1 . 0 0 4  
2 . 8 0 3  0 . 9 7 2 , 1 . 1 1 0  
2 . 7 1 4 ,  3 . 0 9 9  
1  ( F )  
4 0 . 4 0  
2 8 . 4 3  
0 . 9 1 7  3 . 2 2 6  
0 . 3 2 2 ,  0 . 3 5 4  1 . 1 2 6 ,  1 . 2 4 5  
5 0 ( F )  5 8 . 9 0  4 6 . 3 3  
0 . 3 0 3  0 . 6 5 4  0 . 0 1 0 ,  0 . 0 0 1  
0 . 0 2 2 ,  0 . 0 1 5  
3 0  ( M )  2 8 . 4 0  2 2 . 1 1  1 . 8 9 0  8 . 5 5 0  
0 . 0 8 2 ,  0 . 0 3 8  
0 . 3 7 1 '  0 . 1 7 1  
3 4 ( M )  
4 1 . 0 0  3 4 . 5 0  0 . 5 0 0  1 . 4 4 9  
0 . 0 1 2 ,  0 . 0 1 8  0 . 0 3 5 ,  0 . 0 5 2  
6 1  ( M )  3 4 . 7 0  3 8 . 1 1  1 . 4 3 9  3 . 7 7 6  
0 . 5 5 1 ,  0 . 3 6 8  1 . 4 4 6 ,  0 . 9 6 6  
5 4  ( F )  
3 5 . 9 0  
1 8 . 6 7  
0 . 1 4 4  0 . 7 7 1  
0 . 0 9 2 ,  0 . 0 9 6  0 . 4 9 3 ,  0 . 5 1 4  
2 7  ( F )  4 3 . 4 0  1 8 . 0 1  0 . 1 9 6  
1 . 0 8 8  0 .  1 1  0 ,  0 .  1 8 4  
0 . 6 1 1 ,  1 . 0 2 2  
2 8  ( F )  
4 4 . 7 0  2 5 . 5 2  0 . 7 2 3  2 . 8 3 3  
0 . 1 8 0 ,  0 . 1 7 5  0 .  7 0 5 ,  0 . 6 8 6  
2 1  ( M )  4 4 . 9 0  3 1 . 2 4  0 . 7 6 9  
2 . 4 6 2  0 . 2 6 4 ,  0 .  1  7 2  
0 . 8 4 5 ,  0 . 5 5 1  
4 3  ( M )  3 8 . 4 0  2 5 . 3 0  
0 . 4 0 3  1 . 5 9 3  0 . 0 8 5 ,  0 . 0 9 1  
0 . 3 3 6 ,  0 . 3 6 0  
2 6  ( F )  5 6 . 6 0  2 7 . 0 0  
0 . 3 6 0  1 . 3 3 3  0 . 0 7 2 ,  0 . 0 2 1  
0 . 2 6 7 ,  0 . 0 7 7  
3 1  ( M )  4 9 . 1 0  3 2 . 5 3  0 . 6 0 3  1 . 8 5 4  
0 . 3 8 8 ,  0 . 3 4 9  1 .  1 9 3 ,  1 . 0 7 3  
4 9  ( M )  
4 1 . 0 0  2 8 . 9 4  0 . 4 7 8  
1 . 6 5 2  0 . 3 4 9 ,  0 . 2 4 7  
1 . 2 0 6 ,  0 . 8 5 3  
2 3  ( M )  4 8 . 6 0  3 0 . 1 1  0 . 2 6 0  0 . 8 6 4  
0 . 0 6 8 ,  0 . 0 7 0  0 . 2 2 6 ,  0 . 2 3 2  
2 9  ( F )  4 8 . 0 0  2 7 . 7 7  0 . 7 0 0  2 . 5 2 1  
0 . 4 0 7 ,  0 . 0 9 1  1 . 4 6 6 ,  0 . 3 2 8  
4 0  ( F )  4 4 . 1 0  3 4 . 7 5  
1 . 1 4 5  3 . 2 9 0  0 . 8 5 7 ,  0 . 3 6 4  
2 . 4 6 6 ,  1 . 0 4 7  
4 6  ( F )  4 4 . 0 0  3 2 . 2 8  
0 . 6 6 3  2 . 0 5 4  0 . 4 0 2 ,  0 . 3 9 8  
1 . 2 4 5 ,  1 . 2 3 3  
4 7  ( F )  4 4 . 6 0  3 3 . 7 2  0 . 7 1 8  
2 . 1 2 9  0 . 2 9 4 ,  0 . 4 0 3  
0 . 8 7 2 ,  1 . 1 9 5  
4 8  ( F )  4 5 . 3 0  2 8 . 8 1  
0 . 6 8 1  2 . 3 6 4  0 . 0 9 3 ,  0 . 0 9 7  
0 . 3 2 3 ,  0 . 3 3 7  
5 2  ( F )  4 3 . 6 0  2 5 . 8 0  0 . 5 4 9  
2 . 1 2 8  0 . 1 9 7 ,  0 . 1 6  0 . 7 6 4 ,  1 . 5 4 3  
5 7  ( F )  5 2 . 3 0  2 5 . 4 1  0 . 7 6 1  
2 . 9 9 5  0 . 6 8 4 ,  0 . 0 4 8  
2 . 6 9 2 ,  0 . 1 8 9  
6 3  ( F )  5 1 . 6 0  2 5 . 6 9  0 . 4 8 4  1 . 8 8 4  
0 . 3 9 6 ,  0 . 0 7 2  1 . 5 4 1 ,  0 . 2 8 0  
4 4  ( M )  5 5 . 9 0  3 1 . 7 2  1 . 1 7 1  
3 . 6 9 2  0 . 0 0 5 ,  0 . 0 0 5  
0 . 0 1 6 ,  0 . 0 1 6  
3 3  ( M )  5 6 . 0 0  3 3 . 7 3  
1 . 6 3 9  4 . 8 4 9  0 . 0 3 8 ,  0 . 0 1 4  0 .  1 1 3 ,  0 . 0 4 2  
5 9  ( M )  5 5 . 9 0  3 3 . 9 1  0 . 2 8 5  0 . 8 4 0  0 . 1 3 6 ,  0 . 0 7 1  
0 . 4 0 1 ,  0 . 2 0 9  
6 0  ( M )  5 7 . 3 0  
3 4 . 8 8  
0 . 4 4 3  1 . 2 7 0  0 . 1 6 5 ,  0 . 1 1 2  
0 . 4 7 3 ,  0 . 3 2 1  
4 2  ( F )  
6 0 . 1 0  
2 9 . 4 1  
0 . 3 1 6  1 . 0 7 4  2 . 2 7 2 ,  0 . 4 7 2  
7 .  7 2 5 ,  1 . 6 0 5  
3 7  ( M )  6 7 . 3 0  3 2 . 8 2  0 . 8 1 9  
2 . 4 9 5  0 . 6 2 0 ,  0 . 2 8 6  1 . 8 8 9 ,  0 . 8 7 1  
4 9  ( M )  4 1 . 0 0  2 8 . 9 4  0 . 4 7 8  1 . 6 5 2  
0 . 3 4 9 ,  0 . 2 4 7  1 . 2 0 6 ,  0 . 8 5 3  
7 2  ( F )  4 0 . 7 0  3 2 . 2 7  0 . 9 0 4  2 . 8 0 1  
0 . 9 4 4 ,  0 . 6 5 4  2 . 9 2 5 ,  2 . 0 2 7  
1 6  ( F )  
5 6 . 0 0  2 4 . 2 6  2 . 1 2 0  8 . 7 4 0  
0 . 0 4 6 ,  0 . 0 8 6  0 .  1 9 0 ,  0 . 3 5 4  
5 1  ( F )  7 3 . 4 0  2 6 . 8 2  0 . 2 8 9  
1 . 0 7 8  1 . 1 3 5 ,  0 . 5 7 0  
4 . 2 3 2 ,  2 . 1 2 5 j  
7 4  ( F )  
6 9 . 7 0  
2 7 . 3 0  
0 . 2 8 3  1 . 0 3 7  0 . 0 7 7 ,  0 . 0 8 3  0 . 2 8 2 ,  0 . 3 0 4  
7 3  ( F )  
4 6 . 1 0  
4 1  ( F )  6 8 . 4 0  
6 7  ( F )  8 2 . 0 0  
1 7  ( F )  
3 8 . 6 0  
3 2  ( F )  3 9 . 1 0  
5 3  ( F )  2 9 . 0 0  
5 6  ( F )  3 2 . 7 0  
6 6  ( F )  3 3 . 6 0  
6 9  ( M )  5 7 . 6 0  
3 8  ( M )  
5 0 . 0 0  
I  
5 8  ( M )  4 5 . 0 0  
7 6  ( F )  4 4 . 0 0  
3 9  ( F )  5 2 . 7 0  
6 4  ( F )  4 8 . 9 0  
m e a n  
4 8 . 3 8  2 9 . 7 6  0 . 7 0 0  2 . 3 9 7  
0 . 3 0 9  1 . 0 3 0  
S D  
1 0 . 9 2  5 . 3 9  
0 . 4 5 9  1 . 7 6 8  0 . 4 0 9  1 . 2 9 9 !  
S E M  
1 . 5 1  0 . 8 7  0 . 0 7 5  
0 . 2 8 7  0 . 0 4 7  0 . 1 4 9  
n  
5 2  
3 8  3 8  3 8  7 6  7 6  
- -
A p p e n d i x  I I I .  A g e d  C 5 7 B L / 6  g l d  m i c e .  A g e  a t  d e a t h  a n d  w e i g h t s  o f  s p l e e n ,  a L N  a n d  w h o l e  
b o d y  a r e  s h o w n  f o r  a g e d  C 5 7 B L / 6  g l d  m i c e .  S p l e e n  a n d  a L N  w e i g h t s  a r e  a l s o  s h o w n  a s  a  
p e r c e n t a g e  o f  b o d y  w e i g h t  ( B W ) .  O r g a n  a n d  b o d y  w e i g h t s  a r e  s h o w n  f o r  m i c e  o n  w h i c h  a  f u l l  
a u t o p s y  w a s  p e r f o n n e d .  
3 1 8  
Mouse (sex) Age (weeks) Body weight (g) Spleen weight Spleen% BW al.N weight al.N% BW 
69(M) 89.6 37.86 0.195 0.515 0.001' 0.001 0.003, 0.003 
39(M) 91.6 41.16 0.16 0.389 0.01, 0.01 0.024, 0.024 
66 (M) 78.9 30.08 0.287 0.954 0.001' 0.001 0.003, 0.003 
16 (M) 95.3 33.16 0.991 2.989 0.020, 0.001 0.060, 0.003 
42 (F) 46.6 27.28 0.162 0.594 0.046, 0.055 0.169, 0.202 
43 (F) 46.3 32.94 0.419 1.272 0.337, 0.317 1.023, 0.962 
44 (F) 46.3 25.19 0.482 1.913 0.086, 0.079 0.341' 0.314 
59 (M) 44.7 38.15 0.445 1.166 0. 112, 0. 167 0.294, 0.438 
28 (M) 67.4 30.16 0.419 1.389 0.035, 0.009 0.116, 0.030 
46 (M) 67.4 30.92 0.424 1.371 0.032, 0.035 0.103, 0.113 
19 (M) 77.4 33.23 0.295 0.888 0.018, 0.009 0.054, 0.027 
51 (M) 73.6 28.05 0.1 0.357 0.048, 0.010 0.1 52, 0.036 
30 (M) 73.1 22.7 0.25 1.101 0.001' 0.001 0.003, 0.003 
31 (M) 72.7 38.68 0.447 1.156 0.001' 0.001 0.003, 0.003 
33 (F) 59.6 31.53 0.431 1.367 0. 117, 0.223 0.371' 0.707 
24 (F) 51.6 25.1 0.298 1.187 0.095, 0.110 0.378, 0.438 
26 (F) 61.6 25.55 0.914 3.577 0.049, 0.023 0.192, 0.090 
49 (F) 58.3 23.92 0.24 1.003 0.065, 0.060 0.272, 0.251 
29 (M) 61.9 34.97 0.264 0.755 0.02, 0.051 0.057, 0.156 
52 (F) 72.9 27.32 0.202 0.739 0.162, 0.030 0.593, 0.110 
37 (M) 81.4 33.89 0.139 0.41 0.07, 0.01 0.207, 0.030 
63 (F) 69.3 31.13 0.571 1.834 1.332, 0.434 4.279, 1.394 
56 (F) 68.6 29.02 0.345 1.189 0.062, 0.001 0.214, 0.003 
54 (M) 70.4 30.12 0.22 0.73 0.001' 0.001 0.003, 0.003 
70 (M) 67.9 27.77 0.291 1.048 0.01, 0.035 0.036, 0.1 26 
40 (F) 80.7 23.03 0.167 0.725 0.039, 0.027 0.169, 0.117 
58 (F) 76.7 22.71 0.442 1.946 0.031' 0.014 0.137, 0.062 
20 (M) 93.6 
27 (F) 45 
48 (F) 41.9 
50 (F) 40.1 
53 (F) 33.7 
57 (F) 37 
67 (M) 42.7 
41 (M) 46.9 
34 (F) 50.4 
23 (F) 51 
62 (F) 47.7 
32 (F) 63.7 
9 (F) 82.8 
21 (M) 70.1 
61 (F) 64.7 
48 (F) 54.9 
68 (F) 66 
36 (F) 76.4 
22 (M) 79.6 
mean 63.91 30.21 0.356 1.206 0.084 0.276 
SD 16.13 5.13 0.211 0.742 0.194 0.621 
SEM 2.38 0.96 0.041 0.143 0.026 0.085 
n 46 27 27 27 54 54 
Appendix IV. Aged C57BL/6 gld TNF_1_ mice. Age at death and weights of spleen, aLN and 
whole body are shown for aged C57BL/6 gld TNF1- mice. Spleen and aLN weights are also 
shown as a percentage of BW. Organ and body weights are shown for mice on which a full 
autopsy was performed. 
